

# STIC Search Report

## Biotech-Chem Library

STIC Database Tracking Number: 205136

TO: Rei-Tsang Shiao  
Location: REM-5A10/5C18  
Art Unit: 1626  
Thursday, October 26, 2006

Case Serial Number: 10/849089

From: Deirdre Arnold  
Location: Biotech-Chem Library  
REM 1A55  
Phone: 571-272-2532

Deirdre.Arnold@uspto.gov

### Search Notes

*Please feel free to contact me if you have any questions or would like to rework the search.*

Thank you for using STIC services.

Regards,  
Deirdre Arnold



The Page Don't (app.)



# STIC SEARCH RESULTS FEEDBACK FORM

## Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact*:

Mary Hale, Information Branch Supervisor  
571-272-2507 Remsen 1 A51

## Voluntary Results Feedback Form

➤ I am an examiner in Workgroup:  Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature  
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library Remsen Bldg.



110 Page Blank copy



7-839

FOR OFFICIAL USE ONLY

205/38

ACCESS DB #

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

# SEARCH REQUEST FORM

Requester's Full Name: Robert (Ruth) Shiao Examiner #: 79521 Date: 10/19/06  
 Art Unit: 1626 Phone Number: 2-0707 Serial Number: 10/849,089  
 Location (Bldg/Room#): REM (Mailbox #): 5A10 Results Format Preferred (circle): PAPER DISK  
 \*\*\*\*\*  
 \*\*\*\*\*  
 \*\*\*\*\*

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Azardole-densine on factor x  
 Inventors (please provide full names): Nazze et al.


Earliest Priority Date: \_\_\_\_\_

## Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

I. sub cpdz (see claim 1) and 8



\* D is pyridine

\* Q is a bond,  
C, N, S, O

\* R<sup>0</sup> is aryl,  
heterocycle, heteroaryl

\* R<sub>1</sub>, R<sub>3</sub> R<sub>2</sub> V, G  
are sub


\* M is H, alkyl,  
-CO, C, heteryl,  
heterocycle, cycloalkyl.

II. search methods of use  
of cpdz

The Page Design (1)

We claim:

1. A compound of the formula I,



wherein

- 5  $R^0$  is
- 1) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R8,
  - 2) a monocyclic or bicyclic 4- to 15-membered heterocyclyl selected from the group consisting of benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl, indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyridyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl and 1,4,5,6-tetrahydro-pyridazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or
  - 3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and is additionally substituted by a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;
- 15
- 20
- R8 is
- 1) halogen,
  - 2)  $-NO_2$ ,
  - 3)  $-CN$ ,
  - 25 4)  $-C(O)-NH_2$ ,
  - 5)  $-OH$ ,
  - 6)  $-NH_2$ ,
  - 7)  $-O-CF_3$ ,
  - 8) a monocyclic or bicyclic 6- to 14-membered aryl, wherein the aryl is mono-, di- or trisubstituted independently of one another by halogen or  $-O-(C_1-C_8)$ -alkyl,
- 30

Chicago Plant (exp.)

9)  $-(C_1-C_8)\text{-alkyl}$ , wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen,  $NH_2$ ,  $-OH$  or methoxy,


10)  $-O-(C_1-C_8)\text{-alkyl}$ , wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen,  $NH_2$ ,  $-OH$  or methoxy,

5 11)  $-SO_2-CH_3$  or

12)  $-SO_2-CF_3$ ,

provided that when  $R^0$  is a monocyclic or bicyclic 6- to 14-membered aryl, then  $R_8$  is least one of the substituent of the aryl is halogen,  $-C(O)-NH_2$  or  $-O-(C_1-C_8)\text{-alkyl}$ ;

10 the substructure



in formula I is a 4-to 8 membered saturated, partially unsaturated or aromatic cyclic group containing zero, 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen and is unsubstituted or substituted 1, 2, 3, 4, 5 or 6 times by  $R_3$ , or substituted 1 or 2 times by  $=O$ ,  
15 provided that said cyclic group is not a phenyl residue;

Q is a direct bond,  $-(C_0-C_2)\text{-alkylene-C(O)-NR}^{10}$ -,  $-\text{NR}^{10}\text{-C(O)-NR}^{10}$ -,  $-\text{NR}^{10}\text{-C(O)-}$ -,  $-SO_2$ -,  
 $-(C_1-C_6)\text{-alkylene}$ -,  $-(CH_2)_m\text{-NR}^{10}\text{-C(O)-NR}^{10}\text{-(CH}_2)_n$ -,  $-(CH_2)_m\text{-NR}^{10}\text{-C(O)-(CH}_2)_n$ -,  
 $-(CH_2)_m\text{-S-(CH}_2)_n$ -,  $-(CH_2)_m\text{-C(O)-(CH}_2)_n$ -,  $-(CH_2)_m\text{-SO}_2\text{-NR}^{10}\text{-(CH}_2)_n$ -,  
 20  $-(CH_2)_m\text{-NR}^{10}\text{-SO}_2\text{-(CH}_2)_n$ -,  $-(CH_2)_m\text{-NR}^{10}\text{-SO}_2\text{-NR}^{10}\text{-(CH}_2)_n$ -,  
 $-(CH_2)_m\text{-CH(OH)-(CH}_2)_n$ -,  $-(CH_2)_m\text{-O-C(O)-NR}^{10}\text{-(CH}_2)_n$ -,  
 $-(C_2-C_3)\text{-alkylene-O-(C}_0\text{-C}_3\text{)-alkylene-}$ -,  $-(C_2-C_3)\text{-alkylene-S(O)-}$ -,  
 $-(C_2-C_3)\text{-alkylene-S(O)}_2$ -,  $-(CH_2)_m\text{-NR}^{10}\text{-C(O)-O-(CH}_2)_n$ -,  
 $-(C_2-C_3)\text{-alkylene-S(O)}_2\text{-NH-(R}^{10})$ -,  $-(C_2-C_3)\text{-alkylene-N(R}^{10})$ - or  
 25  $-(C_0-C_3)\text{-alkylene-C(O)-O-(CH}_2)_m$ -,

wherein  $-(CH_2)_m$ - or  $-(CH_2)_n$ - are alkylene that is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen,  $-NH_2$  or  $-OH$ , or  $-(C_3-C_6)\text{-cycloalkylene}$ , that is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen,  $-NH_2$  or  $-OH$ ;

This Page Blank (copy)

5  $R^1$  is hydrogen,  $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or substituted one to three times  
 by  $R^{13}$ ,  $-(C_1-C_3)$ -alkylene- $C(O)-NH-$   $R^0$ ,  $-(C_1-C_3)$ -alkylene- $C(O)-O-R^{15}$ , a monocyclic or  
 bicyclic 6- to 14-membered aryl, wherein the aryl is mono-, di- or trisubstituted independently  
 of one another by  $R^8$ ; a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing  
 one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen,  
 $-(C_1-C_3)$ -perfluoroalkylene,  $-(C_1-C_3)$ -alkylene- $S(O)-(C_1-C_4)$ -alkyl,  
 $-(C_1-C_3)$ -alkylene- $S(O)_2-(C_1-C_3)$ -alkyl,  $-(C_1-C_3)$ -alkylene- $S(O)_2-N(R^{4'})-R^{5'}$ ,  
 $-(C_1-C_3)$ -alkylene- $O-(C_1-C_4)$ -alkyl,  $-(C_0-C_3)$ -alkylene- $(C_3-C_8)$ -cycloalkyl, or  
 10  $-(C_0-C_3)$ -alkylene-het, wherein the het is a 3- to 7-membered cyclic residue, containing up to  
 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, and is unsubstituted or  
 mono-, di- or trisubstituted independently of one another by  $R^{14}$ ,

15  $R^{4'}$  and  $R^{5'}$  are independent of one another are identical or different and are hydrogen atom or -  
 $(C_1-C_4)$ -alkyl,

20  $R^2$  is a direct bond or  $-(C_1-C_4)$ -alkylene, or

25  $R^1$  and  $R^3$  together with the atoms to which they are bonded form a  
 6- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from  
 nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or  
 trisubstituted independently of one another by  $R^{14}$ , or

30  $R^1-N-R^2-V$  form a 4- to 7-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen  
 from nitrogen, sulfur or oxygen, and wherein said cyclic group is unsubstituted or  
 mono-, di- or trisubstituted independently of one another by  $R^{14}$ ;

35  $R^{14}$  is halogen,  $-OH$ ,  $=O$ ,  $-(C_1-C_8)$ -alkyl,  $-(C_1-C_4)$ -alkoxy,  $-NO_2$ ,  $-C(O)-OH$ ,  $-CN$ ,  $-NH_2$ ,  
 $-C(O)-O-(C_1-C_4)$ -alkyl,  $-(C_0-C_8)$ -alkyl- $SO_2-(C_1-C_4)$ -alkyl,  
 $-(C_0-C_8)$ -alkyl- $SO_2-(C_1-C_3)$ -perfluoroalkyl,  $-(C_0-C_8)$ -alkyl- $SO_2-N(R^{18})-R^{21}$ ,  
 $-C(O)-NH-(C_1-C_8)$ -alkyl,  $-C(O)-N-[(C_1-C_8)$ -alkyl] $_2$ ,  $-NR^{18}-C(O)-NH-(C_1-C_8)$ -alkyl,  
 40  $-C(O)-NH_2$ ,  $-S-R^{18}$ , or  $-NR^{18}-C(O)-NH-[(C_1-C_8)$ -alkyl] $_2$ ,  
 wherein  $R^{18}$  and  $R^{21}$  are independently from each other hydrogen,  $-(C_1-C_3)$ -perfluoroalkyl  
 or  $-(C_1-C_6)$ -alkyl;

The Page Blank (copy)



- ✓ V is
- 1) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein the cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
  - 2) a 6- to 14-membered aryl, wherein the aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
  - 3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

- 5
- ✓ G is
- a direct bond,  $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n-$ ,  $-(CH_2)_m-CH(OH)-(CH_2)_n-$ ,  $-(CH_2)_m-$ ,  $-(CH_2)_m-O-(CH_2)_n-$ ,  $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n-$ ,  $-(CH_2)-SO_2-(CH_2)_n-$ ,  $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n-$ ,  $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n-$ ,  $-(CH_2)_m-C(O)-(CH_2)_n-$ ,  $-(CH_2)-S-(CH_2)_n-$ ,  $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n-$ ,  $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n-$ ,  $-(CH_2)_m-NR^{10}-$ ,  $-(CH_2)_m-O-C(O)-NR^{10}-(CH_2)_n-$  or  $-(CH_2)_m-NR^{10}-C(O)-O-(CH_2)_n-$ ;

15

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6;

- ✓ M is
- 1) hydrogen,
  - 2)  $-(C_1-C_8)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
  - 3)  $-C(O)-N(R11)-R12$ ,
  - 4)  $-(CH_2)_m-NR^{10}$ ,
  - 5) a 6- to 14-membered aryl, wherein the aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
  - 6) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
  - 7)  $-(C_3-C_8)$ -cycloalkyl, wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
  - 8) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

✓ R3 is 1) hydrogen,


1000 Egg Bank (3000)

- 2) halogen,
- 3)  $-(C_1-C_4)\text{-alkyl}$ , wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 4)  $-(C_1-C_3)\text{-perfluoroalkyl}$ ,
- 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 6)  $-(C_0-C_4)\text{-alkylene-O-R19}$ ,
- 7)  $-\text{NO}_2$ ,
- 8)  $-\text{CN}$ ,
- 9)  $-\text{SO}_s\text{-R}^{11}$ , wherein s is 1 or 2,
- 10)  $-\text{SO}_t\text{-N(R}^{11})\text{-R}^{12}$ , wherein t is 1 or 2,
- 11)  $-(C_0-C_4)\text{-alkylene-C(O)-R}^{11}$ ,
- 12)  $-(C_0-C_4)\text{-alkylene-C(O)-O-R}^{11}$ ,
- 13)  $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11})\text{-R}^{12}$ ,
- 14)  $-(C_0-C_4)\text{-alkylene-N(R}^{11})\text{-R}^{12}$ ,
- 15)  $-\text{NR}^{10}\text{-SO}_2\text{-R}^{10}$ ,
- 16)  $-\text{S-R}^{10}$ ,
- 17)  $-(C_0-C_2)\text{alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-(C}_1\text{-C}_4\text{)-alkyl}$ ,
- 18)  $-\text{C(O)-O-C(R15, R16)-O-C(O)-R17}$ ,
- 19)  $-(C_0-C_2)\text{alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-O-(C}_1\text{-C}_6\text{)-alkyl}$ ,
- 20)  $-\text{C(O)-O-C(R15, R16)-O-C(O)-O-R17}$ ,
- 21)  $-(C_0-C_4)\text{-alkylene-(C}_6\text{-C}_{14}\text{)-aryl}$ , wherein aryl is mono-, di- or trisubstituted independently of one another by R13,
- 22)  $-(C_0-C_4)\text{-alkylene-(C}_4\text{-C}_{15}\text{)-heterocyclyl}$ , wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13
- 23)  $-(C_0-C_4)\text{-alkylene-(C}_3\text{-C}_8\text{)-cycloalkyl}$ , wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 24)  $-(C_0-C_4)\text{-alkylene-het}$ , wherein the het is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 25)  $-(C_0-C_4)\text{-alkylene-O-CH}_2\text{-(C}_1\text{-C}_3\text{)-perfluoroalkylene-CH}_2\text{-O-(C}_0\text{-C}_4\text{)-alkyl}$ ,
- 26)  $-\text{SO}_w\text{-N(R}^{11})\text{-R}^{13}$ , wherein w is 1 or 2,
- 27)  $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11})\text{-R}^{13}$ ,

This Page Blank (asp.4)

28)  $-(C_0-C_4)\text{-alkylene-N(R}^{11})\text{-R}^{13}$ , or

29) a residue selected from the group consisting of



wherein Me is methyl;

R19 is a) hydrogen,

10 b)  $-(C_1-C_4)\text{-alkyl}$ , wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

c)  $-\text{CF}_3$ , or

d)  $-\text{CHF}_2$ ,

15 or two -OR19 residues and adjacent atoms through which they are attached may form together a 5- or 6- membered ring, that is unsubstituted or substituted one, two, three or four times by R13;

R11 and R12 are independently of one another identical or different and are

1) hydrogen,

20 2)  $-(C_1-C_6)\text{-alkyl}$ , wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

3)  $-(C_0-C_6)\text{-alkyl-(C}_3\text{-C}_8\text{)-cycloalkyl}$ ,


4)  $-\text{SO}_t\text{-R}^{10}$ , wherein t is 1 or 2,

The Page Blank (asp19)

- 5)  $-(C_0-C_6)\text{-alkyl-(}C_6-C_{14}\text{)-aryl}$ , wherein the alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13,
- 6)  $-(C_1-C_3)\text{-perfluoroalkyl}$ ,
- 7)  $-O-R^{17}$ , or
- 8)  $-(C_0-C_6)\text{-alkyl-(}C_4-C_{15}\text{)-heterocyclyl}$ , wherein the alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, or


R11 and R12 together with the nitrogen atom to which they are bonded form a 4- to 7-membered monocyclic heterocyclic ring which in addition to the nitrogen atom contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

R13 is halogen,  $-\text{NO}_2$ ,  $-\text{CN}$ ,  $=\text{O}$ ,  $-\text{OH}$ ,  $-\text{CF}_3$ ,  $-\text{C}(\text{O})-\text{O}-\text{R}^{10}$ ,  $-\text{C}(\text{O})-\text{N}(\text{R}^{10})-\text{R}^{20}$ ,  $-\text{N}(\text{R}^{10})-\text{R}^{20}$ ,  $-(C_3-C_8)\text{-cycloalkyl}$ ,  $-(C_0-C_3)\text{-alkylene-O}-\text{R}^{10}$ ,  $-\text{Si}(\text{CH}_3)_3$ ,  $-\text{N}(\text{R}^{10})-\text{S}(\text{O})_u-\text{R}^{10}$ , wherein u is 1 or 2,  $-\text{S}-\text{R}^{10}$ ,  $-\text{SO}_r-\text{R}^{10}$ , wherein r is 1 or 2,  $-\text{S}(\text{O})_v-\text{N}(\text{R}^{10})-\text{R}^{20}$ , wherein v is 1 or 2,  $-\text{C}(\text{O})-\text{R}^{10}$ ,  $-(C_1-C_8)\text{-alkyl}$ ,  $-(C_1-C_8)\text{-alkoxy}$ , phenyl, phenyloxy-,  $-\text{O}-\text{CF}_3$ ,  $-(C_0-C_4)\text{-alkyl-C}(\text{O})-\text{O}-\text{C}(\text{R}^{15}, \text{R}^{16})-\text{O}-\text{C}(\text{O})-\text{R}^{17}$ ,  $-(C_1-C_4)\text{-alkoxy-phenyl}$ ,  $-(C_0-C_4)\text{-alkyl-C}(\text{O})-\text{O}-\text{C}(\text{R}^{15}, \text{R}^{16})-\text{O}-\text{C}(\text{O})-\text{O}-\text{R}^{17}$ ,  $-(C_1-C_3)\text{-perfluoroalkyl}$ ,  $-\text{O}-\text{R}^{15}$ ,  $-\text{NH}-\text{C}(\text{O})-\text{NH}-\text{R}^{10}$ ,  $-\text{NH}-\text{C}(\text{O})-\text{O}-\text{R}^{10}$  or a residue selected from the group consisting of



This Page Blank (up to)





and , wherein Me is methyl;

R<sup>10</sup> and R<sup>20</sup> are independently of one another hydrogen, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, -(C<sub>0</sub>-C<sub>4</sub>)-alkyl-OH,

5 -(C<sub>0</sub>-C<sub>4</sub>)-alkyl-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or -(C<sub>1</sub>-C<sub>3</sub>)-perfluoroalkyl;

R<sub>15</sub> and R<sub>16</sub> are independently of one another hydrogen, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or together with the carbon atom to which they are bonded form a 3- to 6 membered carbocyclic ring which is unsubstituted or substituted one to three times by R<sup>10'</sup> and

10

R<sub>17</sub> is -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-OH, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, -(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-O-(C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>)-alkyl-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by -OH, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or R<sup>10</sup>;

15 or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof.

2. The compound according to claim 1, wherein

R<sup>0</sup> as 1) is phenyl, naphthyl, biphenyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R<sub>8</sub>, or

20

3) is acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolyl, 1H-indazolyl, indolinyl, indoliziny, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazoliny, isoxazolidinyl, 2-

25

This Page Blank (uspto)

- a) hydrogen or  
 b)  $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

5 R11 and R12 are independently of one another identical or different and are

- 1) hydrogen or  
 2)  $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or

10 R11 and R12 together with the nitrogen atom to which they are bonded form azetidine, imidazolidine, morpholine, (1,4)-oxazepane piperazine, piperidine, pyrrolidine or thiomorpholine;

R13 is fluorine, =O, -OH,  $-CF_3$ ,  $-C(O)-O-R^{10}$ ,  $-C(O)-N(R^{10})-R^{20}$ ,  $-N(R^{10})-R^{20}$ , or  $-(C_0-C_3)$ -alkylene- $O-R^{10}$ ; and

15

R<sup>10</sup> and R<sup>20</sup> are independently of one another hydrogen,  $-(C_1-C_4)$ -alkyl or  $-(C_1-C_3)$ -perfluoroalkyl.


8. The compound according to claim 1, wherein the compound is

- 20 ~~1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,~~  
~~1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester,~~  
~~1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid,~~  
 25 ~~1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2,5-dicarboxylic acid 5-amide 2-[(1-isopropyl-piperidin-4-yl)-amide],~~  
~~1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[3,2-b]pyridine-2- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide ,~~  
~~1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid ,~~  
 30 ~~1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide ,~~  
~~1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylcarbamoyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid methyl ester,~~

This Page Blank (uapto)

- 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylcarbamoyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid ,  
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-methoxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid-(1-isopropyl-piperidin-4-yl)-amide,  
 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-hydroxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide ,  
 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2-methoxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,  
 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2-hydroxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide ,  
 1-(6-Chloro-benzo[b]thiophen-2-ylmethyl)-5-(2-methoxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide or  
 1-(6-Chloro-benzo[b]thiophen-2-ylmethyl)-5-(2-hydroxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide .


9. A process for the preparation of a compound according to claim 1, which comprises condensing a compound of formula 29 with a compound of the formula  $HR^{8'}$  to give a compound of formula 30 and converting the compound of the formula 30 into a compound of the formula I,



- wherein the residue  $R^{8'}$  has the donation of  $-N(R^1)-R^2-V-G-M$  as indicated claim 1, but where in  $R^{8'}$  functional groups can also be present in the form of groups that are subsequently transformed into the final functional groups present in  $-N(R^1)-R^2-V-G-M$ , and where the residue  $R^{54}$  denotes the group  $-Q-R^0$  or can denote a group which is subsequently transformed into the group  $-Q-R^0$ , and where the group  $-C(O)-R^{53}$  can be a carboxylic acid group or derivatives thereof, and where the groups  $R^{3a}$  in the formulae 29 and 30 have the corresponding definitions of  $R^3$  in formula I as defined in claim 1 or functional groups in them can also be present in protected form or in the form of precursor groups.
10. A pharmaceutical composition, comprising at least one compound according to claim 1 and a pharmaceutically acceptable carrier.

This Page Blank (uspto)

Example -



This Page Blank (uspto)





## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov




Bib Data Sheet

CONFIRMATION NO. 5674

<b>SERIAL NUMBER</b> 10/849,089	<b>FILING OR 371(c) DATE</b> 05/19/2004 <b>RULE</b>	<b>CLASS</b> 548	<b>GROUP ART UNIT</b> 1626	<b>ATTORNEY DOCKET NO.</b> DEAV2003/0033 US NP	
<b>APPLICANTS</b> Marc Nazare, Idstein, GERMANY; Volkmar Wehner, Sandberg, GERMANY; David William Will, Kriftel, GERMANY; Kurt Ritter, Frankfurt am Main, GERMANY; Matthias Urmann, Eschborn, GERMANY; Hans Matter, Langenselbold, GERMANY;					
<b>** CONTINUING DATA *****</b> This appln claims benefit of 60/507,141 09/30/2003					
<b>** FOREIGN APPLICATIONS *****</b> EUROPEAN PATENT OFFICE (EPO) 03011304.7 05/19/2003 <i>RB. 7/19/06</i>					
<b>IF REQUIRED, FOREIGN FILING LICENSE GRANTED</b> <b>** 07/19/2004</b>					
Foreign Priority claimed <input checked="" type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after met Verified and <i>Allowance</i> Acknowledged <i>Examiner's Signature</i> <i>Initials</i>		<b>STATE OR COUNTRY</b> GERMANY	<b>SHEETS DRAWING</b> 0	<b>TOTAL CLAIMS</b> 15	<b>INDEPENDENT CLAIMS</b> 1
<b>ADDRESS</b> 05487					
<b>TITLE</b> Azaindole-derivatives as factor Xa inhibitors					
<b>FILING FEE RECEIVED</b> 900	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		

**This Page Blank (usp. 4)**

L5 STR



DEFAULT ECLEVEL IS LIMITED


NUMBER OF NODES IS 12

L7 45329 SEA FILE=REGISTRY SSS FUL L5

45329 ANSWERS

SEARCH TIME: 00.00.04

L5 STR



DEFAULT MLEVEL IS ATOM


DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L7 45329 SEA FILE=REGISTRY SSS FUL L5  
L11 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L14 753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11

100.0% PROCESSED 45329 ITERATIONS

753 ANSWERS


SEARCH TIME: 00.00.02

=> d que stat 18

L8 103939 SEA FILE=REGISTRY ABB=ON PLU=ON NC4-NC5/ES

=> d que stat 115

L5 STR



```

VAR G1=C/N
VAR G2=C/N
VAR G3=C/N
VAR G4=C/N
NODE ATTRIBUTES:
NSPEC   IS RC      AT  10
NSPEC   IS RC      AT  11
CONNECT IS E1  RC AT  12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```


GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  12

```

```

STEREO ATTRIBUTES: NONE
L7      45329 SEA FILE=REGISTRY SSS FUL L5
L8      103939 SEA FILE=REGISTRY ABB=ON  PLU=ON  NC4-NC5/ES
L11     STR

```



```

VAR G1=C/N
VAR G2=C/N
VAR G3=C/N
VAR G4=C/N
NODE ATTRIBUTES:
NSPEC   IS RC      AT  10
NSPEC   IS RC      AT  11
CONNECT IS E1  RC AT  12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  13


```

```

STEREO ATTRIBUTES: NONE


```

```
=> d que stat 121
L5          STR
```



GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 12

```
STEREO ATTRIBUTES: NONE
L7          45329 SEA FILE=REGISTRY SSS FUL L5
L19          STR
```



```

NODE ATTRIBUTES:
NSPEC      IS RC      AT      2
NSPEC      IS RC      AT      3
CONNECT    IS E1     RC AT      4
DEFAULT    MLEVEL IS ATOM
GGCAT      IS PCY     AT      1
DEFAULT    ECLEVEL IS LIMITED
ECOUNT     IS E7 C    E2 N    E0 O    E0 S    AT      1

```

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE  
L21            733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19

100.0% PROCESSED 45329 ITERATIONS


733 ANSWERS

=> d que stat 122

DEFAULT ECLEVEL IS LIMITED

NUMBER OF NODES IS 12

L11 STR




DEFAULT ECLEVEL IS LIMITED

Page 5

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L14 753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11  
L19 STR



NODE ATTRIBUTES:

NSPEC IS RC AT 2  
NSPEC IS RC AT 3  
CONNECT IS E1 RC AT 4  
DEFAULT MLEVEL IS ATOM  
GGCAT IS PCY AT 1  
DEFAULT ECLEVEL IS LIMITED  
ECOUNT IS E7 C E2 N E0 O E0 S AT 1

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE

L21 733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19  
L22 0 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND L21

=> d que stat 139

L5 STR



VAR G1=C/N  
VAR G2=C/N  
VAR G3=C/N  
VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10  
NSPEC IS RC AT 11  
CONNECT IS E1 RC AT 12  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 12




STEREO ATTRIBUTES: NONE

L7 45329 SEA FILE=REGISTRY SSS FUL L5

L37 STR

C@14 N@15 S@16 O@17



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

VAR G5=14/15/16/17

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

NSPEC IS RC AT 14

NSPEC IS RC AT 15

NSPEC IS RC AT 16

NSPEC IS RC AT 17

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L39 3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37


100.0% PROCESSED 31774 ITERATIONS

3990 ANSWERS

SEARCH TIME: 00.00.11

=&gt; d que stat 142

L5 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:


NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L7 45329 SEA FILE=REGISTRY SSS FUL L5  
 L8 103939 SEA FILE=REGISTRY ABB=ON PLU=ON NC4-NC5/ES  
 L19 STR



NODE ATTRIBUTES:


NSPEC IS RC AT 2  
 NSPEC IS RC AT 3  
 CONNECT IS E1 RC AT 4  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS PCY AT 1  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E7 C E2 N E0 O E0 S AT 1

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE

L21 733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19  
 L37 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

VAR G5=14/15/16/17

NODE ATTRIBUTES:

NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 NSPEC IS RC AT 14

```

NSPEC      IS RC      AT 15
NSPEC      IS RC      AT 16
NSPEC      IS RC      AT 17
CONNECT    IS E1      RC AT 12
DEFAULT    MLEVEL IS ATOM
DEFAULT    ECLEVEL IS LIMITED


```

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

```
L39      3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37
L40      77  SEA FILE=REGISTRY ABB=ON  PLU=ON  L8 AND L39
L41      82  SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 AND L39
L42      82  SEA FILE=REGISTRY ABB=ON  PLU=ON  (L40 OR L41)
```

```
=> d que stat 153
L5          STR
```



```
VAR G1=C/N
VAR G2=C/N
VAR G3=C/N
VAR G4=C/N
```

NODE ATTRIBUTES:

```


NSPEC      IS RC      AT  10
NSPEC      IS RC      AT  11
CONNECT    IS E1      RC AT  12
DEFAULT    MLEVEL IS ATOM
DEFAULT    ECLEVEL IS LIMITED

```

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE


```
L7      45329 SEA FILE=REGISTRY SSS FUL L5
L8      103939 SEA FILE=REGISTRY ABB=ON  PLU=ON  NC4-NC5/ES
L11     STR
```



VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE  
 L14 753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11  
 L15 0 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L14  
 L19 STR




NODE ATTRIBUTES:  
 NSPEC IS RC AT 2  
 NSPEC IS RC AT 3  
 CONNECT IS E1 RC AT 4  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS PCY AT 1  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E7 C E2 N E0 O E0 S AT 1

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE  
 L21 733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19  
 L22 0 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND L21  
 L37 STR

C@14    N@15    S@16    O@17



VAR G1=C/N  
VAR G2=C/N  
VAR G3=C/N  
VAR G4=C/N  
VAR G5=14/15/16/17

NODE ATTRIBUTES:

NSPEC    IS RC    AT    10  
NSPEC    IS RC    AT    11  
NSPEC    IS RC    AT    14  
NSPEC    IS RC    AT    15  
NSPEC    IS RC    AT    16  
NSPEC    IS RC    AT    17  
CONNECT IS E1    RC AT    12  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS    18

STEREO ATTRIBUTES: NONE

L39            3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37  
L40            77 SEA FILE=REGISTRY ABB=ON    PLU=ON    L8 AND L39  
L41            82 SEA FILE=REGISTRY ABB=ON    PLU=ON    L21 AND L39  
L42            82 SEA FILE=REGISTRY ABB=ON    PLU=ON    (L40 OR L41)  
L53            82 SEA FILE=REGISTRY ABB=ON    PLU=ON    L42 OR L22 OR L15

=> d que nos 154

L5            STR  
L7            45329 SEA FILE=REGISTRY SSS FUL L5  
L8            103939 SEA FILE=REGISTRY ABB=ON    PLU=ON    NC4-NC5/ES  
L11           STR  
L14           753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11  
L15           0 SEA FILE=REGISTRY ABB=ON    PLU=ON    L8 AND L14  
L19           STR  
L21           733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19  
L22           0 SEA FILE=REGISTRY ABB=ON    PLU=ON    L14 AND L21  
L37           STR  
L39           3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37  
L40           77 SEA FILE=REGISTRY ABB=ON    PLU=ON    L8 AND L39  
L41           82 SEA FILE=REGISTRY ABB=ON    PLU=ON    L21 AND L39  
L42           82 SEA FILE=REGISTRY ABB=ON    PLU=ON    (L40 OR L41)  
L53           82 SEA FILE=REGISTRY ABB=ON    PLU=ON    L42 OR L22 OR L15  
L54           ANALYZE    PLU=ON    L53 1- LC :            7 TERMS

=&gt; d 154 1-

L54 ANALYZE L53 1- LC : 7 TERMS

TERM #	# OCC	# DOC	% DOC	LC
1	77	77	93.90	CA
2	77	77	93.90	CAPLUS
3	36	36	43.90	TOXCENTER
4	35	35	42.68	USPATFULL
5	33	33	40.24	CASREACT
6	5	5	6.10	USPAT2
7	4	4	4.88	CHEMCATS

\*\*\*\*\* END OF L54\*\*\*

=&gt; d que nos 158

```

L5          STR
L7          45329 SEA FILE=REGISTRY SSS FUL L5
L8          103939 SEA FILE=REGISTRY ABB=ON PLU=ON NC4-NC5/ES
L11         STR
L14         753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11
L15         0 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L14
L19         STR
L21         733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19
L22         0 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND L21
L37         STR
L39         3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37
L40         77 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L39
L41         82 SEA FILE=REGISTRY ABB=ON PLU=ON L21 AND L39
L42         82 SEA FILE=REGISTRY ABB=ON PLU=ON (L40 OR L41)
L53         82 SEA FILE=REGISTRY ABB=ON PLU=ON L42 OR L22 OR L15
L55         11 SEA FILE=HCAPLUS ABB=ON PLU=ON L42 OR L53
L56         QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY
            <2004 OR REVIEW/DT
L58         7 SEA FILE=HCAPLUS ABB=ON PLU=ON L55 AND L56

```

=&gt; d his 170

(FILE 'TOXCENTER, USPATFULL, USPAT2, CASREACT, CHEMCATS' ENTERED AT  
14:53:12 ON 24 OCT 2006)

L70 9 S L69 AND L56

=&gt; d que nos 170

```

L5          STR
L7          45329 SEA FILE=REGISTRY SSS FUL L5
L8          103939 SEA FILE=REGISTRY ABB=ON PLU=ON NC4-NC5/ES
L11         STR
L14         753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11
L15         0 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L14
L19         STR
L21         733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19
L22         0 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND L21
L37         STR
L39         3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37
L40         77 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L39
L41         82 SEA FILE=REGISTRY ABB=ON PLU=ON L21 AND L39
L42         82 SEA FILE=REGISTRY ABB=ON PLU=ON (L40 OR L41)
L53         82 SEA FILE=REGISTRY ABB=ON PLU=ON L42 OR L22 OR L15
L56         QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY

```

&lt;2004 OR REVIEW/DT

L69 24 SEA L42 OR L53  
L70 9 SEA L69 AND L56

=&gt; dup rem 158 170

DUPLICATE IS NOT AVAILABLE IN 'CHEMCATS'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
FILE 'HCAPLUS' ENTERED AT 15:34:25 ON 24 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 15:34:25 ON 24 OCT 2006  
COPYRIGHT (C) 2006 ACS

FILE 'USPATFULL' ENTERED AT 15:34:25 ON 24 OCT 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:34:25 ON 24 OCT 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CASREACT' ENTERED AT 15:34:25 ON 24 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)  
PROCESSING COMPLETED FOR L58  
PROCESSING COMPLETED FOR L70

L73 12 DUP REM L58 L70 (4 DUPLICATES REMOVED)  
ANSWERS '1-7' FROM FILE HCAPLUS  
ANSWERS '8-12' FROM FILE USPATFULL

=&gt; file stnguide

FILE 'STNGUIDE' ENTERED AT 15:34:29 ON 24 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Oct 20, 2006 (20061020/UP).

1. The first part of the paper is devoted to the study of the

2.


3.

4.



=> d que stat 17

L5 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L7 45329 SEA FILE=REGISTRY SSS FUL L5


100.0% PROCESSED 758487 ITERATIONS

45329 ANSWERS

SEARCH TIME: 00.00.04

=> d que stat 114

L5 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L7 45329 SEA FILE=REGISTRY SSS FUL L5

L11 STR


$$\text{VAR } G1 = C/N$$
$$\text{VAR } G2 = C/N$$
$$\text{VAR } G3 = C/N$$

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L14 753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11

100.0% PROCESSED 45329 ITERATIONS

753 ANSWERS


SEARCH TIME: 00.00.02

=> d que stat 18

L8 103939 SEA FILE=REGISTRY ABB=ON PLU=ON NC4-NC5/ES

=> d que stat 115

L5 STR



```

VAR G1=C/N
VAR G2=C/N
VAR G3=C/N
VAR G4=C/N
NODE ATTRIBUTES:
NSPEC   IS RC      AT 10
NSPEC   IS RC      AT 11
CONNECT IS E1  RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12

```

```


STEREO ATTRIBUTES: NONE

```

```

L7      45329 SEA FILE=REGISTRY SSS FUL L5
L8      103939 SEA FILE=REGISTRY ABB=ON  PLU=ON  NC4-NC5/ES
L11     STR

```



```

VAR G1=C/N
VAR G2=C/N
VAR G3=C/N
VAR G4=C/N
NODE ATTRIBUTES:
NSPEC   IS RC      AT 10
NSPEC   IS RC      AT 11
CONNECT IS E1  RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

```

```


STEREO ATTRIBUTES: NONE

```

L14 753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11  
 L15 0 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L14

=> d que stat l21


L5 STR



VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE  
 L7 45329 SEA FILE=REGISTRY SSS FUL L5  
 L19 STR



NODE ATTRIBUTES:  
 NSPEC IS RC AT 2  
 NSPEC IS RC AT 3  
 CONNECT IS E1 RC AT 4  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS PCY AT 1  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E7 C E2 N E0 O E0 S AT 1

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE  
 L21 733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19


100.0% PROCESSED 45329 ITERATIONS

733 ANSWERS

SEARCH TIME: 00.00.02

=&gt; d que stat 122

L5 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L7 45329 SEA FILE=REGISTRY SSS FUL L5

L11 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM


DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L14 753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11  
L19 STR



NODE ATTRIBUTES:

NSPEC IS RC AT 2  
NSPEC IS RC AT 3  
CONNECT IS E1 RC AT 4  
DEFAULT MLEVEL IS ATOM  
GGCAT IS PCY AT 1  
DEFAULT ECLEVEL IS LIMITED  
ECOUNT IS E7 C E2 N E0 O E0 S AT 1

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE

L21 733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19  
L22 0 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND L21

=> d que stat l39

L5 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10  
NSPEC IS RC AT 11  
CONNECT IS E1 RC AT 12  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L7 45329 SEA FILE=REGISTRY SSS FUL L5

L37 STR

C @14 N @15 S @16 O @17



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

VAR G5=14/15/16/17

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

NSPEC IS RC AT 14

NSPEC IS RC AT 15

NSPEC IS RC AT 16

NSPEC IS RC AT 17

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L39 3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37


100.0% PROCESSED 31774 ITERATIONS

3990 ANSWERS

SEARCH TIME: 00.00.11

=&gt; d que stat 142

L5 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:


NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L7 45329 SEA FILE=REGISTRY SSS FUL L5  
 L8 103939 SEA FILE=REGISTRY ABB=ON PLU=ON NC4-NC5/ES  
 L19 STR



NODE ATTRIBUTES:

NSPEC IS RC AT 2  
 NSPEC IS RC AT 3  
 CONNECT IS E1 RC AT 4  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS PCY AT 1  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E7 C E2 N E0 O E0 S AT 1


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE

L21 733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19  
 L37 STR

C @14 N @15 S @16 O @17



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

VAR G5=14/15/16/17

NODE ATTRIBUTES:

NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 NSPEC IS RC AT 14



NSPEC IS RC AT 15  
 NSPEC IS RC AT 16  
 NSPEC IS RC AT 17  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 18

## STEREO ATTRIBUTES: NONE

L39 3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37  
 L40 77 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L39  
 L41 82 SEA FILE=REGISTRY ABB=ON PLU=ON L21 AND L39  
 L42 82 SEA FILE=REGISTRY ABB=ON PLU=ON (L40 OR L41)

=> d que stat l53

L5 STR



VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N

## NODE ATTRIBUTES:


NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 12

## STEREO ATTRIBUTES: NONE

L7 45329 SEA FILE=REGISTRY SSS FUL L5  
 L8 103939 SEA FILE=REGISTRY ABB=ON PLU=ON NC4-NC5/ES  
 L11 STR



```

VAR G1=C/N
VAR G2=C/N
VAR G3=C/N
VAR G4=C/N
NODE ATTRIBUTES:
NSPEC   IS RC      AT  10
NSPEC   IS RC      AT  11
CONNECT IS E1  RC AT  12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```


GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  13

```

```

STEREO ATTRIBUTES: NONE
L14      753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11
L15      0 SEA FILE=REGISTRY ABB=ON  PLU=ON  L8 AND L14
L19      STR

```



```

NODE ATTRIBUTES:
NSPEC   IS RC      AT  2
NSPEC   IS RC      AT  3
CONNECT IS E1  RC AT  4
DEFAULT MLEVEL IS ATOM
GGCAT   IS PCY AT  1
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E7 C  E2 N  E0 O  E0 S  AT  1

```

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  4


```

```

STEREO ATTRIBUTES: NONE
L21      733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19
L22      0 SEA FILE=REGISTRY ABB=ON  PLU=ON  L14 AND L21
L37      STR

```

C@14 N@15 S@16 O@17



VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 VAR G5=14/15/16/17

## NODE ATTRIBUTES:

NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 NSPEC IS RC AT 14  
 NSPEC IS RC AT 15  
 NSPEC IS RC AT 16  
 NSPEC IS RC AT 17  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 18

## STEREO ATTRIBUTES: NONE

L39 3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37  
 L40 77 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L39  
 L41 82 SEA FILE=REGISTRY ABB=ON PLU=ON L21 AND L39  
 L42 82 SEA FILE=REGISTRY ABB=ON PLU=ON (L40 OR L41)  
 L53 82 SEA FILE=REGISTRY ABB=ON PLU=ON L42 OR L22 OR L15

=&gt; d que nos 154

L5 STR  
 L7 45329 SEA FILE=REGISTRY SSS FUL L5  
 L8 103939 SEA FILE=REGISTRY ABB=ON PLU=ON NC4-NC5/ES  
 L11 STR  
 L14 753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11  
 L15 0 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L14  
 L19 STR  
 L21 733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19  
 L22 0 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND L21  
 L37 STR  
 L39 3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37  
 L40 77 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L39  
 L41 82 SEA FILE=REGISTRY ABB=ON PLU=ON L21 AND L39  
 L42 82 SEA FILE=REGISTRY ABB=ON PLU=ON (L40 OR L41)  
 L53 82 SEA FILE=REGISTRY ABB=ON PLU=ON L42 OR L22 OR L15  
 L54 ANALYZE PLU=ON L53 1- LC : 7 TERMS

=&gt; d l54 1-

L54 ANALYZE L53 1- LC : 7 TERMS

TERM #	# OCC	# DOC	% DOC	LC
1	77	77	93.90	CA
2	77	77	93.90	CAPLUS
3	36	36	43.90	TOXCENTER
4	35	35	42.68	USPATFULL
5	33	33	40.24	CASREACT
6	5	5	6.10	USPAT2
7	4	4	4.88	CHEMCATS

\*\*\*\*\* END OF L54\*\*\*

=&gt; d que nos l58

```

L5          STR
L7          45329 SEA FILE=REGISTRY SSS FUL L5
L8          103939 SEA FILE=REGISTRY ABB=ON PLU=ON NC4-NC5/ES
L11         STR
L14         753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11
L15         0 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L14
L19         STR
L21         733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19
L22         0 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND L21
L37         STR
L39         3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37
L40         77 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L39
L41         82 SEA FILE=REGISTRY ABB=ON PLU=ON L21 AND L39
L42         82 SEA FILE=REGISTRY ABB=ON PLU=ON (L40 OR L41)
L53         82 SEA FILE=REGISTRY ABB=ON PLU=ON L42 OR L22 OR L15
L55         11 SEA FILE=HCAPLUS ABB=ON PLU=ON L42 OR L53
L56         QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY
             <2004 OR REVIEW/DT
L58         7 SEA FILE=HCAPLUS ABB=ON PLU=ON L55 AND L56

```

=&gt; d his l70

(FILE 'TOXCENTER, USPATFULL, USPAT2, CASREACT, CHEMCATS' ENTERED AT  
14:53:12 ON 24 OCT 2006)

L70 9 S L69 AND L56

=&gt; d que nos l70

```

L5          STR
L7          45329 SEA FILE=REGISTRY SSS FUL L5
L8          103939 SEA FILE=REGISTRY ABB=ON PLU=ON NC4-NC5/ES
L11         STR
L14         753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11
L15         0 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L14
L19         STR
L21         733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19
L22         0 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND L21
L37         STR
L39         3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37
L40         77 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L39
L41         82 SEA FILE=REGISTRY ABB=ON PLU=ON L21 AND L39
L42         82 SEA FILE=REGISTRY ABB=ON PLU=ON (L40 OR L41)
L53         82 SEA FILE=REGISTRY ABB=ON PLU=ON L42 OR L22 OR L15
L56         QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY

```

&lt;2004 OR REVIEW/DT

L69 24 SEA L42 OR L53  
L70 9 SEA L69 AND L56

=&gt; dup rem 158 170

DUPLICATE IS NOT AVAILABLE IN 'CHEMCATS'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

FILE 'HCAPLUS' ENTERED AT 15:34:25 ON 24 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 15:34:25 ON 24 OCT 2006

COPYRIGHT (C) 2006 ACS

FILE 'USPATFULL' ENTERED AT 15:34:25 ON 24 OCT 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:34:25 ON 24 OCT 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CASREACT' ENTERED AT 15:34:25 ON 24 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

PROCESSING COMPLETED FOR L58

PROCESSING COMPLETED FOR L70

L73 12 DUP REM L58 L70 (4 DUPLICATES REMOVED)

ANSWERS '1-7' FROM FILE HCAPLUS

ANSWERS '8-12' FROM FILE USPATFULL

=&gt; file stnguide

FILE 'STNGUIDE' ENTERED AT 15:34:29 ON 24 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Oct 20, 2006 (20061020/UP).

=d ibib ed ab hitstr

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL' - CONTINUE? (Y)/N:y

L73 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1  
 ACCESSION NUMBER: 2004:1011968 HCAPLUS  
 DOCUMENT NUMBER: 142:6514  
 TITLE: Preparation of thienylisoxazolylmethylazaindoles as factor Xa and/or factor VIIa inhibitors  
 INVENTOR(S): Nazare, Marc; Wehner, Volkmar; Will, David William; Ritter, Kurt; Urmann, Matthias; Matter, Hans  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
 SOURCE: Eur. Pat. Appl., 82 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1479680	A1	20041124	EP 2003-11304	20030519 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004238500	A1	20041125	AU 2004-238500	20040505 <--
CA 2526084	AA	20041125	CA 2004-2526084	20040505 <--
WO 2004101563	A1	20041125	WO 2004-EP4754	20040505 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1636226	A1	20060322	EP 2004-731161	20040505 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010429	A	20060606	BR 2004-10429	20040505 <--
CN 1791601	A	20060621	CN 2004-80013936	20040505 <--
US 2005009828	A1	20050113	US 2004-849089	20040519 <--
NO 2005005911	A	20060210	NO 2005-5911	20051213 <--
PRIORITY APPLN. INFO.:			EP 2003-11304	A 20030519 <--
			US 2003-507141P	P 20030930 <--
			WO 2004-EP4754	W 20040505

OTHER SOURCE(S): CASREACT 142:6514; MARPAT 142:6514

ED Entered STN: 24 Nov 2004

AB Title compds. [I; R = (substituted) mono- or bicyclic aryl, heterocyclyl; R1 = H, (substituted) alkyl, aminocarbonylalkyl, mono- or bicyclic aryl, heterocyclyl, etc.; R2 = bond, alkylene; R3 = H, halo, NO2, cyano, perfluoroalkyl, (substituted) alkyl, Ph, etc.; R1R3 = atoms to form a (substituted) 6-8 membered ring containing 1-4 heteroatoms; R1NR2V = atoms to form a (substituted) 4-7 membered ring containing 1-4 heteroatoms; V = (substituted) 3-7 membered heterocyclyl, 6-14 membered aryl, 4-15 membered heterocyclyl; G = (CH2)m, (CH2)mO(CH2)n, CH2SO2(CH2)n, (CH2)mNR10SO2NR10(CH2)n, (CH2)mCH(OH)(CH2)n, etc.; M = H, (substituted)

alkyl, 6-14 membered aryl, 4-15 membered heterocyclyl, cycloalkyl, etc.; m, n = 0-6; R10 = H, alkyl, hydroxyalkyl, alkoxyalkyl, perfluoroalkyl; D = atoms to form a (substituted) (aromatic) 4-8 membered ring containing 0-4 heteroatoms], were prepared. Thus, 1-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (preparation given), N-ethylmorpholine, and TOTU were stirred together for 20 min. in DMF; 1-isopropylpiperidin-4-ylamine dihydrochloride was added followed by stirring for 4 h to give 1-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (1-isopropylpiperidin-4-yl)amide. This inhibited factor Xa with  $K_i = 0.006 \mu\text{M}$ .

IT 797060-39-0P 797060-40-3P 797060-41-4P

797060-42-5P 797060-43-6P 797060-44-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of thienylisoxazolylmethylazaindoles as factor

Xa and/or factor VIIa inhibitors)


RN 797060-39-0 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)




RN 797060-40-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 797060-41-4 HCAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 797060-42-5 HCAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-2,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N2-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)






RN 797060-43-6 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 797060-44-7 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



IT 797060-45-8P 797060-46-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thienylisoxazolylmethylazaindoles as factor Xa and/or factor VIIa inhibitors)


RN 797060-45-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N2-[1-(1-methylethyl)-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797060-42-5


CMF C25 H27 Cl N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 797060-46-9 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797060-44-7


CMF C25 H26 Cl N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 797060-56-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thienylisoxazolylmethylazaindoles as factor Xa and/or factor VIIa inhibitors)


RN 797060-56-1 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797060-55-0


CMF C26 H28 Cl N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib ed ab hitstr 2-7

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL' - CONTINUE? (Y)/N:y

✓ L73 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3  
ACCESSION NUMBER: 2001:661388 HCAPLUS  
DOCUMENT NUMBER: 135:226878  
TITLE: Synthesis of N-benzyl-indolyl(benzyloxy)amido derivatives as PDE-IV inhibitors  
INVENTOR(S): Labelle, Marc; Sturino, Claudio; Lachance, Nicolas; MacDonald, Dwight  
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.  
SOURCE: PCT Int. Appl., 75 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064639	A2	20010907	WO 2001-CA270	20010302 <--
WO 2001064639	A3	20020228		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002068756	A1	20020606	US 2001-797083	20010301 <--
US 6436965	B2	20020820		
CA 2401667	AA	20010907	CA 2001-2401667	20010302 <--
EP 1263728	A2	20021211	EP 2001-913422	20010302 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525273	T2	20030826	JP 2001-563482	20010302 <--
PRIORITY APPLN. INFO.:				
			US 2000-186571P	P 20000302 <--
			WO 2001-CA270	W 20010302 <--

OTHER SOURCE(S): MARPAT 135:226878

ED Entered STN: 10 Sep 2001


AB Title compds. I [A, B, D, E = N or CR2 and the others = CR2; q = 0 - 1; p, m = 0 - 2; R1 = H, (hydroxy)alkyl; R2 = H, halo, (halo)alkyl, hydroxyalkyl, CN, aromatic or nonarom. ring system containing 1 - 4 heteroatoms selected from O, S, N, alkoxy, oxyamide, etc.; X = cycloalkyl or Ar; Ar = (un)substituted (Ph, thienyl, thiazolyl, pyridyl, oxazolyl, tetrazolyl, pyrimidinyl, pyrazinyl and pyridazinyl)] were prepared Over 150 compds. were disclosed. For instance, Me 2-aminobenzoate was alkylated with 4-fluorobenzyl bromide (K2CO3, MEK, reflux, 8 h.). The resulting ester was saponified (NaOH, MeOHaq reflux, 2 h.), N-alkylated with Me bromoacetate (K2CO3, MeOHaq, reflux, 18 h.) and treated with CH2N2 to afford II. Diester II was cyclized (NaOMe, MeOH, reflux, 30 min.), O-alkylated with benzyl bromide (K2CO3, MEK, reflux, 2 h.), saponified (NaOH, EtOHaq, 90°C, 40 min.) and finally coupled to 3-aminopyridine (SOCl2, i-Pr2NEt, room temperature, 3 h.) to yield III. I are PDE-IV inhibitors (no data) useful for treating, e.g., inflammation, muscle spasm, chronic bronchitis, etc.

IT 359002-18-9P 359002-19-0P 359002-29-2P  
 359002-30-5P 359002-31-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug; synthesis of N-benzyl-indolyl(benzyloxy)amido derivs. as PDE-IV inhibitors)


RN 359002-18-9 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, N-(3,4-difluorophenyl)-3-(phenylmethoxy)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)





RN 359002-19-0 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, N-(6-methoxy-3-pyridinyl)-3-(phenylmethoxy)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 359002-29-2 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[4-(difluoromethoxy)phenyl]methyl]-N-(6-methoxy-3-pyridinyl)-3-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 359002-30-5 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[4-(difluoromethoxy)phenyl]methyl]-3-(4-pyridinylmethoxy)-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)



RN 359002-31-6 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[4-(difluoromethoxy)phenyl]methyl]-N-(2-methoxy-4-pyridinyl)-3-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



✓ 173 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2001:12443 HCAPLUS

DOCUMENT NUMBER: 134:86539

TITLE: Preparation of benzimidazolecarboxylic acid amino acid amides as IκB kinase inhibitors.

INVENTOR(S): Ritzeler, Olaf; Stilz, Hans Ulrich; Neises, Bernhard; Bock, William Jerome, Jr.; Walser, Armin; Flynn, Gary A.

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000610	A1	20010104	WO 2000-EP5340	20000609 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19928424	A1	20001228	DE 1999-19928424	19990623 <--
DE 10006297	A1	20010816	DE 2000-10006297	20000212 <--
CA 2377085	AA	20010104	CA 2000-2377085	20000609 <--
BR 2000012450	A	20020402	BR 2000-12450	20000609 <--
EP 1194425	A1	20020410	EP 2000-938780	20000609 <--
EP 1194425	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003503400	T2	20030128	JP 2001-507019	20000609 <--
EE 200100619	A	20030217	EE 2001-619	20000609 <--
NZ 516348	A	20030630	NZ 2000-516348	20000609 <--
AU 769350	B2	20040122	AU 2000-54042	20000609 <--
AT 301651	E	20050815	AT 2000-938780	20000609 <--
RU 2261248	C2	20050927	RU 2002-101485	20000609 <--
NO 2001006154	A	20020219	NO 2001-6154	20011217 <--
HK 1047582	A1	20050304	HK 2002-108645	20021129 <--
PRIORITY APPLN. INFO.:				
			DE 1999-19928424	A 19990623 <--
			DE 2000-10006297	A 20000212 <--
			WO 2000-EP5340	W 20000609 <--
OTHER SOURCE(S): MARPAT 134:86539				
ED	Entered STN: 05 Jan 2001			
AB	Title compds. [I; 1 of R1-R4 = DNR8CHR9Z; D = CO, SO, SO2; R8 = H, alkyl; R9 = amino acid residue, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, etc.; Z = (substituted) aryl, heteroaryl, heterocyclyl, etc.; the remainder of R1-R4 = H, halo, alkyl, (substituted) heteroaryl, heterocyclyl, alkyl, cyano, aralkoxy, alkoxy, etc.; R5 = H, OH, O; R6 = (substituted) aryl, Ph, heteroaryl, heterocyclyl, were prepared Thus, 2-pyrid-4-ylbenzimidazol-4-carboxylic acid (preparation given), H-Leu-OMe, TOTU, and (Me2CH)2EtN were stirred in MeCN to give 98% 2-pyrid-4-ylbenzimidazol-4-carboxylleucine Me ester. I inhibited IκB kinase with IC50 = 0.07-72 μM.			
IT	313065-02-0P 313065-14-4P 313065-17-7P 313065-60-0P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzimidazolecarboxylic acid amino acid amides as IκB kinase inhibitors)			
RN	313065-02-0 HCAPLUS			
CN	1H-Indole-2-carboxamide, 2,3-dihydro-1-[[2-(4-pyridinyl)-1H-benzimidazol-5- yl]carbonyl]- (9CI) (CA INDEX NAME)			






RN 313065-14-4 HCAPLUS

CN 1H-Indole-2-carboxamide, 2,3-dihydro-1-[[2-(4-pyridinyl)-1H-benzimidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 313065-17-7 HCAPLUS


CN 1H-Indole-2-carboxamide, octahydro-1-[[2-(4-pyridinyl)-1H-benzimidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 313065-60-0 HCAPLUS

CN 1H-Indole-2-carboxamide, 2,3-dihydro-1-[[2-(4-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ L73 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:308438 HCAPLUS  
 DOCUMENT NUMBER: 140:321242  
 TITLE: Preparation of pyrrolo[3,2-b]pyridines as p38 kinase inhibitors  
 INVENTOR(S): Brookings, Daniel Christopher; Cubbon, Rachel Jane; Davis, Jeremy Martin; Langham, Barry John  
 PATENT ASSIGNEE(S): Celltech R & D Limited, UK  
 SOURCE: PCT Int. Appl., 81 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031188	A1	20040415	WO 2003-GB4214	20030930 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500844	AA	20040415	CA 2003-2500844	20030930 <--
AU 2003271870	A1	20040423	AU 2003-271870	20030930 <--
EP 1549648	A1	20050706	EP 2003-753708	20030930 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006504712	T2	20060209	JP 2004-540940	20030930 <--
US 2006122212	A1	20060608	US 2005-529413	20050623 <--
PRIORITY APPLN. INFO.:			GB 2002-22743	A 20021001 <--
			WO 2003-GB4214	W 20030930 <--


OTHER SOURCE(S): MARPAT 140:321242

ED Entered STN: 15 Apr 2004


AB Title compds. I [A = (un)substituted N, C; Ra = H, halo, etc.; X, Y = N or (un)substituted C; L = C(O), C(S), (un)substituted C; n = 0-1; Alk1 = (unsubstituted) (hetero)aliphatic chain; L1 = bond, linker atom/group; Cyl = (un)substituted cycloaliph., etc.; Ar = (hetero)aromatic, etc. with specific exceptions] are prepared For instance, 1-Benzenesulfonyl-4-phenyl-1,4-

dihydro-5H-pyrrolo[3,2-b]pyridin-5-one (preparation given) is treated with NaOH (2M, 2 h) and the resulting product alkylated with benzyl chloride (THF, NaH) to give II. Example compds. have IC50 values of around 2 pM and below for p38 kinase and are useful for the treatment of immune or inflammatory disorders.

- IT 677303-55-8P, 1-(3-Chloro-4-fluorobenzyl)-N-methoxy-N-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
 677303-57-0P, N-Methoxy-N-methyl-1-(3-methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-59-2P  
 , 1-(3-Chlorobenzyl)-N-methoxy-N-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-60-5P,  
 1-(3-Chloro-4-fluorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-62-7P, 1-(3-Methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
 677303-64-9P, 1-(3-Chlorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-68-3P,  
 1-(3-Chlorobenzyl)-N,N-dimethyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-69-4P, 1-(3-Chlorobenzyl)-N-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
 677303-70-7P, 1-(3-Chlorobenzyl)-4-phenyl-2-[(pyrrolidin-1-yl)carbonyl]-1,4-dihydro-5H-pyrrolo[3,2-b]pyridin-5-one  
 677303-71-8P 677303-77-4P, 1-(3-Chlorobenzyl)-4-(1H-indol-5-yl)-5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
 677303-83-2P, 1-(2-Cyanobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-85-4P,  
 1-(4-Fluoro-3-methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-86-5P, 1-(3-Chlorobenzyl)-4-(4-methylphenyl)-5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
 677303-87-6P 677303-96-7P, (S)-2-[[2-(Hydroxymethyl)pyrrolidin-1-yl]carbonyl]-1-(3-methylbenzyl)-4-phenyl-1,4-dihydro-5H-pyrrolo[3,2-b]pyridin-5-one  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (bicyclic heteroarom. compds. as kinase inhibitors)  
 RN 677303-55-8 HCAPLUS  
 CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chloro-4-fluorophenyl)methyl]-4,5-dihydro-N-methoxy-N-methyl-5-oxo-4-phenyl- (9CI)  
 (CA INDEX NAME)




- RN 677303-57-0 HCAPLUS  
 CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 4,5-dihydro-N-methoxy-N-methyl-1-[(3-methylphenyl)methyl]-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-59-2 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-N-methoxy-N-methyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-60-5 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chloro-4-fluorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-62-7 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 4,5-dihydro-1-[(3-methylphenyl)methyl]-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-64-9 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-68-3 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-N,N-dimethyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)





RN 677303-69-4 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-N-methyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)



RN 677303-70-7 HCAPLUS


CN Pyrrolidine, 1-[[1-[(3-chlorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 677303-71-8 HCAPLUS


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid, 1-[(3-chlorophenyl)methyl]-

4,5-dihydro-5-oxo-4-phenyl-, hydrazide (9CI) (CA INDEX NAME)




RN 677303-77-4 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-4-(1H-indol-5-yl)-5-oxo- (9CI) (CA INDEX NAME)




RN 677303-83-2 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(2-cyanophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-85-4 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(4-fluoro-3-methylphenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-86-5 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-4-(4-methylphenyl)-5-oxo- (9CI) (CA INDEX NAME)



RN 677303-87-6 HCAPLUS


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-4-(4-methylphenyl)-5-oxo-, hydrazide (9CI) (CA INDEX NAME)



RN 677303-96-7 HCAPLUS

CN 2-Pyrrolidinemethanol, 1-[[4,5-dihydro-1-[(3-methylphenyl)methyl]-5-oxo-4-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:316965 HCAPLUS

DOCUMENT NUMBER: 132:334446

TITLE: Preparation of amide group-containing indoles and mono- or diazaindoles as cyclooxygenase-2 inhibitors and anti-inflammatory agents

INVENTOR(S): Matsuo, Koji; Takahashi, Tadakatsu; Maruyama, Tensho; Ishizawa, Takenobu; Kato, Yasuharu

PATENT ASSIGNEE(S): Chugai Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000136182	A2	20000516	JP 1998-310209	19981030 <--
PRIORITY APPLN. INFO.:			JP 1998-310209	19981030 <--

OTHER SOURCE(S): MARPAT 132:334446

ED Entered STN: 16 May 2000

AB The compds. I [A1, A2 = CH, N; R = C:QNYZ, CO2R3; R1 = alkyl, amino; R2 = (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; Q = O, S, N:CN; Y, Z = H, (un)substituted alkyl, (un)substituted alkoxy, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted heterocyclyl; YNZ may form (un)substituted ring (having addnl. O, N, and/or S)], their pharmacol. acceptable salts, or their hydrates are prepared Me 1-benzenesulfonyl-5-methylthio-1H-pyrrolo[2,3-b]pyridine-2-carboxylate was oxidized, treated with 4-fluorobenzyl bromide, and amidated with NMeH2 to give I (A1 = CH, A2 = N; R = CONHMe, R1 = Me, R2 4-FC6H4), which inhibited human cyclooxygenase-1 and 2 with IC50 of >20 and 0.4 μM, resp.

IT 268212-11-9P 268212-12-0P 268212-13-1P

268212-14-2P 268212-15-3P 268212-16-4P

268212-17-5P 268212-18-6P 268212-70-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indoles as cyclooxygenase-2 inhibitors and anti-inflammatory agents)




RN 268212-11-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)





RN 268212-12-0 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-ethyl-1-[(4-fluorophenyl)methyl]-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 268212-13-1 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-5-(methylsulfonyl)-N-propyl- (9CI) (CA INDEX NAME)





RN 268212-14-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-N,N-dimethyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 268212-15-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-N-methoxy-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 268212-16-4 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-N-methoxy-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 268212-17-5 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 268212-18-6 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-5-(methylsulfonyl)-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 268212-70-0 HCAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-(cyclohexylmethyl)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



✓ L73 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2000:908698 HCAPLUS  
 DOCUMENT NUMBER: 134:42443  
 TITLE: Preparation and use of benzimidazole derivatives for treatment of illness.  
 INVENTOR(S): Ritzeler, Olaf; Stilz, Hans Ulrich; Neises, Bernhard; Bock, William Jerome, Jr.; Walser, Armin; Flynn, Gary A.  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany  
 SOURCE: Ger. Offen., 36 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19928424	A1	20001228	DE 1999-19928424	19990623 <--
CA 2377085	AA	20010104	CA 2000-2377085	20000609 <--
WO 2001000610	A1	20010104	WO 2000-EP5340	20000609 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000012450	A	20020402	BR 2000-12450	20000609 <--
EP 1194425	A1	20020410	EP 2000-938780	20000609 <--
EP 1194425	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003503400	T2	20030128	JP 2001-507019	20000609 <--
EE 200100619	A	20030217	EE 2001-619	20000609 <--
NZ 516348	A	20030630	NZ 2000-516348	20000609 <--
AU 769350	B2	20040122	AU 2000-54042	20000609 <--
AT 301651	E	20050815	AT 2000-938780	20000609 <--
RU 2261248	C2	20050927	RU 2002-101485	20000609 <--
PT 1194425	T	20051031	PT 2000-938780	20000609 <--
ES 2246240	T3	20060216	ES 2000-938780	20000609 <--
<del>US 6358978</del>	B1	20020319	US 2000-599390	20000622 <--
ZA 2001010127	A	20021105	ZA 2001-10127	20011210 <--
NO 2001006154	A	20020219	NO 2001-6154	20011217 <--
HK 1047582	A1	20050304	HK 2002-108645	20021129 <--

PRIORITY APPLN. INFO.:

DE 1999-19928424 A 19990623 <--  
DE 2000-10006297 A 20000212 <--  
WO 2000-EP5340 W 20000609 <--

OTHER SOURCE(S): MARPAT 134:42443

ED Entered STN: 28 Dec 2000


AB Title compds., e.g. (I), were prepared (no data) for use in treating diseases which feature an intensified activity by transcription factor NFkB. An example is given of solid-phase synthesis of (II). In in vitro tests, I had IC50 of 1 µM for IkB-kinase, while inhibiting other kinase activities (protein kinases A and C, and casein kinase) 36, 63, and 70%, resp. In the same tests, II showed IC50 of 25 µM for IkB, and inhibited the other kinases 24, 7, and 17%, resp.

IT 313065-02-0P 313065-14-4P 313065-17-7P  
313065-60-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation and use of benzimidazole derivs. for treatment of illness)


RN 313065-02-0 HCAPLUS

CN 1H-Indole-2-carboxamide, 2,3-dihydro-1-[[2-(4-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 313065-14-4 HCAPLUS

CN 1H-Indole-2-carboxamide, 2,3-dihydro-1-[[2-(4-pyridinyl)-1H-benzimidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 313065-17-7 HCAPLUS


CN 1H-Indole-2-carboxamide, octahydro-1-[[2-(4-pyridinyl)-1H-benzimidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 313065-60-0 HCAPLUS

CN 1H-Indole-2-carboxamide, 2,3-dihydro-1-[[2-(4-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



B73 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1987:439778 HCAPLUS  
 DOCUMENT NUMBER: 107:39778  
 TITLE: Pyrrolopyridines  
 INVENTOR(S): Dormoy, Jean Robert; Heymes, Alain  
 PATENT ASSIGNEE(S): SANOFI, Fr.  
 SOURCE: Fr. Demande, 20 pp.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2574406	A1	19860613	FR 1984-19029	19841212 <--
FR 2574406	B1	19870227		
EP 187631	A1	19860716	EP 1985-870178	19851211 <--
EP 187631	B1	19900905		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 56212	E	19900915	AT 1985-870178	19851211 <--
CA 1299183	A1	19920421	CA 1985-497380	19851211 <--
DK 8505768	A	19860613	DK 1985-5768	19851212 <--
JP 61155385	A2	19860715	JP 1985-280176	19851212 <--
US 4831144	A	19890516	US 1988-141508	19880107 <--
PRIORITY APPLN. INFO.:			FR 1984-19029	A 19841212 <--

US 1985-806544

A2 19851209 &lt;--

EP 1985-870178

A 19851211 &lt;--

OTHER SOURCE(S): CASREACT 107:39778; MARPAT 107:39778

ED Entered STN: 08 Aug 1987


AB The title compds. [I; R = protecting group; R1 = H, Li, alkyl, CHO, CO2H, alkoxy carbonyl, etc.], useful as intermediates for anthelmintics, are prepared PhSO2Cl was added to a mixture of I (R = R1 = H), NaOH, and Bu4NHSO4 in CH2Cl2 over for 1 h. The temperature of the reaction mixture rose from 20° to 40°. The resulting mixture was then stirred for 1 h to give 83-85% I (R = PhSO2, R1 = H).

IT 109113-48-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as intermediate for anthelmintics)

RN 109113-48-6 HCAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-2-carboxamide, N,N-diethyl-1-(phenylsulfonyl)-  
(9CI) (CA INDEX NAME)



=&gt; d ibib ab hitstr 8-12

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL' - CONTINUE? (Y)/N:y

L73 ANSWER 8 OF 12 USPATFULL on STN

DUPLICATE 2

ACCESSION NUMBER: 2002:133898 USPATFULL

TITLE: PDE IV inhibiting amides, compositions and methods of treatment

INVENTOR(S): Labelle, Marc, St. Lazare, CANADA  
Sturino, Claudio, Dorval, CANADA  
Lachance, Nicolas, Pierrefonds, CANADA  
Macdonald, Dwight, L'ile Bizard, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002068756	A1	20020606	<--
	US 6436965	B2	20020820	
APPLICATION INFO.:	US 2001-797083	A1	20010301 (9)	<--

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-186571P	20000302 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2355		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds represented by formula I: ##STR1##

as well as pharmaceutically acceptable salts and hydrates thereof are disclosed as useful for treating or preventing diseases and conditions mediated by PDE-IV.

Pharmaceutical compositions and methods of treatment are also included.


IT 359002-18-9P 359002-19-0P 359002-29-2P

359002-30-5P 359002-31-6P

(drug; synthesis of N-benzyl-indolyl(benzyloxy)amido derivs. as PDE-IV inhibitors)


RN 359002-18-9 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, N-(3,4-difluorophenyl)-3-(phenylmethoxy)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)





RN 359002-19-0 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, N-(6-methoxy-3-pyridinyl)-3-(phenylmethoxy)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 359002-29-2 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[4-(difluoromethoxy)phenyl]methyl]-N-(6-methoxy-3-pyridinyl)-3-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



RN 359002-30-5 USPATFULL


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[4-(difluoromethoxy)phenyl]methyl]-3-(4-pyridinylmethoxy)-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)



RN 359002-31-6 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[4-(difluoromethoxy)phenyl]methyl]-N-(2-methoxy-4-pyridinyl)-3-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)





✓ L73 ANSWER 9 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2006:144693 USPATFULL

TITLE: Bicyclic heteroaromatic compounds as kinase inhibitors

INVENTOR(S): Brookings, Daniel Christopher, c/o Celltech R&D Limited, 208 Bath Road, Slough, Berkshire, UNITED KINGDOM SL1 3WE  
Cubbon, Rachel Jane, Slough Berkshire, UNITED KINGDOM  
Davis, Jeremy Martin, Wokingham Berkshire, UNITED KINGDOM  
PATENT ASSIGNEE(S): Langham, Barry John, Reading Berkshire, UNITED KINGDOM  
Celltech R&D Limited, Slough, Berkshire, UNITED KINGDOM, S11 3WE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006122212	A1	20060608
APPLICATION INFO.:	US 2003-529413	A1	20030930 (10) <--
	WO 2003-GB4214		20030930 <--
			20050623 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-22743	20021001 <--
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3189	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.

IT 677303-55-8P, 1-(3-Chloro-4-fluorobenzyl)-N-methoxy-N-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
677303-57-0P, N-Methoxy-N-methyl-1-(3-methylbenzyl)-5-oxo-4-

phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
**677303-59-2P**, 1-(3-Chlorobenzyl)-N-methoxy-N-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
**677303-60-5P**, 1-(3-Chloro-4-fluorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-62-7P**,  
 1-(3-Methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-64-9P**, 1-(3-Chlorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-68-3P**,  
 1-(3-Chlorobenzyl)-N,N-dimethyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-69-4P**, 1-(3-Chlorobenzyl)-N-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
**677303-70-7P**, 1-(3-Chlorobenzyl)-4-phenyl-2-[(pyrrolidin-1-yl)carbonyl]-1,4-dihydro-5H-pyrrolo[3,2-b]pyridin-5-one  
**677303-71-8P 677303-77-4P**, 1-(3-Chlorobenzyl)-4-(1H-indol-5-yl)-5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
**677303-83-2P**, 1-(2-Cyanobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-85-4P**,  
 1-(4-Fluoro-3-methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-86-5P**, 1-(3-Chlorobenzyl)-4-(4-methylphenyl)-5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
**677303-87-6P 677303-96-7P**, (S)-2-[[2-(Hydroxymethyl)pyrrolidin-1-yl]carbonyl]-1-(3-methylbenzyl)-4-phenyl-1,4-dihydro-5H-pyrrolo[3,2-b]pyridin-5-one  
 (bicyclic heteroarom. compds. as kinase inhibitors)


RN 677303-55-8 USPTAFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chloro-4-fluorophenyl)methyl]-4,5-dihydro-N-methoxy-N-methyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-57-0 USPTAFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 4,5-dihydro-N-methoxy-N-methyl-1-[(3-methylphenyl)methyl]-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-59-2 USPTAFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-N-methoxy-N-methyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-60-5 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chloro-4-fluorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-62-7 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 4,5-dihydro-1-[(3-methylphenyl)methyl]-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-64-9 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-68-3 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-N,N-dimethyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)





RN 677303-69-4 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-N-methyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-70-7 USPATFULL

CN Pyrrolidine, 1-[[1-[(3-chlorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 677303-71-8 USPATFULL


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl-, hydrazide (9CI) (CA INDEX NAME)



RN 677303-77-4 USPATFULL


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-

dihydro-4-(1H-indol-5-yl)-5-oxo- (9CI) (CA INDEX NAME)




RN 677303-83-2 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(2-cyanophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-85-4 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(4-fluoro-3-methylphenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-86-5 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-4-(4-methylphenyl)-5-oxo- (9CI) (CA INDEX NAME)



RN 677303-87-6 USPATFULL


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-4-(4-methylphenyl)-5-oxo-, hydrazide (9CI) (CA INDEX NAME)



RN 677303-96-7 USPATFULL

CN 2-Pyrrolidinemethanol, 1-[[4,5-dihydro-1-[(3-methylphenyl)methyl]-5-oxo-4-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 10 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2005:11693 USPATFULL

TITLE: Azaindole-derivatives as factor Xa inhibitors

INVENTOR(S): Nazare, Marc, Idstein, GERMANY, FEDERAL REPUBLIC OF  
Wehner, Volkmar, Sandberg, GERMANY, FEDERAL REPUBLIC OF

Will, David William, Kriftel, GERMANY, FEDERAL REPUBLIC  
OF  
Ritter, Kurt, Frankfurt am Main, GERMANY, FEDERAL  
REPUBLIC OF  
Urmann, Matthias, Eschborn, GERMANY, FEDERAL REPUBLIC  
OF  
Matter, Hans, Langenselbold, GERMANY, FEDERAL REPUBLIC  
OF  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland, Frankfurt am Main, GERMANY,  
FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005009828	A1	20050113
APPLICATION INFO.:	US 2004-849089	A1	20040519 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2003-11304	20030519
	US 2003-507141P	20030930 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE  
202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807  
NUMBER OF CLAIMS: 15  
EXEMPLARY CLAIM: 1  
LINE COUNT: 4713

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of the formula I ##STR1##


wherein R.sup.0, R.sup.1, R.sup.2, R.sup.3, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

IT 797060-39-0P 797060-40-3P 797060-41-4P  
797060-42-5P 797060-43-6P 797060-44-7P

(claimed compound; preparation of thienylisoxazolylmethylazaindoles as factor Xa and/or factor VIIa inhibitors)


RN 797060-39-0 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)



RN 797060-40-3 USPATFULL


CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 797060-41-4 USPATFULL


CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)






RN 797060-42-5 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N2-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)




RN 797060-43-6 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)



RN 797060-44-7 USPTFULL

CN 1H-Pyrrolo[3,2-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-(9CI) (CA INDEX NAME)



IT 797060-45-8P 797060-46-9P

(preparation of thienylisoxazolylmethylazaindoles as factor Xa and/or factor VIIa inhibitors)


RN 797060-45-8 USPTFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N2-[1-(1-methylethyl)-4-piperidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 797060-42-5

CMF C25 H27 Cl N6 O3 S



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 797060-46-9 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 797060-44-7  
CMF C25 H26 Cl N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 797060-56-1P

(preparation of thienylisoxazolylmethylazaindoles as factor Xa and/or factor VIIa inhibitors)


RN 797060-56-1 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797060-55-0


CMF C26 H28 Cl N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L73 ANSWER 11 OF 12 USPATFULL on STN  
ACCESSION NUMBER: 2002:57810 USPATFULL  
TITLE: Substituted benzimidazoles  
INVENTOR(S): Ritzeler, Olaf, Frankfurt am Main, GERMANY, FEDERAL  
REPUBLIC OF  
Stilz, Hans Ulrich, Frankfurt, GERMANY, FEDERAL  
REPUBLIC OF  
Neises, Bernhard, Offenburg, GERMANY, FEDERAL REPUBLIC  
OF  
Bock, Jr., William Jerome, Tucson, AZ, United States  
Walser, Armin, Tucson, AZ, United States  
Flynn, Gary A., Tucson, AZ, United States  
Habermann, Jorg, Bad Soden, GERMANY, FEDERAL REPUBLIC  
OF  
Jahne, Gerhard, Frankfurt am Main, GERMANY, FEDERAL  
REPUBLIC OF  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Frankfurt, GERMANY,  
FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6358978	B1	20020319	<--
APPLICATION INFO.:	US 2000-599390		20000622 (9)	<--

	NUMBER	DATE	
PRIORITY INFORMATION:	DE 1999-19928424	19990623	<--
	DE 2000-10006297	20000212	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Raymond, Richard L.		
ASSISTANT EXAMINER:	Truong, Tamthom N.		
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett, & Dunner, L.L.P.		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	3420		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Compounds of formula I ##STR1##		


are suitable for the production of pharmaceuticals for the prophylaxis  
and therapy of disorders in whose course an increased activity of  
NFkB is involved.

IT 313065-02-0P 313065-14-4P 313065-17-7P  
313065-60-0P

(preparation and use of benzimidazole derivs. for treatment of illness)


RN 313065-02-0 USPATFULL

CN 1H-Indole-2-carboxamide, 2,3-dihydro-1-[[2-(4-pyridinyl)-1H-benzimidazol-5-  
yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 313065-14-4 USPATFULL

CN 1H-Indole-2-carboxamide, 2,3-dihydro-1-[[2-(4-pyridinyl)-1H-benzimidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 313065-17-7 USPATFULL


CN 1H-Indole-2-carboxamide, octahydro-1-[[2-(4-pyridinyl)-1H-benzimidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 313065-60-0 USPATFULL

CN 1H-Indole-2-carboxamide, 2,3-dihydro-1-[[2-(4-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 12 OF 12 USPATFULL on STN

ACCESSION NUMBER: 89:39083 USPATFULL

TITLE: 1H-pyrrolo [3,2-c]pyrrolidines protected in 1-position  
useful as intermediates  
INVENTOR(S): Dormoy, Jean-Robert, Sisteron, France  
Heymes, Alain, Sisteron, France  
PATENT ASSIGNEE(S): SANOFI, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4831144		19890516 <--
APPLICATION INFO.:	US 1988-141508		19880107 (7) <--
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1985-806544, filed on 9 Dec 1985, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1984-19029	19841212 <--
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Lee, Mary C.	
ASSISTANT EXAMINER:	Dentz, Bernard I.	
LEGAL REPRESENTATIVE:	Bacon & Thomas	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	754	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to a process for fixing an electrophilic group in the 2-position of 1H-pyrrolo[3,2-c]pyridine N-protected in the 1-position, process which consists in protecting the 1-position in question with a labile protecting group, reacting the compound so obtained with a lithiation agent selected from a lithium amide and an alkyl lithium at a temperature between -80° C. and -20° C. and in the presence of tetramethylethylenediamine to obtain the corresponding 2-lithio derivative and then condensing the metal derivative so obtained at a temperature between -80° C. and room-temperature with a reagent capable of giving rise to an electrophilic group to form N-protected 1H-pyrrolo[3,2-c]pyridine substituted in the 2-position by an electrophilic group.

IT 109113-48-6P

(preparation of, as intermediate for anthelmintics)

RN 109113-48-6 USPATFULL

CN 1H-Pyrrolo[3,2-c]pyridine-2-carboxamide, N,N-diethyl-1-(phenylsulfonyl)-(9CI) (CA INDEX NAME)



=> d que nos 159

```

L5          STR
L7          45329 SEA FILE=REGISTRY SSS FUL L5
L8          103939 SEA FILE=REGISTRY ABB=ON  PLU=ON  NC4-NC5/ES
L11         STR
L14         753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11
L15         0 SEA FILE=REGISTRY ABB=ON  PLU=ON  L8 AND L14
L19         STR
L21         733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19
L22         0 SEA FILE=REGISTRY ABB=ON  PLU=ON  L14 AND L21
L37         STR
L39         3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37
L40         77 SEA FILE=REGISTRY ABB=ON  PLU=ON  L8 AND L39
L41         82 SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 AND L39
L42         82 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L40 OR L41)
L53         82 SEA FILE=REGISTRY ABB=ON  PLU=ON  L42 OR L22 OR L15
L55         11 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L42 OR L53
L56         QUE ABB=ON  PLU=ON  AY<2004 OR PY<2004 OR PRY<2004 OR MY
          <2004 OR REVIEW/DT
L58         7 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L55 AND L56
L59         4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L55 NOT L58
    
```

=> d his 171

(FILE 'TOXCENTER, USPATFULL, USPAT2, CASREACT, CHEMCATS' ENTERED AT  
14:53:12 ON 24 OCT 2006)

L71 15 S L69 NOT L70

=> d que nos 171

```

L5          STR
L7          45329 SEA FILE=REGISTRY SSS FUL L5
L8          103939 SEA FILE=REGISTRY ABB=ON  PLU=ON  NC4-NC5/ES
L11         STR
L14         753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11
L15         0 SEA FILE=REGISTRY ABB=ON  PLU=ON  L8 AND L14
L19         STR
L21         733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19
L22         0 SEA FILE=REGISTRY ABB=ON  PLU=ON  L14 AND L21
L37         STR
L39         3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37
L40         77 SEA FILE=REGISTRY ABB=ON  PLU=ON  L8 AND L39
L41         82 SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 AND L39
L42         82 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L40 OR L41)
L53         82 SEA FILE=REGISTRY ABB=ON  PLU=ON  L42 OR L22 OR L15
L56         QUE ABB=ON  PLU=ON  AY<2004 OR PY<2004 OR PRY<2004 OR MY
          <2004 OR REVIEW/DT
L69         24 SEA L42 OR L53
L70         9 SEA L69 AND L56
L71         15 SEA L69 NOT L70
    
```

=> dup rem 159 171

DUPLICATE IS NOT AVAILABLE IN 'CHEMCATS'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
FILE 'HCAPLUS' ENTERED AT 15:36:07 ON 24 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)



FILE 'TOXCENTER' ENTERED AT 15:36:07 ON 24 OCT 2006  
COPYRIGHT (C) 2006 ACS

FILE 'CASREACT' ENTERED AT 15:36:07 ON 24 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CHEMCATS' ENTERED AT 15:36:07 ON 24 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)  
PROCESSING COMPLETED FOR L59  
PROCESSING COMPLETED FOR L71  
L74           16 DUP REM L59 L71 (3 DUPLICATES REMOVED)  
              ANSWERS '1-4' FROM FILE HCAPLUS  
              ANSWERS '5-16' FROM FILE CHEMCATS

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 15:36:12 ON 24 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Oct 20, 2006 (20061020/UP).

=> d ibib ed ab hitstr 1-4

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, CHEMCATS' - CONTINUE? (Y)/N:y

L74 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2006:976769 HCAPLUS

DOCUMENT NUMBER: 145:356777

TITLE: Benzazole derivatives and their preparation, compositions, and methods of use as  $\beta$ -secretase inhibitors

INVENTOR(S): Mjalli, Adnan M.; Jones, David; Gohimmukkula, Devi Reddy; Huang, Guoxiang; Zhu, Jeff; Rao, Mohan; Andrews, Robert C.; Ren, Tan

PATENT ASSIGNEE(S): Transtech Pharma, Inc., USA

SOURCE: PCT Int. Appl., 268pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006099379	A2	20060921	WO 2006-US9049	20060314
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2006223849	A1	20061005	US 2006-374723	20060314
PRIORITY APPLN. INFO.:			US 2005-661349P	P 20050314

ED Entered STN: 21 Sep 2006


AB The invention is directed to benzazole compds. of formula I that inhibit  $\beta$ -site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which BACE is involved. Compds. of formula I wherein A is O, S, and NH and derivs.; L1, L6, and L7 are independently CH<sub>2</sub>, O, NH and derivs., CO, CONH and derivs., NHCO and derivs., NHCONH and derivs., NHCO<sub>2</sub> and derivs., NHSO<sub>2</sub> and derivs., etc.; Q1 and Q6 are independently a bond, alkylene, alkenylene, and alkynylene; G1 is heterocyclylene, cycloalkylene, heterocyclylene, (hetero)arylene, fused arylcycloalkylene, etc.; G6 is H, heterocyclyl, cycloalkyl, (hetero)aryl, fused arylcycloalkyl, fused cycloalkyl(hetero)aryl, etc.; R1 - R4 are independently H, NH<sub>2</sub>, carboxy, CN, halo, NO<sub>2</sub>, OH, alkyl, (alkylene)aryl, etc.; and their pharmaceutically acceptable salts, esters, and prodrugs thereof are claimed. Example compound II was prepared by amidation of 2,3-diaminobenzoic acid Me ester with isoquinoline-3-carboxylic acid; the resulting 2-amino-3-[(isoquinoline-3-carbonyl)amino]benzoic acid Me ester underwent cyclization to give 2-(isoquinolin-3-yl)-1H-benzimidazole-4-carboxylic acid Me ester, which

IT 910118-58-0P

(drug candidate; preparation of benzazole derivs. as  $\beta$ -secretase inhibitors useful in treatment and prevention of diseases)

RN 910118-58-0 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED



L74 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2006:76452 HCAPLUS

DOCUMENT NUMBER: 144:170972

TITLE: Preparation of octahydropyrrolo[2,3-c]pyridines as inhibitors of matrix metalloproteinase

INVENTOR(S) : Swinnen, Dominique; Bombrun, Agnes

PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Neth.  
Antilles

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.		KIND	DATE	APPLICATION NO.		DATE	
-----		---	-----	-----		-----	
WO 2006008303		A1	20060126	WO 2005-EP53501		20050720	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ						

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2004-103483 A 20040721  
US 2004-589621P P 20040721

OTHER SOURCE(S): CASREACT 144:170972; MARPAT 144:170972

ED Entered STN: 27 Jan 2006

AB The title octahydropyrrolo[2,3-c]pyridine derivs. I [wherein R1 = (hetero)aryl or (hetero)cycloalkyl; R2 = H, SO<sub>2</sub>, alkyl, alkenyl, alkynyl, acyl, etc.; R3-R6 = independently H, halo, or alkyl], or isomers, enantiomers, diastereomers, racemates, or pharmaceutically acceptable salts thereof were prepared as inhibitors of matrix metalloproteinase (MMP). For example, racemic compound II was prepared in a multi-step synthesis. II showed inhibitory activity against MMP-2, MMP-9, and MMP-12 with IC<sub>50</sub> of 0.05, 0.041, and 0.05  $\mu$ M, resp. The compds. are useful for the prophylaxis and/or treatment of autoimmune disorders, cancer, inflammation, cardiovascular diseases, neurodegenerative diseases, respiratory diseases, or fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver, and pulmonary fibrosis (no data). Formulations containing I as active ingredients were described.

IT 874306-79-3P 874306-80-6P 874306-81-7P  
874306-82-8P 874306-83-9P 874306-84-0P  
874306-85-1P 874306-86-2P 874306-87-3P  
874306-88-4P 874306-89-5P 874306-90-8P  
874306-91-9P 874306-92-0P 874306-93-1P  
874306-94-2P 874306-95-3P 874306-96-4P  
874306-97-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of octahydropyrrolo[2,3-c]pyridines as MMP inhibitors)

RN 874306-79-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-benzoyloctahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-80-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-acetyloctahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-81-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-6-(3-methyl-1-oxobutyl)-, (2R,3aR,7aS)-rel- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 874306-82-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-(3-cyclopentyl-1-oxopropyl)octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-83-9 HCAPLUS

CN 6H-Pyrrolo[2,3-c]pyridine-6-carboxylic acid, octahydro-2-  
[(hydroxyamino) carbonyl]-1-[(4-methoxyphenyl)sulfonyl]-, 2-methoxyethyl  
ester, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-84-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-1-[(4-  
methoxyphenyl)sulfonyl]-6-(1-oxododecyl)-, (2R,3aR,7aS)-rel- (9CI) (CA  
INDEX NAME)


Relative stereochemistry.



RN 874306-85-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-(cyclopentylcarbonyl)octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-86-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-6-(1-oxo-3-phenylpropyl)-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-87-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-6-(methylsulfonyl)-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 874306-88-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-1,6-bis[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 874306-89-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-6-(methylsulfonyl)-1-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-90-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-([1,1'-biphenyl]-4-ylcarbonyl)octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-91-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-([1,1'-biphenyl]-4-ylsulfonyl)octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-92-0 HCAPLUS

CN 6H-Pyrrolo[2,3-c]pyridine-6-acetamide, N,N-diethyloctahydro-2-[(hydroxyamino)carbonyl]-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-93-1 HCAPLUS

CN 6H-Pyrrolo[2,3-c]pyridine-6-acetamide, N-ethyloctahydro-2-[(hydroxyamino) carbonyl]-1-[(4-methoxyphenyl) sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-94-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2,6-dicarboxamide, hexahydro-N2-hydroxy-1-[(4-methoxyphenyl) sulfonyl]-N6-phenyl-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-95-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 874306-96-4 HCAPLUS

CN 6H-Pyrrolo[2,3-c]pyridine-6-carboxylic acid, octahydro-2-[(hydroxyamino)carbonyl]-1-[(4-methoxyphenyl)sulfonyl]-, phenylmethyl ester, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 874306-97-5 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-acetyl-4,5,6,7-tetrahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



IT 874307-03-6P 874307-07-0P 874307-11-6P  
 874307-15-0P 874307-21-8P 874307-26-3P  
 874307-28-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (intermediate; preparation of octahydropyrrolo[2,3-c]pyridines as MMP  
 inhibitors)  
 RN 874307-03-6 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-benzoyloctahydro-1-[(4-methoxyphenyl)sulfonyl]-N-(phenylmethoxy)-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874307-07-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-acetyloctahydro-1-[(4-methoxyphenyl)sulfonyl]-N-(phenylmethoxy)-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874307-11-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-1-[(4-methoxyphenyl)sulfonyl]-6-(3-methyl-1-oxobutyl)-N-(phenylmethoxy)-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874307-15-0 HCAPLUS

CN 6H-Pyrrolo[2,3-c]pyridine-6-acetamide, N-ethyloctahydro-1-[(4-methoxyphenyl)sulfonyl]-2-[[ (phenylmethoxy) amino]carbonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874307-21-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2,6-dicarboxamide, hexahydro-1-[(4-methoxyphenyl)sulfonyl]-N6-phenyl-N2-(phenylmethoxy)-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874307-26-3 HCAPLUS

CN 6H-Pyrrolo[2,3-c]pyridine-6-carboxylic acid, octahydro-1-[(4-methoxyphenyl)sulfonyl]-2-[[ (phenylmethoxy) amino]carbonyl]-, phenylmethyl ester, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874307-28-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-acetyl-4,5,6,7-tetrahydro-1-[(4-methoxyphenyl)sulfonyl]-N-(phenylmethoxy)- (9CI) (CA INDEX NAME)





REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L74 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:468246 HCAPLUS

DOCUMENT NUMBER: 144:488656

TITLE: Preparation of 1H-imidazo[4,5-b]pyridine-2-carboxamides and related compounds as D1 dopamine receptor inhibitors

INVENTOR(S): Gmeiner, Peter; Schlotter, Karin; Huebner, Harald; Schmidt, Dirk; Buchholz, Monika

PATENT ASSIGNEE(S): Schwarz Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006050976	A1	20060518	WO 2005-EP12127	20051111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

DE 102004054634 A1 20060518 DE 2004-102004054634 20041112

PRIORITY APPLN. INFO.: DE 2004-102004054634A 20041112

OTHER SOURCE(S): MARPAT 144:488656

ED Entered STN: 19 May 2006

AB Title compds. I [A = aromatic 6-membered ring with provisos; B = aromatic 5-membered ring with provisos; Q1 = N, S, O, etc.; Q2 = CH, CR1, etc.; Q3 = N, CN, CR1; R1 = OH, alkyl, alkyloxy, etc.] and their pharmaceutically acceptable salts were prepared For example, coupling of amine II and 3H-imidazo[4,5-b]pyridine-2-carboxylic acid afforded claimed

imidazolpyridinylcarboxamide III in 36% yield. In D1 dopamine receptor inhibition assays, 4-examples of compds. I exhibited  $K_i$  values ranging from 440-1500 nM.

IT 887307-43-9P 887307-45-1P 887307-63-3P


887307-67-7P 887307-70-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolpyridinylcarboxamides and related compds. as D1 dopamine receptor inhibitors)


RN 887307-43-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 887307-45-1 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 887307-63-3 HCAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-[4-[4-(2,3-dihydro-7-benzofuranyl)-1-piperazinyl]butyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 887307-67-7 HCAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-[4-[4-(3,4-dihydro-2H-1-benzopyran-8-yl)-1-piperazinyl]butyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

NAME)



RN 887307-70-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-(phenylsulfonyl)-N-[4-[4-(2,3,4,5-tetrahydro-1-benzoxepin-9-yl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L74 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:64500 HCAPLUS

DOCUMENT NUMBER: 144:205149

TITLE: Design, synthesis, and biological activity of novel factor Xa inhibitors: Improving metabolic stability by S1 and S4 ligand modification

AUTHOR(S): Komoriya, Satoshi; Kobayashi, Shozo; Osanai, Ken; Yoshino, Toshiharu; Nagata, Tsutomu; Haginoya, Noriyasu; Nakamoto, Yumi; Mochizuki, Akiyoshi; Nagahara, Takayasu; Suzuki, Makoto; Shimada, Takashi; Watanabe, Kengo; Isobe, Yumiko; Furugoori, Taketoshi

CORPORATE SOURCE: Tokyo R&D Center, Daiichi Pharmaceutical Co. Ltd, 16-13, Kita-Kasai 1-Chome, Edogawa-ku, Tokyo, 134-8630, Japan

SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(5), 1309-1330

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 24 Jan 2006

AB Serine protease factor Xa (fXa) inhibitor I showed good ex vivo anti-fXa activity upon oral administration in rats. However, it has been revealed that I had low metabolic stability against human liver microsomes. To improve the metabolic stability, we attempted to modify the S1 and S4

ligands of I. These modifications resulted in a compound which exhibited selective anti-fXa activity and excellent anti-coagulation activity.


IT 875573-41-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(factor Xa inhibitors with improved metabolic stability)

RN 875573-41-4 HCAPLUS

CN Piperazine, 1-[(5-chloro-1H-indol-2-yl)sulfonyl]-4-[[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d ide 5

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, CHEMCATS' - CONTINUE? (Y)/N:y


L74 ANSWER 5 OF 16 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2005:3866708 CHEMCATS  
Catalog Name (CO): Ambinter Stock Screening Collection  
Publication Date (PD): 3 Jul 2005  
Order Number (ON): 1R-1070  
Chemical Name (CN): 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide,  
N-(4-chlorophenyl)-1-(phenylsulfonyl)-  
CAS Registry No. (RN): 477872-25-6  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




=> d ide 6-16

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, CHEMCATS' - CONTINUE? (Y)/N:y

L74 ANSWER 6 OF 16 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2005:3866707 CHEMCATS  
Catalog Name (CO): Ambinter Stock Screening Collection  
Publication Date (PD): 3 Jul 2005  
Order Number (ON): 1R-1067  
Chemical Name (CN): Morpholine, 4-[[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]carbonyl]-  
CAS Registry No. (RN): 477872-24-5  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L74 ANSWER 7 OF 16 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2005:3866706 CHEMCATS  
Catalog Name (CO): Ambinter Stock Screening Collection  
Publication Date (PD): 3 Jul 2005  
Order Number (ON): 1R-1066  
Chemical Name (CN): 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-(4-chloro-2-methylphenyl)-1-(phenylsulfonyl)-  
CAS Registry No. (RN): 477872-23-4  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L74 ANSWER 8 OF 16 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2005:3866705 CHEMCATS  
Catalog Name (CO): Ambinter Stock Screening Collection  
Publication Date (PD): 3 Jul 2005  
Order Number (ON): 1R-1063  
Chemical Name (CN): 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-(4-methoxyphenyl)-1-(phenylsulfonyl)-


CAS Registry No. (RN): 477872-22-3  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :



L74 ANSWER 9 OF 16 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2005:1905446 CHEMCATS  
Catalog Name (CO): Interchim Intermediates  
Publication Date (PD): 18 Jan 2005  
Order Number (ON): 1R-1070  
Chemical Name (CN): 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide,  
N-(4-chlorophenyl)-1-(phenylsulfonyl)-  
CAS Registry No. (RN): 477872-25-6  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L74 ANSWER 10 OF 16 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2005:1905445 CHEMCATS  
Catalog Name (CO): Interchim Intermediates  
Publication Date (PD): 18 Jan 2005  
Order Number (ON): 1R-1067  
Chemical Name (CN): Morpholine, 4-[[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]carbonyl]-  
CAS Registry No. (RN): 477872-24-5  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L74 ANSWER 11 OF 16 CHEMCATS COPYRIGHT 2006 ACS on STN

Accession No. (AN): 2005:1905444 CHEMCATS  
Catalog Name (CO): Interchim Intermediates  
Publication Date (PD): 18 Jan 2005  
Order Number (ON): 1R-1066  
Chemical Name (CN): 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide,  
N-(4-chloro-2-methylphenyl)-1-(phenylsulfonyl)-  
CAS Registry No. (RN): 477872-23-4  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L74 ANSWER 12 OF 16 CHEMCATS COPYRIGHT 2006 ACS on STN

Accession No. (AN): 2005:1905443 CHEMCATS  
Catalog Name (CO): Interchim Intermediates  
Publication Date (PD): 18 Jan 2005  
Order Number (ON): 1R-1063  
Chemical Name (CN): 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide,  
N-(4-methoxyphenyl)-1-(phenylsulfonyl)-  
CAS Registry No. (RN): 477872-22-3  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




## L74 ANSWER 13 OF 16 CHEMCATS COPYRIGHT 2006 ACS on STN

Accession No. (AN): 2000:936515 CHEMCATS  
Catalog Name (CO): Bionet Screening Compounds  
Publication Date (PD): 27 Mar 2006  
Order Number (ON): 1R-1063  
Chemical Name (CN): N-(4-methoxyphenyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide  
CAS Registry No. (RN): 477872-22-3  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :



## L74 ANSWER 14 OF 16 CHEMCATS COPYRIGHT 2006 ACS on STN


Accession No. (AN): 2000:581548 CHEMCATS  
Catalog Name (CO): Bionet Screening Compounds  
Publication Date (PD): 27 Mar 2006  
Order Number (ON): 1R-1070  
Chemical Name (CN): N-(4-chlorophenyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide  
CAS Registry No. (RN): 477872-25-6  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




## L74 ANSWER 15 OF 16 CHEMCATS COPYRIGHT 2006 ACS on STN

Accession No. (AN): 2000:581545 CHEMCATS  
Catalog Name (CO): Bionet Screening Compounds  
Publication Date (PD): 27 Mar 2006  
Order Number (ON): 1R-1067  
Chemical Name (CN): morpholino[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]methanone  
CAS Registry No. (RN): 477872-24-5  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :






L74 ANSWER 16 OF 16 CHEMCATS COPYRIGHT 2006 ACS on STN  
 Accession No. (AN): 2000:581544 CHEMCATS  
 Catalog Name (CO): Bionet Screening Compounds  
 Publication Date (PD): 27 Mar 2006  
 Order Number (ON): 1R-1066  
 Chemical Name (CN): N-(4-chloro-2-methylphenyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide  
 CAS Registry No. (RN): 477872-23-4  
 Supplementary Term (ST): CHEMICAL LIBRARY  
 Structure :



=> d que stat 123

L5 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L23 8608 SEA FILE=BEILSTEIN SSS FUL L5


100.0% PROCESSED 121484 ITERATIONS ( 8 INCOMPLETE)

8608 ANSWERS

SEARCH TIME: 00.01.02

=> d que stat 124

L5 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L11 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L23 8608 SEA FILE=BEILSTEIN SSS FUL L5

L24 96 SEA FILE=BEILSTEIN SUB=L23 SSS FUL L11


100.0% PROCESSED 8608 ITERATIONS ( 8 INCOMPLETE)

96 ANSWERS

SEARCH TIME: 00.00.08

=> d que stat 125

L5 STR




VAR G1=C/N

VAR G2=C/N

VAR G3=C/N  
 VAR G4=C/N  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE  
 L19 STR




NODE ATTRIBUTES:  
 NSPEC IS RC AT 2  
 NSPEC IS RC AT 3  
 CONNECT IS E1 RC AT 4  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS PCY AT 1  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E7 C E2 N E0 O E0 S AT 1

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE  
 L23 8608 SEA FILE=BEILSTEIN SSS FUL L5  
 L25 29 SEA FILE=BEILSTEIN SUB=L23 SSS FUL L19

100.0% PROCESSED 8608 ITERATIONS ( 8 INCOMPLETE) 29 ANSWERS  
 SEARCH TIME: 00.00.05

=> d que stat l26  
 L5 STR



VAR G1=C/N  
 VAR G2=C/N

```

VAR G3=C/N
VAR G4=C/N
NODE ATTRIBUTES:
NSPEC   IS RC      AT  10
NSPEC   IS RC      AT  11
CONNECT IS E1  RC AT  12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```


GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  12

```

```

STEREO ATTRIBUTES: NONE
L11                STR

```



```

VAR G1=C/N
VAR G2=C/N
VAR G3=C/N
VAR G4=C/N
NODE ATTRIBUTES:
NSPEC   IS RC      AT  10
NSPEC   IS RC      AT  11
CONNECT IS E1  RC AT  12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```


GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  13

```

```

STEREO ATTRIBUTES: NONE
L19                STR

```



```

NODE ATTRIBUTES:
NSPEC   IS RC      AT  2
NSPEC   IS RC      AT  3
CONNECT IS E1  RC AT  4
DEFAULT MLEVEL IS ATOM
GGCAT   IS PCY AT  1
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E7 C  E2 N  E0 O  E0 S  AT  1

```


GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE

L23 8608 SEA FILE=BEILSTEIN SSS FUL L5  
L24 96 SEA FILE=BEILSTEIN SUB=L23 SSS FUL L11  
L25 29 SEA FILE=BEILSTEIN SUB=L23 SSS FUL L19  
L26 8 SEA FILE=BEILSTEIN ABB=ON PLU=ON L24 AND L25

=> d que stat l44

L5 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L23 8608 SEA FILE=BEILSTEIN SSS FUL L5

L37 STR

C @14 N @15 S @16 O @17



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

VAR G5=14/15/16/17



## NODE ATTRIBUTES:

NSPEC IS RC AT 2  
 NSPEC IS RC AT 3  
 CONNECT IS E1 RC AT 4  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS PCY AT 1  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E7 C E2 N E0 O E0 S AT 1


## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 4

## STEREO ATTRIBUTES: NONE

L23 8608 SEA FILE=BEILSTEIN SSS FUL L5  
 L25 29 SEA FILE=BEILSTEIN SUB=L23 SSS FUL L19  
 L37 STR

C @14 N @15 S @16 O @17



VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 VAR G5=14/15/16/17

## NODE ATTRIBUTES:

NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 NSPEC IS RC AT 14  
 NSPEC IS RC AT 15  
 NSPEC IS RC AT 16  
 NSPEC IS RC AT 17  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 18

## STEREO ATTRIBUTES: NONE

L44 610 SEA FILE=BEILSTEIN SUB=L23 SSS FUL L37  
 L45 8 SEA FILE=BEILSTEIN ABB=ON PLU=ON L25 AND L44

=> fil beilst

FILE 'BEILSTEIN' ENTERED AT 15:38:13 ON 24 OCT 2006  
 COPYRIGHT (c) 2006 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
 licensed to Beilstein GmbH and MDL Information Systems GmbH



FILE LAST UPDATED ON JUNE 16, 2006

FILE COVERS 1771 TO 2006.

\*\*\* FILE CONTAINS 9,606,495 SUBSTANCES \*\*\*

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

\*\*\*\*\*  
\* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. \*  
\* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE \*  
\* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE \*  
\* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. \*  
\* FOR PRICE INFORMATION SEE HELP COST \*  
\*\*\*\*\*

NEW


\* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.  
\* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

=> s l26 or l45  
L75 8 L26 OR L45

=&gt; d ide 1

L75 ANSWER 1 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN): 5203985  
 Molec. Formula (MF): C20 H13 N5 O9  
 Molecular Weight (MW): 467.35  
 Lawson Number (LN): 31217, 14140  
 Compound Type (CTYPE): heterocyclic  
 Constitution ID (CONSID): 4651404  
 Tautomer ID (TAUTID): 5034535  
 Beilstein Citation (BSO): 6-27  
 Entry Date (DED): 1992/08/28  
 Update Date (DUPD): 1992/08/28



## Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1
IR	Infrared Spectrum	1

MP	Melting Point	1
RSTR	Related Structure	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

=> d rx 1

L75 ANSWER 1 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Reaction:

RX

Reaction ID (.ID):	1821561
Reactant BRN (.RBRN):	4470693, 1588666
Reactant (.RCT):	5-nitrosalicylaldehyde benzylamine Schiff base, 2-chloro-1,3,5-trinitro-benzene
Product BRN (.PBRN):	5203985
Product (.PRO):	C20H13N5O9
No. of React. Details (.NVAR):	1

Reaction Details:


RX

Reaction RID (.RID):	1821561.1
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	Triethylamine
Solvent (.SOL):	benzene
Time (.TIM):	7 day(s)
Other Conditions (.COND):	Ambient temperature
Note(s) (.COM):	Yield given
Reference(s):	1. Olekhovich, L. P.; Mikhailov, I. E.; Minkin, V. I.; Furmanova, N. G.; Kompan, O. E.; et al., J.Org.Chem.USSR (Engl.Transl.), CODEN: JOCYA9, 18(2), <1982>, 425-432, Zh.Org.Khim., CODEN: ZORKAE, 18(2), <1982>, 484-493; BABS-5632319

=> d ide 2

L75 ANSWER 2 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN):	5201172
Molec. Formula (MF):	C24 H16 N4 O7
Molecular Weight (MW):	472.41
Lawson Number (LN):	31234, 14140
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	4651380
Tautomer ID (TAUTID):	5024792
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1992/08/28
Update Date (DUPD):	1992/08/28



## Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
RSTR	Related Structure	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

=> d rx 2

L75 ANSWER 2 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

## Reaction:

RX

Reaction ID (.ID): 1821657  
 Reactant BRN (.RBRN): 5271343, 1588666

Reactant (.RCT): 1-Benzyliminomethyl-naphthol-(2),  
2-chloro-1,3,5-trinitro-benzene  
Product BRN (.PBRN): 5201172  
Product (.PRO): C24H16N4O7  
No. of React. Details (.NVAR): 1

## Reaction Details:

RX

Reaction RID (.RID): 1821657.1  
Reaction Classification (.CL): Preparation  
Reagent (.RGT): Triethylamine  
Solvent (.SOL): benzene  
Time (.TIM): 7 day(s)  
Other Conditions (.COND): Ambient temperature  
Note(s) (.COM): Yield given


## Reference(s):

1. Olekhovich, L. P.; Mikhailov, I. E.; Minkin, V. I.; Furmanova, N. G.;  
Kompan, O. E.; et al., J.Org.Chem.USSR (Engl.Transl.), CODEN: JOCYA9,  
18(2), <1982>, 425-432, Zh.Org.Khim., CODEN: ZORKAE, 18(2), <1982>,  
484-493; BABS-5632319

=&gt; d ide 3

L75 ANSWER 3 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN): 5198492  
Molec. Formula (MF): C20 H13 Br N4 O7  
Molecular Weight (MW): 501.25  
Lawson Number (LN): 31217, 14140  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 4603161  
Tautomer ID (TAUTID): 4926699  
Beilstein Citation (BSO): 6-27  
Entry Date (DED): 1992/08/28  
Update Date (DUPD): 1992/08/28



## Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
RSTR	Related Structure	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

=> d rx 3

L75 ANSWER 3 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Reaction:

RX

Reaction ID (.ID): 1821625

Reactant BRN (.RBRN): 5012083, 1588666  
 Reactant (.RCT): 2-(benzylimino-methyl)-4-bromo-phenol,  
 2-chloro-1,3,5-trinitro-benzene  
 Product BRN (.PBRN): 5198492  
 Product (.PRO): C20H13BrN4O7  
 No. of React. Details (.NVAR): 1

Reaction Details:


RX

Reaction RID (.RID): 1821625.1  
 Reaction Classification (.CL): Preparation  
 Reagent (.RGT): Triethylamine  
 Solvent (.SOL): benzene  
 Time (.TIM): 7 day(s)  
 Other Conditions (.COND): Ambient temperature  
 Note(s) (.COM): Yield given  
 Reference(s):  
 1. Olekhnovich, L. P.; Mikhailov, I. E.; Minkin, V. I.; Furmanova, N. G.;  
 Kompan, O. E.; et al., J.Org.Chem.USSR (Engl.Transl.), CODEN: JOCYA9,  
 18(2), <1982>, 425-432, Zh.Org.Khim., CODEN: ZORKAE, 18(2), <1982>,  
 484-493; BABS-5632319

=> d ide 4

L75 ANSWER 4 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN): 5194486  
 Molec. Formula (MF): C20 H16 N4 O7  
 Molecular Weight (MW): 424.37  
 Lawson Number (LN): 31234, 2836  
 Compound Type (CTYPE): heterocyclic  
 Constitution ID (CONSID): 4598518  
 Tautomer ID (TAUTID): 4927149  
 Beilstein Citation (BSO): 6-27  
 Entry Date (DED): 1992/08/28  
 Update Date (DUPD): 1992/08/28



## Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1
CDEN	Density (Crystal)	1
CRYPH	Crystal Phase	1
CSG	Crystal Space Group	1
CSYS	Crystal System	1
GEO	Interatomic Distanc and Angle	1
IR	Infrared Spectrum	1
MP	Melting Point	1
RSTR	Related Structure	1
UVS	UV and Visible Spectrum	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	4
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	3

=> d rx 4



L75 ANSWER 4 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

## Reaction:

RX

Reaction ID (.ID): 3008806  
Reactant BRN (.RBRN): 5179110  
Reactant (.RCT): 2-<<isopropyl-(2,4,6-trinitro-phenyl)-amino>-methylene>-2H-naphthalen-1-one  
Product BRN (.PBRN): 5194486, 5176613  
Product (.PRO): C20H16N4O7, isopropyl-<2-(2,4,6-trinitro-phenoxy)-naphthalen-1-ylmethylene>-amine  
No. of React. Details (.NVAR): 1

## Reaction Details:

RX

Reaction RID (.RID): 3008806.1  
Reaction Classification (.CL): Chemical behaviour  
Solvent (.SOL): bis-(2-methoxy-ethyl) ether  
Temperature (.T): 25 Cel  
Other Conditions (.COND):  $\delta$ H,  $\delta$ S,  $\delta$ G  
Subject Studied (.SUBJ): Equilibrium constant, Thermodynamic data  
Reference(s):  
1. Olekhnovich, L. P.; Mikhailov, I. E.; Minkin, V. I.; Furmanova, N. G.; Kompan, O. E.; et al., J.Org.Chem.USSR (Engl.Transl.), CODEN: JOCYA9, 18(2), <1982>, 425-432, Zh.Org.Khim., CODEN: ZORKAE, 18(2), <1982>, 484-493; BABS-5632319

## Reaction:

RX

Reaction ID (.ID): 3007874  
Reactant BRN (.RBRN): 5176613  
Reactant (.RCT): isopropyl-<2-(2,4,6-trinitro-phenoxy)-naphthalen-1-ylmethylene>-amine  
Product BRN (.PBRN): 5194486, 5179110  
Product (.PRO): C20H16N4O7, 2-<<isopropyl-(2,4,6-trinitro-phenyl)-amino>-methylene>-2H-naphthalen-1-one  
No. of React. Details (.NVAR): 1

## Reaction Details:

RX

Reaction RID (.RID): 3007874.1  
Reaction Classification (.CL): Chemical behaviour  
Solvent (.SOL): bis-(2-methoxy-ethyl) ether  
Temperature (.T): 25 Cel  
Other Conditions (.COND):  $\delta$ H,  $\delta$ S,  $\delta$ G  
Subject Studied (.SUBJ): Equilibrium constant, Thermodynamic data  
Reference(s):  
1. Olekhnovich, L. P.; Mikhailov, I. E.; Minkin, V. I.; Furmanova, N. G.; Kompan, O. E.; et al., J.Org.Chem.USSR (Engl.Transl.), CODEN: JOCYA9, 18(2), <1982>, 425-432, Zh.Org.Khim., CODEN: ZORKAE, 18(2), <1982>, 484-493; BABS-5632319

## Reaction:

RX

Reaction ID (.ID): 1821654  
Reactant BRN (.RBRN): 5256551, 1588666  
Reactant (.RCT): 1-(isopropylimino-methyl)-naphthalen-2-ol,

2-chloro-1,3,5-trinitro-benzene  
Product BRN (.PBRN): 5194486  
Product (.PRO): C20H16N4O7  
No. of React. Details (.NVAR): 1

## Reaction Details:

RX

Reaction RID (.RID): 1821654.1  
Reaction Classification (.CL): Preparation  
Reagent (.RGT): Triethylamine  
Solvent (.SOL): benzene  
Time (.TIM): 7 day(s)  
Other Conditions (.COND): Ambient temperature  
Note(s) (.COM): Yield given  
Reference(s):  
1. Olekhovich, L. P.; Mikhailov, I. E.; Minkin, V. I.; Furmanova, N. G.;  
Kompan, O. E.; et al., J.Org.Chem.USSR (Engl.Transl.), CODEN: JOCYA9,  
18(2), <1982>, 425-432, Zh.Org.Khim., CODEN: ZORKAE, 18(2), <1982>,  
484-493; BABS-5632319

## Reaction:

RX

Reaction ID (.ID): 3014862  
Reactant BRN (.RBRN): 5194486  
Reactant (.RCT): C20H16N4O7  
Product BRN (.PBRN): 5179110, 5176613  
Product (.PRO): 2-<<isopropyl-(2,4,6-trinitro-phenyl)-  
amino>-methylene>-2H-naphthalen-1-one,  
isopropyl-<2-(2,4,6-trinitro-phenoxy)-  
naphthalen-1-ylmethylene>-amine  
No. of React. Details (.NVAR): 1

## Reaction Details:

RX


Reaction RID (.RID): 3014862.1  
Reaction Classification (.CL): Chemical behaviour  
Solvent (.SOL): bis-(2-methoxy-ethyl) ether  
Temperature (.T): 25 Cel  
Other Conditions (.COND):  $\delta$ H,  $\delta$ S,  $\delta$ G  
Subject Studied (.SUBJ): Equilibrium constant, Thermodynamic data  
Reference(s):  
1. Olekhovich, L. P.; Mikhailov, I. E.; Minkin, V. I.; Furmanova, N. G.;  
Kompan, O. E.; et al., J.Org.Chem.USSR (Engl.Transl.), CODEN: JOCYA9,  
18(2), <1982>, 425-432, Zh.Org.Khim., CODEN: ZORKAE, 18(2), <1982>,  
484-493; BABS-5632319

=&gt; d ide 5

L75 ANSWER 5 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN): 5193735  
Molec. Formula (MF): C20 H14 N4 O7  
Molecular Weight (MW): 422.35  
Lawson Number (LN): 31216, 14140  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 4589044  
Tautomer ID (TAUTID): 4920110  
Beilstein Citation (BSO): 6-27

Entry Date (DED): 1992/08/28  
Update Date (DUPD): 1992/08/28



## Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
RSTR	Related Structure	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

=> d rx 5

L75 ANSWER 5 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

## Reaction:

RX

Reaction ID (.ID): 1821478  
Reactant BRN (.RBRN): 2211337, 1588666  
Reactant (.RCT): N-salicylidene-benzylamine,  
2-chloro-1,3,5-trinitro-benzene  
Product BRN (.PBRN): 5193735  
Product (.PRO): C20H14N4O7  
No. of React. Details (.NVAR): 1

## Reaction Details:


RX

Reaction RID (.RID): 1821478.1  
Reaction Classification (.CL): Preparation  
Reagent (.RGT): Triethylamine  
Solvent (.SOL): benzene  
Time (.TIM): 7 day(s)  
Other Conditions (.COND): Ambient temperature  
Note(s) (.COM): Yield given  
Reference(s):  
1. Olekhovich, L. P.; Mikhailov, I. E.; Minkin, V. I.; Furmanova, N. G.;  
Kompan, O. E.; et al., J.Org.Chem.USSR (Engl.Transl.), CODEN: JOCYA9,  
18(2), <1982>, 425-432, Zh.Org.Khim., CODEN: ZORKAE, 18(2), <1982>,  
484-493; BABS-5632319

=&gt; d ide 6

L75 ANSWER 6 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN): 5190225  
Molec. Formula (MF): C18 H12 N4 O7  
Molecular Weight (MW): 396.32  
Lawson Number (LN): 31234, 2817  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 4592752  
Tautomer ID (TAUTID): 4925211  
Beilstein Citation (BSO): 6-27  
Entry Date (DED): 1992/08/28  
Update Date (DUPD): 1992/08/28



## Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
RSTR	Related Structure	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

=> d rx 6

L75 ANSWER 6 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Reaction:

RX

Reaction ID (.ID): 1821492

Reactant BRN (.RBRN): 2614214, 1588666  
Reactant (.RCT): N-(2-hydroxynaphthylmethylidene)methylamine,  
2-chloro-1,3,5-trinitro-benzene  
Product BRN (.PBRN): 5190225  
Product (.PRO): C18H12N4O7  
No. of React. Details (.NVAR): 1

## Reaction Details:


RX

Reaction RID (.RID): 1821492.1  
Reaction Classification (.CL): Preparation  
Reagent (.RGT): Triethylamine  
Solvent (.SOL): benzene  
Time (.TIM): 7 day(s)  
Other Conditions (.COND): Ambient temperature  
Note(s) (.COM): Yield given  
Reference(s):  
1. Olekhnovich, L. P.; Mikhailov, I. E.; Minkin, V. I.; Furmanova, N. G.;  
Kompan, O. E.; et al., J.Org.Chem.USSR (Engl.Transl.), CODEN: JOCYA9,  
18(2), <1982>, 425-432, Zh.Org.Khim., CODEN: ZORKAE, 18(2), <1982>,  
484-493; BABS-5632319

=&gt; d ide 7

L75 ANSWER 7 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN): 5184431  
Molec. Formula (MF): C16 H14 N4 O7  
Molecular Weight (MW): 374.31  
Lawson Number (LN): 31216, 2836  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 4565460  
Tautomer ID (TAUTID): 4908601  
Beilstein Citation (BSO): 6-27  
Entry Date (DED): 1992/08/28  
Update Date (DUPD): 1992/08/28



## Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
RSTR	Related Structure	1
UVS	UV and Visible Spectrum	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	3
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	2

=> d rx 7

L75 ANSWER 7 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

## Reaction:

RX

Reaction ID (.ID): 2998525  
Reactant BRN (.RBRN): 5154948  
Reactant (.RCT): isopropyl-<2-(2,4,6-trinitro-phenoxy)-benzylidene>-amine  
Product BRN (.PBRN): 5184431  
Product (.PRO): C16H14N4O7  
No. of React. Details (.NVAR): 1

## Reaction Details:

RX

Reaction RID (.RID): 2998525.1  
Reaction Classification (.CL): Chemical behaviour  
Solvent (.SOL): bis-(2-methoxy-ethyl) ether  
Temperature (.T): 25 Cel  
Other Conditions (.COND):  $\delta H$ ,  $\delta S$ ,  $\delta G$   
Subject Studied (.SUBJ): Equilibrium constant, Thermodynamic data  
Reference(s):  
1. Olekhovich, L. P.; Mikhailov, I. E.; Minkin, V. I.; Furmanova, N. G.; Kompan, O. E.; et al., J.Org.Chem.USSR (Engl.Transl.), CODEN: JOCYA9, 18(2), <1982>, 425-432, Zh.Org.Khim., CODEN: ZORKAE, 18(2), <1982>, 484-493; BABS-5632319

## Reaction:

RX

Reaction ID (.ID): 1821484  
Reactant BRN (.RBRN): 2500602, 1588666  
Reactant (.RCT): 2-(isopropylimino-methyl)-phenol, 2-chloro-1,3,5-trinitro-benzene  
Product BRN (.PBRN): 5184431  
Product (.PRO): C16H14N4O7  
No. of React. Details (.NVAR): 1

## Reaction Details:

RX

Reaction RID (.RID): 1821484.1  
Reaction Classification (.CL): Preparation  
Reagent (.RGT): Triethylamine  
Solvent (.SOL): benzene  
Time (.TIM): 7 day(s)  
Other Conditions (.COND): Ambient temperature  
Note(s) (.COM): Yield given  
Reference(s):  
1. Olekhovich, L. P.; Mikhailov, I. E.; Minkin, V. I.; Furmanova, N. G.; Kompan, O. E.; et al., J.Org.Chem.USSR (Engl.Transl.), CODEN: JOCYA9, 18(2), <1982>, 425-432, Zh.Org.Khim., CODEN: ZORKAE, 18(2), <1982>, 484-493; BABS-5632319

## Reaction:

RX

Reaction ID (.ID): 3011068  
Reactant BRN (.RBRN): 5184431  
Reactant (.RCT): C16H14N4O7  
Product BRN (.PBRN): 5154948  
Product (.PRO): isopropyl-<2-(2,4,6-trinitro-phenoxy)-benzylidene>-amine  
No. of React. Details (.NVAR): 1



## Reaction Details:


RX

Reaction RID (.RID): 3011068.1  
Reaction Classification (.CL): Chemical behaviour  
Solvent (.SOL): bis-(2-methoxy-ethyl) ether  
Temperature (.T): 25 Cel  
Other Conditions (.COND):  $\delta H$ ,  $\delta S$ ,  $\delta G$   
Subject Studied (.SUBJ): Equilibrium constant, Thermodynamic data  
Reference(s):  
1. Olekhovich, L. P.; Mikhailov, I. E.; Minkin, V. I.; Furmanova, N. G.;  
Kompan, O. E.; et al., J.Org.Chem.USSR (Engl.Transl.), CODEN: JOCYA9,  
18(2), <1982>, 425-432, Zh.Org.Khim., CODEN: ZORKAE, 18(2), <1982>,  
484-493; BABS-5632319

=&gt; d ide 8

L75 ANSWER 8 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN): 5180159  
Molec. Formula (MF): C14 H10 N4 O7  
Molecular Weight (MW): 346.26  
Lawson Number (LN): 31216, 2817  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 4564446  
Tautomer ID (TAUTID): 4906214  
Beilstein Citation (BSO): 6-27  
Entry Date (DED): 1992/08/28  
Update Date (DUPD): 1992/08/28



## Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
RSTR	Related Structure	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

=> d rx 8

L75 ANSWER 8 OF 8 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

## Reaction:

RX

Reaction ID (.ID): 1821480  
 Reactant BRN (.RBRN): 2324695, 1588666  
 Reactant (.RCT): N-salicylidene methylamine,  
 2-chloro-1,3,5-trinitro-benzene  
 Product BRN (.PBRN): 5180159  
 Product (.PRO): C14H10N4O7  
 No. of React. Details (.NVAR): 1

## Reaction Details:

RX

Reaction RID (.RID): 1821480.1  
 Reaction Classification (.CL): Preparation  
 Reagent (.RGT): Triethylamine  
 Solvent (.SOL): benzene  
 Time (.TIM): 7 day(s)  
 Other Conditions (.COND): Ambient temperature  
 Note(s) (.COM): Yield given  
 Reference(s):  
 1. Olekhovich, L. P.; Mikhailov, I. E.; Minkin, V. I.; Furmanova, N. G.;  
 Kompan, O. E.; et al., J.Org.Chem.USSR (Engl.Transl.), CODEN: JOCYA9,  
 18(2), <1982>, 425-432, Zh.Org.Khim., CODEN: ZORKAE, 18(2), <1982>,  
 484-493; BABS-5632319

=> d que 129

L29 1 SEA FILE=BABS ABB=ON PLU=ON 5632319/BABSAN

=> d que 148

L29 1 SEA FILE=BABS ABB=ON PLU=ON 5632319/BABSAN

L47 1 SEA FILE=BABS ABB=ON PLU=ON 5632319/AN

L48 1 SEA FILE=BABS ABB=ON PLU=ON L47 OR L29

=> d ibib ed ab 148

YOU HAVE REQUESTED DATA FROM FILE 'BABS' - CONTINUE? (Y)/N:y

L48 ANSWER 1 OF 1 BABS COPYRIGHT 2006 BEILSTEIN MDL on STN

ACCESSION NUMBER: 5632319 BABS

TITLE: ACYLOTROPIC TAUTOMERISM. XIV. STRUCTURE AND  
TAUTOMERISM IN O-2,4,6-TRINITROARYL DERIVATIVES OF  
o-HYDROXYALDEHYDES AND THEIR IMINES

AUTHOR(S): Olekhnovich, L. P.; Mikhailov, I. E.; Minkin, V. I.;  
Furmanova, N. G.; Kompan, O. E.; et al.

SOURCE: J.Org.Chem.USSR (Engl.Transl.) (1982), 18(2), 425-432  
CODEN: JOCYA9

SOURCE: Zh.Org.Khim. (1982), 18(2), 484-493  
CODEN: ZORKAE

DOCUMENT TYPE: Journal

LANGUAGE: English; Russian

SUMMARY LANGUAGE: English

ED 20041015

AB The 2,4,6-trinitrophenyl derivatives of aromatic o-hydroxy aldehydes, which according to IR spectroscopy exist as benzenoid O-isomers in the crystalline state, are present in solutions in tautomeric equilibrium with bipolar spirocyclic  $\pi$ - $\pi$  complexes of the Meisenheimer type. The position of the equilibrium, which is sensitive to the polarity of the solvent, was studied by electronic spectroscopy and PMR spectra. Unlike the hydroxy aldehydes, the 2,4,6-trinitrophenyl derivatives of their alkylimines in the crystalline state and in solutions are more stable in the form of the bipolar spiro  $\pi$ - $\pi$  complexes. In addition to solvatochromism, they exhibit thermochromism when the temperature of the solution is varied. X-ray crystallographic analysis of the 2',4',6'-trinitrophenyl derivative of N-isopropyl-2-hydroxy-1-naphthaldehyde imine indicates that it has a spirocyclic structure in the crystalline state. The geometric characteristics and interatomic distances in the spiro unit indicate a preference for isomerization of the spiro  $\pi$ - $\pi$  complex into the O-aryl isomer.

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 15:40:52 ON 24 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE


AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Oct 20, 2006 (20061020/UP).

=&gt; d que stat l31

L5 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L31 215 SEA FILE=CHEMINFORMRX SSS FUL L5 ( 1481 REACTIONS)


100.0% DONE 22392 VERIFIED 1481 HIT RXNS

215 DOCS

SEARCH TIME: 00.00.37

=&gt; d que stat l33

L5 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L11 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L31 215 SEA FILE=CHEMINFORMRX SSS FUL L5 ( 1481 REACTIONS)

L33 5 SEA FILE=CHEMINFORMRX SUB=L31 SSS FUL L11 ( 17 REACTIONS)


100.0% DONE 1481 VERIFIED 17 HIT RXNS

5 DOCS

SEARCH TIME: 00.00.06

=> d que stat l35

L5 STR




VAR G1=C/N

VAR G2=C/N

VAR G3=C/N  
 VAR G4=C/N  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE  
 L19 STR




NODE ATTRIBUTES:  
 NSPEC IS RC AT 2  
 NSPEC IS RC AT 3  
 CONNECT IS E1 RC AT 4  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS PCY AT 1  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E7 C E2 N E0 O E0 S AT 1

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE  
 L31 215 SEA FILE=CHEMINFORMRX SSS FUL L5 ( 1481 REACTIONS)  
 L35 1 SEA FILE=CHEMINFORMRX SUB=L31 SSS FUL L19 ( 1 REACTIONS)

100.0% DONE 1481 VERIFIED 1 HIT RXNS 1 DOCS  
 SEARCH TIME: 00.00.01

=> d que stat l36  
 L5 STR




VAR G1=C/N  
 VAR G2=C/N

```
VAR G3=C/N
VAR G4=C/N
NODE ATTRIBUTES:
NSPEC      IS RC      AT 10
NSPEC      IS RC      AT 11
CONNECT IS E1 RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 12

```
STEREO ATTRIBUTES: NONE
L11                STR
```




```

VAR G1=C/N
VAR G2=C/N
VAR G3=C/N
VAR G4=C/N
NODE ATTRIBUTES:
NSPEC      IS RC      AT 10
NSPEC      IS RC      AT 11
CONNECT IS E1 RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ELEVEL IS LIMITED

```

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 13

```
STEREO ATTRIBUTES: NONE
L19                STR
```



```

NODE ATTRIBUTES:
NSPEC      IS RC      AT      2
NSPEC      IS RC      AT      3
CONNECT    IS E1      RC AT      4
DEFAULT    MLEVEL IS ATOM
GGCAT      IS PCY      AT      1
DEFAULT    ECLEVEL IS LIMITED
ECOUNT     IS E7 C     E2 N     E0 O     E0 S     AT      1


```

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE

L31 215 SEA FILE=CHEMINFORMRX SSS FUL L5 ( 1481 REACTIONS)  
L33 5 SEA FILE=CHEMINFORMRX SUB=L31 SSS FUL L11 ( 17 REACTIONS)  
L35 1 SEA FILE=CHEMINFORMRX SUB=L31 SSS FUL L19 ( 1 REACTIONS)  
L36 0 SEA FILE=CHEMINFORMRX ABB=ON PLU=ON L33 AND L35

=> d que stat 150  
L5 STR




VAR G1=C/N  
VAR G2=C/N  
VAR G3=C/N  
VAR G4=C/N  
NODE ATTRIBUTES:  
NSPEC IS RC AT 10  
NSPEC IS RC AT 11  
CONNECT IS E1 RC AT 12  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L31 215 SEA FILE=CHEMINFORMRX SSS FUL L5 ( 1481 REACTIONS)  
L37 STR

C @14 N @15 S @16 O @17



VAR G1=C/N  
VAR G2=C/N  
VAR G3=C/N  
VAR G4=C/N  
VAR G5=14/15/16/17



## NODE ATTRIBUTES:

NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 NSPEC IS RC AT 14  
 NSPEC IS RC AT 15  
 NSPEC IS RC AT 16  
 NSPEC IS RC AT 17  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 18


## STEREO ATTRIBUTES: NONE

L50 11 SEA FILE=CHEMINFORMRX SUB=L31 SSS FUL L37 ( 56 REACTIONS)

100.0% DONE 872 VERIFIED 56 HIT RXNS 11 DOCS  
 SEARCH TIME: 00.00.05

=> d que stat l51

L5 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

## NODE ATTRIBUTES:


NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 12

## STEREO ATTRIBUTES: NONE

L19 STR



## NODE ATTRIBUTES:

NSPEC IS RC AT 2  
 NSPEC IS RC AT 3  
 CONNECT IS E1 RC AT 4  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS PCY AT 1  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E7 C E2 N E0 O E0 S AT 1


## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 4

## STEREO ATTRIBUTES: NONE

L31 215 SEA FILE=CHEMINFORMRX SSS FUL L5 ( 1481 REACTIONS)  
 L35 1 SEA FILE=CHEMINFORMRX SUB=L31 SSS FUL L19 ( 1 REACTIONS)  
 L37 STR

C @14 N @15 S @16 O @17



VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 VAR G5=14/15/16/17

## NODE ATTRIBUTES:

NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 NSPEC IS RC AT 14  
 NSPEC IS RC AT 15  
 NSPEC IS RC AT 16  
 NSPEC IS RC AT 17  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 18

## STEREO ATTRIBUTES: NONE

L50 11 SEA FILE=CHEMINFORMRX SUB=L31 SSS FUL L37 ( 56 REACTIONS)  
 L51 0 SEA FILE=CHEMINFORMRX ABB=ON PLU=ON L35 AND L50

=> fil toxcenter uspatall casreact chemcats  
 FILE 'TOXCENTER' ENTERED AT 15:43:34 ON 24 OCT 2006  
 COPYRIGHT (C) 2006 ACS

FILE 'USPATFULL' ENTERED AT 15:43:34 ON 24 OCT 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:43:34 ON 24 OCT 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CASREACT' ENTERED AT 15:43:34 ON 24 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CHEMCATS' ENTERED AT 15:43:34 ON 24 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.


PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

=> d que 170

L5

STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L7 45329 SEA FILE=REGISTRY SSS FUL L5

L8 103939 SEA FILE=REGISTRY ABB=ON PLU=ON NC4-NC5/ES


L11 STR



VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 13


STEREO ATTRIBUTES: NONE  
 L14 753 SEA FILE=REGISTRY SUB=L7 SSS FUL L11  
 L15 0 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L14  
 L19 STR



NODE ATTRIBUTES:  
 NSPEC IS RC AT 2  
 NSPEC IS RC AT 3  
 CONNECT IS E1 RC AT 4  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS PCY AT 1  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E7 C E2 N E0 O E0 S AT 1

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE  
 L21 733 SEA FILE=REGISTRY SUB=L7 SSS FUL L19  
 L22 0 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND L21  
 L37 STR



VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 VAR G5=14/15/16/17

## NODE ATTRIBUTES:

NSPEC IS RC AT 10  
NSPEC IS RC AT 11  
NSPEC IS RC AT 14  
NSPEC IS RC AT 15  
NSPEC IS RC AT 16  
NSPEC IS RC AT 17  
CONNECT IS E1 RC AT 12  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 18

## STEREO ATTRIBUTES: NONE

L39 3990 SEA FILE=REGISTRY SUB=L7 SSS FUL L37  
L40 77 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L39  
L41 82 SEA FILE=REGISTRY ABB=ON PLU=ON L21 AND L39  
L42 82 SEA FILE=REGISTRY ABB=ON PLU=ON (L40 OR L41)  
L53 82 SEA FILE=REGISTRY ABB=ON PLU=ON L42 OR L22 OR L15  
L56 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY  
<2004 OR REVIEW/DT  
L69 24 SEA L42 OR L53  
L70 9 SEA L69 AND L56

=> s 153 and 160-166

'PA' IS NOT A VALID FIELD CODE  
'SO' IS NOT A VALID FIELD CODE  
'SO' IS NOT A VALID FIELD CODE  
'AU' IS NOT A VALID FIELD CODE  
'CS' IS NOT A VALID FIELD CODE  
'SO' IS NOT A VALID FIELD CODE  
'PA' IS NOT A VALID FIELD CODE  
L76 5 L53 AND (L60 OR L61 OR L62 OR L63 OR L64 OR L65 OR L66)

=> save temp l76 shi089mulsin/a

ANSWER SET L76 HAS BEEN SAVED AS 'SHI089MULSIN/A'

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 15:44:35 ON 24 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Oct 20, 2006 (20061020/UP).

=> => d his ful

(FILE 'HOME' ENTERED AT 13:31:25 ON 24 OCT 2006)

FILE 'ZCAPLUS' ENTERED AT 13:31:37 ON 24 OCT 2006  
E US2004-849089/APPS

L1 FILE 'HCAPLUS' ENTERED AT 13:31:55 ON 24 OCT 2006  
1 SEA ABB=ON PLU=ON US2004-849089/APPS  
SAVE TEMP L1 SHI089HCAAPP/ SHI089HCAAPP/A

FILE 'STNGUIDE' ENTERED AT 13:32:24 ON 24 OCT 2006

FILE 'HCAPLUS' ENTERED AT 13:32:28 ON 24 OCT 2006  
D IBIB ED AB IND

FILE 'STNGUIDE' ENTERED AT 13:32:28 ON 24 OCT 2006

L2 FILE 'WPIX' ENTERED AT 13:34:21 ON 24 OCT 2006  
1 SEA ABB=ON PLU=ON US2004-849089/APPS,APTS  
SAVE TEMP L2 SHI089WPIAPP/A  
D IALL CODE

FILE 'STNGUIDE' ENTERED AT 13:35:08 ON 24 OCT 2006

FILE 'REGISTRY' ENTERED AT 13:37:11 ON 24 OCT 2006

L3 FILE 'HCAPLUS' ENTERED AT 13:37:15 ON 24 OCT 2006  
TRA PLU=ON L1 1- RN : 34 TERMS

L4 FILE 'REGISTRY' ENTERED AT 13:37:18 ON 24 OCT 2006  
34 SEA ABB=ON PLU=ON L3  
SAVE TEMP L4 SHI089REGAPP/A  
D SCAN

FILE 'STNGUIDE' ENTERED AT 13:37:54 ON 24 OCT 2006

L5 FILE 'LREGISTRY' ENTERED AT 13:39:32 ON 24 OCT 2006  
STR

L6 FILE 'REGISTRY' ENTERED AT 13:42:34 ON 24 OCT 2006  
50 SEA SSS SAM L5  
D QUE STAT

FILE 'STNGUIDE' ENTERED AT 13:43:28 ON 24 OCT 2006

L7 FILE 'REGISTRY' ENTERED AT 13:43:59 ON 24 OCT 2006  
D QUE STAT  
45329 SEA SSS FUL L5  
SAVE TEMP L7 SHI089PSET1/A

L\*\*\* DEL 2055 S NC5-NC6/ES

L\*\*\* DEL 0 S L8 AND L4

L8 103939 SEA ABB=ON PLU=ON NC4-NC5/ES

L9 14 SEA ABB=ON PLU=ON L4 NOT L8  
D SCAN

L10 740 SEA ABB=ON PLU=ON L7 AND L8

L11 FILE 'LREGISTRY' ENTERED AT 13:48:25 ON 24 OCT 2006  
STR L5

L12 FILE 'REGISTRY' ENTERED AT 13:49:12 ON 24 OCT 2006  
38 SEA SUB=L7 SSS SAM L11  
D QUE STAT

FILE 'STNGUIDE' ENTERED AT 13:50:46 ON 24 OCT 2006

L13 FILE 'REGISTRY' ENTERED AT 13:52:10 ON 24 OCT 2006  
23 SEA ABB=ON PLU=ON L4 NOT L7  
D SCAN  
D QUE STAT L12

L14 753 SEA SUB=L7 SSS FUL L11  
SAVE TEMP L14 SHI089RSET1/A

L15 0 SEA ABB=ON PLU=ON L8 AND L14

L16 0 SEA ABB=ON PLU=ON L14 AND L4

L17 20 SEA ABB=ON PLU=ON L4 AND L8  
D SCAN

FILE 'STNGUIDE' ENTERED AT 13:55:53 ON 24 OCT 2006  
D SCAN

FILE 'REGISTRY' ENTERED AT 13:58:40 ON 24 OCT 2006

FILE 'REGISTRY' ENTERED AT 13:58:48 ON 24 OCT 2006  
SAVE TEMP L15 SHI089RSET2/A

FILE 'STNGUIDE' ENTERED AT 13:59:31 ON 24 OCT 2006

L\*\*\* FILE 'LREGISTRY' ENTERED AT 13:59:45 ON 24 OCT 2006  
DEL STR L11

L18 FILE 'LREGISTRY' ENTERED AT 14:00:21 ON 24 OCT 2006  
STR

FILE 'REGISTRY' ENTERED AT 14:03:38 ON 24 OCT 2006

L19 FILE 'LREGISTRY' ENTERED AT 14:03:57 ON 24 OCT 2006  
STR L18

L20 FILE 'REGISTRY' ENTERED AT 14:04:22 ON 24 OCT 2006  
36 SEA SUB=L7 SSS SAM L19  
D QUE STAT

FILE 'STNGUIDE' ENTERED AT 14:05:31 ON 24 OCT 2006

FILE 'REGISTRY' ENTERED AT 14:06:44 ON 24 OCT 2006  
D QUE STAT

L21 733 SEA SUB=L7 SSS FUL L19  
SAVE TEMP L21 SHI089RSET3/A

L22 0 SEA ABB=ON PLU=ON L14 AND L21  
SAVE TEMP L22 SHI089RSET4/A

FILE 'STNGUIDE' ENTERED AT 14:08:16 ON 24 OCT 2006  
D SAVED

FILE 'BEILSTEIN' ENTERED AT 14:10:12 ON 24 OCT 2006  
D QUE L7

L23 8608 SEA SSS FUL L5  
SAVE TEMP L23 SHI089BEIP/A  
D QUE L14

L24 96 SEA SUB=L23 SSS FUL L11  
SAVE TEMP L24 SHI089BEIR1/A  
D QUE STAT  
D QUE L21  
L25 29 SEA SUB=L23 SSS FUL L19  
SAVE TEMP L25 SHI089BEIR2/A  
L26 8 SEA ABB=ON PLU=ON L24 AND L25  
SAVE TEMP L26 SHI089BEIR3/A  
L27 8 SEA ABB=ON PLU=ON L26 NOT RN/FA  
L28 0 SEA ABB=ON PLU=ON L27 NOT BABSAN/FA  
SELECT L27 1-8 BABSAN

FILE 'BABS' ENTERED AT 14:16:41 ON 24 OCT 2006

L29 1 SEA ABB=ON PLU=ON 5632319/BABSAN  
SAVE TEMP L29 SHI089BAB/A  
D SCAN

FILE 'STNGUIDE' ENTERED AT 14:17:11 ON 24 OCT 2006

FILE 'CHEMINFORMRX' ENTERED AT 14:18:12 ON 24 OCT 2006

D QUE STAT L7  
L30 12 SEA SSS SAM L5 ( 66 REACTIONS)  
L31 215 SEA SSS FUL L5 ( 1481 REACTIONS)  
SAVE TEMP L31 SHI089CHMP/A  
D QUE STAT L14  
L32 0 SEA SUB=L31 SSS SAM L11 ( 0 REACTIONS)  
D QUE STAT  
L33 5 SEA SUB=L31 SSS FUL L11 ( 17 REACTIONS)  
SAVE TEMP L33 SHI089CHMR1/A  
D QUE STAT L21  
L34 0 SEA SUB=L31 SSS SAM L19 ( 0 REACTIONS)  
D QUE STAT  
L35 1 SEA SUB=L31 SSS FUL L19 ( 1 REACTIONS)  
SAVE TEMP L35 SHI089CHMR2/A  
L36 0 SEA ABB=ON PLU=ON L33 AND L35  
SAVE TEMP L36 SHI089CHMR3/A

FILE 'STNGUIDE' ENTERED AT 14:22:16 ON 24 OCT 2006

D SAVED  
D QUE STAT L7  
D QUE STAT L14  
D COST

FILE 'LREGISTRY' ENTERED AT 14:26:15 ON 24 OCT 2006

L37 STR L11

FILE 'REGISTRY' ENTERED AT 14:28:52 ON 24 OCT 2006

L38 50 SEA SUB=L7 SSS SAM L37  
D QUE STAT

FILE 'STNGUIDE' ENTERED AT 14:29:26 ON 24 OCT 2006

FILE 'REGISTRY' ENTERED AT 14:32:10 ON 24 OCT 2006

D QUE STA  
L39 3990 SEA SUB=L7 SSS FUL L37  
SAVE TEMP L39 SHI089RSET5/A  
D QUE L8  
L40 77 SEA ABB=ON PLU=ON L8 AND L39  
D QUE L21  
L41 82 SEA ABB=ON PLU=ON L21 AND L39



L42 82 SEA ABB=ON PLU=ON (L40 OR L41)  
SAVE TEMP L42 SHI089RSET6/A

FILE 'BEILSTEIN' ENTERED AT 14:34:34 ON 24 OCT 2006  
D QUE STAT L39

L43 32 SEA SUB=L23 SSS SAM L37

L44 610 SEA SUB=L23 SSS FUL L37  
SAVE TEMP L44 SHI089BEIR4/A  
D QUE STAT L42  
D QUE L24  
D QUE L25

L45 8 SEA ABB=ON PLU=ON L25 AND L44  
SAVE TEMP L45 SHI089BEIR5/A

L46 0 SEA ABB=ON PLU=ON L45 NOT BABSAN/FA  
SELECT L45 1- BABSAN

FILE 'BABS' ENTERED AT 14:38:27 ON 24 OCT 2006

L47 1 SEA ABB=ON PLU=ON 5632319/AN

L48 1 SEA ABB=ON PLU=ON L47 OR L29  
SAVE TEMP L48 SHI089BAB2/A

FILE 'CHEMINFORMRX' ENTERED AT 14:39:36 ON 24 OCT 2006

D QUE L39

L49 0 SEA SUB=L31 SSS SAM L37 ( 0 REACTIONS)

L50 11 SEA SUB=L31 SSS FUL L37 ( 56 REACTIONS)

SAVE TEMP L50 SHI089CHMR4/A

D QUE L35

L51 0 SEA ABB=ON PLU=ON L35 AND L50  
SAVE TEMP L51 SHI089CHMR5/A

FILE 'STNGUIDE' ENTERED AT 14:41:36 ON 24 OCT 2006

D SAVED

FILE 'BEILSTEIN' ENTERED AT 14:42:22 ON 24 OCT 2006

L52 8 SEA ABB=ON PLU=ON L26 OR L45

FILE 'REGISTRY' ENTERED AT 14:43:14 ON 24 OCT 2006

D QUE L42

L53 82 SEA ABB=ON PLU=ON L42 OR L22 OR L15

L54 ANALYZE PLU=ON L53 1- LC : 7 TERMS  
D 1-

FILE 'HCAPLUS' ENTERED AT 14:45:16 ON 24 OCT 2006

D QUE L53

L55 11 SEA ABB=ON PLU=ON L42 OR L53

FILE 'STNGUIDE' ENTERED AT 14:45:51 ON 24 OCT 2006

FILE 'ZCAPLUS' ENTERED AT 14:45:54 ON 24 OCT 2006

L56 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY<2004  
OR REVIEW/DT

L57 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004

FILE 'HCAPLUS' ENTERED AT 14:46:36 ON 24 OCT 2006

L58 7 SEA ABB=ON PLU=ON L55 AND L56

SAVE TEMP L58 SHI089HCA1B/A

L59 4 SEA ABB=ON PLU=ON L55 NOT L58

SAVE TEMP L59 SHI089HCA1A/A

FILE 'ZCAPLUS' ENTERED AT 14:47:42 ON 24 OCT 2006

L60 QUE ABB=ON PLU=ON NAZARE, M?/AU  
L61 QUE ABB=ON PLU=ON WEHNER, V?/AU  
L62 QUE ABB=ON PLU=ON WILL, D?/AU  
L63 QUE ABB=ON PLU=ON RITTER, K?/AU  
L64 QUE ABB=ON PLU=ON MATTER, H?/AU  
L65 QUE ABB=ON PLU=ON URMANN, M?/AU  
L66 QUE ABB=ON PLU=ON (AVENTIS OR SANOFI)/CS,SO,PA

FILE 'HCAPLUS' ENTERED AT 14:50:16 ON 24 OCT 2006

L67 4 SEA ABB=ON PLU=ON L55 AND (L60 OR L61 OR L62 OR L63 OR L64  
OR L65 OR L66)  
SAVE TEMP L67 SHI089HCAIN1/A

FILE 'STNGUIDE' ENTERED AT 14:50:55 ON 24 OCT 2006

FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 OCT 2006  
L68 25 SEA ABB=ON PLU=ON L4 NOT L53  
D SCAN

FILE 'STNGUIDE' ENTERED AT 14:51:24 ON 24 OCT 2006

FILE 'TOXCENTER, USPATFULL, USPAT2, CASREACT, CHEMCATS' ENTERED AT  
14:53:12 ON 24 OCT 2006

L69 24 SEA ABB=ON PLU=ON L42 OR L53  
L70 9 SEA ABB=ON PLU=ON L69 AND L56  
SAVE TEMP L70 SHI089MULS1B/A  
L71 15 SEA ABB=ON PLU=ON L69 NOT L70  
SAVE TEMP L71 SHI089MULS1A/A

FILE 'STNGUIDE' ENTERED AT 14:55:24 ON 24 OCT 2006  
D SAVED

FILE 'REGISTRY' ENTERED AT 14:56:20 ON 24 OCT 2006  
L72 9 SEA ABB=ON PLU=ON L53 AND L4  
D SCAN

FILE 'STNGUIDE' ENTERED AT 14:57:13 ON 24 OCT 2006

D QUE STAT L7  
D QUE STAT L14  
D QUE STAT L8  
D QUE STAT L15  
D QUE STAT L21  
D QUE STAT L22  
D QUE STAT L39  
D QUE STAT L42  
D QUE STAT L53  
D QUE NOS L54  
D L54 1-  
D QUE NOS L58  
D QUE NOS L70

FILE 'HCAPLUS, TOXCENTER, USPATFULL, USPAT2, CASREACT' ENTERED AT  
15:34:25 ON 24 OCT 2006

L73 12 DUP REM L58 L70 (4 DUPLICATES REMOVED)  
ANSWERS '1-7' FROM FILE HCAPLUS  
ANSWERS '8-12' FROM FILE USPATFULL

FILE 'STNGUIDE' ENTERED AT 15:34:29 ON 24 OCT 2006

FILE 'HCAPLUS, USPATFULL' ENTERED AT 15:34:38 ON 24 OCT 2006

D IBIB ED AB HITSTR

FILE 'STNGUIDE' ENTERED AT 15:34:39 ON 24 OCT 2006

FILE 'HCAPLUS, USPATFULL' ENTERED AT 15:35:01 ON 24 OCT 2006  
D IBIB ED AB HITSTR 2-7

FILE 'STNGUIDE' ENTERED AT 15:35:03 ON 24 OCT 2006

FILE 'HCAPLUS, USPATFULL' ENTERED AT 15:35:29 ON 24 OCT 2006  
D IBIB AB HITSTR 8-12

FILE 'STNGUIDE' ENTERED AT 15:35:31 ON 24 OCT 2006  
D QUE NOS L59  
D QUE NOS L71

FILE 'HCAPLUS, TOXCENTER, CASREACT, CHEMCATS' ENTERED AT 15:36:07 ON 24 OCT 2006

L74 16 DUP REM L59 L71 (3 DUPLICATES REMOVED)  
ANSWERS '1-4' FROM FILE HCAPLUS  
ANSWERS '5-16' FROM FILE CHEMCATS

FILE 'STNGUIDE' ENTERED AT 15:36:12 ON 24 OCT 2006

FILE 'HCAPLUS, CHEMCATS' ENTERED AT 15:36:30 ON 24 OCT 2006  
D IBIB ED AB HITSTR 1-4

FILE 'STNGUIDE' ENTERED AT 15:36:33 ON 24 OCT 2006

FILE 'CHEMCATS' ENTERED AT 15:36:45 ON 24 OCT 2006

FILE 'STNGUIDE' ENTERED AT 15:36:57 ON 24 OCT 2006

FILE 'HCAPLUS, CHEMCATS' ENTERED AT 15:37:16 ON 24 OCT 2006  
D IDE 5

FILE 'STNGUIDE' ENTERED AT 15:37:16 ON 24 OCT 2006

FILE 'HCAPLUS, CHEMCATS' ENTERED AT 15:37:31 ON 24 OCT 2006  
D IDE 6-16

FILE 'STNGUIDE' ENTERED AT 15:37:31 ON 24 OCT 2006  
D QUE STAT L23  
D QUE STAT L24  
D QUE STAT L25  
D QUE STAT L26  
D QUE STAT L44  
D QUE STAT L45

L75 FILE 'BEILSTEIN' ENTERED AT 15:38:13 ON 24 OCT 2006  
8 SEA ABB=ON PLU=ON L26 OR L45  
D IDE 1  
D RX 1  
D IDE 2  
D RX 2  
D IDE 3  
D RX 3  
D IDE 4  
D RX 4  
D IDE 5

D RX 5  
D IDE 6  
D RX 6  
D IDE 7  
D RX 7  
D IDE 8  
D RX 8  
D QUE L29  
D QUE L48

FILE 'BABS' ENTERED AT 15:40:44 ON 24 OCT 2006  
D IBIB ED AB L48

FILE 'BEILSTEIN' ENTERED AT 15:40:46 ON 24 OCT 2006

FILE 'STNGUIDE' ENTERED AT 15:40:52 ON 24 OCT 2006

D QUE STAT L31  
D QUE STAT L33  
D QUE STAT L35  
D QUE STAT L36  
D QUE STAT L50  
D QUE STAT L51

FILE 'TOXCENTER, USPATFULL, USPAT2, CASREACT, CHEMCATS' ENTERED AT  
15:43:34 ON 24 OCT 2006

L76                   D QUE L70  
                  5 SEA ABB=ON PLU=ON L53 AND (L60 OR L61 OR L62 OR L63 OR L64  
                  OR L65 OR L66)  
                  SAVE TEMP L76 SHI089MULSIN/A

FILE 'STNGUIDE' ENTERED AT 15:44:35 ON 24 OCT 2006  
D SAVED

FILE 'REGISTRY' ENTERED AT 15:49:35 ON 24 OCT 2006  
D QUE L53  
SAVE TEMP L53 SHI089REGFIN/A

FILE 'STNGUIDE' ENTERED AT 15:50:10 ON 24 OCT 2006  
D SAVED

FILE HOME

FILE ZCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 24 Oct 2006 VOL 145 ISS 18  
FILE LAST UPDATED: 23 Oct 2006 (20061023/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

#### FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Oct 2006 VOL 145 ISS 18  
FILE LAST UPDATED: 23 Oct 2006 (20061023/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

#### FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Oct 20, 2006 (20061020/UP).

#### FILE WPIX

FILE LAST UPDATED: 23 OCT 2006 <20061023/UP>  
MOST RECENT THOMSON SCIENTIFIC UPDATE: 200668 <200668/DW>  
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX  
PLEASE VISIT:

[http://www.stn-international.de/stndatabases/details/dwpi\\_r.html](http://www.stn-international.de/stndatabases/details/dwpi_r.html) <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:

[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf)

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE

[http://www.stn-international.de/stndatabases/details/ipc\\_reform.html](http://www.stn-international.de/stndatabases/details/ipc_reform.html) and

<http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf>

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX  
PLEASE SEE

[http://www.stn-international.de/stndatabases/details/dwpi\\_r.html](http://www.stn-international.de/stndatabases/details/dwpi_r.html) <<<

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

A preliminary version of the Database Summary Sheet is available at:

<http://www.stn-international.de/stndatabases/details/wpi.pdf>

## FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 OCT 2006 HIGHEST RN 911100-17-9

DICTIONARY FILE UPDATES: 23 OCT 2006 HIGHEST RN 911100-17-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

## FILE LREGISTRY

LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

## FILE BEILSTEIN

FILE LAST UPDATED ON JUNE 16, 2006

FILE COVERS 1771 TO 2006.

**FILE CONTAINS 9,606,495 SUBSTANCES**

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

\*\*\*\*\*  
\* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. \*  
\* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE \*  
\* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE \*  
\* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. \*  
\* FOR PRICE INFORMATION SEE HELP COST \*  
\*\*\*\*\*

## NEW

\* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.  
\* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

## FILE BABS

FILE LAST UPDATED: 25 SEP 2006 <20060925/UP>  
FILE COVERS 1980 TO DATE.

## FILE CHEMINFORMRX

FILE LAST UPDATED: 19 SEP 2006 <20060919/UP>

>>> CAS Registry Numbers are available for  
substances prior to 1995 <<<

## FILE TOXCENTER

FILE COVERS 1907 TO 24 Oct 2006 (20061024/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The MEDLINE file segment has been updated with 2006 MEDLINE data and features. See HELP RLOAD for details.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

See <http://www.nlm.nih.gov/mesh/>

[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_med\\_data\\_changes.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html)

[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_2006\\_MeSH.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html)

for a description of changes.

## FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 Oct 2006 (20061024/PD)

FILE LAST UPDATED: 24 Oct 2006 (20061024/ED)

HIGHEST GRANTED PATENT NUMBER: US7127745

HIGHEST APPLICATION PUBLICATION NUMBER: US2006236437

CA INDEXING IS CURRENT THROUGH 24 Oct 2006 (20061024/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Oct 2006 (20061024/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2006

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2006

## FILE USPAT2

FILE COVERS 2001 TO PUBLICATION DATE: 24 Oct 2006 (20061024/PD)

FILE LAST UPDATED: 24 Oct 2006 (20061024/ED)

HIGHEST GRANTED PATENT NUMBER: US2006139723

HIGHEST APPLICATION PUBLICATION NUMBER: US2006236276

CA INDEXING IS CURRENT THROUGH 24 Oct 2006 (20061024/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Oct 2006 (20061024/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2006

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2006

## FILE CASREACT

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 22 Oct 2006 VOL 145 ISS 17

New CAS Information Use Policies, enter HELP USAGETERMS for details.

\*\*\*\*\*  
\*  
\* CASREACT now has more than 10 million reactions \*  
\*  
\*\*\*\*\*

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE CHEMCATS

FILE LAST UPDATED 21 OCTOBER 2006 (20061021/UP)


For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow prompt. For the list of suppliers currently in the file, enter HELP SPA, HELP SPBC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPQZ. For the list of current catalogs, enter HELP CTA, HELP CTBC, HELP CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis. Please consult the suppliers for current information regarding pricing, regional availability, available quantities, purities, etc. THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not liable for any loss of profit, goodwill or any other damages arising out of the use of this database.

CHEMCATS now contains more than 10 million records. See HELP CONTENT and NEWS FILE for details.



=> => d que stat 12  
L1 STR



VAR G1=C/N  
VAR G2=C/N  
VAR G3=C/N  
VAR G4=C/N  
NODE ATTRIBUTES:  
NSPEC IS RC AT 10  
NSPEC IS RC AT 11  
CONNECT IS E1 RC AT 12  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE  
L2 45329 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 758487 ITERATIONS  
SEARCH TIME: 00.00.04

45329 ANSWERS

=> d que stat 134  
L1 STR



VAR G1=C/N  
VAR G2=C/N  
VAR G3=C/N  
VAR G4=C/N  
NODE ATTRIBUTES:  
NSPEC IS RC AT 10  
NSPEC IS RC AT 11  
CONNECT IS E1 RC AT 12  
DEFAULT MLEVEL IS ATOM


DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L2 45329 SEA FILE=REGISTRY SSS FUL L1  
L32 STR



Cy @14

C~Cy  
@15 16

N~Cy  
@17 18

S~Cy  
@19 20

O~Cy  
@21 22

VAR G1=C/N  
VAR G2=C/N  
VAR G3=C/N  
VAR G4=C/N  
VAR G5=14/15/17/19/21

NODE ATTRIBUTES:

NSPEC IS RC AT 10  
NSPEC IS RC AT 11  
NSPEC IS RC AT 15  
NSPEC IS RC AT 17  
NSPEC IS RC AT 19  
NSPEC IS RC AT 21  
CONNECT IS E1 RC AT 12  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 22


STEREO ATTRIBUTES: NONE

L34 4740 SEA FILE=REGISTRY SUB=L2 SSS FUL L32

100.0% PROCESSED 45329 ITERATIONS  
SEARCH TIME: 00.00.02

4740 ANSWERS

=> d que stat 145  
L1 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L2 45329 SEA FILE=REGISTRY SSS FUL L1

L42 STR



VAR G1=12/21/30/39

NODE ATTRIBUTES:

NSPEC IS RC AT 1

NSPEC IS RC AT 2

CONNECT IS E1 RC AT 3

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE


L45 1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42

100.0% PROCESSED 8121 ITERATIONS  
SEARCH TIME: 00.00.01

1247 ANSWERS

=> d que stat 146

L1 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L2 45329 SEA FILE=REGISTRY SSS FUL L1

L32 STR



Cy @14

C~Cy  
@15 16

N~Cy  
@17 18


S~Cy  
@19 20

O~Cy  
@21 22

VAR G1=C/N  
VAR G2=C/N  
VAR G3=C/N  
VAR G4=C/N  
VAR G5=14/15/17/19/21  
NODE ATTRIBUTES:  
NSPEC IS RC AT 10  
NSPEC IS RC AT 11  
NSPEC IS RC AT 15  
NSPEC IS RC AT 17  
NSPEC IS RC AT 19  
NSPEC IS RC AT 21  
CONNECT IS E1 RC AT 12  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE  
L34 4740 SEA FILE=REGISTRY SUB=L2 SSS FUL L32  
L42 STR



VAR G1=12/21/30/39  
NODE ATTRIBUTES:  
NSPEC IS RC AT 1  
NSPEC IS RC AT 2  
CONNECT IS E1 RC AT 3  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE  
L45 1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42  
L46 93 SEA FILE=REGISTRY ABB=ON PLU=ON L34 AND L45

=> d que nos 147

```

L1          STR
L2          45329 SEA FILE=REGISTRY SSS FUL L1
L32         STR
L34         4740 SEA FILE=REGISTRY SUB=L2 SSS FUL L32
L42         STR
L45         1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42
L46         93  SEA FILE=REGISTRY ABB=ON  PLU=ON  L34 AND L45
L47         ANALYZE  PLU=ON  L46 1- LC :          7 TERMS

```

=> d 147 1-

```

L47          ANALYZE L46 1- LC :          7 TERMS

```

TERM #	# OCC	# DOC	% DOC	LC
1	87	87	93.55	CA
2	87	87	93.55	CAPLUS
3	42	42	45.16	CASREACT
4	35	35	37.63	USPATFULL
5	33	33	35.48	TOXCENTER
6	5	5	5.38	USPAT2
7	4	4	4.30	CHEMCATS

\*\*\*\*\* END OF L47\*\*\*

=> d que nos 151

```

L1          STR
L2          45329 SEA FILE=REGISTRY SSS FUL L1
L32         STR
L34         4740 SEA FILE=REGISTRY SUB=L2 SSS FUL L32
L42         STR
L45         1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42
L46         93  SEA FILE=REGISTRY ABB=ON  PLU=ON  L34 AND L45
L48         13  SEA FILE=HCAPLUS ABB=ON  PLU=ON  L46
L49         QUE  ABB=ON  PLU=ON  AY<2004 OR PY<2004 OR PRY<2004 OR MY
              <2004 OR REVIEW/DT
L51         7  SEA FILE=HCAPLUS ABB=ON  PLU=ON  L48 AND L49

```

=> d his 183

(FILE 'USPATFULL, USPAT2, TOXCENTER, CASREACT, CHEMCATS' ENTERED AT  
13:14:58 ON 25 OCT 2006)

```

L83          11 S L82 AND L49

```

=> d que nos 183

```


L1          STR
L2          45329 SEA FILE=REGISTRY SSS FUL L1
L32         STR
L34         4740 SEA FILE=REGISTRY SUB=L2 SSS FUL L32
L42         STR
L45         1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42
L46         93  SEA FILE=REGISTRY ABB=ON  PLU=ON  L34 AND L45
L49         QUE  ABB=ON  PLU=ON  AY<2004 OR PY<2004 OR PRY<2004 OR MY
              <2004 OR REVIEW/DT
L82         27 SEA L46
L83         11 SEA L82 AND L49

```

=> d que stat 114

L13

STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L14 8608 SEA FILE=BEILSTEIN SSS FUL L13

100.0% PROCESSED 121484 ITERATIONS ( 8 INCOMPLETE)


8608 ANSWERS

SEARCH TIME: 00.01.02

=&gt; d que stat 190

L13

STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

## STEREO ATTRIBUTES: NONE

L14 8608 SEA FILE=BEILSTEIN SSS FUL L13

L32 STR



Cy @14

C~Cy  
@15 16N~Cy  
@17 18S~Cy  
@19 20O~Cy  
@21 22

VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

VAR G5=14/15/17/19/21

## NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

NSPEC IS RC AT 15

NSPEC IS RC AT 17

NSPEC IS RC AT 19

NSPEC IS RC AT 21

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 22

## STEREO ATTRIBUTES: NONE

L90 698 SEA FILE=BEILSTEIN SUB=L14 SSS FUL L32

100.0% PROCESSED 8608 ITERATIONS ( 8 INCOMPLETE)


698 ANSWERS

SEARCH TIME: 00.00.08

=&gt; d que stat l91

L13 STR







```

VAR G1=C/N
VAR G2=C/N
VAR G3=C/N
VAR G4=C/N
NODE ATTRIBUTES:
NSPEC      IS RC      AT 10
NSPEC      IS RC      AT 11
CONNECT IS E1 RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 12

```
STEREO ATTRIBUTES: NONE
L14      8608 SEA FILE=BEILSTEIN SSS FUL L13
L42      STR
```



```
VAR G1=12/21/30/39
NODE ATTRIBUTES:
NSPEC      IS RC      AT      1
NSPEC      IS RC      AT      2
CONNECT IS E1  RC AT      3
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE

L91 86 SEA FILE=BEILSTEIN SUB=L14 SSS FUL L42


100.0% PROCESSED 1043 ITERATIONS

86 ANSWERS

SEARCH TIME: 00.00.02

=> d que stat 192

L13 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L14 8608 SEA FILE=BEILSTEIN SSS FUL L13

L32 STR



Cy @14

C~Cy  
@15 16

N~Cy  
@17 18

S~Cy  
@19 20


O~Cy  
@21 22

VAR G1=C/N

VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 VAR G5=14/15/17/19/21  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 NSPEC IS RC AT 15  
 NSPEC IS RC AT 17  
 NSPEC IS RC AT 19  
 NSPEC IS RC AT 21  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE  
 L42 STR



VAR G1=12/21/30/39  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 1  
 NSPEC IS RC AT 2  
 CONNECT IS E1 RC AT 3  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE  
 L90 698 SEA FILE=BEILSTEIN SUB=L14 SSS FUL L32  
 L91 86 SEA FILE=BEILSTEIN SUB=L14 SSS FUL L42  
 L92 10 SEA FILE=BEILSTEIN ABB=ON PLU=ON L90 AND L91

=> d his 192-195

(FILE 'BEILSTEIN' ENTERED AT 14:01:05 ON 25 OCT 2006)

SAVE TEMP L91 SHI089BEIRB/A  
L92 10 S L90 AND L91  
SAVE TEMP L92 SHI089BEIRC/A  
L93 10 S L92 NOT L29  
L94 1 S L93 NOT BABSAN/FA  
SELECT L92 1- BABSAN

FILE 'BABS' ENTERED AT 14:08:26 ON 25 OCT 2006


L95 1 S E1

=> d que stat l95

L95 1 SEA FILE=BABS ABB=ON PLU=ON 6410903/BABSAN

=> d que stat l31

L30 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N

NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L31 215 SEA FILE=CHEMINFORMRX SSS FUL L30 ( 1481 REACTIONS)


100.0% DONE 22392 VERIFIED 1481 HIT RXNS

215 DOCS

SEARCH TIME: 00.00.37

=> d que stat l97

L30 STR




VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L31 215 SEA FILE=CHEMINFORMRX SSS FUL L30 ( 1481 REACTIONS)  
 L32 STR



Cy @14

C~Cy  
@15 16

N~Cy  
@17 18

S~Cy  
@19 20

O~Cy  
 @21 22

VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 VAR G5=14/15/17/19/21  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 NSPEC IS RC AT 15  
 NSPEC IS RC AT 17  
 NSPEC IS RC AT 19  
 NSPEC IS RC AT 21


CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE  
 L97 13 SEA FILE=CHEMINFORMRX SUB=L31 SSS FUL L32 ( 73 REACTIONS)

100.0% DONE 1481 VERIFIED 73 HIT RXNS 13 DOCS  
 SEARCH TIME: 00.00.20


=> d que stat l99  
 L30 STR



VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE  
 L31 215 SEA FILE=CHEMINFORMRX SSS FUL L30 ( 1481 REACTIONS)  
 L42 STR



VAR G1=12/21/30/39

NODE ATTRIBUTES:

NSPEC IS RC AT 1  
 NSPEC IS RC AT 2  
 CONNECT IS E1 RC AT 3  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 40


STEREO ATTRIBUTES: NONE

L99 3 SEA FILE=CHEMINFORMRX SUB=L31 SSS FUL L42 ( 16 REACTIONS)

100.0% DONE 170 VERIFIED 16 HIT RXNS 3 DOCS  
 SEARCH TIME: 00.00.02

=> d que stat 1100

L30 STR



VAR G1=C/N

VAR G2=C/N

VAR G3=C/N

VAR G4=C/N


NODE ATTRIBUTES:

NSPEC IS RC AT 10

NSPEC IS RC AT 11  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE  
 L31 215 SEA FILE=CHEMINFORMRX SSS FUL L30 ( 1481 REACTIONS)  
 L32 STR



O~Cy  
 @21 22

VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 VAR G5=14/15/17/19/21


NODE ATTRIBUTES:

NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 NSPEC IS RC AT 15  
 NSPEC IS RC AT 17  
 NSPEC IS RC AT 19  
 NSPEC IS RC AT 21  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE  
 L42 STR





VAR G1=12/21/30/39

NODE ATTRIBUTES:

NSPEC IS RC AT 1  
 NSPEC IS RC AT 2  
 CONNECT IS E1 RC AT 3  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE

L97 13 SEA FILE=CHEMINFORMRX SUB=L31 SSS FUL L32 ( 73 REACTIONS)  
 L99 3 SEA FILE=CHEMINFORMRX SUB=L31 SSS FUL L42 ( 16 REACTIONS)  
 L100 0 SEA FILE=CHEMINFORMRX ABB=ON PLU=ON L97 AND L99

=> d que stat l103

L32 STR



O~Cy  
 @21 22

VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N

```

VAR G4=C/N
VAR G5=14/15/17/19/21
NODE ATTRIBUTES:
NSPEC   IS RC      AT   10
NSPEC   IS RC      AT   11
NSPEC   IS RC      AT   15
NSPEC   IS RC      AT   17
NSPEC   IS RC      AT   19
NSPEC   IS RC      AT   21
CONNECT IS E1  RC AT  12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 22

```

```

STEREO ATTRIBUTES: NONE
L103          347 SEA FILE=WPIX SSS FUL L32

```

```

100.0% PROCESSED    50428 ITERATIONS
SEARCH TIME: 00.00.38


```

347 ANSWERS

```

=> d que stat l105
L32          STR

```



Cy @14

C~Cy  
@15 16N~Cy  
@17 18S~Cy  
@19 20

```

O~Cy
@21 22

```

```

VAR G1=C/N
VAR G2=C/N
VAR G3=C/N
VAR G4=C/N
VAR G5=14/15/17/19/21
NODE ATTRIBUTES:
NSPEC   IS RC      AT   10
NSPEC   IS RC      AT   11
NSPEC   IS RC      AT   15
NSPEC   IS RC      AT   17
NSPEC   IS RC      AT   19
NSPEC   IS RC      AT   21
CONNECT IS E1  RC AT  12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```



## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 22

## STEREO ATTRIBUTES: NONE

L42 STR



VAR G1=12/21/30/39

## NODE ATTRIBUTES:

NSPEC IS RC AT 1

NSPEC IS RC AT 2

CONNECT IS E1 RC AT 3

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 40

## STEREO ATTRIBUTES: NONE

L103 347 SEA FILE=WPIX SSS FUL L32

L105 49 SEA FILE=WPIX SUB=L103 SSS FUL L42

100.0% PROCESSED 55 ITERATIONS

49 ANSWERS

SEARCH TIME: 00.00.01

=&gt; d his l105-l114

(FILE 'WPIX' ENTERED AT 14:27:58 ON 25 OCT 2006)

```

L105      49 S L42 SSS FUL SUB=L103
          SAVE TEMP L105 SHI089WPIS2/A
          SELECT L103 SDCN 1-
L106      72 S E2-E348/DCN
L107      72 S L103/DCR
L108      10 S L106-L107 AND L101
          SELECT L105 1- SDCN
L109      5 S E349-E397/DCN
L110      5 S L105/DCR
L111      10 S L108-L110
L112      14 S (L111 OR L106 OR L107) AND L69-L75

```

```

L113      3 S L112 AND L111
           SAVE TEMP L113 SHI089WPIINV/A
L114      8 S L111 AND L50

=> d que nos l114
L32       STR
L42       STR
L50       QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004
L101      QUE ABB=ON PLU=ON D720/M0,M1,M2,M3,M4,M5,M6
L103      347 SEA FILE=WPIX SSS FUL L32
L105      49 SEA FILE=WPIX SUB=L103 SSS FUL L42
L106      72 SEA FILE=WPIX ABB=ON PLU=ON (RA0XZP/DCN OR RAAHRA/DCN OR
           RAAHRY/DCN OR RAAZSD/DCN OR RAAZSF/DCN OR RAAZSH/DCN OR
           RAAZSI/DCN OR RAAZSJ/DCN OR RAAZSK/DCN OR RAAZSL/DCN OR
           RAAZSM/DCN OR RAAZSN/DCN OR RAAZSO/DCN OR RAAZSX/DCN OR
           RAA1TM/DCN OR RAB2D0/DCN OR RACKXP/DCN OR RAETE4/DCN OR
           RAE3EB/DCN OR RAE3EC/DCN OR RAE3ED/DCN OR RAE3EE/DCN OR
           RAE3EF/DCN OR RAE3EG/DCN OR RAE3EK/DCN OR RAE3EL/DCN OR
           RAE3EM/DCN OR RAE3EN/DCN OR RAE3EQ/DCN OR RAE3EU/DCN OR
           RAE3EV/DCN OR RAE3EW/DCN OR RAE3EX/DCN OR RAE3F2/DCN OR
           RAFI3X/DCN OR RAFI3Y/DCN OR RAFI41/DCN OR RAFZM3/DCN OR
           RAFZM4/DCN OR RAFZM6/DCN OR RAF8IU/DCN OR RAF8IV/DCN OR
           RAF8IW/DCN OR RAF8IX/DCN OR RAGFDN/DCN OR RAGFDO/DCN OR
           RAGFDP/DCN OR RAGFDQ/DCN OR RAGFDS/DCN OR RAGFDT/DCN OR
           RAGFDU/DCN OR RAGFDV/DCN OR RAGFDW/DCN OR RAGFDX/DCN OR
           RAGFDY/DCN OR RAGFDZ/DCN OR RAGFEB/DCN OR RAGFEC/DCN OR
           RAGFED/DCN OR RAGFEG/DCN OR RAGFEH/DCN OR RAGFEI/DCN OR
           RAGFEJ/DCN OR RAGFEM/DCN OR RAGFEN/DCN OR RAGFEO/DCN OR
           RAGFEP/DCN OR RAGFEQ/DCN OR RAGFE0/DCN OR RAGFE1/DCN OR
           RAGFE2/DCN OR RAGFE3/DCN OR RAGFE4/DCN OR RAGFE5/DCN OR
           RAGFE6/DCN OR RAGFE7/DCN OR RAGFE8/DCN OR RAGFE9/DCN OR
           RAGFFQ/DCN OR RAGFFR/DCN OR RAGFFS/DCN OR RAGFFT/DCN OR
           RAGFFU/DCN OR RAGSRH/DCN OR RAGSRO/DCN OR RAGSRP/DCN OR
           RAGSRQ/DCN OR RAGSRR/DCN OR RAG3GM/DCN OR RAG3GN/DCN OR
           RAG6CZ/DCN OR RAG6DA/DCN OR RAG6DD/DCN OR RAG6DF/DCN OR
           RAG6DI/DCN OR RAG6D2/DCN OR RAG6D3/DCN OR RAG6D5/DCN OR
           RAG6D6/DCN OR RAG6D8/DCN OR RAG7BA/DCN OR RAG7BB/DCN OR
           RAG7BC/DCN OR RAG7BI/DCN OR RAG7BK/DCN OR RAG7BM/DCN OR
           RAHI2S/DCN OR RAHI2U/DCN OR RAHI2V/DCN OR RAHOVW/DCN OR
           RAI01E/DCN OR RAI019/DCN OR RAKGLI/DCN OR RAKGLK/DCN OR
           RAKGLP/DCN OR RAKGLW/DCN OR RAKGLX/DCN OR RAKGLY/DCN OR
           RAKGLZ/DCN OR RAKGM0/DCN OR RAKNAV/DCN OR RAKW9U/DCN OR
           RALDFO/DCN OR RALDFP/DCN OR RALDFQ/DCN OR RALDFR/DCN OR
           RALDFS/DCN OR RALDFT/DCN OR RALDFU/DCN OR RALDFV/DCN OR
           RALDFW/DCN OR RALDFX/DCN OR RALDFY/DCN OR RALDFZ/DCN OR
           RALDG0/DCN OR RALDG1/DCN OR RALDG2/DCN OR RALDG3/DCN OR
           RALDG4/DCN OR RALDG5/DCN OR RALHNR/DCN OR RALHO3/DCN OR RAL
L107      72 SEA FILE=WPIX ABB=ON PLU=ON L103/DCR
L108      10 SEA FILE=WPIX ABB=ON PLU=ON (L106 OR L107) AND L101
L109      5 SEA FILE=WPIX ABB=ON PLU=ON (RAE3EB/DCN OR RAE3EC/DCN OR
           RAE3ED/DCN OR RAE3EE/DCN OR RAE3EF/DCN OR RAE3EG/DCN OR
           RAE3EK/DCN OR RAE3EL/DCN OR RAE3EM/DCN OR RAE3EN/DCN OR
           RAE3EQ/DCN OR RAE3EU/DCN OR RAE3EV/DCN OR RAE3EW/DCN OR
           RAE3EX/DCN OR RAE3F2/DCN OR RAG7BA/DCN OR RAG7BB/DCN OR
           RAG7BC/DCN OR RAG7BI/DCN OR RAG7BK/DCN OR RAG7BM/DCN OR
           RALDFO/DCN OR RALDFP/DCN OR RALDFQ/DCN OR RALDFR/DCN OR
           RALDFS/DCN OR RALDFT/DCN OR RALDFU/DCN OR RALDFV/DCN OR
           RALDFW/DCN OR RALDFX/DCN OR RALDFY/DCN OR RALDFZ/DCN OR
           RALDG0/DCN OR RALDG1/DCN OR RALDG2/DCN OR RALDG3/DCN OR
           RALDG4/DCN OR RALDG5/DCN OR RAMQJD/DCN OR RAMQJF/DCN OR

```

RAMQJT/DCN OR RAMQJV/DCN OR RAMQJX/DCN OR RA211B/DCN OR  
RA2117/DCN OR RA2118/DCN OR RA2119/DCN)


L110 5 SEA FILE=WPIX ABB=ON PLU=ON L105/DCR  
L111 10 SEA FILE=WPIX ABB=ON PLU=ON (L108 OR L109 OR L110)  
L114 8 SEA FILE=WPIX ABB=ON PLU=ON L111 AND L50

=&gt; d l94 ide

YOU HAVE REQUESTED DATA FROM FILE 'BEILSTEIN' - CONTINUE? (Y)/N:y

L94 ANSWER 1 OF 1 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN): 9636957  
 Chemical Name (CN): 9-benzyl-2,9-dihydro-2,4,6,9-tetraaza-  
 fluoren-1-one  
 Autonom Name (AUN): 9-benzyl-2,9-dihydro-2,4,6,9-tetraaza-  
 fluoren-1-one  
 Molec. Formula (MF): C16 H12 N4 O  
 Molecular Weight (MW): 276.30  
 Lawson Number (LN): 30496, 14140  
 Compound Type (CTYPE): heterocyclic  
 Constitution ID (CONSID): 8123090  
 Tautomer ID (TAUTID): 9032336  
 Entry Date (DED): 2004/07/21  
 Update Date (DUPD): 2004/07/21



## Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
DED	Entry Date	1
DUPD	Update Date	1

=> dup rem l51 l83 l95 l114

DUPLICATE IS NOT AVAILABLE IN 'CHEMCATS'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

FILE 'HCAPLUS' ENTERED AT 16:21:26 ON 25 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:21:26 ON 25 OCT 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:21:26 ON 25 OCT 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 16:21:26 ON 25 OCT 2006

COPYRIGHT (C) 2006 ACS

FILE 'CASREACT' ENTERED AT 16:21:26 ON 25 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BABS' ENTERED AT 16:21:26 ON 25 OCT 2006

COPYRIGHT (c) 2006 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'WPIX' ENTERED AT 16:21:26 ON 25 OCT 2006

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

PROCESSING COMPLETED FOR L51

PROCESSING COMPLETED FOR L83

PROCESSING COMPLETED FOR L95

PROCESSING COMPLETED FOR L114

L161 17 DUP REM L51 L83 L95 L114 (10 DUPLICATES REMOVED)

ANSWERS '1-7' FROM FILE HCAPLUS

ANSWERS '8-13' FROM FILE USPATFULL

ANSWERS '14-17' FROM FILE WPIX

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 16:21:34 ON 25 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Oct 25, 2006 (20061025/UP).

=&gt; d ibib ed ab hitstr

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, WPIX' - CONTINUE? (Y)/N:y

L161 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1  
 ACCESSION NUMBER: 2004:308438 HCAPLUS  
 DOCUMENT NUMBER: 140:321242  
 TITLE: Preparation of pyrrolo[3,2-b]pyridines as p38 kinase inhibitors  
 INVENTOR(S): Brookings, Daniel Christopher; Cubbon, Rachel Jane; Davis, Jeremy Martin; Langham, Barry John  
 PATENT ASSIGNEE(S): Celltech R & D Limited, UK  
 SOURCE: PCT Int. Appl., 81 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031188	A1	20040415	WO 2003-GB4214	20030930 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500844	AA	20040415	CA 2003-2500844	20030930 <--
AU 2003271870	A1	20040423	AU 2003-271870	20030930 <--
EP 1549648	A1	20050706	EP 2003-753708	20030930 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006504712	T2	20060209	JP 2004-540940	20030930 <--
US 2006122212	A1	20060608	US 2005-529413	20050623 <--
PRIORITY APPLN. INFO.:			GB 2002-22743	A 20021001 <--
			WO 2003-GB4214	W 20030930 <--

OTHER SOURCE(S): MARPAT 140:321242

ED Entered STN: 15 Apr 2004

AB Title compds. I [A = (un)substituted N, C; Ra = H, halo, etc.; X, Y = N or (un)substituted C; L = C(O), C(S), (un)substituted C; n = 0-1; Alk1 = (unsubstituted) (hetero)aliphatic chain; L1 = bond, linker atom/group; Cyl = (un)substituted cycloaliph., etc.; Ar = (hetero)aromatic, etc. with specific exceptions] are prepared For instance, 1-Benzenesulfonyl-4-phenyl-1,4-dihydro-5H-pyrrolo[3,2-b]pyridin-5-one (preparation given) is treated with NaOH (2M, 2 h) and the resulting product alkylated with benzyl chloride (THF, NaH) to give II. Example compds. have IC50 values of around 2 pM and below for p38 kinase and are useful for the treatment of immune or inflammatory disorders.

IT 677303-55-8P, 1-(3-Chloro-4-fluorobenzyl)-N-methoxy-N-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
 677303-57-0P, N-Methoxy-N-methyl-1-(3-methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-59-2P  
 , 1-(3-Chlorobenzyl)-N-methoxy-N-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-60-5P,




1-(3-Chloro-4-fluorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-62-7P**, 1-(3-Methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-64-9P**, 1-(3-Chlorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-68-3P**, 1-(3-Chlorobenzyl)-N,N-dimethyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-69-4P**, 1-(3-Chlorobenzyl)-N-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-70-7P**, 1-(3-Chlorobenzyl)-4-phenyl-2-[(pyrrolidin-1-yl)carbonyl]-1,4-dihydro-5H-pyrrolo[3,2-b]pyridin-5-one **677303-71-8P** **677303-77-4P**, 1-(3-Chlorobenzyl)-4-(1H-indol-5-yl)-5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-83-2P**, 1-(2-Cyanobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-85-4P**, 1-(4-Fluoro-3-methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-86-5P**, 1-(3-Chlorobenzyl)-4-(4-methylphenyl)-5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **677303-87-6P** **677303-96-7P**, (S)-2-[[2-(Hydroxymethyl)pyrrolidin-1-yl]carbonyl]-1-(3-methylbenzyl)-4-phenyl-1,4-dihydro-5H-pyrrolo[3,2-b]pyridin-5-one  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(bicyclic heteroarom. compds. as kinase inhibitors)


RN 677303-55-8 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chloro-4-fluorophenyl)methyl]-4,5-dihydro-N-methoxy-N-methyl-5-oxo-4-phenyl- (9CI)  
 (CA INDEX NAME)




RN 677303-57-0 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 4,5-dihydro-N-methoxy-N-methyl-1-[(3-methylphenyl)methyl]-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-59-2 HCAPLUS


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-N-methoxy-N-methyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-60-5 HCAPLUS  
 CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chloro-4-fluorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-62-7 HCAPLUS  
 CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 4,5-dihydro-1-[(3-methylphenyl)methyl]-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)



RN 677303-64-9 HCAPLUS  
 CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-68-3 HCAPLUS  
 CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-N,N-dimethyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)





RN 677303-69-4 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-N-methyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-70-7 HCAPLUS

CN Pyrrolidine, 1-[[1-[(3-chlorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 677303-71-8 HCAPLUS


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl-, hydrazide (9CI) (CA INDEX NAME)



RN 677303-77-4 HCAPLUS


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-

dihydro-4-(1H-indol-5-yl)-5-oxo- (9CI) (CA INDEX NAME)




RN 677303-83-2 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(2-cyanophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-85-4 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(4-fluoro-3-methylphenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-86-5 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-4-(4-methylphenyl)-5-oxo- (9CI) (CA INDEX NAME)




RN 677303-87-6 HCAPLUS  
 CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-4-(4-methylphenyl)-5-oxo-, hydrazide (9CI) (CA INDEX NAME)



RN 677303-96-7 HCAPLUS  
 CN 2-Pyrrolidinemethanol, 1-[[4,5-dihydro-1-[(3-methylphenyl)methyl]-5-oxo-4-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib ed ab hitstr 2-7

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, WPIX' - CONTINUE? (Y)/N:y

L161 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2  
 ACCESSION NUMBER: 2004:1011968 HCAPLUS  
 DOCUMENT NUMBER: 142:6514  
 TITLE: Preparation of thienylisoxazolylmethylazaindoles as  
 factor Xa and/or factor VIIa inhibitors  
 INVENTOR(S): Nazare, Marc; Wehner, Volkmar; Will, David William;  
 Ritter, Kurt; Urmann, Matthias; Matter, Hans  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
 SOURCE: Eur. Pat. Appl., 82 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1479680	A1	20041124	EP 2003-11304	20030519 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004238500	A1	20041125	AU 2004-238500	20040505 <--
CA 2526084	AA	20041125	CA 2004-2526084	20040505 <--
WO 2004101563	A1	20041125	WO 2004-EP4754	20040505 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1636226	A1	20060322	EP 2004-731161	20040505 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010429	A	20060606	BR 2004-10429	20040505 <--
CN 1791601	A	20060621	CN 2004-80013936	20040505 <--
US 2005009828	A1	20050113	US 2004-849089	20040519 <--
NO 2005005911	A	20060210	NO 2005-5911	20051213 <--
PRIORITY APPLN. INFO.:				
			EP 2003-11304	A 20030519 <--
			US 2003-507141P	P 20030930 <--
			WO 2004-EP4754	W 20040505 <--

OTHER SOURCE(S): CASREACT 142:6514; MARPAT 142:6514

ED Entered STN: 24 Nov 2004

AB Title compds. [I; R = (substituted) mono- or bicyclic aryl, heterocyclyl;  
 R1 = H, (substituted) alkyl, aminocarbonylalkyl, mono- or bicyclic aryl,  
 heterocyclyl, etc.; R2 = bond, alkylene; R3 = H, halo, NO2, cyano,  
 perfluoroalkyl, (substituted) alkyl, Ph, etc.; R1R3 = atoms to form a  
 (substituted) 6-8 membered ring containing 1-4 heteroatoms; R1NR2V = atoms to  
 form a (substituted) 4-7 membered ring containing 1-4 heteroatoms; V =  
 (substituted) 3-7 membered heterocyclyl, 6-14 membered aryl, 4-15 membered  
 heterocyclyl; G = (CH2)m, (CH2)mO(CH2)n, CH2SO2(CH2)n,  
 (CH2)mNR10SO2NR10(CH2)n, (CH2)mCH(OH)(CH2)n, etc.; M = H, (substituted)  
 alkyl, 6-14 membered aryl, 4-15 membered heterocyclyl, cycloalkyl, etc.;  
 m, n = 0-6; R10 = H, alkyl, hydroxyalkyl, alkoxyalkyl, perfluoroalkyl; D =

atoms to form a (substituted) (aromatic) 4-8 membered ring containing 0-4 heteroatoms], were prepared Thus, 1-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (preparation given), N-ethylmorpholine, and TOTU were stirred together for 20 min. in DMF; 1-isopropylpiperidin-4-ylamine dihydrochloride was added followed by stirring for 4 h to give 1-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (1-isopropylpiperidin-4-yl)amide. This inhibited factor Xa with  $K_i = 0.006 \mu\text{M}$ .

IT 797060-39-0P 797060-40-3P 797060-41-4P

797060-42-5P 797060-43-6P 797060-44-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of thienylisoxazolylmethylazaindoles as factor

Xa and/or factor VIIa inhibitors)


RN 797060-39-0 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 797060-40-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 797060-41-4 HCAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidinyll amino]carbonyl]-(9CI) (CA INDEX NAME)



RN 797060-42-5 HCAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-2,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N2-[1-(1-methylethyl)-4-piperidinyll]-(9CI) (CA INDEX NAME)






RN 797060-43-6 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 797060-44-7 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



IT 797060-45-8P 797060-46-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thienylisoxazolylmethylazaindoles as factor Xa and/or factor VIIa inhibitors)


RN 797060-45-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N2-[1-(1-methylethyl)-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797060-42-5


CMF C25 H27 Cl N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 797060-46-9 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797060-44-7


CMF C25 H26 Cl N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 797060-56-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thienylisoxazolylmethylazaindoles as factor Xa and/or factor VIIa inhibitors)


RN 797060-56-1 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797060-55-0


CMF C26 H28 Cl N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L161 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3  
 ACCESSION NUMBER: 2003:448666 HCAPLUS  
 DOCUMENT NUMBER: 139:133446  
 TITLE: Unexpected ring transformation to pyrrolo[3.2-b]pyridine derivatives. Fused azolium salts. 22  
 AUTHOR(S): Riedl, Zsuzsanna; Koeber, Peter; Soos, Tibor; Hajos, Gyoergy; Egyed, Orsolya; Fabian, Laszlo; Messmer, Andras  
 CORPORATE SOURCE: Chemical Research Center, Institute of Chemistry, Hungarian Academy of Sciences, Budapest, H-1525, Hung.  
 SOURCE: Journal of Organic Chemistry (2003), 68(14), 5652-5659  
 CODEN: JOCEAH; ISSN: 0022-3263  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 139:133446  
 ED Entered STN: 12 Jun 2003  
 AB 2-Arylsulfanyl and 2-benzylsulfanylpyridinium N-arylimides, easily prepared from 3-aryltetrazolopyridinium salts, with aryl and benzylthiolates,

resp., reacted with various dipolarophiles yielding cycloadducts that underwent transformation to give tetrahydropyrrolo[3,2-b]pyridines, e.g., I, in good yields. A similar rearrangement was also observed in the case of parent derivs. being unsubstituted in position 2. The absence of any significant solvent effect, comparison of the sulfur and non-sulfur analogs, as well as the stereoselective nature of the observed ring transformation seem to support a sigmatropic mechanism. Structure elucidation of the products has been carried out by single-crystal X-ray diffraction and <sup>1</sup>H NMR expts.

IT 569338-60-9P


RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(crystal structure; unexpected ring transformation of pyrazolo[2,3-a]pyridines to pyrrolo[3,2-b]pyridine derivs. via 1,5-sigmatropic rearrangement)

RN 569338-60-9 HCAPLUS

CN Pyrrolo[3',4':4,5]pyrrolo[3,2-b]pyridine-6,8(4aH,7H)-dione, 5-(4-chlorophenyl)-5,5a,8a,8b-tetrahydro-7-phenyl-2-[(phenylmethyl)thio]-, (4aR,5aS,8aR,8bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 569338-80-3P 569338-82-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(unexpected ring transformation of pyrazolo[2,3-a]pyridines to pyrrolo[3,2-b]pyridine derivs. via 1,5-sigmatropic rearrangement)

RN 569338-80-3 HCAPLUS

CN Pyrrolo[3',4':4,5]pyrrolo[3,2-b]pyridine-6,8(4aH,7H)-dione, 5-(4-chlorophenyl)-2-[(4-chlorophenyl)thio]-5,5a,8a,8b-tetrahydro-7-phenyl-, (4aR,5aS,8aR,8bR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 569338-82-5 HCAPLUS

CN Pyrrolo[3',4':4,5]pyrrolo[3,2-b]pyridine-6,8(4aH,7H)-dione,  
5-(4-chlorophenyl)-5,5a,8a,8b-tetrahydro-2-[(4-methylphenyl)thio]-7-phenyl-  
, (4aR,5aS,8aR,8bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 569338-63-2P 569338-70-1P 569338-83-6P

569338-84-7P 569338-90-5P 569338-91-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(unexpected ring transformation of pyrazolo[2,3-a]pyridines to  
pyrrolo[3.2-b]pyridine derivs. via 1,5-sigmatropic rearrangement)


RN 569338-63-2 HCAPLUS

CN Pyrrolo[3',4':4,5]pyrrolo[3,2-b]pyridine-6,8(5H,7H)-dione,  
5-(4-chlorophenyl)-7-phenyl-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 569338-70-1 HCAPLUS


CN Pyrrolo[3',4':4,5]pyrrolo[3,2-b]pyridine-6,8(5H,7H)-dione,  
5-(4-chlorophenyl)-7-phenyl- (9CI) (CA INDEX NAME)



RN 569338-83-6 HCAPLUS


CN Pyrrolo[3',4':4,5]pyrrolo[3,2-b]pyridine-6,8(4aH,7H)-dione,  
5-(4-fluorophenyl)-5,5a,8a,8b-tetrahydro-2-[(4-methylphenyl)thio]-7-phenyl-  
, (4aR,5aS,8aR,8bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 569338-84-7 HCAPLUS  
 CN Pyrrolo[3',4':4,5]pyrrolo[3,2-b]pyridine-6,8(4aH,7H)-dione,  
 5,5a,8a,8b-tetrahydro-5-[4-(1-methylethyl)phenyl]-2-[(4-methylphenyl)thio]-  
 7-phenyl-, (4aR,5aS,8aR,8bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 569338-90-5 HCAPLUS  
 CN Pyrrolo[3',4':4,5]pyrrolo[3,2-b]pyridine-6,8(5H,7H)-dione,  
 5-(4-chlorophenyl)-2-[(4-chlorophenyl)thio]-7-phenyl- (9CI) (CA INDEX  
 NAME)



RN 569338-91-6 HCAPLUS  
 CN Pyrrolo[3',4':4,5]pyrrolo[3,2-b]pyridine-6,8(5H,7H)-dione,  
 5-(4-chlorophenyl)-2-[(4-methylphenyl)thio]-7-phenyl- (9CI) (CA INDEX  
 NAME)





REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ L161 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 5  
 ACCESSION NUMBER: 2001:661388 HCAPLUS  
 DOCUMENT NUMBER: 135:226878  
 TITLE: Synthesis of N-benzyl-indolyl(benzyloxy)amido derivatives as PDE-IV inhibitors  
 INVENTOR(S): Labelle, Marc; Sturino, Claudio; Lachance, Nicolas; MacDonald, Dwight  
 PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.  
 SOURCE: PCT Int. Appl., 75 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064639	A2	20010907	WO 2001-CA270	20010302 <--
WO 2001064639	A3	20020228		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002068756	A1	20020606	US 2001-797083	20010301 <--
US 6436965	B2	20020820		
CA 2401667	AA	20010907	CA 2001-2401667	20010302 <--
EP 1263728	A2	20021211	EP 2001-913422	20010302 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525273	T2	20030826	JP 2001-563482	20010302 <--
PRIORITY APPLN. INFO.: US 2000-186571P P 20000302 <--				
WO 2001-CA270 W 20010302 <--				
OTHER SOURCE(S): MARPAT 135:226878				
ED Entered STN: 10 Sep 2001				
AB Title compds. I [A, B, D, E = N or CR2 and the others = CR2; q = 0 - 1; p, m = 0 - 2; R1 = H, (hydroxy)alkyl; R2 = H, halo, (halo)alkyl,				


hydroxyalkyl, CN, aromatic or nonarom. ring system containing 1 - 4 heteroatoms selected from O, S, N, alkoxy, oxyamide, etc.; X = cycloalkyl or Ar; Ar = (un)substituted (Ph, thienyl, thiazolyl, pyridyl, oxazolyl, tetrazolyl, pyrimidinyl, pyrazinyl and pyridazinyl)] were prepared Over 150 compds. were disclosed. For instance, Me 2-aminobenzoate was alkylated with 4-fluorobenzyl bromide (K<sub>2</sub>CO<sub>3</sub>, MEK, reflux, 8 h.). The resulting ester was saponified (NaOH, MeOHaq reflux, 2 h.), N-alkylated with Me bromoacetate (K<sub>2</sub>CO<sub>3</sub>, MeOHaq, reflux, 18 h.) and treated with CH<sub>2</sub>N<sub>2</sub> to afford II. Diester II was cyclized (NaOMe, MeOH, reflux, 30 min.), O-alkylated with benzyl bromide (K<sub>2</sub>CO<sub>3</sub>, MEK, reflux, 2 h.), saponified (NaOH, EtOHaq, 90°C, 40 min.) and finally coupled to 3-aminopyridine (SOCl<sub>2</sub>, i-Pr<sub>2</sub>NEt, room temperature, 3 h.) to yield III. I are PDE-IV inhibitors (no data) useful for treating, e.g., inflammation, muscle spasm, chronic bronchitis, etc.

IT 359002-18-9P 359002-19-0P 359002-29-2P  
359002-30-5P 359002-31-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug; synthesis of N-benzyl-indolyl(benzyloxy)amido derivs. as PDE-IV inhibitors)


RN 359002-18-9 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, N-(3,4-difluorophenyl)-3-(phenylmethoxy)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)





RN 359002-19-0 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, N-(6-methoxy-3-pyridinyl)-3-(phenylmethoxy)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 359002-29-2 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[4-(difluoromethoxy)phenyl]methyl]-N-(6-methoxy-3-pyridinyl)-3-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 359002-30-5 HCAPLUS

1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[4-(difluoromethoxy)phenyl]methyl]-3-(4-pyridinylmethoxy)-N-1H-tetrazol-5-yl-(9CI) (CA INDEX NAME)



RN 359002-31-6 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[4-(difluoromethoxy)phenyl]methyl]-N-(2-methoxy-4-pyridinyl)-3-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



L161 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 6  
 ACCESSION NUMBER: 2000:316965 HCAPLUS  
 DOCUMENT NUMBER: 132:334446  
 TITLE: Preparation of amide group-containing indoles and mono- or diazaindoles as cyclooxygenase-2 inhibitors and anti-inflammatory agents  
 INVENTOR(S): Matsuoka, Koji; Takahashi, Tadakatsu; Maruyama, Tensho; Ishizawa, Takenobu; Kato, Yasuharu  
 PATENT ASSIGNEE(S): Chugai Pharmaceutical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000136182	A2	20000516	JP 1998-310209	19981030 <--
PRIORITY APPLN. INFO.:			JP 1998-310209	19981030 <--

OTHER SOURCE(S): MARPAT 132:334446

ED Entered STN: 16 May 2000

AB The compds. I [A1, A2 = CH, N; R = C:QNYZ, CO2R3; R1 = alkyl, amino; R2 = (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; Q = O, S, N:CN; Y, Z = H, (un)substituted alkyl, (un)substituted alkoxy, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted heterocyclyl; YNZ may form (un)substituted ring (having addnl. O, N, and/or S)], their pharmacol. acceptable salts, or their hydrates are prepared Me 1-benzenesulfonyl-5-methylthio-1H-pyrrolo[2,3-b]pyridine-2-carboxylate was oxidized, treated with 4-fluorobenzyl bromide, and amidated with NMeH2 to give I (A1 = CH, A2 = N; R = CONHMe, R1 = Me, R2 4-FC6H4), which inhibited human cyclooxygenase-1 and 2 with IC50 of >20 and 0.4  $\mu$ M, resp.


IT 268212-11-9P 268212-12-0P 268212-13-1P  
 268212-14-2P 268212-15-3P 268212-16-4P  
 268212-17-5P 268212-18-6P 268212-70-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indoles as cyclooxygenase-2 inhibitors and anti-inflammatory agents)


RN 268212-11-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)





RN 268212-12-0 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-ethyl-1-[(4-fluorophenyl)methyl]-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 268212-13-1 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-5-(methylsulfonyl)-N-propyl- (9CI) (CA INDEX NAME)





RN 268212-14-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-N,N-dimethyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 268212-15-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-N-methoxy-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 268212-16-4 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-N-methoxy-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 268212-17-5 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 268212-18-6 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[(4-fluorophenyl)methyl]-5-(methylsulfonyl)-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 268212-70-0 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-(cyclohexylmethyl)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



✓ L161 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 1994:508763 HCAPLUS

DOCUMENT NUMBER: 121:108763

TITLE: Preparation of condensed pyridine derivatives as inhibitors of the biological effects of oxygen free radicals

INVENTOR(S): Bachy, Andre; Fraisse, Laurent; Keane, Peter; Mendes, Etienne; Vernieres, Jean Claude; Simiand, Jacques

PATENT ASSIGNEE(S): Elf Sanofi SA, Fr.

SOURCE: Eur. Pat. Appl., 24 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 587473	A1	19940316	EP 1993-402095	19930825 <--
EP 587473	B1	19981111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
FR 2695126	A1	19940304	FR 1992-10329	19920827 <--
FR 2695126	B1	19941110		
US 5360799	A	19941101	US 1993-109073	19930819 <--
AU 9344747	A1	19940303	AU 1993-44747	19930820 <--
AU 659027	B2	19950504		
AT 173258	E	19981115	AT 1993-402095	19930825 <--
ES 2125315	T3	19990301	ES 1993-402095	19930825 <--
CA 2104883	AA	19940228	CA 1993-2104883	19930826 <--
NO 9303051	A	19940228	NO 1993-3051	19930826 <--
HU 64957	A2	19940328	HU 1993-2425	19930826 <--
HU 217623	B	20000328		
JP 06184145	A2	19940705	JP 1993-211451	19930826 <--
FI 103889	B1	19991015	FI 1993-3756	19930826 <--
US 5468750	A	19951121	US 1994-273943	19940712 <--

FI 9602714 A 19960701 FI 1996-2714 19960701 <--  
 FI 103277 B1 19990531  
 PRIORITY APPLN. INFO.: FR 1992-10329 A 19920827 <--  
 US 1993-109073 A3 19930819 <--  
 FI 1993-3756 A 19930826 <--

OTHER SOURCE(S): MARPAT 121:108763

ED Entered STN: 03 Sep 1994


AB Title compds. [I; R1 = OH, alkyl, alkoxy, Ph, PhCH2, PhCH2O, (substituted) amino, aminoalkyl; R2 = OH, SH, alkoxy, alkylthio, (substituted) amino; R3 = H, alkyl, alkylthio, alkoxy, Ph, PhCH2; A = S, N; R = null, H, (substituted) alkyl; B = (substituted) Ph, pyridyl, or thienyl nucleus], were prepared Thus, aminoacetate II was stirred 10 h with KOCMe3 in PhMe/HOCMe3 to give title compound III. I inhibited the toxic effects of KCN in mice with IC50 = 2-30 mg/kg i.v.

IT 156565-83-2P 156565-99-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as inhibitor of biol. effects of free radicals)


RN 156565-83-2 HCAPLUS

CN 1H-Pyrrolo[3,2-c]quinoline-2-carboxamide, 8-chloro-3-hydroxy-1-(phenylmethyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 156565-99-0 HCAPLUS

CN 1H-Pyrrolo[3,2-c]quinoline-2-carboxamide, 8-(diethylamino)-3-hydroxy-1-(phenylmethyl)-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L161 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1987:439778 HCAPLUS

DOCUMENT NUMBER: 107:39778

TITLE: Pyrrolopyridines

INVENTOR(S): Dormoy, Jean Robert; Heymes, Alain

PATENT ASSIGNEE(S): SANOFI, Fr.



SOURCE: Fr. Demande, 20 pp.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2574406	A1	19860613	FR 1984-19029	19841212 <--
FR 2574406	B1	19870227		
EP 187631	A1	19860716	EP 1985-870178	19851211 <--
EP 187631	B1	19900905		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 56212	E	19900915	AT 1985-870178	19851211 <--
CA 1299183	A1	19920421	CA 1985-497380	19851211 <--
DK 8505768	A	19860613	DK 1985-5768	19851212 <--
JP 61155385	A2	19860715	JP 1985-280176	19851212 <--
US 4831144	A	19890516	US 1988-141508	19880107 <--
PRIORITY APPLN. INFO.:			FR 1984-19029	A 19841212 <--
			US 1985-806544	A2 19851209 <--
			EP 1985-870178	A 19851211 <--

OTHER SOURCE(S): CASREACT 107:39778; MARPAT 107:39778

ED Entered STN: 08 Aug 1987


AB The title compds. [I; R = protecting group; R1 = H, Li, alkyl, CHO, CO2H, alkoxy carbonyl, etc.], useful as intermediates for anthelmintics, are prepared PhSO2Cl was added to a mixture of I (R = R1 = H), NaOH, and Bu4NH4SO4 in CH2Cl2 over for 1 h. The temperature of the reaction mixture rose from 20° to 40°. The resulting mixture was then stirred for 1 h to give 83-85% I (R = PhSO2, R1 = H).

IT 109113-48-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as intermediate for anthelmintics)

RN 109113-48-6 HCAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-2-carboxamide, N,N-diethyl-1-(phenylsulfonyl)-(9CI) (CA INDEX NAME)



=> d ibib ab hitstr 8-13

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, WPIX' - CONTINUE? (Y)/N:y

L161 ANSWER 8 OF 17 USPATFULL on STN

DUPLICATE 4

ACCESSION NUMBER: 2002:133898 USPATFULL

TITLE: PDE IV inhibiting amides, compositions and methods of treatment

INVENTOR(S): Labelle, Marc, St. Lazare, CANADA

Sturino, Claudio, Dorval, CANADA  
 Lachance, Nicolas, Pierrefonds, CANADA  
 Macdonald, Dwight, L'ile Bizard, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002068756	A1	20020606	<--
	US 6436965	B2	20020820	
APPLICATION INFO.:	US 2001-797083	A1	20010301 (9)	<--

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-186571P	20000302 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2355		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Compounds represented by formula I: ##STR1##		

as well as pharmaceutically acceptable salts and hydrates thereof are disclosed as useful for treating or preventing diseases and conditions mediated by PDE-IV.

Pharmaceutical compositions and methods of treatment are also included.


IT 359002-18-9P 359002-19-0P 359002-29-2P

359002-30-5P 359002-31-6P

(drug; synthesis of N-benzyl-indolyl(benzyloxy)amido derivs. as PDE-IV inhibitors)


RN 359002-18-9 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, N-(3,4-difluorophenyl)-3-(phenylmethoxy)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)





RN 359002-19-0 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, N-(6-methoxy-3-pyridinyl)-3-(phenylmethoxy)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 359002-29-2 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[4-(difluoromethoxy)phenyl]methyl]-N-(6-methoxy-3-pyridinyl)-3-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 359002-30-5 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[4-(difluoromethoxy)phenyl]methyl]-3-(4-pyridinylmethoxy)-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)



RN 359002-31-6 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[4-(difluoromethoxy)phenyl]methyl]-N-(2-methoxy-4-pyridinyl)-3-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



L161 ANSWER 9 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2006:144693 USPATFULL

TITLE: Bicyclic heteroaromatic compounds as kinase inhibitors

INVENTOR(S): Brookings, Daniel Christopher, c/o Celltech R&amp;D Limited, 208 Bath Road, Slough, Berkshire, UNITED KINGDOM S11 3WE

Cubbon, Rachel Jane, Slough Berkshire, UNITED KINGDOM

Davis, Jeremy Martin, Wokingham Berkshire, UNITED KINGDOM

PATENT ASSIGNEE(S): Langham, Barry John, Reading Berkshire, UNITED KINGDOM  
Celltech R&D Limited, Slough, Berkshire, UNITED KINGDOM, S11 3WE (non-U.S. corporation)

	NUMBER	KIND	DATE		
PATENT INFORMATION:	US 2006122212	A1	20060608		
APPLICATION INFO.:	US 2003-529413	A1	20030930	(10)	<--
	WO 2003-GB4214		20030930		<--
			20050623	PCT 371 date	

	NUMBER	DATE	
PRIORITY INFORMATION:	GB 2002-22743	20021001	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103, US		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3189		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.

IT 677303-55-8P, 1-(3-Chloro-4-fluorobenzyl)-N-methoxy-N-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
677303-57-0P, N-Methoxy-N-methyl-1-(3-methylbenzyl)-5-oxo-4-

phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
 677303-59-2P, 1-(3-Chlorobenzyl)-N-methoxy-N-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
 677303-60-5P, 1-(3-Chloro-4-fluorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-62-7P,  
 1-(3-Methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-64-9P, 1-(3-Chlorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-68-3P,  
 1-(3-Chlorobenzyl)-N,N-dimethyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-69-4P, 1-(3-Chlorobenzyl)-N-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
 677303-70-7P, 1-(3-Chlorobenzyl)-4-phenyl-2-[(pyrrolidin-1-yl)carbonyl]-1,4-dihydro-5H-pyrrolo[3,2-b]pyridin-5-one  
 677303-71-8P 677303-77-4P, 1-(3-Chlorobenzyl)-4-(1H-indol-5-yl)-5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
 677303-83-2P, 1-(2-Cyanobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-85-4P,  
 1-(4-Fluoro-3-methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 677303-86-5P, 1-(3-Chlorobenzyl)-4-(4-methylphenyl)-5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
 677303-87-6P 677303-96-7P, (S)-2-[[2-(Hydroxymethyl)pyrrolidin-1-yl]carbonyl]-1-(3-methylbenzyl)-4-phenyl-1,4-dihydro-5H-pyrrolo[3,2-b]pyridin-5-one  
 (bicyclic heteroarom. compds. as kinase inhibitors)


RN 677303-55-8 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chloro-4-fluorophenyl)methyl]-4,5-dihydro-N-methoxy-N-methyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-57-0 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 4,5-dihydro-N-methoxy-N-methyl-1-[(3-methylphenyl)methyl]-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-59-2 USPATFULL


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-N-methoxy-N-methyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-60-5 USPATFULL  
 CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chloro-4-fluorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-62-7 USPATFULL  
 CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 4,5-dihydro-1-[(3-methylphenyl)methyl]-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)



RN 677303-64-9 USPATFULL  
 CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-68-3 USPATFULL  
 CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-N,N-dimethyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)





RN 677303-69-4 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-N-methyl-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)




RN 677303-70-7 USPATFULL

CN Pyrrolidine, 1-[[1-[(3-chlorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 677303-71-8 USPATFULL


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl-, hydrazide (9CI) (CA INDEX NAME)



RN 677303-77-4 USPATFULL


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-

dihydro-4-(1H-indol-5-yl)-5-oxo- (9CI) (CA INDEX NAME)




RN 677303-83-2 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(2-cyanophenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)



RN 677303-85-4 USPATFULL


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(4-fluoro-3-methylphenyl)methyl]-4,5-dihydro-5-oxo-4-phenyl- (9CI) (CA INDEX NAME)



RN 677303-86-5 USPATFULL


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-4-(4-methylphenyl)-5-oxo- (9CI) (CA INDEX NAME)





RN 677303-87-6 USPATFULL


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid, 1-[(3-chlorophenyl)methyl]-4,5-dihydro-4-(4-methylphenyl)-5-oxo-, hydrazide (9CI) (CA INDEX NAME)



RN 677303-96-7 USPATFULL

CN 2-Pyrrolidinemethanol, 1-[[4,5-dihydro-1-[(3-methylphenyl)methyl]-5-oxo-4-phenyl-1H-pyrrolo[3,2-b]pyridin-2-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L161 ANSWER 10 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2005:11693 USPATFULL

TITLE: Azaindole-derivatives as factor Xa inhibitors

INVENTOR(S): Nazare, Marc, Idstein, GERMANY, FEDERAL REPUBLIC OF  
Wehner, Volkmar, Sandberg, GERMANY, FEDERAL REPUBLIC OF

Will, David William, Kriftel, GERMANY, FEDERAL REPUBLIC  
OF  
Ritter, Kurt, Frankfurt am Main, GERMANY, FEDERAL  
REPUBLIC OF  
Urmann, Matthias, Eschborn, GERMANY, FEDERAL REPUBLIC  
OF  
Matter, Hans, Langenselbold, GERMANY, FEDERAL REPUBLIC  
OF  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland, Frankfurt am Main, GERMANY,  
FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005009828	A1	20050113
APPLICATION INFO.:	US 2004-849089	A1	20040519 (10)

	NUMBER	DATE	
PRIORITY INFORMATION:	EP 2003-11304	20030519	<--
	US 2003-507141P	20030930 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	4713		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB The present invention relates to compounds of the formula I ##STR1##

wherein R.sup.0, R.sup.1, R.sup.2, R.sup.3, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.


IT 797060-39-0P 797060-40-3P 797060-41-4P  
797060-42-5P 797060-43-6P 797060-44-7P

(claimed compound; preparation of thienylisoxazolylmethylazaindoles as factor

Xa and/or factor VIIa inhibitors)


RN 797060-39-0 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)




RN 797060-40-3 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 797060-41-4 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 797060-42-5 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N2-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)




RN 797060-43-6 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)



RN 797060-44-7 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-  
(9CI) (CA INDEX NAME)



IT 797060-45-8P 797060-46-9P

(preparation of thienylisoxazolylmethylazaindoles as factor Xa and/or factor VIIa inhibitors)


RN 797060-45-8 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N2-[1-(1-methylethyl)-4-piperidiny]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 797060-42-5

CMF C25 H27 Cl N6 O3 S



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 797060-46-9 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797060-44-7  
CMF C25 H26 Cl N5 O4 S



10/26/2006

0/26/2006

Shiao-10/849,089


10/849,089

10/26/2006

CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 797060-56-1P

(preparation of thienylisoxazolylmethylazaindoles as factor Xa and/or factor VIIa inhibitors)


RN 797060-56-1 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797060-55-0


CMF C26 H28 Cl N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L161 ANSWER 11 OF 17 USPATFULL on STN  
 ACCESSION NUMBER: 95:103512 USPATFULL  
 TITLE: Heterocycle-coupled substituted pyrrolo[3,2-c]pyridin-2-carboxylic acids  
 INVENTOR(S): Bachy, Andre, Toulouse, France  
 Fraisse, Laurent, Jurancon, France  
 Keane, Peter, Portet sur Garonne, France  
 Mendes, Etienne, Toulouse, France  
 Vernieres, Jean-Claude, Muret, France  
 Simiand, Jacques, Muret, France  
 PATENT ASSIGNEE(S): Elf Sanofi, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5468750		19951121 <--
APPLICATION INFO.:	US 1994-273943		19940712 (8) <--
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-109073, filed on 19 Aug 1993, now patented, Pat. No. US 5360799		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1992-10329	19920827 <--
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Henley, III, Raymond	
ASSISTANT EXAMINER:	Spivack, Phyllis G.	
LEGAL REPRESENTATIVE:	Jacobson, Price, Holman & Stern	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1001	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of formula ##STR1## in which A represents S;

R.sub.1 is selected from the group consisting of OH, (C.sub.1 -C.sub.12)alkyl, (C.sub.1 -C.sub.12)alkoxy, benzyloxy, phenyl, benzyl (C.sub.1 -C.sub.4)alkyl NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 ;

R.sub.2 is selected from the group consisting of OH, SH, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)alkylthio, and NZ.sub.1 Z.sub.2 ;

R.sub.3 is selected from the group consisting of H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)alkoxy, phenyl, and benzyl;

B is selected from the group consisting of phenyl; pyridyl; phenyl substituted by one or more groups selected from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 wherein Z.sub.1 and Z.sub.2 are selected, independently of each other, from the group consisting of H, (C.sub.1 -C.sub.6)alkyl, formyl, and benzyl or --NZ.sub.1 Z.sub.2 is selected from the group consisting of pyrrolidinyl, piperidinyl, morpholino, hexahydroazepino, ##STR2## piperazino, piperazino substituted in position 4 by (C.sub.1 -C.sub.8)alkyl, benzyl or diphenylmethyl; and pyridyl substituted by one or more groups selected from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 wherein Z.sub.1 and Z.sub.2 are selected, independently of each other, from the group consisting of H, (C.sub.1 -C.sub.6)alkyl, formyl, and benzyl, or NZ.sub.1 Z.sub.2 is selected from the group consisting of pyrrolidinyl, piperidinyl, morpholino, hexahydroazepino, ##STR3## piperazino, and piperazino substituted in




position 4 by (C.sub.1 -C.sub.8)alkyl, benzyl or diphenylmethyl; or its salt with an acid or a base.

IT 156565-83-2P 156565-99-0P

(preparation of, as inhibitor of biol. effects of free radicals)


RN 156565-83-2 USPATFULL

CN 1H-Pyrrolo[3,2-c]quinoline-2-carboxamide, 8-chloro-3-hydroxy-1-(phenylmethyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 156565-99-0 USPATFULL

CN 1H-Pyrrolo[3,2-c]quinoline-2-carboxamide, 8-(diethylamino)-3-hydroxy-1-(phenylmethyl)-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L161 ANSWER 12 OF 17 USPATFULL on STN

ACCESSION NUMBER: 94:95413 USPATFULL

TITLE: Substituted thienyl- or pyrrolylcarboxylic acid derivatives, their preparation and medicines containing them

INVENTOR(S): Bachy, Andre, Toulouse, France  
Fraisie, Laurent, Jurancon, France  
Keane, Peter, Portet Sur Garonne, France  
Mendes, Etienne, Toulouse, France  
Vernieres, Jean-Claude, Muret, France  
Simiand, Jacques, Muret, France

PATENT ASSIGNEE(S): Elf Sanofi, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5360799		19941101	<--
APPLICATION INFO.:	US 1993-109073		19930819	<--

NUMBER DATE

-----  
 PRIORITY INFORMATION: FR 1992-10329 19920827 <--  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Cintins, Marianne M.  
 ASSISTANT EXAMINER: Spivack, Phyllis G.  
 LEGAL REPRESENTATIVE: Wegner, Cantor, Mueller & Player  
 NUMBER OF CLAIMS: 10  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 997

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Compounds of formula ##STR1## in which R.sub.1 represents OH, (C.sub.1 -C.sub.12)alkyl, (C.sub.1 -C.sub.12)alkoxy, benzyloxy, benzyl, phenyl, (C.sub.1 -C.sub.4)alkylNZ.sub.1 Z.sub.2 or NZ.sub.1 Z.sub.2 ; R.sub.2 represents OH, SH, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)alkylthio or NZ.sub.1 Z.sub.2 ; R.sub.3 represents H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)alkoxy, phenyl or benzyl; A represents N and R represents H or (C.sub.1 -C.sub.4)alkyl which can be substituted by phenyl or NZ.sub.1 Z.sub.2 ; B represents phenyl which is coupled to the pyridyl ring and is optionally substituted by one or more groups chosen from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2 or NZ.sub.1 Z.sub.2 ; and Z.sub.1 and Z.sub.2 represent, independently of each other, H, (C.sub.1 -C.sub.6) alkyl, formyl or benzyl, or they form with the nitrogen atom to which they are attached an optionally substituted saturated heterocycle and their salts.

IT 156565-83-2P 156565-99-0P

(preparation of, as inhibitor of biol. effects of free radicals)


RN 156565-83-2 USPTAFULL

CN 1H-Pyrrolo[3,2-c]quinoline-2-carboxamide, 8-chloro-3-hydroxy-1-(phenylmethyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 156565-99-0 USPTAFULL

CN 1H-Pyrrolo[3,2-c]quinoline-2-carboxamide, 8-(diethylamino)-3-hydroxy-1-(phenylmethyl)-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L161 ANSWER 13 OF 17 USPTAFULL on STN  
 ACCESSION NUMBER: 89:39083 USPTAFULL  
 TITLE: 1H-pyrrolo [3,2-c]pyrrolidines protected in 1-position  
 useful as intermediates  
 INVENTOR(S): Dormoy, Jean-Robert, Sisteron, France  
 Heymes, Alain, Sisteron, France  
 PATENT ASSIGNEE(S): SANOFI, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4831144		19890516	<--
APPLICATION INFO.:	US 1988-141508		19880107 (7)	<--
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1985-806544, filed on 9 Dec 1985, now abandoned			

	NUMBER	DATE	
PRIORITY INFORMATION:	FR 1984-19029	19841212	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lee, Mary C.		
ASSISTANT EXAMINER:	Dentz, Bernard I.		
LEGAL REPRESENTATIVE:	Bacon & Thomas		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
LINE COUNT:	754		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a process for fixing an electrophilic group in the 2-position of 1H-pyrrolo[3,2-c]pyridine N-protected in the 1-position, process which consists in protecting the 1-position in question with a labile protecting group, reacting the compound so obtained with a lithiation agent selected from a lithium amide and an alkyl lithium at a temperature between -80° C. and -20° C. and in the presence of tetramethylethylenediamine to obtain the corresponding 2-lithio derivative and then condensing the metal derivative so obtained at a temperature between -80° C. and room-temperature with a reagent capable of giving rise to an electrophilic group to form N-protected 1H-pyrrolo[3,2-c]pyridine substituted in the 2-position by an electrophilic group.


IT 109113-48-6P

(preparation of, as intermediate for anthelmintics)

RN 109113-48-6 USPTAFULL

CN 1H-Pyrrolo[3,2-c]pyridine-2-carboxamide, N,N-diethyl-1-(phenylsulfonyl)-

(9CI) (CA INDEX NAME)



=&gt; diall abeq tech abex hitstr 14-17

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, WPIX' - CONTINUE? (Y)/N:y

✓ L161 ANSWER 14 OF 17 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 ACCESSION NUMBER: 2006-036445 [04] WPIX  
 CROSS REFERENCE: 2003-381525; 2004-812834; 2005-417035; 2005-562788;  
 2006-017475  
 DOC. NO. CPI: C2006-012982 [04]  
 TITLE: New lactam-containing compounds are trypsin serine  
 protease enzyme inhibitors useful for the treatment of  
 thromboembolic disorder e.g. stroke, atherosclerosis,  
 peripheral occlusive arterial disease and venous  
 thrombosis  
 DERWENT CLASS: B02; B03  
 INVENTOR: HAN W; KOCH S L; LAM P Y S; LI Y; ORWAT M J; PINTO D J P;  
 QIAO J X; QUAN M L  
 PATENT ASSIGNEE: (HANW-I) HAN W; (KOCH-I) KOCH S L; (LAMP-I) LAM P Y S;  
 (LIYY-I) LI Y; (ORWA-I) ORWAT M J; (PINT-I) PINTO D J P;  
 (QIAO-I) QIAO J X; (QUAN-I) QUAN M L  
 COUNTRY COUNT: 1

## PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20050267097	A1	20051201	(200604)*	EN	186[0]	A61K031-553

## APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20050267097	A1	Provisional	US 2001-324165P 20010921
US 20050267097	A1	Provisional	US 2002-402317P 20020809
US 20050267097	A1	Div Ex	US 2002-245122 20020917
US 20050267097	A1	Div Ex	US 2004-850587 20040520
US 20050267097	A1		US 2005-198801 20050805

PRIORITY APPLN. INFO: US 2005-198801 20050805  
 US 2001-324165P 20010921  
 US 2002-402317P 20020809  
 US 2002-245122 20020917  
 US 2004-850587 20040520

INT. PATENT CLASSIF.:

MAIN: A61K031-553

SECONDARY: A61K031-55

BASIC ABSTRACT:

US 20050267097 A1 UPAB: 20060116

NOVELTY - Lactam-containing compounds (I) and their stereoisomers or salts are new.

DETAILED DESCRIPTION - Lactam-containing compounds (I) of formula (P4-P1-M-M4) and their stereoisomers or salts are new.

M = 3-10 carbocycle or 4-10 heterocycle consisting of C atom or 1-3 heteroatoms of O, S(O)p, N or NZ2;

ring M = substituted by 0-3 R-1a or 0-2 carbonyl and there are 0-3 ring double bonds;

P = fused onto ring M or 5-7 carbocycle or heterocycle consisting C and 1-3 heteroatoms of O, S(O)p or N; and

ring P = substituted by 0-3 R-1a and 0-2 carbonyl or 0-3 ring double bonds (alternatively ring P is absent and P4 is directly attached to ring M (provided that when ring P is absent, P4 and M4 are attached to the 1,2, 1,3, or 1,4 positions of ring M)).

and provisos. INDEPENDENT CLAIMS are also included for

(1) a method for treating a thromboembolic disorder comprising administering (I) and second therapeutic agent such as Xa inhibitor, anti-coagulant agent, anti-platelet agent, thrombin inhibiting agent, thrombolytic agent or fibrinolytic agent; and

(2) an article of manufacture comprising a first container (a); pharmaceutical composition (b) comprising (I) which is located within the first container; and a package (c) insert stating that the pharmaceutical composition can be used for the treatment of a thromboembolic disorder.

ACTIVITY - Thrombolytic ; Anticoagulant; Cardiovascular-Gen.; Antianginal; Cardiant; Vasotropic; Cerebroprotective; Antiarteriosclerotic.

MECHANISM OF ACTION - Trypsin serine protease enzyme inhibitor.

(I) were tested for trypsin-like serine protease enzyme inhibitory activity in mammal. The inhibitory constant value of 1-(3-chloro-4-fluorophenyl)-6-(4-(2-oxo-1-piperidinyl) phenyl)-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo(3,4-c)pyridine-7-one was less than or equal to 0.001  $\mu$ M.

USE - (I) are useful for treatment of thromboembolic disorder such as arterial, venous or thromboembolic cardiovascular thromboembolic disorders in the chambers of the heart, unstable angina, acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism and thrombosis resulting from prosthetic valves or other implants, indwelling catheters, stents, cardiopulmonary bypass, hemodialysis or other procedures in which blood is exposed to an artificial surface that promotes thrombosis (claimed).

ADVANTAGE - (I) improves pharmaceutical properties, dosage requirements, factors which decrease blood concentration peak-to-trough characteristics, factors that increase the concentration of active drug at the receptor, factors that decrease the liability for clinical drug-drug interactions, factors that decrease the potential for adverse side-effects and manufacturing costs or feasibility.

MANUAL CODE: CPI: B06-H; B07-H; B14-D07C; B14-F01; B14-F02; B14-F04; B14-F07

TECH ORGANIC CHEMISTRY - Preparation: Preparation of (I) comprises standard coupling of acid compounds of formula (G-G1-P-M-(acid chloride, acid, sulfonylchloride, amino or alkylhalide) with NH2-A-B, HO-A-B, HS-A-B and ClCH2-A-B. Preferred Components: The second therapeutic agent is warfarin,

unfractionated heparin, low molecular weight heparin, synthetic pentasaccharide, hirudin, argatrobanas, aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, piroxicam, ticlopidine, clopidogrel (preferred), tirofiban, eptifibatide, abciximab, melagatran, melagatran, disulfatohirudin, tissue plasminogen activator, modified tissue plasminogen activator, anistreplase, urokinase or streptokinase. The article of manufacture further comprises a second container, where (a) and (b) are located within the second container and component (c) is located within or outside of the second container.

ABEX DEFINITIONS - Full Definitions: - M = 3-10 carbocycle or 4-10 heterocycle consisting of C atom or 1-3 heteroatoms of O, S(O)p, N or NZ2; - ring M = substituted by 0-3 R-1a or 0-2 carbonyl and there are 0-3 ring double bonds; - P = fused onto ring M or 5-7 carbocycle or heterocycle consisting C and 1-3 heteroatoms of O, S(O)p or N; - ring P = substituted by 0-3 R-1a and 0-2 carbonyl or 0-3 ring double bonds (alternatively ring P is absent and P4 is directly attached to ring M (provided that when ring P is absent, P4 and M4 are attached to the 1,2, 1,3, or 1,4 positions of ring M)); - one of P4, M4 = -Z-A-B1 or other -G1-G; - G = phenyl compounds of formula (IIa-IIb); - ring D = two atoms of ring E to attached 5-6 ring consisting of C and 0-2 heteroatoms of N, O or S(O)p or substituted by 0-2 R and 0-3 ring double bonds; - E = phenyl, pyridyl, pyrimidyl, pyrazinyl or pyridazinyl substituted by 1-2R (alternatively ring D is absent and ring E is phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl or thiazolyl and substituted by 1-2 R or with 5-6 heterocycle consisting of C or 1-4 heteroatoms of N, O or S(O)p, 5-6 heterocycle substituted by 0-1 carbonyl and 1-2 R and there are 0-3 ring double bonds); - R =H, 1-4C alkyl, F, Cl, Br, I, OH, OCH3, OCH2CH3, OCH(CH3)2, OCH2CH2CH3, CN, C(=NR8)NR7R9, NHC(=NR8)NR7 R9, ONHC(=NR8)NR7R9, NR8CH(=NR7), NH2, NH(1-3C alkyl), N(1-3C alkyl)2, C(=NH)NH2, CH2NH2, CH2NH(1-3C alkyl), CH2N(1-3C alkyl)2, CH2CH2NH2, CH2CH2NH(1-3C alkyl), CH2CH2N(1-3C) alkyl)2, (CR8R9)tC(O)H, (CR8R9)tC(O)R2c, (CR8R9)tNR7R8, (CR8R9)tC(O)NR7R8, (CR8R9)tNR7C(O)R7, (CR8R9)-tOR3, (CR8R9)ts(O)pNR7R8, (CR8R9)tNR7S(O)pR7, (CR8R9)tsR3, (CR8R9)ts(O)R3, (CR8R9)ts(O)2R3 or OCF3 (alternatively, when 2 R attached to the adjacent atoms form a methylenedioxy or ethylenedioxy); - A = 3-10C carbocycle substituted by 0-2 R4 or 5-12 heterocycle consisting of C and 1-4 heteroatoms of N, O or S(O)p and substituted by 0-2 R4 (provided that A is other than a dihydro-benzopyran and B1 is cyclic amine compounds of formula (IIc); provided that Z and B are attached to different atoms on A and that the A-X-N moiety forms other than a N-N-N group; provided that B is other than triazolone, quinolone or isoquinolone (all optionally substituted)); - Q1 = C=O or SO2; - ring Q = 4-8 monocyclic or bicyclic ring consisting of addition to the N-Q1 consisting C or 0-2 heteroatoms NR4C, O, S, S(O) or S(O)2, 0-2 double bonds are present within the ring and the ring is substituted by 0-2 R4a (alternatively ring Q is 4-8 monocyclic or bicyclic ring to which another ring is fused 4-7 membered ring consists of addition to the amide, C or 0-2 heteroatoms of NR4C, O, S, S(O) or S(O)2 or 0-2 double bonds are present within the ring, fusion ring is phenyl or 5-6 heteroaromatic of C and 1-2 heteroatoms NR4C, O, S, S(O) or S(O)2; ring Q which includes the 4-7 membered ring and the fusion ring, is substituted with 0-3 R-4a; two non-adjacent atoms of one of the rings of ring Q are bridged with 1-2C NR4C, O, S, S(O) or S(O)2 (provided bonds other than O-O, S(O)p-O, S(O)p-S(O)p, N-O or N-S(O)p are present); - X = (CR2R-2a)1-4, CR2, (CR2R-2b) (CH2)t, C(O), C(=NR-1c), CR-2(NR-1CR2), CR2 (OR2), CR2 (SR2), C(O)CR2R-2a, CR2R-2aC(O), S(O), S(O)2, SCR2R-2a, S(O)CR2R-2a, S(O)2CR2R-2a, CR2R-2aS(O), CR2R-2aS(O)2, S(O)2NR2CR2R-2a, NR2S(O)2, CR2R-2aNR2S(O)2-, -NR2S(O)2CR2R2a, NR2C(O), C(O)NR2CR2R-2a-, NR2C(O)CR2R-2a, CR2R-2aNR-2C(O), NR-2CR2R-2a or OCR2R-2a; - G1 = (CR3R-3a)1-5, (CR3R-3a)0-2CR3=CR3 (CR3R-3a)0-2, (CR3R-3a)0-2C=C(CR3R-3a)0-

2, (CR3R-3a)uC(O) (CR3R-3a)w, (CR3R-3a)uC(O)O(CR3R-3a)w, (CR3R-3a)uOC(O) (CR3R-3a)w, (CR3R-3a)uO(CR3R-3a)w, (CR3R-3a)uN-3b(CR3R-3a)w, (CR3R-3a)uC(O)N-3b(CR3R-3a)w, (CR3R-3a)uN-3bC(O) (CR3R-3a)w, (CR3R-3a)uOC(O)N-3b(CR3R-3a), (CR3R-3a)uN3-bC(O)O (CR3R-3a) (CR3R-3a)uN-3bC(O)N-3b(CR3R6R-3a)w, (CR3R3a)uN-3bC(S)N-3b(CR3R3a)w, (CR3R3a)uS(CR3R-3a)w, (CR3R-3a)uS(O) (CR3R-3a)w, (CR3R-3a)uS(O)2(CR3R-3a)w, (CR3R-3a)S(O)N-3b(CR3R-3a)w, (CR3R-3a)uN-3bS(O)2(CR3R3a)w, (CR3R-3a)uS(O)2N-3b(CR3R-3a)w, (CR3R-3a)uN3-bS(O)2N-3b(CR3R-3a)w, (CR3R-3a)uNR-3e(CR3R-3a)w, (CR3R-3a)uC(O), (CR3R-3a)uC(O) (CR3R-3a)w, (CR3R-3a)uNR-3b(CR3R-3a)uC(O)NR-3b(CR3R-3a)w, (CR3R-3a)uNR-3bC(O) (CR3R-3a)uC(O) (CR3R-3a)w, (CR3R-3a)uC(O) (CR3R-3a)uC(O)NR-3b(CR3R-3a)w, (CR3R-3a)uS(O)NR-3bC(O) (CR3R-3a)w, (CR3R-3a)uC(O)NR-3bS(O)2(CR3R-3a)w or (CR3R-3a)uS(O)2NR-3bC(O)NR-3bCR3R-3a)w; - u+w = 0-4 (provided that G1 does not form an N-S, NCH2N, NCH2O or NCH2S bond with either group to which it is attached); - Z = (CR3R-3e)-14, (CR3R-3e)qO(CR3R-3e)q1, (CR3R-3e)qNR-3b(CR3R-3e)q1, (CR3R-3e)qC(O), (CR3R-3e)q1, (CR3R-3e)qC(O)O(CR3R-3e)q1, (CR3R-3e)OC(O)(CR3R-3e)q1, (CR3R-3e)qC(O)NR-3b(CR3R-3e)q1, (CR3R-3e)qNR-3bC(O) (CR3R-3e)q1, (CR3R-3e)qOC(O)O(CR3R-3e)q1, (CR3R-3e)qOC(O)NR-3b(CR3R-3e)q1, (CR3R-3e)qNR-3bC(O)O(CR3R-3e)q1, (CR3R-3e)qNR-3bC(O)NR-3b(CR3R-3e)q1, (CR3R-3e)qC(O) (CR3R-3e)qC(O) (CR3R-3e) (CR3R-3e)qNR-3b(CR3R-3e)qC(O)NR-3b(CR3R-3e)q1, (CR3R-3e)qNR-3bC(O) (CR3R-3e)qC(O) (CR3R-3e)q1, (CR3R-3e)qC(O) (CR3R-3e)qC(O)NR-3b(CR3R-3e)q1, (CR3R-3e)qNR-3bC(O) (CR3R-3e)qC(O)NR-3b(CR3R-3e)q1, (CR3R-3e)qS(CR3R-3e)q1, (CR3R-3e)qS(O)2(CR3R-3e)q1, (CR3R-3e)qSO2NR-3b(CR3R-3e)q1, (CR3R-3e)qNR-3bSO2(CR3R-3e)q1, (CR3R-3e)qS(O)NR-3bC(O) (CR3R-3e)q1, (CR3R-3e)qC(O)NR-3bS(O)2(CR3R-3e)q1 or (CR3R-3e)qNR-3bSO2NR-3b(CR3R-3e)q1; - q+q1 = 0-4 (provided that Z does not form a N-S, NCH2N, NCH2O, or NCH2S bond with either group to which it is attached; provided that B-A-Z form other than a pyridone-phenyl-CH2, pyridone-pyridyl-CH2, or pyridone-pyrimidyl-CH2, pyridone, phenyl, pyridyl or pyrimidyl (all optionally substituted); - Z2 = H, S(O)2NHR-3b, C(O)R-3b, C(O)NHR-3b, C(O)OR-3f, S(O)R-3f, S(O)2R-3f, 1-6C alkyl (all optionally substituted with 0-2 R-1a, 2-6C alkenyl 0-2 R-1a, 2-6C alkynyl, 0-2 R-1a, -(0-4C alkyl)-3-10C carbocycle, 0-3 R-1a, -(0-4C alkyl)-5-10 membered heterocycle substituted with 0-3 R-1a or consisting of C atoms or 1-4 heteroatoms of N, O or S(O)p); - R-1a = H, -(CR3R-3a)r-R-1b, -(CR3R-3a)r-CR3R-1bR-1b, -(CR3R-3a)r-(CR3R-3a)rR-1b, -2-6C alkenylene-R-1b, -2-6C alkynylene-R-1b, -(CR3R-3a)r-C(=NR-1b)NR3R-1b, NR3CR3R-3aR-1c, OCR3R-3aR-1c, SCR3R-3aR-1c, NR3(CR3R-3a)2(CR3R-3a)R-1b, C(O)NR2(CR3R-3a)2(CR3R-3a)tR-1b, CO2(CR3R-3a)2(CR3R-3a)R-1b, O(CR3R-3a)2(CR3R-3a)tR-1b, S(CR3R-3a)2(CR3R-3a)R-1b, S(O) (CR3R-3a)rR-1d, O(CR3R-3a)rR-1d, NR3(CR3R-3a)rR-1d, OC(O)NR3(CR3R-3a)rR-1d, NR3C(O)NR3(CR3R-3a)rR-1d, NR3C(O)O(CR3R-3a)rR-1d or NR3C(O) (CR3R-3a)rR-1d, (provided that R-1a forms other than an N-halo, N-S, O-O, or N-CN bond) (alternatively when two R-1a is 5-7 membered ring consisting of C atoms or 0-2 heteroatoms of N, O or S(O)p, this ring being substituted with 0-2 R-4b or 0-3 ring double bonds); - R-1b = H, 1-3C alkyl, F, Cl, Br, I, -CN, -NO2, -CHO, (CF2)rCF3, (CR3R-3a)rOR2, NR2R-2a, C(O)R-2b, CO2R-2b, OC(O)R2, (CF2)rCO2R-2a, S(O)pR-2b, NR2(CH2)rOR2, C(=NR-2C)NR2R-2a, NR-2C(O)R-2b, NR2C(O)NHR2, NR-2C(O)2R-2a, OC(O)NR2R-2a, C(O)NR2R-2a, C(O)NR2(CH2)rOR2, SO2NR2R-2a, NR2SO2R2, C(O)NR2SO2R2, 3-6C carbocycle substituted with 0-2 R-4b, or 5-10 membered heterocycle consisting of C atoms from 1-4 heteroatoms of N, O or S(O)p (all optionally substituted with 0-2 R-4b) (provided that R-1b forms other than an O-O, N-halo, N-S, or N-CN bond); - R-1c = H, CH(CH2OR2)2, C(O)R-2c, C(O)NR2R-2a, S(O)R2, S(O)2R2 or SO2NR2R-2a; - R-1d = 3-6C carbocycle (optionally substituted with 0-2 R-4b) or 5-10 membered heterocycle consisting of C atoms or 1-4 heteroatoms of N, O or S(O)p (optionally substituted with 0-2

R-4b) (provided that R-1d forms other than an N-S bond); - R2 = H, CF3, 1-6C alkyl, benzyl, -(CH2)r-3-10C carbocycle (all optionally substituted with 0-2 R-4b) or -(CH2)r-5-10 membered heterocycle of C atoms or 1-4 heteroatoms of N, O or S(O)p or (optionally substituted with 0-2 R4b); - R-2a = H, CF3, 1-6C alkyl, benzyl, -(CH2)r-3-10C carbocycle (all optionally substituted with 0-2 R-4b) or -(CH2)r-5-10 membered heterocycle consisting of C atoms or 1-4 heteroatoms of N, O or S(O)p or substituted with 0-2 R-4b); - R2 + R-2a = 5-6 membered saturated (partially optionally saturated ring (optionally substituted with 0-2 R-4b) 0-1 additional heteroatoms of N, O or S(O)p); - R-2b = CF3, 1-4C alkoxy (optionally substituted with 0-2 R-4b), 1-6C alkyl (optionally substituted with 0-2 R-4b), -(CH2)r-3-10C carbocycle substituted with 0-2 R-4b) or -(CH2)r-5-10 membered heterocycle of C atoms or 1-4 heteroatoms of N, O or S(O)p or substituted with 0-2 R-4b; - R-2c = CF3, OH, 1-4C alkoxy, 1-6C alkyl, -(CH2)r-3-10C carbocycle (optionally substituted with 0-2 R-4b), or -(CH2)r-5-10 membered heterocycle 1-4 heteroatoms of N, O or S(O)p, (optionally substituted with 0-2 R4b); - R3 = H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, benzyl or phenyl; - R-3a = H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, benzyl, or phenyl; - NR3R-3a = 5 or 6 membered saturated, partially unsaturated, or unsaturated ring of C atoms, N atom, R3, R-3a or 0-1 additional heteroatoms of N, O or S(O)p; - R-3b = H, 1-6C alkyl (optionally substituted with 0-2 R-1a, 2-6C alkenyl substituted with 0-2 R-1a, 2-6C alkynyl substituted with 0-2 R-1a, -(0-4C alkyl)-5-10 membered carbocycle substituted with 0-3 R-1a or -(0-4C alkyl)-5-10 membered heterocycle substituted with 0-3 R-1a consisting of C atoms or 1-4 heteroatoms of N, O or S(O)p; - R-3c = CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, benzyl or phenyl; - R3d = H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2CH2CH2CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, 1-4C alkyl-phenyl or C(=O)R-3c; - R-3e = H, SO2NHR3, SO2NR3R3, C(O)R3, C(O)NHR3, C(O)OR-3f, S(O)R-3f, S(O)2R-3f, 1-6C alkyl (all optionally substituted with 0-2 R-1a, 2-6C alkenyl substituted with 0-2 R-1a, 2-6C alkynyl substituted with 0-2 R-1a, -(0-4C alkyl)-5-10 membered carbocycle substituted with 0-3 R-1a, -(0-4C alkyl)-5-10 membered heterocycle substituted with 0-3 R-1a or consisting of C atoms or 1-4 heteroatoms of N, O, and S(O)p; - R-3f = R-3e; - R4 = H, =O, (CR3R-3a)rOR2, F, Cl, Br, I, 1-4C alkyl, (CR3R-3a)rCN, (CR3R-3a)rNO2, (CR3R-3a)rNR2R-2a, (CR3R-3a)rC(O)R-2c, (CR3R-3a)rNR2C(O)R-2b, (CR3R-3a)rC(O)NR2R-2a, (CR3R-3a)rNR2C(O)NR2R-2a, (CR3R-3a)rC(=NR2)NR2R-2a, (CR3R-3a)rC(=NS(O)2R5)NR2R-2a, (CR3R-3a)rNHC(=NR2)NR2R-2a, (CR3R-3a)rC(O)NHC(=NR2)NR2R-2a, (CR3R-3a)rSO2NR2R-2a, (CR3R-3a)rNR2SO2NR2R-2a, (CR3R-3a)rNR2SO2-1-4C alkyl, (CR3R-3a)rNR2SO2R5, (CR3R-3a)rS(O)pR-3a, (CR3R-3a)r(CF2)rCF3, NHCH2R-1b, OCH2R-1c, SCH2R-1c, NH(CH2)2(CH2)tr-1b, O(CH2)2(CH2)tr-1b, S(CH2)2(CH2)tr-1b, (CR3R-3a)r-5-6 membered carbocycle substituted with 0-1 R5 or (CR3R-3a)r-5-6 membered heterocycle consisting of C or 1-4 heteroatoms of N, O or S(O)p or substituted with 0-1 R5; - R-4a = H, -O, (CR3R-3a)rOR2, (CR3R-3a)rF, (CR3R-3a)rBr, (CR3R-3a)rCl, 1-4C (CR3R-3a)rNR2R-2a alkyl, (CR3R-3a)rCN, (CR3R-3a)rN(CR3R-3a)rC(O)R-2R-2a (CR3R-3a)rNR-2C(O)R-2b, (CR3R-3a)rC(O)NR2R-2a, (CR3R-3a)rN=CHOR3, (CR3R-3a)rC(O)NH(CH2)2NR2R-2a, (CR3R-3a)rNR-2C(O)NR2R-2a, (CR3R-3a)rC(=NR2)NR2R-2a, (CR3R-3a)rNHC(=NR2)NR2R-2a, (CR3R-3a)rSO2NR2R-2a, (CR3R-3a)rNR2SO2NR2R-2a, (CR3R-3a)rNR2SO2-1-4C alkyl, (CR3R-3a)rC(O)NHSO2-(CR3R-3a)NR2SO2R5, 1-4C alkyl, (CR3R-3a)rS(O)pR-3a, (CR3R-3a)r(CF2)rCF3, (CR3R-3a)r-5-6 membered carbocycle substituted with 0-1 R5, or (CR3R-3a)r-5-6 membered heterocycle consisting of C atoms or 1-4 heteroatoms of N, O or S(O)p, or substituted with 0-1 R5; - R-4b = H, =O, (CH2)rOR3, (CH2)rF, (CH2)rCl, (CH2)rBr, (CH2)rI, 1-4C alkyl, (CH2)rCN, (CH2)rNO2, (CH2)rNR3R-3a, (CH2)rC(O)R3, (CH2)rC(O)OR-3c, (CH2)rNR-3C(O)R-3a, (CH2)r-C(O)NR3R-3a, (CH2)rNR-3C(O)NR3R-3a, (CH2)r-C(=NR3)NR3R-3a, (CH2)rNR-3C(=NR3)NR3R-3a, (CH2)rSO2NR3R-3a,



(CH<sub>2</sub>)rNR<sub>3</sub>SO<sub>2</sub>NR<sub>3</sub>R-3a, (CH<sub>2</sub>)rNR<sub>3</sub>SO<sub>2</sub>, 1-4C alkyl, (CH<sub>2</sub>)rNR<sub>3</sub>SO<sub>2</sub>-phenyl, (CH<sub>2</sub>)rNR<sub>3</sub>SO<sub>2</sub>CF<sub>3</sub>, (CH<sub>2</sub>)rS(O)pCF<sub>3</sub>, 1-4C alkyl, (CH<sub>2</sub>)rS(O)p-phenyl or (CH<sub>2</sub>)r(CF<sub>2</sub>)rCF<sub>3</sub>; - R-4c = H, 1-4C alkyl (CR<sub>3</sub>R-3a)r<sub>1</sub>R<sub>2</sub>, (CR<sub>3</sub>R-3a)r<sub>1</sub>F, (CR<sub>3</sub>R-3a)r<sub>1</sub>Br, (CR<sub>3</sub>R-3a)r<sub>1</sub>Cl, (CR<sub>3</sub>R-3a)r<sub>1</sub>CN, (CR<sub>3</sub>R-3a)r<sub>1</sub>NO<sub>2</sub>, (CR<sub>3</sub>R-3a)r<sub>1</sub>NR<sub>2</sub>R-2a, (CR<sub>3</sub>R-3a)rC(O)R-2c, (CR<sub>3</sub>R-3a)r<sub>1</sub>NR<sub>2</sub>C(O)R-2b, (CR<sub>3</sub>R-3a)rC(O)NR<sub>2</sub>R-2a, (CR<sub>3</sub>R-3a)r<sub>1</sub>N=CHOR<sub>3</sub>, (CR<sub>3</sub>R-3a)rC(O)NH(CH<sub>2</sub>)<sub>2</sub>NR<sub>2</sub>R-2a, (CR<sub>3</sub>R-3a)r<sub>1</sub>NR<sub>2</sub>C(O)NR<sub>2</sub>R-2a, (CR<sub>3</sub>R-3a)r<sub>1</sub>C(=NR<sub>2</sub>)NR<sub>2</sub>R-2a, (CR<sub>3</sub>R-3a)rNHC(=NR<sub>2</sub>)NR<sub>2</sub>R-2a, (CR<sub>3</sub>R-3a)rSO<sub>2</sub>NR<sub>2</sub>R-2a, (CR<sub>3</sub>R-3a)rNR<sub>2</sub>SO<sub>2</sub>NR<sub>2</sub>R-2a alkyl, (CR<sub>3</sub>R-3a)rNR<sub>2</sub>SO<sub>2</sub>-(CR<sub>3</sub>R-3a)rC(O)NHSO<sub>2</sub>-(CR<sub>3</sub>R-3a)rNR<sub>2</sub>SO<sub>2</sub>R<sub>5</sub>, (CR<sub>3</sub>R-3a)rS(O)pR-5a, (CR<sub>3</sub>R-3a)r(CF<sub>2</sub>)rCF<sub>3</sub>, (CR<sub>3</sub>R-3a)r-5-6 membered carbocycle substituted with 0-1 R<sub>5</sub> or CR<sub>3</sub>R-3a)r-5-6 membered heterocycle consisting of C atoms and 1-4 heteroatoms of N, O or S(O)p and substituted with 0-1 R<sub>5</sub>; - R<sub>5</sub> = H, 1-6C alkyl, =O, (CH<sub>2</sub>)rOR<sub>3</sub>, F, Cl, Br, I, -CN, NO<sub>2</sub>, (CH<sub>2</sub>)rNR<sub>3</sub>R-3a, (CH<sub>2</sub>)rC(O)R<sub>3</sub>, (CH<sub>2</sub>)rC(O)OR<sub>3</sub>C, (CH<sub>2</sub>)rNR<sub>3</sub>C(O)R-3a, (CH<sub>2</sub>)rC(O)NR<sub>3</sub>R-3a, (CH<sub>2</sub>)rNR<sub>3</sub>C(O)NR<sub>3</sub>R-3a, (CH<sub>2</sub>)rCH(=NOR-3a), (CH<sub>2</sub>)rC(=NR<sub>3</sub>)NR<sub>3</sub>R-3a, (CH<sub>2</sub>)rNR<sub>3</sub>C(=NR<sub>3</sub>)NR<sub>3</sub>R-3a, (CH<sub>2</sub>)rSO<sub>2</sub>NR<sub>3</sub>R-3a, (CH<sub>2</sub>)rNR<sub>3</sub>SO<sub>2</sub>NR<sub>3</sub>R-3a, (CH<sub>2</sub>)rNR<sub>3</sub>SO<sub>2</sub>-1-4C alkyl, (CH<sub>2</sub>)rNR<sub>3</sub>SO<sub>2</sub>CF<sub>3</sub>, (CH<sub>2</sub>)rNR<sub>3</sub>SO<sub>2</sub>-phenyl, (CH<sub>2</sub>)rS(O)pCF<sub>3</sub>, (CH<sub>2</sub>)S(O)p-alkyl, (CH<sub>2</sub>)rS(O)p-phenyl, (CF<sub>2</sub>)rCF<sub>3</sub> or phenyl, naphthyl or benzyl (all substituted with 0-2 R<sub>6</sub>); - R-5a = 1-6C alkyl, (CH<sub>2</sub>)rOR<sub>3</sub>, (CH<sub>2</sub>)rNR<sub>3</sub>R-3a, (CH<sub>2</sub>)rC(O)R<sub>3</sub>, (CH<sub>2</sub>)rC(O)OR<sub>3</sub>C, (CH<sub>2</sub>)rNR<sub>3</sub>C(O)R-3a, (CH<sub>2</sub>)rC(O)NR<sub>3</sub>R-3a, (CF<sub>2</sub>)rCF<sub>3</sub> or phenyl, naphthyl or benzyl (all substituted with 0-2 R<sub>6</sub>) (provided that R-5a does not form a S-N or S(O)p-C(O) bond); - R<sub>6</sub> = H, OH, (CH<sub>2</sub>)rOR<sub>2</sub>, halo, 1-4C alkyl, CN, NO<sub>2</sub>, (CH<sub>2</sub>)rNR<sub>2</sub>R-2a, (CH<sub>2</sub>)rC(O)R-2b, NR<sub>2</sub>C(O)R-2b, NR<sub>2</sub>C(O)NR<sub>2</sub>R-2a; C(=NH)NH<sub>2</sub>, NHC(=NH)NH<sub>2</sub>, SO<sub>2</sub>NR<sub>2</sub>R-2a, NR<sub>2</sub>SO<sub>2</sub>NR<sub>2</sub>R-2a or NR<sub>2</sub>SO<sub>2</sub> (1-4C) alkyl; - R<sub>7</sub> = H, OH, 1-6C alkyl, 1-6C alkyl-C(O)-, 1-6C alkyl-O-, (CH<sub>2</sub>)n-phenyl, 1-4C alkyl-OC(O)-, 6-10C aryl-O-, 6-10C aryl-OC(O)-, 6-10C aryl-CH<sub>2</sub>-C(O)-, 1-4C alkyl-C(O)O-1-4C alkyl-OC(O)-, 6-10C aryl-C(O)O-1-6C alkyl-OC(O)-, 1-6C alkyl-NH<sub>2</sub>-C(O)-, phenyl-NH<sub>2</sub>-C(O)- or phenyl-1-4C alkyl-C(O)-; - R<sub>8</sub> = H, 1-6C alkyl or (CH<sub>2</sub>)n-phenyl (alternatively NR<sub>7</sub>R<sub>8</sub> form a 5-10 membered heterocyclic ring consisting of C atoms and 0-2 additional heteroatoms of N, O or S(O)p); - R<sub>9</sub> = H, 1-6C alkyl or (CH<sub>2</sub>)n-phenyl; - n = 0-3; - p = 0-2; - r = 0-6; and - t = 0-3. - Provided that when ring M is phenyl and is substituted 1,2 by M<sub>4</sub> and P<sub>4</sub> and G<sub>1</sub> is present, then Z-A is other than NHC(O)-thienyl, NHCH<sub>2</sub>-thienyl, NHC(O)-benzothienyl or NHCH<sub>2</sub>-benzothienyl; and B<sub>1</sub> is 2-oxo-1-pyrrolidinyl and rings P-M are 1,7-dihydro-2-methyl-6H-purin-6-one, then G-G<sub>1</sub> is other than unsubstituted phenyl. Preferred Definitions: - A = indolinyl, phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-Fphenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl or 2-methoxyphenyl; - G = 59 heteroaryl compounds e.g. anisol-4-yl, phenylamin-3-yl, chlorobenzen-3-yl, 2-chloro anilin-5-yl or benzamid-2-yl; - A-B = 1-(3-fluoro-4-yl-phenyl)-1H-pyridin-2-one; - R-2a = H, CH<sub>3</sub> or CH<sub>2</sub>CH<sub>3</sub>; - R-2b = CF<sub>3</sub>, 1-4C alkoxy, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub> or benzyl; - R-2c = OH, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, CH<sub>3</sub> or CH<sub>2</sub>CH<sub>3</sub>; and - R<sub>3</sub>, R-3a, R-3c = H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, benzyl or phenyl.

ADMINISTRATION - Administration of (I) is oral (0.001-1000 (preferably 1-20) mg/kg/day), intravenous (1-10 mg/kg/min), intranasal, transdermal or topical.

SPECIFIC COMPOUNDS - 199 Compounds (I) are specifically claimed e.g. 1-(3-amino-1,2-benzisoxazol-5-yl)-5-((5-(2-oxo-1-piperidinyl)-2,3-dihydro-1H-indol-1-yl)carbonyl)-1H-pyrazole-3-carboxamide (Ia).


EXAMPLE - 1-(3-Chloro-4-fluorophenyl)-6-(4-iodophenyl)-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo(3,4-c)pyridine-7-one (0.54 g), 5-valerolactam (0.12 g), 1,2-diaminocyclohexane (11.4 mg), potassium phosphate (0.42 g) and cuprous iodide (2 mg) were added to 1,4-dioxane (5 ml). The mixture was degassed under argon and stirred at 110degreesC under nitrogen gas for 48 hours. The mixture was then cooled to room temperature. The mixture was worked up to give 1-(3-chloro-4-fluorophenyl)-6-(4-(2-oxo-1-piperidinyl)

phenyl)-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo(3,4-c)pyridine-7-one (80%).

AN.S DCR-1209418

CN.S 5-Chloro-1-{2-[4-(2-oxo-2H-pyridin-1-yl)-benzoylamino]-cyclohexyl}-1H-indole-2-carboxylic acid amide

SDCN RAKNAV



L161 ANSWER 15 OF 17 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
ACCESSION NUMBER: 2005-344282 [35] WPIX  
DOC. NO. CPI: C2005-106588 [35]  
DOC. NO. NON-CPI: N2005-281254 [35]  
TITLE: New combinatorial library (comprising a library comprising a plurality of different pyrrolocarboxylic amide derivatives) useful for screening pharmacological activity  
DERWENT CLASS: B02; B04; S03  
INVENTOR: CAI J; GOODNOW R A  
PATENT ASSIGNEE: (CAIJ-I) CAI J; (GOOD-I) GOODNOW R A; (HOFF-C) HOFFMANN  
LA ROCHE & CO AG F  
COUNTRY COUNT: 106

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20050089936	A1	20050428	(200535)*	EN	20[0]	G01N033-53
WO 2005040111	A2	20050506	(200535)	EN		C07D209-04

## APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20050089936	A1 Provisional	US 2003-513785P	20031023
US 20050089936	A1	US 2004-957161	20041001
WO 2005040111	A2	WO 2004-EP11468	20041013

PRIORITY APPLN. INFO: US 2004-957161 20041001  
US 2003-513785P 20031023

## INT. PATENT CLASSIF.:

MAIN: C07D209-04; G01N033-53

SECONDARY: A61K031-405; A61K031-4745; C07D471-02

## BASIC ABSTRACT:

US 20050089936 A1 UPAB: 20051222

NOVELTY - Combinatorial library (comprising a library (A) comprising a plurality of different pyrrolocoarboxylic amide derivatives (I)) is new.

DETAILED DESCRIPTION - Combinatorial library (comprising a library (A) comprising a plurality of different pyrrolocoarboxylic amide derivatives of formula (I)) is new.

P1 = a fused ring substituent, which is an aromatic ring, a heteroaromatic ring or a cycloaliphatic ring (all optionally substituted);

R1, R2 = H, 1-7C alkyl, 2-7C alkenyl, 3-7C alkynyl, mono or bi-cycloaliphatic ring where each ring contains 3-7C, aryl system containing 1-3 fused aromatic rings, heterocycloaliphatic system containing 1-2 fused rings where each ring contains 3-6C with 1-2 hetero atoms (O, S or N), or monocyclic or bicyclic heteroaryl rings each containing 3-6C with 1-4 hetero atoms (N, S or O);

R3 = a ring-containing substituent, which may be an aromatic ring, a heteroaromatic ring or a cycloaliphatic ring (all optionally substituted).

Provided that when the hetero atom is S or O, there are 1-2 hetero atoms in the ring and when the hetero atoms is N, there are 1-4 N atoms in the ring; the hetero ring in the heterocycloaliphatic ring or monocyclic or bicyclic heteroaryl rings can be condensed with an aryl or cycloaliphatic ring; and any of the (hetero)aryl, cycloaliphatic or heteroaliphatic rings in the cycloaliphatic, (hetero)aryl or heteroaliphatic substituents may be connected to (I) by a 1-7C alkylene chain.

INDEPENDENT CLAIMS are also included for preparations of (I).

USE - (I) is useful for screening pharmacological activity, assay the biological activity of compounds and to perform the structural analysis of compounds.

MANUAL CODE: CPI: B06-D05; B06-D08; B06-E03; B06-F03; B11-C01A1  
EPI: S03-E09F; S03-E14A1

TECH ORGANIC CHEMISTRY - Preparation (claimed): Preparation of (I) comprises immobilizing on a solid support an amine of formula R2NH2 to give an immobilized amine of formula T-NHR2; coupling the immobilized amine to an organic acid of formula (1) to give an immobilized amide of formula (2); reacting (2) with a halide of the formula R1Hal (where Hal is halide) to give a protected indole of formula (3), or otherwise protecting the amino group; reacting (3) with a boronic acid of the formula R11O-B(R12O)-R3 to give immobilized (I); and cleaving the immobilized (I) and (Ia) from the solid support.

T = solid support;

P1, R2 = as defined above;

R13 = leaving group (preferably iodo);

R1 = as above, or an amino protecting group; and either

R11, R12 = lower alkyl; or

R11 and R12 together = a lower alkylene bridge between the 2 O atoms.

Preferred Components: (A) contains at least 200-10000 different compounds having the structure of (I). (A) is randomized and (I) is immobilized on a solid support.


Preferred Process: The reaction is carried out by a Suzuki reaction.

ABEX EXAMPLE - To 100 resin segregation devices (each containing Wang Resin HL, 88 micromol equivalent/device) in dimethylformaldehyde (120 ml) was added 3-iodo-1H-indole-2-carboxylic acid (44 mmol), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (44 mmol) and isopropyl ethyl amine (44 mmol). The suspension was shaken overnight at room temperature under an atmosphere of argon. The solvent was filtered and the resin segregation devices were washed 4 times with each of dimethylformaldehyde, methanol, methylene chloride and hexanes. The resin segregation devices were dried under vacuum overnight at room temperature. This washing and drying process was performed after each stage of the reaction. The resin segregation devices were suspended in dimethylformaldehyde (120 ml), tert-butoxycarbonyl anhydride (50.5 ml), 4-(dimethylamino)pyridine (5.38 g) and triethylamine (62 ml, 0.44 mol). To 10 resin segregation devices (0.88 mmol total equivalence) in 10 ml 1,2-dimethoxyethane was added tetrakis(triphenylphosphine)palladium (0) (0.15 g), followed by shaking for 15 minutes. Phenyl boronic acid (4.4 mmol) and sodium carbonate (2 ml) were added to the solution. The suspension was heated at 90degreesC. The solvent was filtered off and the resin segregation devices were washed and were sorted into single cleavage wells and taken into the cleavage using trifluoroacetic acid in dichloromethane at room temperature for 2 hours. The reaction mixture was worked up to give crude 3-phenyl-1H-indole-2-carboxylic acid benzylamides.

AN.S DCR-1067992

CN.S 1-Benzyl-5-chloro-3-phenyl-1H-indole-2-carboxylic acid benzylamide

SDCN RAHOVW



DOC. NO. CPI: C2005-038578 [13]  
 TITLE: New piperazine and tetrahydropyridine derivatives are tubulin polymerization inhibitors used for treating cancer and disaggregating cell masses derived from vascular tissue  
 DERWENT CLASS: B02  
 INVENTOR: LE BRUN A; LE-BRUN A; MAILLIET P; THOMPSON F; TIRABOSCHI G  
 PATENT ASSIGNEE: (AVET-C) AVENTIS PHARMA; (AVET-C) AVENTIS PHARMA SA  
 COUNTRY COUNT: 106

## PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
FR 2857966	A1	20050128	(200513)*	FR	31[0]	
US 20050020593	A1	20050127	(200513)	EN		
WO 2005009947	A2	20050203	(200513)	FR		
MX 2006000479	A1	20060401	(200654)	ES		A61K031-33
AU 2004259112	A1	20050203	(200660)	EN		
BR 2004012254	A	20060919	(200663)	PT		C07D209-42

## APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
FR 2857966 A1		FR 2003-9092	20030724
US 20050020593 A1	Provisional	US 2003-505184P	20030923
AU 2004259112 A1		AU 2004-259112	20040722
WO 2005009947 A2		WO 2004-FR1944	20040722
MX 2006000479 A1		WO 2004-FR1944	20040722
US 20050020593 A1		US 2004-898517	20040723
MX 2006000479 A1		MX 2006-479	20060111
BR 2004012254 A		BR 2004-12254	20040722
BR 2004012254 A		WO 2004-FR1944	20040722

## FILING DETAILS:

PATENT NO	KIND	PATENT NO
MX 2006000479	A1 Based on	WO 2005009947 A
AU 2004259112	A1 Based on	WO 2005009947 A
BR 2004012254	A Based on	WO 2005009947 A

PRIORITY APPLN. INFO: FR 2003-9092 20030724

INT. PATENT CLASSIF.:

MAIN: A61K031-33; C07D209-42  
 SECONDARY: A61P043-00; C07D; C07D209-00; C07D221-00; C07D231-56; C07D333-68; C07D471-04  
 IPC ORIGINAL: A61K0031-33 [I,A]; A61P0043-00 [I,A]; C07D0209-00 [I,A]; C07D0209-42 [I,A]; C07D0221-00 [I,A]; C07D0231-56 [I,A]; C07D0333-68 [I,A]; C07D0471-04 [I,A]  
 IPC RECLASSIF.: A61K0031-496 [I,A]; A61K0031-496 [I,C]; A61K0031-519 [I,C]; A61K0031-52 [I,A]; A61K0031-53 [I,A]; A61K0031-53 [I,C]; C07D0209-00 [I,C]; C07D0209-42 [I,A]; C07D0231-00 [I,C]; C07D0231-56 [I,A]; C07D0333-00 [I,C]; C07D0333-68 [I,A]; C07D0471-00 [I,C]; C07D0471-04 [I,A]

## BASIC ABSTRACT:

FR 2857966 A1 UPAB: 20060121  
 NOVELTY - Piperazine and tetrahydropyridine derivatives (I) and

(II), are new.

DETAILED DESCRIPTION - Piperazine and tetrahydropyridine derivatives of formula (I) and (II), their racemates, enriched in one enantiomer or diastereoisomer, tautomers, prodrugs and salts, are new, excluding compounds of formula (III).

A, B', U', V', W', X, Y = nitrogen or carbon;

L-G-R1 = a group of formula (i) or (ii);

E = CR<sub>4</sub>, N, NR<sub>4</sub> or S;

R1, R2 = aryl or heteroaryl (both optionally substituted);

L = CO, CS or C(=NR<sub>7</sub>);

R3 = halo, trifluoromethyl, cyano, nitro, 1-3C alkyl, 1-3C alkenyl, 1-3C alkynyl, OR<sub>7</sub>, SR<sub>7</sub>, SOR<sub>7</sub>, SO<sub>2</sub>R<sub>7</sub>, NR<sub>7</sub>R<sub>8</sub>, COOR<sub>7</sub>, CONR<sub>7</sub>R<sub>8</sub>, SO<sub>2</sub>NR<sub>7</sub>R<sub>8</sub>, NR<sub>7</sub>COR<sub>8</sub> or NR<sub>7</sub>SO<sub>2</sub>(1-3C)alkyl;

n = 0-3;

R4-R6 = H or 1-3C alkyl;

R7, R8 = H or optionally substituted 1-3C alkyl;

R1a = optionally substituted 2-pyridyl or its N-oxide;

R2a = 2-thienyl, 2-, 3- or 4-pyridyl or their N-oxides, phenyl (optionally substituted by at least one fluoro, hydroxy, methyl, trifluoromethyl, methoxy or nitro;

R4a = methyl, ethyl or 2-fluoroethyl, and

T, U1 = H, methyl, chloro or fluoro, or

R1a = 3- or 4-pyridyl;

R2a = 2-thienyl or phenyl;

R4a = methyl or 2-fluoroethyl, and

T, U1 = H, methyl, chloro or fluoro,

provided that when n = 2, X and Y are not both substituted by R3.

ACTIVITY - Cytostatic.

MECHANISM OF ACTION - Tubulin polymerization inhibitor.

In an in vitro test using pig brain, results showed that.

(4-(3-chlorophenyl)piperazin-1-yl)(1-phenyl-1H-indol-2-yl)methanone (Ia) exhibited an IC<sub>50</sub> value of 0.8 micro-M for inhibition of tubulin.

USE - Used to treat cancer and to promote disaggregation of a mass of cells derived from vascular tissue.

MANUAL CODE: CPI: B06-H; B14-H01


TECH ORGANIC CHEMISTRY - Preparation: Preparation of (I) comprises e.g. reacting a piperazine compound of formula (IV) with an acid compound of formula (V) to give (I: L-G-R1 = (i); L = CO). Preparation of (II) comprises e.g. reacting (IV) with an acid compound of formula (VI) to give (II: L-G-R1 = (i); L = CO).

ABEX EXAMPLE - A solution of 1-phenylindole-2-carboxylic acid (0.5 g) in dichloromethane (DCM; 10 ml) was treated, under argon, with oxalyl chloride (217  $\mu$ l) and a few drops of dimethylformamide, and stirred for 2 hours at room temperature. The reaction mixture was added dropwise to a solution, at 0degreesC and under argon, of 1-(3-chlorophenyl)piperazine (431 mg) in DCM (5 ml), containing triethylamine (355  $\mu$ l). After 20 hours stirring at room temperature, water (20 ml) was added, and the organic phase was decanted, washed with water, dried and concentrated under reduced pressure. The residue was purified by recrystallization from 20:80 methanol:ethanol to give (4-(3-chlorophenyl)piperazin-1-yl)(1-phenyl-1H-indol-2-yl)methanone (Ia) (400 mg), m. pt 168degreesC.

AN.S DCR-1025128

CN.S 3-[4-(1-Phenyl-1H-indole-2-carbonyl)-piperazin-1-yl]-benzamide


SDCN RAGSRR



AN.S DCR-1025127

CN.S [4-(3,5-Dimethoxy-phenyl)-piperazin-1-yl]-(1-phenyl-1H-indol-2-yl)-methanone


SDCN RAGSRQ



AN.S DCR-1025126

CN.S [4-(3,5-Dimethoxy-phenyl)-piperazin-1-yl]-(5-methoxy-1-phenyl-1H-indol-2-yl)-methanone


SDCN RAGSRP



AN.S DCR-1025125

CN.S [4-(3-Chloro-phenyl)-piperazin-1-yl]-(5-methoxy-1-phenyl-1H-indol-2-yl)-methanone

SDCN RAGSRO




AN.S DCR-1025118

CN.S [4-(3-Chloro-phenyl)-piperazin-1-yl]-(1-phenyl-1H-indol-2-yl)-methanone

SDCN RAGSRH





L161 ANSWER 17 OF 17 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 ACCESSION NUMBER: 2000-023259 [02] WPIX  
 DOC. NO. CPI: C2000-005636 [02]  
 TITLE: Compositions for treating e.g. cardiac disorders, renal disorders and central nervous system disorders  
 DERWENT CLASS: B02  
 INVENTOR: NISATO D  
 PATENT ASSIGNEE: (SNFI-C) SANOFI SA; (SNFI-C) SANOFI-SYNTHELABO  
 COUNTRY COUNT: 83

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC	
WO 9955340	A1	19991104	(200002)*	FR	20 [0]	A61K031-535	<--
FR 2778103	A1	19991105	(200002)	FR		A61K031-41	<--
AU 9934259	A	19991116	(200015)	EN			<--

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9955340	A1	WO 1999-FR959	19990422
FR 2778103	A1	FR 1998-5591	19980429
AU 9934259	A	AU 1999-34259	19990422

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9934259	A	Based on
		WO 9955340 A

PRIORITY APPLN. INFO: FR 1998-5591 19980429

INT. PATENT CLASSIF.:

MAIN: A61K031-41; A61K031-535

INDEX: A61K031:40

BASIC ABSTRACT:

WO 1999055340 A1 UPAB: 20050705

NOVELTY - Compositions comprise an association of arginine-vasopressin V1a receptor antagonist (A) and an angiotensin II AT1 receptor antagonist (B).

DETAILED DESCRIPTION - (A) may be any arginine-vasopressin V1a receptor antagonist compound described e.g. in US5612334, WO9622282,

WO9622294, EP469984, EP450097, JP8143565 or JP8059624. (B) may be any known angiotensin II AT1 receptor antagonist described in e.g. EP28834, EP253310, EP324377, US4207324, US4340598, US4576958, WO9114679, WO9117148, or WO9220662.

ACTIVITY - Cardiant; hypotensive; antiarrhythmic; cerebroprotective; antidiabetic; anorectic; nootropic; neuroprotective.

Spontaneously hypertensive rats were treated with an angiotensin (II) antagonist and SR 49059, alone or in combination. Measurement of arterial pressure and cardiac frequency showed that the angiotensin (II) antagonist decreased the arterial pressure and this effect was potentiated by the presence of SR 49059, which had no effect on arterial pressure when administered alone.

MECHANISM OF ACTION - Arginine-vasopressin V1a receptor antagonist and angiotensin II AT1 receptor antagonist.

USE - Treatment of cardiac disorders, especially hypertension, cardiac enfeeblement, venous insufficiency, cardiac ischemia, dilative cardiomyopathia, prevention of death following infarction, and arrhythmias, renal disorders such as nephropathias, central nervous system disorders such as cerebral ischemia, dementia, especially associated with Alzheimer's, memory loss, treatment of diabetes and obesity, sexual disorders, especially loss of erectile function.

ADVANTAGE - There is synergism between (I) and (II), allowing lower doses to be given without loss of therapeutic effect.

MANUAL CODE: CPI: B06-H; B07-H; B14-E12; B14-F01A; B14-F01B; B14-F01C; B14-F02B; B14-F02D1; B14-F02D2; B14-J01A4; B14-S04

ABEX ADMINISTRATION - The compositions preferably contain a unit dosage of 2.5-1000 (especially 2.5-250) mg (A) and 0.5-500 (especially 1-300) mg (B) (claimed). The composition may be formulated for oral, sublingual, inhaled, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration.

SPECIFIC MATERIALS - (A) is preferably (2S)-1-((2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxy benzene sulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl)pyrrolidine-2-carboxamide (SR 49059) (described in EP526348). (B) is preferably irbesartan, losartan, pomisartan, saprisartan, valsartan, telmisartan, candesartan, eprosartan, tasosartan, or embusartan, with irbesartan being particularly preferred. Use of the combination of SR49059 and irbesartan is specifically claimed.


EXAMPLE - Capsules were prepared containing micronized SR49059 (25mg), irbesartan (75mg), lactose monohydrate (252.35mg), modified corn starch (57.77mg), colloidal silica (2.13mg), magnesium stearate (4.25mg), and talc (8.5mg).

AN.S DCR-245258

CN.P SR-49059

CN.S 1-[5-Chloro-1-(3,4-dimethoxy-benzenesulfonyl)-3-hydroxy-3-phenyl-2,3-dihydro-1H-indole-2-carbonyl]-pyrrolidine-2-carboxylic acid amide

SDCN RA0XZP



=> fil hcap  
 FILE 'HCAPLUS' ENTERED AT 16:23:51 ON 25 OCT 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 25 Oct 2006 VOL 145 ISS 18  
 FILE LAST UPDATED: 24 Oct 2006 (20061024/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 179 not 151  
 L162 0 L79 NOT L51


=> d que 1162  
 L1 STR



VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE  
 L2 45329 SEA FILE=REGISTRY SSS FUL L1  
 L32 STR



Cy @14

C~Cy  
@15 16N~Cy  
@17 18S~Cy  
@19 20O~Cy  
@21 22

VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 VAR G5=14/15/17/19/21

NODE ATTRIBUTES:



NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 NSPEC IS RC AT 15  
 NSPEC IS RC AT 17  
 NSPEC IS RC AT 19  
 NSPEC IS RC AT 21  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE

L34 4740 SEA FILE=REGISTRY SUB=L2 SSS FUL L32  
 L42 STR



VAR G1=12/21/30/39

## NODE ATTRIBUTES:

NSPEC IS RC AT 1  
NSPEC IS RC AT 2  
CONNECT IS E1 RC AT 3  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 40

## STEREO ATTRIBUTES: NONE

L45 1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42  
L46 93 SEA FILE=REGISTRY ABB=ON PLU=ON L34 AND L45  
L48 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L46  
L49 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY  
<2004 OR REVIEW/DT  
L51 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L48 AND L49  
L79 1 SEA FILE=HCAPLUS ABB=ON PLU=ON US2004-849089/APPS  
L162 0 SEA FILE=HCAPLUS ABB=ON PLU=ON L79 NOT L51

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 16:24:24 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Oct 25, 2006 (20061025/UP).

=> d que nos 152

L1 STR  
 L2 45329 SEA FILE=REGISTRY SSS FUL L1  
 L32 STR  
 L34 4740 SEA FILE=REGISTRY SUB=L2 SSS FUL L32  
 L42 STR  
 L45 1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42  
 L46 93 SEA FILE=REGISTRY ABB=ON PLU=ON L34 AND L45  
 L48 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L46  
 L49 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY  
 <2004 OR REVIEW/DT  
 L51 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L48 AND L49  
 L52 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L48 NOT L51

=> d his 185

(FILE 'USPATFULL, USPAT2, TOXCENTER, CASREACT, CHEMCATS' ENTERED AT  
 13:14:58 ON 25 OCT 2006)

L85 6 S L82 AND L69-L75

=> d que nos 185

L1 STR  
 L2 45329 SEA FILE=REGISTRY SSS FUL L1  
 L32 STR  
 L34 4740 SEA FILE=REGISTRY SUB=L2 SSS FUL L32  
 L42 STR  
 L45 1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42  
 L46 93 SEA FILE=REGISTRY ABB=ON PLU=ON L34 AND L45  
 L69 QUE ABB=ON PLU=ON NAZARE, M?/AU  
 L70 QUE ABB=ON PLU=ON WEHNER, V?/AU  
 L71 QUE ABB=ON PLU=ON WILL, D?/AU  
 L72 QUE ABB=ON PLU=ON RITTER, K?/AU  
 L73 QUE ABB=ON PLU=ON MATTER, H?/AU  
 L74 QUE ABB=ON PLU=ON URMANN, M?/AU  
 L75 QUE ABB=ON PLU=ON (AVENTIS OR SANOFI)/CS,SO,PA  
 L82 27 SEA L46  
 L85 6 SEA L82 AND (L69 OR L70 OR L71 OR L72 OR L73 OR L74 OR L75)

=> d que nos 1115

L32 STR  
 L42 STR  
 L50 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004  
 L101 QUE ABB=ON PLU=ON D720/M0,M1,M2,M3,M4,M5,M6  
 L103 347 SEA FILE=WPIX SSS FUL L32  
 L105 49 SEA FILE=WPIX SUB=L103 SSS FUL L42  
 L106 72 SEA FILE=WPIX ABB=ON PLU=ON (RA0XZP/DCN OR RAAHRA/DCN OR  
 RAAHRY/DCN OR RAAZSD/DCN OR RAAZSF/DCN OR RAAZSH/DCN OR  
 RAAZSI/DCN OR RAAZSJ/DCN OR RAAZSK/DCN OR RAAZSL/DCN OR  
 RAAZSM/DCN OR RAAZSN/DCN OR RAAZSO/DCN OR RAAZSX/DCN OR  
 RAA1TM/DCN OR RAB2D0/DCN OR RACKXP/DCN OR RAETE4/DCN OR  
 RAE3EB/DCN OR RAE3EC/DCN OR RAE3ED/DCN OR RAE3EE/DCN OR  
 RAE3EF/DCN OR RAE3EG/DCN OR RAE3EK/DCN OR RAE3EL/DCN OR  
 RAE3EM/DCN OR RAE3EN/DCN OR RAE3EQ/DCN OR RAE3EU/DCN OR  
 RAE3EV/DCN OR RAE3EW/DCN OR RAE3EX/DCN OR RAE3F2/DCN OR  
 RAFI3X/DCN OR RAFI3Y/DCN OR RAFI41/DCN OR RAFZM3/DCN OR  
 RAFZM4/DCN OR RAFZM6/DCN OR RAF8IU/DCN OR RAF8IV/DCN OR  
 RAF8IW/DCN OR RAF8IX/DCN OR RAGFDN/DCN OR RAGFDO/DCN OR  
 RAGFDP/DCN OR RAGFDQ/DCN OR RAGFDS/DCN OR RAGFDT/DCN OR

RAGFDU/DCN OR RAGFDV/DCN OR RAGFDW/DCN OR RAGFDX/DCN OR  
 RAGFDY/DCN OR RAGFDZ/DCN OR RAGFEB/DCN OR RAGFEC/DCN OR  
 RAGFED/DCN OR RAGFEG/DCN OR RAGFEH/DCN OR RAGFEI/DCN OR  
 RAGFEJ/DCN OR RAGFEM/DCN OR RAGFEN/DCN OR RAGFEO/DCN OR  
 RAGFEP/DCN OR RAGFEQ/DCN OR RAGFE0/DCN OR RAGFE1/DCN OR  
 RAGFE2/DCN OR RAGFE3/DCN OR RAGFE4/DCN OR RAGFE5/DCN OR  
 RAGFE6/DCN OR RAGFE7/DCN OR RAGFE8/DCN OR RAGFE9/DCN OR  
 RAGFFQ/DCN OR RAGFFR/DCN OR RAGFFS/DCN OR RAGFFT/DCN OR  
 RAGFFU/DCN OR RAGSRH/DCN OR RAGSRO/DCN OR RAGSRP/DCN OR  
 RAGSRQ/DCN OR RAGSRR/DCN OR RAG3GM/DCN OR RAG3GN/DCN OR  
 RAG6CZ/DCN OR RAG6DA/DCN OR RAG6DD/DCN OR RAG6DF/DCN OR  
 RAG6DI/DCN OR RAG6D2/DCN OR RAG6D3/DCN OR RAG6D5/DCN OR  
 RAG6D6/DCN OR RAG6D8/DCN OR RAG7BA/DCN OR RAG7BB/DCN OR  
 RAG7BC/DCN OR RAG7BI/DCN OR RAG7BK/DCN OR RAG7BM/DCN OR  
 RAHI2S/DCN OR RAHI2U/DCN OR RAHI2V/DCN OR RAHOVW/DCN OR  
 RAI01E/DCN OR RAI019/DCN OR RAKGLI/DCN OR RAKGLK/DCN OR  
 RAKGLP/DCN OR RAKGLW/DCN OR RAKGLX/DCN OR RAKGLY/DCN OR  
 RAKGLZ/DCN OR RAKGM0/DCN OR RAKNAV/DCN OR RAKW9U/DCN OR  
 RALDFO/DCN OR RALDFP/DCN OR RALDFQ/DCN OR RALDFR/DCN OR  
 RALDFS/DCN OR RALDFT/DCN OR RALDFU/DCN OR RALDFV/DCN OR  
 RALDFW/DCN OR RALDFX/DCN OR RALDFY/DCN OR RALDFZ/DCN OR  
 RALDG0/DCN OR RALDG1/DCN OR RALDG2/DCN OR RALDG3/DCN OR  
 RALDG4/DCN OR RALDG5/DCN OR RALHNR/DCN OR RALHO3/DCN OR RAL

L107 72 SEA FILE=WPIX ABB=ON PLU=ON L103/DCR  
 L108 10 SEA FILE=WPIX ABB=ON PLU=ON (L106 OR L107) AND L101  
 L109 5 SEA FILE=WPIX ABB=ON PLU=ON (RAE3EB/DCN OR RAE3EC/DCN OR  
 RAE3ED/DCN OR RAE3EE/DCN OR RAE3EF/DCN OR RAE3EG/DCN OR  
 RAE3EK/DCN OR RAE3EL/DCN OR RAE3EM/DCN OR RAE3EN/DCN OR  
 RAE3EQ/DCN OR RAE3EU/DCN OR RAE3EV/DCN OR RAE3EW/DCN OR  
 RAE3EX/DCN OR RAE3F2/DCN OR RAG7BA/DCN OR RAG7BB/DCN OR  
 RAG7BC/DCN OR RAG7BI/DCN OR RAG7BK/DCN OR RAG7BM/DCN OR  
 RALDFO/DCN OR RALDFP/DCN OR RALDFQ/DCN OR RALDFR/DCN OR  
 RALDFS/DCN OR RALDFT/DCN OR RALDFU/DCN OR RALDFV/DCN OR  
 RALDFW/DCN OR RALDFX/DCN OR RALDFY/DCN OR RALDFZ/DCN OR  
 RALDG0/DCN OR RALDG1/DCN OR RALDG2/DCN OR RALDG3/DCN OR  
 RALDG4/DCN OR RALDG5/DCN OR RAMQJD/DCN OR RAMQJF/DCN OR  
 RAMQJT/DCN OR RAMQJV/DCN OR RAMQJX/DCN OR RA211B/DCN OR  
 RA2117/DCN OR RA2118/DCN OR RA2119/DCN)  
 L110 5 SEA FILE=WPIX ABB=ON PLU=ON L105/DCR  
 L111 10 SEA FILE=WPIX ABB=ON PLU=ON (L108 OR L109 OR L110)  
 L114 8 SEA FILE=WPIX ABB=ON PLU=ON L111 AND L50  
 L115 2 SEA FILE=WPIX ABB=ON PLU=ON L111 NOT L114

=> dup rem 152 184 1115

DUPLICATE IS NOT AVAILABLE IN 'CHEMCATS'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

FILE 'HCAPLUS' ENTERED AT 16:26:07 ON 25 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:26:07 ON 25 OCT 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 16:26:07 ON 25 OCT 2006

COPYRIGHT (C) 2006 ACS

FILE 'CASREACT' ENTERED AT 16:26:07 ON 25 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT



COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CHEMCATS' ENTERED AT 16:26:07 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

FILE 'WPIX' ENTERED AT 16:26:07 ON 25 OCT 2006  
COPYRIGHT (C) 2006 THE THOMSON CORPORATION  
PROCESSING COMPLETED FOR L52  
PROCESSING COMPLETED FOR L84  
PROCESSING COMPLETED FOR L115  
L163            19 DUP REM L52 L84 L115 (5 DUPLICATES REMOVED)  
                 ANSWERS '1-6' FROM FILE HCAPLUS  
                 ANSWER '7' FROM FILE USPATFULL  
                 ANSWERS '8-19' FROM FILE CHEMCATS

=> fil chemcats

FILE 'CHEMCATS' ENTERED AT 16:26:36 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

FILE LAST UPDATED 21 OCTOBER 2006 (20061021/UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow prompt. For the list of suppliers currently in the file, enter HELP SPA, HELP SPBC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPQZ. For the list of current catalogs, enter HELP CTA, HELP CTBC, HELP CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis. Please consult the suppliers for current information regarding pricing, regional availability, available quantities, purities, etc. THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not liable for any loss of profit, goodwill or any other damages arising out of the use of this database.

CHEMCATS now contains more than 10 million records. See HELP CONTENT and NEWS FILE for details.

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 16:26:46 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Oct 25, 2006 (20061025/UP).

=&gt; d ibib ed ab retable hitstr

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, CHEMCATS' - CONTINUE? (Y)/N:y

L163 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2006:468246 HCAPLUS

DOCUMENT NUMBER: 144:488656

TITLE: Preparation of 1H-imidazo[4,5-b]pyridine-2-carboxamides and related compounds as D1 dopamine receptor inhibitors

INVENTOR(S): Gmeiner, Peter; Schlotter, Karin; Huebner, Harald; Schmidt, Dirk; Buchholz, Monika

PATENT ASSIGNEE(S): Schwarz Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006050976	A1	20060518	WO 2005-EP12127	20051111
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
DE 102004054634	A1	20060518	DE 2004-102004054634	20041112

PRIORITY APPLN. INFO.:

DE 2004-102004054634A 20041112

OTHER SOURCE(S): MARPAT 144:488656

ED Entered STN: 19 May 2006

AB Title compds. I [A = aromatic 6-membered ring with provisos; B = aromatic 5-membered ring with provisos; Q1 = N, S, O, etc.; Q2 = CH, CR1, etc.; Q3 = N, CN, CR1; R1 = OH, alkyl, alkyloxy, etc.] and their pharmaceutically acceptable salts were prepared. For example, coupling of amine II and 3H-imidazo[4,5-b]pyridine-2-carboxylic acid afforded claimed imidazolpyridinylcarboxamide III in 36% yield. In D1 dopamine receptor inhibition assays, 4-examples of compds. I exhibited Ki values ranging from 440-1500 nM.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
American Home Products	1989			EP 0343961 A	HCAPLUS
Berg, S	2006			WO 2006001754 A	HCAPLUS
Bradley, S	2004			WO 2004104001 A	HCAPLUS
Curtis, N	1999	9	585	BIOORGANIC & MEDICIN	HCAPLUS
Fabrica Espanola de Pro	1992			EP 0496692 A	HCAPLUS
Gov'T Of The U S A	2004			WO 2004024878 A	HCAPLUS
Ikeda, J	2005			EP 1552836 A	HCAPLUS
Merck Sharp & Dohme Ltd	1994			EP 0623618 A	HCAPLUS

Richter Gedeon Vegyesze|2003 | | WO 03028728 A | HCAPLUS

IT 887307-43-9P 887307-45-1P 887307-63-3P


887307-67-7P 887307-70-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolpyridinylcarboxamides and related compds. as D1 dopamine receptor inhibitors)


RN 887307-43-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 887307-45-1 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 887307-63-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-[4-[4-(2,3-dihydro-7-benzofuranyl)-1-piperazinyl]butyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 887307-67-7 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-[4-[4-(3,4-dihydro-2H-1-benzopyran-8-yl)-1-piperazinyl]butyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 887307-70-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 1-(phenylsulfonyl)-N-[4-[4-(2,3,4,5-tetrahydro-1-benzoxepin-9-yl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



=&gt; d ibib ed ab retable hitstr 2-6

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, CHEMCATS' - CONTINUE? (Y)/N:y

L163 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2006:76452 HCAPLUS

DOCUMENT NUMBER: 144:170972

TITLE: Preparation of octahydropyrrolo[2,3-c]pyridines as inhibitors of matrix metalloproteinase

INVENTOR(S): Swinnen, Dominique; Bombrun, Agnes

PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Neth. Antilles

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006008303	A1	20060126	WO 2005-EP53501	20050720
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,				

SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
 ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

EP 2004-103483

A 20040721

US 2004-589621P

P 20040721

OTHER SOURCE(S): CASREACT 144:170972; MARPAT 144:170972

ED Entered STN: 27 Jan 2006

AB The title octahydropyrrolo[2,3-c]pyridine derivs. I [wherein R1 = (hetero)aryl or (hetero)cycloalkyl; R2 = H, SO2, alkyl, alkenyl, alkynyl, acyl, etc.; R3-R6 = independently H, halo, or alkyl], or isomers, enantiomers, diastereomers, racemates, or pharmaceutically acceptable salts thereof were prepared as inhibitors of matrix metalloproteinase (MMP). For example, racemic compound II was prepared in a multi-step synthesis. II showed inhibitory activity against MMP-2, MMP-9, and MMP-12 with IC50 of 0.05, 0.041, and 0.05  $\mu$ M, resp. The compds. are useful for the prophylaxis and/or treatment of autoimmune disorders, cancer, inflammation, cardiovascular diseases, neurodegenerative diseases, respiratory diseases, or fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver, and pulmonary fibrosis (no data). Formulations containing I as active ingredients were described.

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
American Cyanamid Co	2000			WO 0044730 A	HCAPLUS
Amin, E	2001	44	3849	JOURNAL OF MEDICINAL	HCAPLUS
Bristol Myers Squibb Co	2003			WO 03016248 A	HCAPLUS
de Nanteuil, G	2002			WO 02070521 A	HCAPLUS

IT 874306-79-3P 874306-80-6P 874306-81-7P  
 874306-82-8P 874306-83-9P 874306-84-0P  
 874306-85-1P 874306-86-2P 874306-87-3P  
 874306-88-4P 874306-89-5P 874306-90-8P  
 874306-91-9P 874306-92-0P 874306-93-1P  
 874306-94-2P 874306-95-3P 874306-96-4P  
 874306-97-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of octahydropyrrolo[2,3-c]pyridines as MMP inhibitors)

RN 874306-79-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-benzoyloctahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-80-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-acetyloctahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-81-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-6-(3-methyl-1-oxobutyl)-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-82-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-(3-cyclopentyl-1-oxopropyl)octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-83-9 HCAPLUS

CN 6H-Pyrrolo[2,3-c]pyridine-6-carboxylic acid, octahydro-2-[(hydroxyamino)carbonyl]-1-[(4-methoxyphenyl)sulfonyl]-, 2-methoxyethyl ester, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-84-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-6-(1-oxododecyl)-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 874306-85-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-(cyclopentylcarbonyl)octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 874306-86-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-6-(1-oxo-3-phenylpropyl)-, (2R,3aR,7aS)-rel- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 874306-87-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-6-(methylsulfonyl)-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-88-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-1,6-bis[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-89-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-6-[(methoxysulfonyl)-1-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-90-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-([1,1'-biphenyl]-4-ylcarbonyl)octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-91-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-([1,1'-biphenyl]-4-ylsulfonyl)octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-92-0 HCAPLUS

CN 6H-Pyrrolo[2,3-c]pyridine-6-acetamide, N,N-diethyloctahydro-2-[(hydroxyamino)carbonyl]-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-93-1 HCAPLUS

CN 6H-Pyrrolo[2,3-c]pyridine-6-acetamide, N-ethyloctahydro-2-[(hydroxyamino)carbonyl]-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-94-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2,6-dicarboxamide, hexahydro-N2-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-N6-phenyl-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-95-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874306-96-4 HCAPLUS


CN 6H-Pyrrolo[2,3-c]pyridine-6-carboxylic acid, octahydro-2-[(hydroxyamino)carbonyl]-1-[(4-methoxyphenyl)sulfonyl]-, phenylmethyl ester, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 874306-97-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-acetyl-4,5,6,7-tetrahydro-N-hydroxy-1-[(4-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




IT 874307-03-6P 874307-07-0P 874307-11-6P  
874307-15-0P 874307-21-8P 874307-26-3P  
874307-28-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(intermediate; preparation of octahydropyrrolo[2,3-c]pyridines as MMP  
inhibitors)

RN 874307-03-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-benzoyloctahydro-1-[(4-  
methoxyphenyl)sulfonyl]-N-(phenylmethoxy)-, (2R,3aR,7aS)-rel- (9CI) (CA  
INDEX NAME)


Relative stereochemistry.



RN 874307-07-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-acetyloctahydro-1-[(4-  
methoxyphenyl)sulfonyl]-N-(phenylmethoxy)-, (2R,3aR,7aS)-rel- (9CI) (CA  
INDEX NAME)


Relative stereochemistry.



RN 874307-11-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, octahydro-1-[(4-methoxyphenyl)sulfonyl]-6-(3-methyl-1-oxobutyl)-N-(phenylmethoxy)-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 874307-15-0 HCAPLUS

CN 6H-Pyrrolo[2,3-c]pyridine-6-acetamide, N-ethyloctahydro-1-[(4-methoxyphenyl)sulfonyl]-2-[[ (phenylmethoxy) amino]carbonyl]-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.






RN 874307-21-8 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2,6-dicarboxamide, hexahydro-1-[(4-methoxyphenyl)sulfonyl]-N6-phenyl-N2-(phenylmethoxy)-, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 874307-26-3 HCAPLUS  
 CN 6H-Pyrrolo[2,3-c]pyridine-6-carboxylic acid, octahydro-1-[(4-methoxyphenyl)sulfonyl]-2-[[[(phenylmethoxy)amino]carbonyl]-, phenylmethyl ester, (2R,3aR,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 874307-28-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 6-acetyl-4,5,6,7-tetrahydro-1-[(4-methoxyphenyl)sulfonyl]-N-(phenylmethoxy)- (9CI) (CA INDEX NAME)



L163 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2006:740676 HCAPLUS

DOCUMENT NUMBER: 145:188900

TITLE: Preparation of tricyclic compounds as mGluR1 antagonists

INVENTOR(S): Matasi, Julius J.; Tulshian, Deen; Burnett, Duane A.;  
Wu, Wen-Lian; Korakas, Peter; Silverman, Lisa S.;  
Sasikumar, Thavalakulamgara K.; Qiang, Li; Domalski,  
Martin S.

PATENT ASSIGNEE(S): Schering Corp., USA

SOURCE: U.S. Pat. Appl. Publ., 366 pp., Cont.-in-part of U.S.  
Ser. No. 152,535.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

3/6

2006

Shiao 46/849,089

10/26/2006

US 2006167029	A1	20060727	US 2005-301672	20051213
US 2006009477	A1	20060112	US 2005-152535	20050614
PRIORITY APPLN. INFO.:			US 2004-579920P	P 20040615
			US 2005-152535	A2 20050614

OTHER SOURCE(S): MARPAT 145:188900

ED Entered STN: 28 Jul 2006


AB The title compds. I [J1-J4 = independently N, N(O) or C(R), provided that 0-2 of J1-J4 are N or N(O); R = H, halo, amino, CHF2O, etc.; X = O, S, C(O), (un)substituted CH2 or NH; R1 = H, halo, alkyl, etc.; R2 = H, halo, alkyl, etc.; R3 = H, alkyl, aryl, etc.; R4 = H, :O, :S, alkyl, etc.; R5 = R3 or is absent; and pharmaceutically acceptable salts or solvates thereof] were prepared as metabotropic glutamate receptor (mGluR1) antagonists. Thus, reacting II with 2-fluoro-4-methoxyaniline in the presence of glacial acetic acid in toluene afforded 13% III. Compds. I were tested for inhibition of hmGluR1 (data given). Compds. I and their pharmaceutical compns. are useful for treatment of mGluR1 associated diseases, such as pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease (no data).

IT 872886-94-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of tricyclic compds. as mGluR1 antagonists)

RN 872886-94-7 HCAPLUS

CN 4H-Pyrido[3',2':4,5]pyrrolo[3,2-d]pyrimidin-4-one, 9-(dimethylamino)-3,5-dihydro-5-[(4-methoxyphenyl)methyl]-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)




IT 872886-95-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic compds. as mGluR1 antagonists)

RN 872886-95-8 HCAPLUS

CN 4H-Pyrido[3',2':4,5]pyrrolo[3,2-d]pyrimidin-4-one, 3,5-dihydro-5-[(4-methoxyphenyl)methyl]-9-(methylamino)-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)



L163 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2006:15100 HCAPLUS  
 DOCUMENT NUMBER: 144:108348  
 TITLE: Preparation of tricyclic compounds as mGluR1 antagonists  
 INVENTOR(S): Matasi, Julius J.; Tulshian, Deen; Burnett, Duane A.;  
 Wu, Wen-Lian; Korakas, Peter; Silverman, Lisa S.;  
 Sasikumar, Thavalakulamgara K.; Qiang, Li; Domalski,  
 Martin S.  
 PATENT ASSIGNEE(S): Schering Corporation, USA  
 SOURCE: PCT Int. Appl., 309 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002051	A1	20060105	WO 2005-US20972	20050614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-579920P P 20040615  
 OTHER SOURCE(S): MARPAT 144:108348  
 ED Entered STN: 06 Jan 2006  
 AB Title compds. represented by the formula I [wherein J1-J4 = independently  
 N, N→O or C(R), provided that 0-2 of J1-J4 are N or N→O; R =  
 H, halo, amino, CHF2O, etc.; X = O, S, amino, C=O or (un)substituted C;  
 R1-R5 = independently H, halo, alkyl, etc.; and pharmaceutically  
 acceptable salts or solvates thereof] were prepared as metabotropic  
 glutamate receptor (mGluR1) antagonists. For example, II was provided in

a multi-step synthesis starting from the reaction of cyanoacetamide with dimethylacetamide dimethylacetal. I were tested for inhibition of hmGluR1. Thus, I and their pharmaceutical compns. are useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, for treatment of mGluR1 associated diseases, such as pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease (no data).

## RETABLE


Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ambler, S	2001			WO 0132632 A	HCAPLUS
Hayakawa, M	2002			US 2002151544 A1	HCAPLUS
Itahana, H	2002			WO 02062803 A	HCAPLUS
Kadushkin, A	1993	27	40	KHIMIKO-FARMATSEVTIC	HCAPLUS
Kamble, D	1999	9	23	INDIAN JOURNAL OF HE	HCAPLUS
Mahajan, S	1987	19B	402	INDIAN JOURNAL OF CH	HCAPLUS
Merour, J	1982	19	1425	JOURNAL OF HETEROCYC	HCAPLUS
Russo, F	1983	38	762	FARMACO, EDIZIONE SC	HCAPLUS

IT 872886-94-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of tricyclic compds. as mGluR1 antagonists)

RN 872886-94-7 HCAPLUS

CN 4H-Pyrido[3',2':4,5]pyrrolo[3,2-d]pyrimidin-4-one, 9-(dimethylamino)-3,5-dihydro-5-[(4-methoxyphenyl)methyl]-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)




IT 872886-95-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of tricyclic compds. as mGluR1 antagonists)

RN 872886-95-8 HCAPLUS

CN 4H-Pyrido[3',2':4,5]pyrrolo[3,2-d]pyrimidin-4-one, 3,5-dihydro-5-[(4-methoxyphenyl)methyl]-9-(methylamino)-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)



L163 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:64500 HCAPLUS

DOCUMENT NUMBER: 144:205149

TITLE: Design, synthesis, and biological activity of novel factor Xa inhibitors: Improving metabolic stability by S1 and S4 ligand modification

AUTHOR(S): Komoriya, Satoshi; Kobayashi, Shozo; Osanai, Ken; Yoshino, Toshiharu; Nagata, Tsutomu; Haginoya, Noriyasu; Nakamoto, Yumi; Mochizuki, Akiyoshi; Nagahara, Takayasu; Suzuki, Makoto; Shimada, Takashi; Watanabe, Kengo; Isobe, Yumiko; Furugoori, Taketoshi

CORPORATE SOURCE: Tokyo R&amp;D Center, Daiichi Pharmaceutical Co. Ltd, 16-13, Kita-Kasai 1-Chome, Edogawa-ku, Tokyo, 134-8630, Japan

SOURCE: Bioorganic &amp; Medicinal Chemistry (2006), 14(5), 1309-1330

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 24 Jan 2006

AB Serine protease factor Xa (fXa) inhibitor I showed good ex vivo anti-fXa activity upon oral administration in rats. However, it has been revealed that I had low metabolic stability against human liver microsomes. To improve the metabolic stability, we attempted to modify the S1 and S4 ligands of I. These modifications resulted in a compound which exhibited selective anti-fXa activity and excellent anti-coagulation activity.

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Afonso, A	1996			Int Pub No WO 96/314	
Alder, M	2000	39	12534	Biochemistry	
Altland, H	1977	14	129	J Heterocycl Chem	HCAPLUS
Artursson, P	1991	175	880	Biochem Biophys Res	HCAPLUS
Artursson, P	1990	79	476	J Pharm Sci	HCAPLUS
Badger, J	1997	277	344	Methods Enzymol	HCAPLUS
Brandstetter, H	1996	271	29988	J Biol Chem	HCAPLUS
Chiba, J	2005	15	41	Bioorg Med Chem Lett	HCAPLUS
Cunico, R	1992	57	3331	J Org Chem	HCAPLUS
Evans, D	2000	39	2536	Angew Chem, Int Ed	HCAPLUS


Frisch, M	1995			GAUSSIAN94	
Furugohri, T	2005	514	35	Eur J Pharm	HCAPLUS
Guertin, K	2002	12	1671	Bioorg Med Chem Lett	HCAPLUS
Haginoya, N	2004	12	5579	Bioorg Med Chem	HCAPLUS
Haginoya, N	2004	63	1555	Heterocycles	HCAPLUS
Haginoya, N	2004	47	5167	J Med Chem	HCAPLUS
Hamilton, P	1978	31	609	J Clin Pathol	HCAPLUS
Hara, T	1995	74	635	Thromb Haemost	HCAPLUS
Jones, T	1985	115	157	Methods Enzymol	HCAPLUS
Kaiser, B	1998	23	423	Drugs Future	HCAPLUS
Klemm, L	1984	21	785	J Heterocycl Chem	HCAPLUS
Komoriya, S	2005	13	3927	Bioorg Med Chem	HCAPLUS
Kozikowski, A	1994	77	1256	Helv Chim Acta	
MacKay, D	1965			Disseminated Intrava	
Maignan, S	2000	43	3226	J Med Chem	HCAPLUS
Maignan, S	2003	46	685	J Med Chem	HCAPLUS
Morishima, Y	1997	78	1366	Thromb Haemost	HCAPLUS
Murshudov, G	1997	D53	240	Acta Crystallogr	HCAPLUS
Musser, J	1984	14	947	Synth Commun	HCAPLUS
Nagahara, T	1994	37	1200	J Med Chem	HCAPLUS
Nordstoga, K	1977	37	180	Thromb Haemost	MEDLINE
Obach, R	1999	27	1350	Drug Metab Dispos	HCAPLUS
Padmanabhan, K	1993	232	947	J Mol Biol	HCAPLUS
Pflugrath, J	1999	D55	1718	Acta Crystallogr	HCAPLUS
Prager, N	1995	92	962	Circulation	HCAPLUS
Sorkin, E	1948	31	65	Helv Chim Acta	HCAPLUS
Stura, E	1999		99	Crystallization of N	
Takahashi, T	1944	64	235	Yakugaku Zasshi	HCAPLUS
Yamazaki, M	1996	22	255	Semin Thromb Haemost	MEDLINE
Yamazaki, M	1994	71	314	Thromb Haemost	

IT 875573-41-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(factor Xa inhibitors with improved metabolic stability)

RN 875573-41-4 HCAPLUS

CN Piperazine, 1-[(5-chloro-1H-indol-2-yl)sulfonyl]-4-[[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



L163 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:633533 HCAPLUS

DOCUMENT NUMBER: 144:390790

TITLE: Pyrrolopyridine o-aminonitriles in heterocyclic  
synthesis: Synthesis and antimicrobial effects of  
novel pyridopyrrolopyrimidines and related molecules

AUTHOR(S): Gaber, Hatem M.; Erian, Ayman W.; Sherif, Sherif M.;

Ouf, Salama A.  
 CORPORATE SOURCE: National Organization for Drug Control and Research  
 (NODCAR), Cairo, Egypt  
 SOURCE: Afinidad (2005), 62(516), 143-150  
 CODEN: AFINAE; ISSN: 0001-9704  
 PUBLISHER: Asociacion de Quimicos e Ingenieros del Instituto  
 Quimico de Sarria  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 ED Entered STN: 21 Jul 2005  
 AB A convenient and efficient method has been developed for the synthesis of  
 new versatile building blocks pyrrolopyridine o-aminonitriles I (Ar = Ph,  
 p-MeC<sub>6</sub>H<sub>4</sub>). They were easily converted into the corresponding pyrrol-1-yl  
 derivs. by reacting with 2,5-dimethoxytetrahydrofuran. Derivs. of  
 pyridopyrrolopyrimidine containing imidazole, 1,2,4-triazole, and  
 quinazolinone (II) rings were obtained by treating the key precursors I  
 with different chemical reagents. The synthetic applications of I for the  
 formation of some dipyrrolopyrroles were also explored. Some  
 representative products were tested as antimicrobial agents. Some of them  
 showed remarkable activity. Detailed syntheses and spectroscopic and  
 biol. data were presented.

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Abu-Dari, K	1993	20B	12	Pure and Applied Sci	HCAPLUS
Abu-Shanab, F	2002	32	3493	Synth Commun	HCAPLUS
Attia, A	1998	17	1355	Nucleosides Nucleoti	HCAPLUS
Blatt, J	1989	49	2925	Cancer Res	HCAPLUS
de Sevrécourt, M	1981		710	Synthesis	
Eger, K	1993		465	Liebigs Ann Chem	HCAPLUS
El-Gaby, M	2002	57	613	IL Farmaco	HCAPLUS
Elgemeie, G	1992	34	1721	Heterocycles	HCAPLUS
Elgemeie, G	2002	21	411	Nucleosides Nucleoti	HCAPLUS
Elnagdi, M	1998	26		J Chem Res (S)	
Elnagdi, M	1998	188		M	
Elslager, E	1972	9	1123	J Heterocyclic Chem	HCAPLUS
Elslager, E	1972	9	775	J Heterocyclic Chem	HCAPLUS
Ghabrial, S	2003	8	401	Molecules	HCAPLUS
Hess, S	2000	43	4636	J Med Chem	HCAPLUS
Ishida, A	1994			JP 06220059	HCAPLUS
Iwamura, H	1981	6	9	J Pesticide Sci	HCAPLUS
Iwamura, H	1979	18	217	Photochemistry	HCAPLUS
Jorgensen, A	1984	23	73	Chemica Scripta	
Jorgensen, A	1988	28	201	Chemica Scripta	
Kim, D	1972			US 3631036	HCAPLUS
Mizuno, Y	1963	28	3329	J Org Chem	HCAPLUS
Mohareb, R	2003	14	459	Heteroat Chem	HCAPLUS
Mohareb, R	2004	15	15	Heteroat Chem	HCAPLUS
Moharram, H	1989	12	1	Arch Pharm Res	HCAPLUS
Moran, D	2002	67	9061	J Org Chem	HCAPLUS
Muller, C	1990	33	2822	J Med Chem	MEDLINE
Pichler, H	1986		1485	Liebigs Ann Chem	HCAPLUS
Reszka, K	1994	60	450	Photochem Photobiol	HCAPLUS
Sakurai, H	1999		913	Chem Lett	HCAPLUS
Senda, S	1974	22	1459	Chem Pharm Bull	HCAPLUS
Sherif, S	1995	434		J Chem Res (S)	
Sherif, S	1995	2658		M	
Soto, J	1981		529	Synthesis	HCAPLUS
Tolman, R	1969	91	2102	J Amer Chem Soc	HCAPLUS



Wahl, E	1984			Eur Pat Appl EP 108,	HCAPLUS
Wood, H	1971	2	16	Cancer Chemother Rep	
Youssefyeh, R	1984	27	1639	J Med Chem	HCAPLUS


IT 883153-17-1P

RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation and antimicrobial activity of pyridopyrrolopyrimidines)

RN 883153-17-1 HCAPLUS

CN 4H-Pyrido[3',2':4,5]pyrrolo[3,2-d]pyrimidin-4-one, 3,5-dihydro-8-[(4-methoxyphenyl)azo]-5,7,9-triphenyl- (9CI) (CA INDEX NAME)




IT 883153-28-4P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antimicrobial activity of pyridopyrrolopyrimidines)

RN 883153-28-4 HCAPLUS

CN 4H-Pyrido[3',2':4,5]pyrrolo[3,2-d]pyrimidin-4-one, 1,5-dihydro-8-[(4-methoxyphenyl)azo]-5-(4-methylphenyl)-7,9-diphenyl- (9CI) (CA INDEX NAME)



=&gt; d ibib ab hitstr 7

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, CHEMCATS' - CONTINUE? (Y)/N:y

L163 ANSWER 7 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2006:10624 USPATFULL

TITLE: mGluR1 antagonists as therapeutic agents

INVENTOR(S): Matasi, Julius J., Monmouth Junction, NJ, UNITED STATES

Tulshian, Deen, Lebanon, NJ, UNITED STATES

Burnett, Duane A., Bernardsville, NJ, UNITED STATES

Wu, Wen-Lian, Edison, NJ, UNITED STATES  
Korakas, Peter, Roselle Park, NJ, UNITED STATES  
Silverman, Lisa S., Metuchen, NJ, UNITED STATES  
Sasikumar, Thavalakulamgara K., Edison, NJ, UNITED STATES

Qiang, Li, Edison, NJ, UNITED STATES  
Domalski, Martin S., Verona, NJ, UNITED STATES

## PATENT ASSIGNEE(S):

Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006009477	A1	20060112
APPLICATION INFO.:	US 2005-152535	A1	20050614 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-579920P	20040615 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US	
NUMBER OF CLAIMS:	65	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5534	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J.sup.1-J.sup.4, X, and R.sup.1--R.sup.5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease. ##STR1##

IT 872886-94-7P

(preparation of tricyclic compds. as mGluR1 antagonists)

RN 872886-94-7 USPATFULL

CN 4H-Pyrido[3',2':4,5]pyrrolo[3,2-d]pyrimidin-4-one, 9-(dimethylamino)-3,5-dihydro-5-[(4-methoxyphenyl)methyl]-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)




IT 872886-95-8P

(preparation of tricyclic compds. as mGluR1 antagonists)

RN 872886-95-8 USPATFULL

CN 4H-Pyrido[3',2':4,5]pyrrolo[3,2-d]pyrimidin-4-one, 3,5-dihydro-5-[(4-methoxyphenyl)methyl]-9-(methylamino)-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)



=&gt; d ide 8-19

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, CHEMCATS' - CONTINUE? (Y)/N:y

L163 ANSWER 8 OF 19 CHEMCATS COPYRIGHT 2006 ACS on STN

Accession No. (AN): 2005:3866708 CHEMCATS

Catalog Name (CO): Ambinter Stock Screening Collection

Publication Date (PD): 3 Jul 2005


Order Number (ON): 1R-1070

Chemical Name (CN): 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-(4-chlorophenyl)-1-(phenylsulfonyl)-

CAS Registry No. (RN): 477872-25-6

Supplementary Term (ST): CHEMICAL LIBRARY

Structure :



L163 ANSWER 9 OF 19 CHEMCATS COPYRIGHT 2006 ACS on STN


Accession No. (AN): 2005:3866707 CHEMCATS

Catalog Name (CO): Ambinter Stock Screening Collection

Publication Date (PD): 3 Jul 2005


Order Number (ON): 1R-1067

Chemical Name (CN): Morpholine, 4-[[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]carbonyl]-  
CAS Registry No. (RN): 477872-24-5  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L163 ANSWER 10 OF 19 CHEMCATS COPYRIGHT 2006 ACS on STN

Accession No. (AN): 2005:3866706 CHEMCATS  
Catalog Name (CO): Ambinter Stock Screening Collection  
Publication Date (PD): 3 Jul 2005  
Order Number (ON): 1R-1066  
Chemical Name (CN): 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide,  
N-(4-chloro-2-methylphenyl)-1-(phenylsulfonyl)-  
CAS Registry No. (RN): 477872-23-4  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L163 ANSWER 11 OF 19 CHEMCATS COPYRIGHT 2006 ACS on STN


Accession No. (AN): 2005:3866705 CHEMCATS  
Catalog Name (CO): Ambinter Stock Screening Collection  
Publication Date (PD): 3 Jul 2005  
Order Number (ON): 1R-1063  
Chemical Name (CN): 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide,  
N-(4-methoxyphenyl)-1-(phenylsulfonyl)-  
CAS Registry No. (RN): 477872-22-3  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :



L163 ANSWER 12 OF 19 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2005:1905446 CHEMCATS  
Catalog Name (CO): Interchim Intermediates  
Publication Date (PD): 18 Jan 2005  
Order Number (ON): 1R-1070  
Chemical Name (CN): 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide,  
N-(4-chlorophenyl)-1-(phenylsulfonyl)-  
CAS Registry No. (RN): 477872-25-6  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L163 ANSWER 13 OF 19 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2005:1905445 CHEMCATS  
Catalog Name (CO): Interchim Intermediates  
Publication Date (PD): 18 Jan 2005  
Order Number (ON): 1R-1067  
Chemical Name (CN): Morpholine, 4-[[1-(phenylsulfonyl)-1H-pyrrolo[2,3-  
b]pyridin-2-yl]carbonyl]-  
CAS Registry No. (RN): 477872-24-5  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L163 ANSWER 14 OF 19 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2005:1905444 CHEMCATS  
Catalog Name (CO): Interchim Intermediates


Publication Date (PD): 18 Jan 2005  
Order Number (ON): 1R-1066  
Chemical Name (CN): 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide,  
N-(4-chloro-2-methylphenyl)-1-(phenylsulfonyl)-  
CAS Registry No. (RN): 477872-23-4  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :



L163 ANSWER 15 OF 19 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2005:1905443 CHEMCATS  
Catalog Name (CO): Interchim Intermediates  
Publication Date (PD): 18 Jan 2005  
Order Number (ON): 1R-1063  
Chemical Name (CN): 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide,  
N-(4-methoxyphenyl)-1-(phenylsulfonyl)-  
CAS Registry No. (RN): 477872-22-3  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L163 ANSWER 16 OF 19 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2000:936515 CHEMCATS  
Catalog Name (CO): Bionet Screening Compounds  
Publication Date (PD): 27 Mar 2006  
Order Number (ON): 1R-1063  
Chemical Name (CN): N-(4-methoxyphenyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-  
b]pyridine-2-carboxamide  
CAS Registry No. (RN): 477872-22-3  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L163 ANSWER 17 OF 19 CHEMCATS COPYRIGHT 2006 ACS on STN

Accession No. (AN): 2000:581548 CHEMCATS  
Catalog Name (CO): Bionet Screening Compounds  
Publication Date (PD): 27 Mar 2006  
Order Number (ON): 1R-1070  
Chemical Name (CN): N-(4-chlorophenyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide  
CAS Registry No. (RN): 477872-25-6  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :



L163 ANSWER 18 OF 19 CHEMCATS COPYRIGHT 2006 ACS on STN


Accession No. (AN): 2000:581545 CHEMCATS  
Catalog Name (CO): Bionet Screening Compounds  
Publication Date (PD): 27 Mar 2006  
Order Number (ON): 1R-1067  
Chemical Name (CN): morpholino[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]methanone  
CAS Registry No. (RN): 477872-24-5  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :



L163 ANSWER 19 OF 19 CHEMCATS COPYRIGHT 2006 ACS on STN


Accession No. (AN): 2000:581544 CHEMCATS

Catalog Name (CO): Bionet Screening Compounds  
Publication Date (PD): 27 Mar 2006  
Order Number (ON): 1R-1066  
Chemical Name (CN): N-(4-chloro-2-methylphenyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide  
CAS Registry No. (RN): 477872-23-4  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :





=> d que stat 1127  
L1 STR



VAR G1=C/N  
VAR G2=C/N  
VAR G3=C/N  
VAR G4=C/N

NODE ATTRIBUTES:


NSPEC IS RC AT 10  
NSPEC IS RC AT 11  
CONNECT IS E1 RC AT 12  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L2 45329 SEA FILE=REGISTRY SSS FUL L1  
L42 STR



VAR G1=12/21/30/39

NODE ATTRIBUTES:

NSPEC IS RC AT 1  
NSPEC IS RC AT 2  
CONNECT IS E1 RC AT 3  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE

L45 1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42  
L127 608 SEA FILE=REGISTRY ABB=ON PLU=ON L45 AND CL/ELS

=> d que nos l142

L1 STR  
L2 45329 SEA FILE=REGISTRY SSS FUL L1  
L42 STR  
L45 1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42  
L127 608 SEA FILE=REGISTRY ABB=ON PLU=ON L45 AND CL/ELS  
L142 ANALYZE PLU=ON L127 1- LC : 9 TERMS

=> d l142 1-

L142 ANALYZE L127 1- LC : 9 TERMS

TERM #	# OCC	# DOC	% DOC	LC
1	571	571	93.91	CA
2	571	571	93.91	CAPLUS
3	361	361	59.38	USPATFULL
4	32	32	5.26	CASREACT
5	22	22	3.62	CHEMCATS
6	21	21	3.45	TOXCENTER
7	7	7	1.15	CAOLD
8	5	5	0.82	BEILSTEIN
9	1	1	0.16	USPAT2

\*\*\*\*\* END OF L142 \*\*\*\*\*

=> d que nos l145

L1 STR  
L2 45329 SEA FILE=REGISTRY SSS FUL L1  
L32 STR  
L34 4740 SEA FILE=REGISTRY SUB=L2 SSS FUL L32  
L42 STR  
L45 1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42  
L46 93 SEA FILE=REGISTRY ABB=ON PLU=ON L34 AND L45  
L48 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L46  
L49 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY  
<2004 OR REVIEW/DT  
L51 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L48 AND L49  
L127 608 SEA FILE=REGISTRY ABB=ON PLU=ON L45 AND CL/ELS  
L143 39 SEA FILE=HCAPLUS ABB=ON PLU=ON L127  
L144 24 SEA FILE=HCAPLUS ABB=ON PLU=ON L143 AND L49  
L145 20 SEA FILE=HCAPLUS ABB=ON PLU=ON L144 NOT L51

=> d his l150

(FILE 'USPATFULL, USPAT2, TOXCENTER, CASREACT, CHEMCATS' ENTERED AT  
15:54:34 ON 25 OCT 2006)

L150 11 S L149 NOT L83

=> d que nos l150

L1 STR

L2 45329 SEA FILE=REGISTRY SSS FUL L1  
L32 STR  
L34 4740 SEA FILE=REGISTRY SUB=L2 SSS FUL L32  
L42 STR  
L45 1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42  
L46 93 SEA FILE=REGISTRY ABB=ON PLU=ON L34 AND L45  
L49 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY  
<2004 OR REVIEW/DT  
L82 27 SEA L46  
L83 11 SEA L82 AND L49  
L127 608 SEA FILE=REGISTRY ABB=ON PLU=ON L45 AND CL/ELS  
L148 55 SEA L127  
L149 18 SEA L148 AND L49  
L150 11 SEA L149 NOT L83

=> d que nos l154

L1 STR  
L2 45329 SEA FILE=REGISTRY SSS FUL L1  
L42 STR  
L45 1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42  
L127 608 SEA FILE=REGISTRY ABB=ON PLU=ON L45 AND CL/ELS  
L154 3 SEA FILE=CAOLD ABB=ON PLU=ON L127

=> dup rem l145 l150 l154

DUPLICATE IS NOT AVAILABLE IN 'CHEMCATS, CAOLD'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
FILE 'HCAPLUS' ENTERED AT 16:29:32 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:29:32 ON 25 OCT 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:29:32 ON 25 OCT 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CASREACT' ENTERED AT 16:29:32 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAOLD' ENTERED AT 16:29:32 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)  
PROCESSING COMPLETED FOR L145  
PROCESSING COMPLETED FOR L150  
PROCESSING COMPLETED FOR L154

L164 30 DUP REM L145 L150 L154 (4 DUPLICATES REMOVED)  
ANSWERS '1-20' FROM FILE HCAPLUS  
ANSWERS '21-27' FROM FILE USPATFULL  
ANSWERS '28-30' FROM FILE CAOLD

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 16:29:42 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Oct 25, 2006 (20061025/UP).

=> d ibib ed ab hitstr

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, CAOLD' - CONTINUE? (Y)/N:y

L164 ANSWER 1 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:527395 HCAPLUS

DOCUMENT NUMBER: 143:43870

TITLE: Preparation of substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase 1 $\alpha$

INVENTOR(S): Metz, William A.; Halley, Frank; Dutruc-Rosset, Gilles; Choi-Sledeski, Yong Mi; Bernard, Poli Gregory; Fink, David Marc; Doerflinger, Gilles; Huang, Bao-Guo; Gelormini, Ann Marie; Gamboa, Juan Antonio; Giovanni, Andrew; Roehr, Joachim E.; Tsay, Joseph T.; Camacho, Fernando; Hurst, William Joseph; Harnish, Stephen Wayne; Chiang, Yulin

PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 30 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005131012	A1	20050616	US 2004-1533	20041201 <--
AU 2004303826	A1	20050707	AU 2004-303826	20041201 <--
CA 2549183	AA	20050707	CA 2004-2549183	20041201 <--
WO 2005061498	A1	20050707	WO 2004-US40080	20041201 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-528764P P 20031211 <--  
WO 2004-US40080 W 20041201

OTHER SOURCE(S): CASREACT 143:43870; MARPAT 143:43870

ED Entered STN: 19 Jun 2005

AB The present invention discloses and claims compds. of formula (I) [wherein: R1 = H, alkyl; R2 = NR5R6; R3 = aryl, heterocyclyl; R4 = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, CF3, halogen, SH, S-C1-6 alkyl, NO2, NH2 or NR5R6; R5 = H, C1-6 alkyl; R6 = H, C1-6 alkyl; X = S, S(O)n; one of K, L or M is N and the other two members of K, L or M are each C wherein R4 is bonded only to a K, L, M or other ring atom that is C; m = 1-3; n = 1, 2] or a pharmaceutically acceptable salts or stereoisomers thereof as inhibitors of human casein kinase 1 $\alpha$ , and methods of using said compds. of formula I for treating central nervous system diseases and disorders including mood disorders and sleep disorders, more specifically depression, bipolar disorder, circadian rhythm sleep disorder, jet lag syndrome, advanced sleep phase syndrome, and delayed sleep phase syndrome. Thus, to 1H-pyrrolo[3,2-b]pyridine-2-


carboxamide (0.42 mmol) dissolved in dry DMF (10 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (100 mg, 0.31 mmol) and then bis(3-bromophenyl)disulfide (1.1 equivalent, 0.46 mmol), and the resulting mixture was heated under N<sub>2</sub> at 95° for 16 h to give 3-(3-Bromophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide/1H-pyrrolo[3,2-b]pyridine-2-carboxamide (II). II showed IC<sub>50</sub> of 25 nM against human casein kinase 1 $\epsilon$ .

IT **853685-39-9P**, 3-(3-Chlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **853685-41-3P**, 3-(2-Chlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **853685-42-4P**, 3-(4-Chlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **853685-43-5P**, 3-(2,4-Dichlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **853685-45-7P**, 3-(2,3-Dichlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **853685-49-1P**, 3-(2,5-Dichlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide **853685-69-5P**, 3-[(3-Chlorophenyl)sulfanyl]-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid methylamide **853685-83-3P**, 3-[(4-Chlorophenyl)sulfanyl]-1H-pyrrolo[3,2-c]pyridine-2-carboxamide **853685-88-8P**, 3-(3-Chlorophenylsulfanyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted 1H-pyrrolopyridinecarboxamides as inhibitors of casein kinase 1 $\epsilon$  for treating central nervous system disease)


RN 853685-39-9 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 3-[(3-chlorophenyl)thio]- (9CI)  
 (CA INDEX NAME)




RN 853685-41-3 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 3-[(2-chlorophenyl)thio]- (9CI)  
 (CA INDEX NAME)




RN 853685-42-4 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 3-[(4-chlorophenyl)thio]- (9CI)  
 (CA INDEX NAME)




RN 853685-43-5 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 3-[(2,4-dichlorophenyl)thio]-  
(9CI) (CA INDEX NAME)




RN 853685-45-7 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 3-[(2,3-dichlorophenyl)thio]-  
(9CI) (CA INDEX NAME)




RN 853685-49-1 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 3-[(2,5-dichlorophenyl)thio]-  
(9CI) (CA INDEX NAME)




RN 853685-69-5 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 3-[(3-chlorophenyl)thio]-N-methyl-  
(9CI) (CA INDEX NAME)




RN 853685-83-3 HCAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-2-carboxamide, 3-[(4-chlorophenyl)thio] - (9CI)  
(CA INDEX NAME)



RN 853685-88-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 3-[(3-chlorophenyl)thio] - (9CI)  
(CA INDEX NAME)



=> d ibib ed ab hitstr 2-20

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, CAOLD' - CONTINUE? (Y)/N:y

L164 ANSWER 2 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 1997:102094 HCAPLUS

DOCUMENT NUMBER: 126:199575

TITLE: Tricyclic substituted hexahydrobenz[e]isoindole  
alpha-1 adrenergic antagonists

INVENTOR(S): Meyer, Michael D.; Altenbach, Robert J.; Basha, Fatima  
Z.; Carroll, William A.; Drizin, Irene; Elmore, Steven  
W.; Kerwin, James F., Jr.; Lebold, Suzanne A.; Lee,  
Edmund L.; Sippy, Kevin B.; Tietje, Karin R.; Wendt,  
Michael D.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: U.S., 73 pp., Cont.-in-part of U.S. Ser. No. 379,414,  
abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5597823	A	19970128	US 1995-463528	19950605 <--
IL 116405	A1	20010913	IL 1995-116405	19951215 <--
CA 2211212	AA	19960801	CA 1996-2211212	19960111 <--
WO 9622992	A1	19960801	WO 1996-US72	19960111 <--
W: AU, CA, JP, KR, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9647457	A1	19960814	AU 1996-47457	19960111 <--
AU 705283	B2	19990520		
EP 808318	A1	19971126	EP 1996-903340	19960111 <--
EP 808318	B1	20000628		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 194141	E	20000715	AT 1996-903340	19960111 <--
ES 2149451	T3	20001101	ES 1996-903340	19960111 <--
PT 808318	T	20001229	PT 1996-903340	19960111 <--
JP 2001504797	T2	20010410	JP 1996-522867	19960111 <--
GR 3034485	T3	20001229	GR 2000-402174	20000926 <--
PRIORITY APPLN. INFO.:			US 1995-379414	B2 19950127 <--
			US 1995-463528	A 19950605 <--
			WO 1996-US72	W 19960111 <--

OTHER SOURCE(S): MARPAT 126:199575

ED Entered STN: 13 Feb 1997

AB I (W = tricyclic heterocyclic ring system, e. g. pyrazinothienopyrimidinediones, pyridofuopyrimidinediones, pyrazinothienopyrimidinediones; n = 2-6; R1 and R2 = H, alkoxy, hydroxy, alkyl, halo, carboxy, alkoxycarbonyl) and their pharmaceutically acceptable salts were prepared I are  $\alpha$ -1 adrenergic antagonists and useful in the treatment of BPH (benign prostrate hyperplasia).  $\alpha$ -1 Antagonist compns. and a method for antagonizing  $\alpha$ -1 receptors and treating BPH are also disclosed.


IT 181282-28-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation as alpha-1 adrenergic antagonists in treatment of benign prostrate hyperplasia)

RN 181282-28-0 HCAPLUS

CN 1H-Pyrido[3',4':4,5]pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 3-[2-(1,3,3a,4,5,9b-hexahydro-6-methoxy-2H-benz[e]isoindol-2-yl)ethyl]-, monohydrochloride, (3aR-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L164 ANSWER 3 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:405330 HCAPLUS

DOCUMENT NUMBER: 142:463759

TITLE: Preparation of hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors

INVENTOR(S): Wai, John S.; Fisher, Thorsten E.; Zhuang, Linghang; Staas, Donnette D.; Lyle, Terry A.; Kim, Boyoung; Embrey, Mark W.; Wiscount, Catherine M.; Tran, Lekhanh O.; Egbertson, Melissa; Savage, Kelly L.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 181 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041664	A1	20050512	WO 2004-US34420	20041018 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285449	A1	20050512	AU 2004-285449	20041018 <--
CA 2542047	AA	20050512	CA 2004-2542047	20041018 <--
EP 1677599	A1	20060712	EP 2004-795564	20041018 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRIORITY APPLN. INFO.:			US 2003-512678P	P 20031020 <--
			WO 2004-US34420	W 20041018

OTHER SOURCE(S): MARPAT 142:463759

ED Entered STN: 12 May 2005

AB Title compds. I [bond "m" is either single or double; bond "n" is either single or double and when double, R7 and R8 are absent; the central ring

containing A and B is pyrrolyl where one of A or B equals N while the other equals C; R1 = (un)substituted-arylalkyl or -heteroarylalkyl; R2 = H, (un)substituted alkyl; R3 = H, alkenyl, haloalkyl, alkynyl, etc.; R4 = H, (un)substituted-alkyl, -aryl, ester, etc.; R5 = H, (un)substituted alkyl; R6 = H, alkyl, (un)substituted-arylalkyl, etc.; R7 = H, alkyl, or alternatively R5 and R7 together form oxo or thioxo or spirocycloalkyl; R8 = H, alkyl, or alternatively R4 and R8 together form spirocycloalkyl; if R7 and R8 are absent, R4 and R5 together form a (un)substituted-benzene or a -6-membered heteroaryl ring, or a cycloalkane ring], and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of HIV integrase and inhibitors of HIV replication. Thus, e.g., II was prepared via cyclocondensation of Et 3-[N-(3-ethoxy-3-oxopropyl)-N-(4-fluorobenzyl)]amino-3-oxopropanoate (preparation given) to form pyridine III which was sulfonated with trifluoromethanesulfonic acid and reacted with piperazin-2-one under microwave irradiation to provide II. The compds. are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compds. are employed against HIV infection and AIDS as compds. per se or in the form of pharmaceutically acceptable salts. The compds. and their salts can be employed as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.


IT 851726-00-6P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(preparation of hydroxypyridopyrrolopyrazine dione derivs. as HIV integrase inhibitors)

RN 851726-00-6 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-3,4,7,8-tetrahydro-10-hydroxy-7-methyl- (9CI) (CA INDEX NAME)



IT 851726-44-8P 851726-45-9P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydroxypyridopyrrolopyrazine dione derivs. as HIV integrase inhibitors)

RN 851726-44-8 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-3,4,7,8-tetrahydro-10-hydroxy-7-methyl-, (+) - (9CI) (CA INDEX NAME)


Rotation (+).



RN 851726-45-9 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-3,4,7,8-tetrahydro-10-hydroxy-  
7-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




IT 851725-24-1P 851725-28-5P 851725-29-6P  
851725-41-2P 851725-44-5P 851725-50-3P  
851725-55-8P 851725-84-3P 851725-92-3P  
851726-03-9P 851726-04-0P 851726-06-2P  
851726-09-5P 851726-10-8P 851726-12-0P  
851726-18-6P 851726-20-0P 851726-21-1P  
851726-22-2P 851726-23-3P 851726-24-4P  
851726-25-5P 851726-26-6P 851726-27-7P  
851726-30-2P 851726-31-3P 851726-32-4P  
851726-33-5P 851726-34-6P 851726-36-8P  
851726-37-9P 851726-38-0P 851726-39-1P  
851726-40-4P 851726-41-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of hydroxypyridopyrrolopyrazine dione derivs. as HIV integrase  
inhibitors)


RN 851725-24-1 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
8-[(3-chloro-4-fluorophenyl)methyl]-3,4,7,8-tetrahydro-10-hydroxy-2-methyl-  
(9CI) (CA INDEX NAME)




RN 851725-28-5 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
8-[(3,4-dichlorophenyl)methyl]-3,4,7,8-tetrahydro-10-hydroxy-2-methyl-  
(9CI) (CA INDEX NAME)




RN 851725-29-6 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
8-[(3-chlorophenyl)methyl]-3,4,7,8-tetrahydro-10-hydroxy-2-methyl- (9CI)  
(CA INDEX NAME)



RN 851725-41-2 HCAPLUS


CN Pyrido[3',4':4,5]pyrrolo[1,2-a]quinoxaline-6,8(5H,9H)-dione,  
2-chloro-9-[(4-fluorophenyl)methyl]-10,11-dihydro-7-hydroxy- (9CI) (CA  
INDEX NAME)




RN 851725-44-5 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-3,4,7,8-tetrahydro-10-hydroxy-


6-methyl- (9CI) (CA INDEX NAME)




RN 851725-50-3 HCAPLUS  
 CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
 2-[(3-chloro-4-fluorophenyl)methyl]-3,4,7,8-tetrahydro-10-hydroxy-8-(3-  
 pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 851725-55-8 HCAPLUS  
 CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
 2-[(3-chloro-4-fluorophenyl)methyl]-7,8-dihydro-10-hydroxy-4,8-dimethyl-  
 (9CI) (CA INDEX NAME)




RN 851725-84-3 HCAPLUS  
 CN Spiro[cyclopropane-1,6'-(7'H)-pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine]-  
 1',9'-(2'H,8'H)-dione, 2'-[(3-chloro-4-fluorophenyl)methyl]-8'-ethyl-3',4'-  
 dihydro-10'-hydroxy- (9CI) (CA INDEX NAME)




RN 851725-92-3 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-3,4,7,8-tetrahydro-10-hydroxy-  
7,7-dimethyl- (9CI) (CA INDEX NAME)




RN 851726-03-9 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
2-[(3-chloro-4-fluorophenyl)methyl]-8-(cyclopropylmethyl)-3,4,7,8-  
tetrahydro-10-hydroxy-7-methyl- (9CI) (CA INDEX NAME)




RN 851726-04-0 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
2-[(3-chloro-4-fluorophenyl)methyl]-3,4,7,8-tetrahydro-10-hydroxy-7,8-  
dimethyl- (9CI) (CA INDEX NAME)




RN 851726-06-2 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
2-[(3-chloro-4-fluorophenyl)methyl]-8-cyclopropyl-3,4,7,8-tetrahydro-10-  
hydroxy-7-methyl- (9CI) (CA INDEX NAME)




RN 851726-09-5 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carboxylic acid,  
2-[(3-chloro-4-fluorophenyl)methyl]-1,2,3,4,6,7,8,9-octahydro-10-hydroxy-8-  
methyl-1,9-dioxo-, methyl ester (9CI) (CA INDEX NAME)



RN 851726-10-8 HCAPLUS


CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carboxamide,  
2-[(3-chloro-4-fluorophenyl)methyl]-1,2,3,4,6,7,8,9-octahydro-10-hydroxy-  
N,N,8-trimethyl-1,9-dioxo- (9CI) (CA INDEX NAME)



RN 851726-12-0 HCAPLUS


CN Morpholine, 4-[[2-[(3-chloro-4-fluorophenyl)methyl]-1,2,3,4,6,7,8,9-  
octahydro-10-hydroxy-8-methyl-1,9-dioxopyrido[3',4':4,5]pyrrolo[1,2-  
a]pyrazin-4-yl]carbonyl]- (9CI) (CA INDEX NAME)






RN 851726-18-6 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carboxylic acid,  
2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-hydroxy-8-  
methyl-1,9-dioxo-, methyl ester (9CI) (CA INDEX NAME)




RN 851726-20-0 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carboxamide,  
2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-hydroxy-N,8-  
dimethyl-1,9-dioxo- (9CI) (CA INDEX NAME)




RN 851726-21-1 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carboxamide,  
2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-hydroxy-N,N,8-  
trimethyl-1,9-dioxo- (9CI) (CA INDEX NAME)




RN 851726-22-2 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carboxamide,  
2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-hydroxy-8-  
methyl-1,9-dioxo- (9CI) (CA INDEX NAME)



RN 851726-23-3 HCAPLUS


CN Morpholine, 4-[[2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-  
10-hydroxy-8-methyl-1,9-dioxopyrido[3',4':4,5]pyrrolo[1,2-a]pyrazin-4-  
yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 851726-24-4 HCAPLUS


CN Piperazine, 1-[[2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-  
10-hydroxy-8-methyl-1,9-dioxopyrido[3',4':4,5]pyrrolo[1,2-a]pyrazin-4-

yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 851726-25-5 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carboxamide,  
2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-hydroxy-N-  
methoxy-N,8-dimethyl-1,9-dioxo- (9CI) (CA INDEX NAME)



RN 851726-26-6 HCAPLUS


CN Azetidine, 1-[[2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-  
10-hydroxy-8-methyl-1,9-dioxo-pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazin-4-  
yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 851726-27-7 HCAPLUS

CN Pyrrolidine, 1-[[2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-


10-hydroxy-8-methyl-1,9-dioxopyrido[3',4':4,5]pyrrolo[1,2-a]pyrazin-4-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 851726-30-2 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carboxamide,  
2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-1,2,6,7,8,9-hexahydro-10-  
hydroxy-N,6-dimethyl-1,9-dioxo-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851726-31-3 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carboxamide,  
2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-1,2,6,7,8,9-hexahydro-10-  
hydroxy-N,N,6-trimethyl-1,9-dioxo-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851726-32-4 HCAPLUS


CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carbonitrile,

2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-hydroxy-8-methyl-1,9-dioxo- (9CI) (CA INDEX NAME)




RN 851726-33-5 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-7,8-dihydro-10-hydroxy-8-methyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)



RN 851726-34-6 HCAPLUS


CN Methanesulfonamide, N-[2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-hydroxy-8-methyl-1,9-dioxopyrido[3',4':4,5]pyrrolo[1,2-a]pyrazin-4-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 851726-36-8 HCAPLUS


CN Acetamide, N-[2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-hydroxy-8-methyl-1,9-dioxopyrido[3',4':4,5]pyrrolo[1,2-a]pyrazin-4-yl]-N-

methyl- (9CI) (CA INDEX NAME)




RN 851726-37-9 HCAPLUS

CN Carbamic acid, [2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-hydroxy-8-methyl-1,9-dioxypyrido[3',4':4,5]pyrrolo[1,2-a]pyrazin-4-yl)methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 851726-38-0 HCAPLUS

CN Ethanediamide, [2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-hydroxy-8-methyl-1,9-dioxypyrido[3',4':4,5]pyrrolo[1,2-a]pyrazin-4-yl]trimethyl- (9CI) (CA INDEX NAME)




RN 851726-39-1 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione, 4-bromo-2-[(3-chloro-4-fluorophenyl)methyl]-7,8-dihydro-10-hydroxy-8-methyl- (9CI) (CA INDEX NAME)




RN 851726-40-4 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
2-[(3-chloro-4-fluorophenyl)methyl]-7,8-dihydro-10-hydroxy-8-methyl-4-(methylthio)- (9CI) (CA INDEX NAME)



RN 851726-41-5 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
2-[(3-chloro-4-fluorophenyl)methyl]-7,8-dihydro-10-hydroxy-8-methyl-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




IT 851727-08-7 851727-09-8

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of hydroxypyridopyrrolopyrazine dione derivs. as HIV integrase inhibitors)

RN 851727-08-7 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carboxamide,  
2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-8-methyl-1,9-dioxo-10-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 851727-09-8 HCAPLUS  
 CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carboxylic acid,  
 2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-methoxy-8-  
 methyl-1,9-dioxo- (9CI) (CA INDEX NAME)



IT 851726-71-1P 851726-98-2P 851726-99-3P  
 851727-00-9P 851727-01-0P 851727-02-1P  
 851727-03-2P 851727-04-3P 851727-05-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of hydroxypyridopyrrolopyrazine dione derivs. as HIV integrase  
 inhibitors)  
 RN 851726-71-1 HCAPLUS  
 CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione,  
 8-[(3-chloro-4-fluorophenyl)methyl]-3,4,7,8-tetrahydro-2,6-dimethyl-10-[(4-  
 methylphenyl)methoxy]- (9CI) (CA INDEX NAME)






RN 851726-98-2 HCAPLUS


CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carboxylic acid,  
2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-1,2,3,4,6,7,8,9-octahydro-10-  
methoxy-6-methyl-1,9-dioxo-, methyl ester, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851726-99-3 HCAPLUS


CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-4-carboxylic acid,  
2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-methoxy-8-  
methyl-1,9-dioxo-, 2-acetylhydrazide (9CI) (CA INDEX NAME)



RN 851727-00-9 HCAPLUS


CN Carbamic acid, [2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-  
10-methoxy-8-methyl-1,9-dioxopyrido[3',4':4,5]pyrrolo[1,2-a]pyrazin-4-yl]-

, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 851727-01-0 HCAPLUS

CN Carbamic acid, [2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-methoxy-8-methyl-1,9-dioxypyrido[3',4':4,5]pyrrolo[1,2-a]pyrazin-4-yl](methylsulfonyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 851727-02-1 HCAPLUS

CN Methanesulfonamide, N-[2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-methoxy-8-methyl-1,9-dioxypyrido[3',4':4,5]pyrrolo[1,2-a]pyrazin-4-yl]- (9CI) (CA INDEX NAME)




RN 851727-03-2 HCAPLUS

CN Methanesulfonamide, N-[2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-methoxy-8-methyl-1,9-dioxypyrido[3',4':4,5]pyrrolo[1,2-a]pyrazin-4-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 851727-04-3 HCAPLUS

CN Carbamic acid, [2-[(3-chloro-4-fluorophenyl)methyl]-1,2,6,7,8,9-hexahydro-10-methoxy-8-methyl-1,9-dioxypyrido[3',4':4,5]pyrrolo[1,2-a]pyrazin-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 851727-05-4 HCAPLUS

CN Pyrido[3',4':4,5]pyrrolo[1,2-a]pyrazine-1,9(2H,6H)-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-7,8-dihydro-10-methoxy-8-methyl-4-(methylamino)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L164 ANSWER 4 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:324000 HCAPLUS

DOCUMENT NUMBER: 142:392407

TITLE: Preparation of monocyclic and bicyclic lactams, in

particular derivatives of pyrrolidines and  
pyrroloimidazoles, as Factor Xa inhibitors  
INVENTOR(S): Han, Wei; Qiao, Jennifer; Hu, Zilun  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
SOURCE: PCT Int. Appl., 329 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005032468	A2	20050414	WO 2004-US31857	20040929 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005107361	A1	20050519	US 2004-952397	20040928 <--
EP 1667647	A2	20060614	EP 2004-789189	20040929 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:			US 2003-507533P	P 20031001 <--
			US 2004-952397	A 20040928
			WO 2004-US31857	W 20040929

OTHER SOURCE(S): MARPAT 142:392407

ED Entered STN: 15 Apr 2005

AB Title compds. [I and II; V = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; U = (CH<sub>2</sub>)<sub>m</sub>; m = 1-2; one of T1 and T2 = CO, CS, SO<sub>2</sub>, and the other = CO, CS, SO<sub>2</sub>, CH<sub>2</sub>, CHOH; one of Z1 and Z2 = N, and the other = C; G = (un)substituted Ph, pyrimidyl, pyrazinyl, pyridazinyl, etc. optionally fused with a 5-6 membered ring containing 0-2 heteroatoms; G1 = SO<sub>2</sub>NH and derivs., NHCO, NHCSNH and derivs., (un)substituted alkylene, etc.; A = (un)substituted carbocycle, heterocycle; B = alkylene, SO<sub>2</sub>H and derivs., (un)substituted carbocycle, heterocycle, etc.; R1a at each occurrence = H, (un)substituted alkylene, alkenylene, alkynylene, etc.; or R1aCCR1a = (un)substituted 5-7 membered ring; their stereoisomers or pharmaceutically acceptable salts; with provisos], were prepared as inhibitors of trypsin-like serine proteases, specifically Factor Xa. For example, an eleven-step synthesis starting from trans-3-Hydroxy-L-proline is given for lactam III. I displayed Ki ≤ 10 μM for the inhibition of Factor Xa. I were effective thrombin inhibitors; Ki ≤ 10 μM. I are useful antithrombotics.

IT 850000-08-7P, 5-Chloro-N-[[1-[4-[1-(morpholinomethyl)cyclopropyl]phenyl]-5-oxopyrrolidin-3-yl]methyl]-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 850000-09-8P, 5-Chloro-N-[[5-oxo-1-[4-[1-(piperidin-1-ylmethyl)cyclopropyl]phenyl]pyrrolidin-3-yl]methyl]-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 850000-10-1P, 5-Chloro-N-[[1-[4-[1-[(dimethylamino)methyl]cyclopropyl]phenyl]-5-oxopyrrolidin-3-yl]methyl]-1H-pyrrolo[3,2-b]pyridine-2-carboxamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of monocyclic and bicyclic lactams as Factor Xa

inhibitors)


RN 850000-08-7 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 5-chloro-N-[[1-[4-[1-(4-morpholinylmethyl)cyclopropyl]phenyl]-5-oxo-3-pyrrolidinyl]methyl]- (9CI)  
(CA INDEX NAME)




RN 850000-09-8 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 5-chloro-N-[[5-oxo-1-[4-[1-(1-piperidinylmethyl)cyclopropyl]phenyl]-3-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 850000-10-1 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 5-chloro-N-[[1-[4-[1-[(dimethylamino)methyl]cyclopropyl]phenyl]-5-oxo-3-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



L164 ANSWER 5 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:14399 HCAPLUS

DOCUMENT NUMBER: 142:114103

TITLE: Preparation of triazafluorenes as 5-HT<sub>2C</sub> receptor agonists for the treatment of diabetes and obesity.

INVENTOR(S): Blench, Toby Jonathan; Hebeisen, Paul; Richter, Hans; Roever, Stephan

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.; Vernalis Research

SOURCE: Limited  
PCT Int. Appl., 148 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000849	A1	20050106	WO 2004-EP6612	20040618 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004251847	A1	20050106	AU 2004-251847	20040618 <--
CA 2530308	AA	20050106	CA 2004-2530308	20040618 <--
EP 1641796	A1	20060405	EP 2004-740057	20040618 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1812989	A	20060802	CN 2004-80017918	20040618 <--
BR 2004011936	A	20060829	BR 2004-11936	20040618 <--
US 2005026925	A1	20050203	US 2004-876954	20040625 <--
PRIORITY APPLN. INFO.:			GB 2003-14967	A 20030626 <--
			WO 2004-EP6612	W 20040618

OTHER SOURCE(S): MARPAT 142:114103

ED Entered STN: 07 Jan 2005

AB Title compds. (I; R1 = H, alkyl, haloalkyl, cycloalkyl, halo, alkoxy, cycloalkoxy, hydroxyalkyl, etc.; R2 = alkyl, cycloalkyl, alkoxy, cycloalkoxy, halo, OH, hydroxyalkyl, alkoxyalkyl, aralkoxyalkyl, etc.; R3 = H, alkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkoxyalkyl, etc.; R4 = H, alkyl; R5 = alkyl), were prepared Thus, tert-Bu (4R,9aR)-7-fluoro-8-hydroxymethyl-4-methyl-3,4,9,9a-tetrahydro-1H-2,4a,5-triazafluorene-2-carboxylate (preparation given) was stirred 2.5 h with CBr4 and Ph3P in CH2Cl2 to give an oil which was stirred 0.5 h with polymethylhydrosilane and Pd(OAc)2 in THF to give a residue which was stirred 0.5 h with CF3CO2H to give (4R,9aR)-7-fluoro-4,8-dimethyl-3,4,9,9a-tetrahydro-1H-2,4a,5-triazafluorene. The latter in a functional assay using human 5-HT2C receptors showed an EC50 of 13 nM.

IT 823217-65-8P 823217-76-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of triazafluorenes as 5-HT2C receptor agonists for the treatment of diabetes and obesity)

RN 823217-65-8 HCAPLUS

CN Pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazin-6(7H)-one, 2-chloro-3-ethoxy-8,9-dihydro-9-methyl-, (9R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 823217-76-1 HCAPLUS

CN Pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazin-6(7H)-one, 2-chloro-8,9-dihydro-3,9-dimethyl-, (9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L164 ANSWER 6 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1037102 HCAPLUS

DOCUMENT NUMBER: 142:23513

TITLE: Preparation of pyrrolopyridine-2-carboxylic acid amide as inhibitors of glycogen phosphorylase

INVENTOR(S): Bradley, Stuart Edward; Krulle, Thomas Martin; Murray, Peter John; Procter, Martin James; Rowley, Robert John; Sambrook Smith, Colin Peter; Thomas, Gerard Hugh

PATENT ASSIGNEE(S): Osi Pharmaceuticals, Inc., USA; Schofield, Karen Lesley

SOURCE: PCT Int. Appl., 188 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004104001	A2	20041202	WO 2004-US16243	20040520 <--
WO 2004104001	A3	20050303		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

AU 2004240946	A1	20041202	AU 2004-240946	20040520 <--
CA 2525502	AA	20041202	CA 2004-2525502	20040520 <--
US 2005261272	A1	20051124	US 2004-851902	20040520
EP 1636224	A2	20060322	EP 2004-753127	20040520 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010445	A	20060530	BR 2004-10445	20040520 <--
CN 1826340	A	20060830	CN 2004-80021117	20040520 <--
NO 2005005305	A	20051215	NO 2005-5305	20051110 <--
PRIORITY APPLN. INFO.:			US 2003-472375P	P 20030521 <--
			US 2004-551256P	P 20040308
			WO 2004-US16243	W 20040520

OTHER SOURCE(S): MARPAT 142:23513

ED Entered STN: 03 Dec 2004

AB Heterocyclyl acyl amino acid derivs. I [one of X1-X4 is N and the others are C; R1, R1' are each independently halo, hydroxy, cyano, alkyl, alkoxy, fluoromethyl, ethenyl or ethynyl; R2 is alkyl or substituted alkyl, carboxy ester or acyl; Y is alkyl or CH(OH); Z is CH2, CO, O, (cyclo)alkylamino or absent, but when Y is CH(OH), Z or R3 must be bonded to Y through a carbon-carbon bond; R3 is H, carbalkoxy, alkoxy, alkyl, arylalkyl, alkylamino, etc.] or their stereoisomers or pharmaceutically-acceptable salts were prepared as inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis, etc. Thus, pyrrolo[3,2-b]pyridine-2-carboxylic acid L-phenylalaninamide derivative II was prepared via peptide coupling reaction and showed IC50 < 1 mM in the glycogen phosphorylase assay in vitro.

IT 800397-99-3P 800398-33-8P 800398-34-9P  
 800398-35-0P 800398-36-1P 800398-37-2P  
 800398-38-3P 800398-42-9P 800399-22-8P  
 800399-23-9P 800399-85-3P 800400-37-7P  
 800400-46-8P 800400-49-1P 800400-52-6P  
 800400-69-5P 800400-84-4P 800400-89-9P  
 800400-95-7P 800400-97-9P 800400-98-0P  
 800401-07-4P 800401-08-5P 800401-17-6P  
 800401-18-7P 800401-22-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of pyrrolopyridinecarboxylic acid amide as inhibitors of glycogen phosphorylase)

RN 800397-99-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 800398-33-8 HCAPLUS

CN Glycine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 800398-34-9 HCAPLUS


CN Glycine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]- (9CI) (CA INDEX NAME)



RN 800398-35-0 HCAPLUS

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-36-1 HCAPLUS

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-37-2 HCAPLUS

CN Benzenebutanoic acid,  $\beta$ -[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]- $\alpha$ -hydroxy-, methyl ester, ( $\alpha$ R, $\beta$ S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-38-3 HCAPLUS


CN Benzenebutanoic acid,  $\beta$ -[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]- $\alpha$ -hydroxy-, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800398-42-9 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-fluorophenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 800399-22-8 HCAPLUS

CN Benzenebutanoic acid,  $\beta$ -[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]- $\alpha$ -hydroxy-, methyl ester, ( $\alpha$ S, $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-23-9 HCAPLUS

CN Benzenebutanoic acid,  $\beta$ -[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]- $\alpha$ -hydroxy-, ( $\alpha$ S, $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-85-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-(4-amino-1-piperidiny)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-37-7 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-46-8 HCAPLUS

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-4-fluoro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-49-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-52-6 HCAPLUS

CN Carbamic acid, [1-[(2S)-2-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-4-piperidiny]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-69-5 HCAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2S)-2-[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-84-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]methylamino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-89-9 HCAPLUS

CN 4-Pyridinepropanoic acid,  $\alpha$ -[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-, methyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-95-7 HCAPLUS


CN 4-Pyridinepropanoic acid,  $\alpha$ -[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800400-97-9 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-hydroxy-2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 800400-98-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2S)-2-hydroxy-1-(methoxymethyl)-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-07-4 HCAPLUS

CN L-Phenylalanine, N-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)carbonyl]-4-fluoro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-08-5 HCAPLUS

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-17-6 HCAPLUS

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)carbonyl]-4-fluoro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-18-7 HCAPLUS

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-22-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3R)-3-hydroxy-1-pyrrolidiny]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 800397-93-7P 800397-98-2P 800398-00-9P  
 800398-03-2P 800398-04-3P 800398-05-4P  
 800398-06-5P 800398-07-6P 800398-08-7P  
 800398-09-8P 800398-10-1P 800398-11-2P  
 800398-12-3P 800398-13-4P 800398-14-5P  
 800398-21-4P 800398-22-5P 800398-23-6P  
 800398-24-7P 800398-25-8P 800398-26-9P  
 800398-27-0P 800398-28-1P 800398-29-2P



800398-30-5P 800398-31-6P 800398-32-7P  
800398-39-4P 800398-40-7P 800398-41-8P  
800398-43-0P 800398-44-1P 800398-45-2P  
800398-46-3P 800398-47-4P 800398-48-5P  
800398-49-6P 800398-50-9P 800398-51-0P  
800398-52-1P 800398-53-2P 800398-54-3P  
800398-55-4P 800398-56-5P 800398-57-6P  
800398-58-7P 800398-59-8P 800398-60-1P  
800398-61-2P 800398-62-3P 800398-63-4P  
800398-64-5P 800398-65-6P 800398-66-7P  
800398-67-8P 800398-68-9P 800398-69-0P  
800398-70-3P 800398-71-4P 800398-72-5P  
800398-73-6P 800398-74-7P 800398-75-8P  
800398-76-9P 800398-77-0P 800398-78-1P  
800398-79-2P 800398-80-5P 800398-81-6P  
800398-82-7P 800398-83-8P 800398-84-9P  
800398-86-1P 800398-87-2P 800398-89-4P  
800398-91-8P 800398-93-0P 800398-95-2P  
800398-97-4P 800398-98-5P 800398-99-6P  
800399-00-2P 800399-01-3P 800399-02-4P  
800399-03-5P 800399-04-6P 800399-05-7P  
800399-06-8P 800399-07-9P 800399-08-0P  
800399-09-1P 800399-10-4P 800399-11-5P  
800399-12-6P 800399-13-7P 800399-14-8P  
800399-19-3P 800399-20-6P 800399-21-7P  
800399-24-0P 800399-25-1P 800399-26-2P  
800399-27-3P 800399-28-4P 800399-29-5P  
800399-30-8P 800399-31-9P 800399-32-0P  
800399-33-1P 800399-34-2P 800399-35-3P  
800399-36-4P 800399-37-5P 800399-38-6P  
800399-39-7P 800399-40-0P 800399-41-1P  
800399-42-2P 800399-44-4P 800399-45-5P  
800399-47-7P 800399-48-8P 800399-49-9P  
800399-50-2P 800399-51-3P 800399-52-4P  
800399-53-5P 800399-54-6P 800399-55-7P  
800399-56-8P 800399-57-9P 800399-58-0P  
800399-59-1P 800399-60-4P 800399-61-5P  
800399-62-6P 800399-63-7P 800399-64-8P  
800399-65-9P 800399-66-0P 800399-67-1P  
800399-68-2P 800399-70-6P 800399-72-8P  
800399-73-9P 800399-74-0P 800399-75-1P  
800399-76-2P 800399-77-3P 800399-78-4P  
800399-79-5P 800399-80-8P 800399-81-9P  
800399-82-0P 800399-83-1P 800399-84-2P  
800399-86-4P 800399-87-5P 800399-88-6P  
800399-89-7P 800399-90-0P 800399-91-1P  
800399-92-2P 800399-93-3P 800399-94-4P  
800399-95-5P 800399-96-6P 800399-97-7P  
800399-98-8P 800399-99-9P 800400-00-4P  
800400-01-5P 800400-02-6P 800400-03-7P  
800400-04-8P 800400-05-9P 800400-06-0P  
800400-07-1P 800400-08-2P 800400-09-3P  
800400-10-6P 800400-11-7P 800400-12-8P  
800400-13-9P 800400-14-0P 800400-16-2P  
800400-19-5P 800400-21-9P 800400-23-1P  
800400-25-3P 800400-27-5P 800400-29-7P  
800400-31-1P 800400-33-3P 800400-35-5P  
800400-39-9P 800400-41-3P 800400-43-5P  
800400-45-7P 800400-48-0P 800400-54-8P  
800400-56-0P 800400-58-2P 800400-60-6P

800400-61-7P 800400-63-9P 800400-65-1P  
 800400-67-3P 800400-71-9P 800400-73-1P  
 800400-75-3P 800400-77-5P 800400-78-6P  
 800400-80-0P 800400-82-2P 800400-85-5P  
 800400-86-6P 800400-87-7P 800400-88-8P  
 800400-90-2P 800400-91-3P 800400-92-4P  
 800400-93-5P 800400-94-6P 800400-96-8P  
 800400-99-1P 800401-00-7P 800401-01-8P  
 800401-02-9P 800401-03-0P 800401-04-1P  
 800401-05-2P 800401-06-3P 800401-09-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of pyrrolopyridinecarboxylic acid amide as inhibitors of  
 glycogen phosphorylase)

RN 800397-93-7 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-  
 (dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800397-98-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-  
 (dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 800398-00-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-3-[(3S,4R)-  
 3,4-dihydroxy-1-pyrrolidinyl]-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-03-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(2-phenoxylethyl)-  
(9CI) (CA INDEX NAME)


RN 800398-04-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 800398-05-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 800398-06-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(2-thienyl)ethyl]-  
(9CI) (CA INDEX NAME)




RN 800398-07-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 800398-08-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 800398-09-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-(1H-benzimidazol-2-ylmethyl)-5-chloro- (9CI) (CA INDEX NAME)




RN 800398-10-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 800398-11-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 800398-12-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-[(2-chloro-6-fluorophenyl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)




RN 800398-13-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 800398-14-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(1-naphthalenylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 800398-21-4 HCAPLUS


CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 5-chloro-N-(2-phenoxyethyl)-  
(9CI) (CA INDEX NAME)

RN 800398-22-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 800398-23-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-  
[(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)


RN 800398-24-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-oxo-2-(phenylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 800398-25-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-oxo-2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 800398-26-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-oxo-2-[(2-thienylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 800398-27-0 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-[(4-methoxyphenyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 800398-28-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-1-(phenylmethyl)-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-29-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-30-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3S,4R)-3,4-dihydroxy-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-31-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-1-(phenylmethyl)-2-(4-thiomorpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 800398-32-7 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-1-(phenylmethyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-39-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-methoxyphenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 800398-40-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(3,4-difluorophenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 800398-41-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-chlorophenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 800398-43-0 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-fluorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)



RN 800398-44-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(3-pyridinylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-45-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-1-(3-pyridinylmethyl)-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-46-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(2-pyridinylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-47-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-48-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(1-methylethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-49-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-50-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(ethylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-51-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(cyclobutylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-52-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(cyclopentylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-53-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(1R,2R)-2-hydroxycyclopentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-54-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[[[(1S,2S)-2-hydroxycyclohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-55-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[[[(1R,2S)-2-(hydroxymethyl)cyclohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-56-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[[[(tetrahydro-2-furanyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-57-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2-furanylmethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-58-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-(1-azetidiny)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-59-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(1-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-60-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-61-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-62-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-63-4 HCAPLUS



CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-64-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-65-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(3R)-3-(acetylamino)-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-66-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-morpholinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-67-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-68-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2-hydroxyethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-69-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2-methoxyethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-70-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[[2-(methylthio)ethyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-71-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[[2-(dimethylamino)ethyl]amino]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-72-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[bis(2-hydroxyethyl)amino]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-73-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(dimethylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-74-7 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(diethylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-75-8 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 800398-76-9 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800398-77-0 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[(3-pyridinylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-78-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(phenylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-79-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(2,5-dimethyl-1-pyrrolidinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-80-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[bis(2-methoxyethyl)amino]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 800398-81-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3S,4R)-3,4-dimethoxy-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800398-82-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3S,4R)-3,4-dihydroxy-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 800398-83-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-

(cyclohexylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-84-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(3-thiazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-86-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 800398-87-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[(tetrahydro-2H-thiopyran-4-yl)amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-89-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[[3-(dimethylamino)propyl]amino]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-91-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3-hydroxypropyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-93-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(2-hydroxyethyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-95-2 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(1-pyrrolidinyl)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-97-4 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(4-oxo-1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-98-5 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(cyclopropylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-99-6 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(4-hydroxybutyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-00-2 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3-methoxypropyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-01-3 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(2,3-dihydroxypropyl)amino]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800399-02-4 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-03-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[[3-(cyclohexylamino)propyl]amino]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-04-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[3-(4-morpholinylsulfonyl)-1-azetidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-05-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[3-(1-azetidinylsulfonyl)-1-azetidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-06-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(3-hydroxy-1-azetidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-07-9 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(3-hydroxy-1-azetidinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-08-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(3-hydroxy-1-azetidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 800399-09-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-hydroxy-1-piperidiny)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 800399-10-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-morpholinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 800399-11-5 HCAPLUS


CN Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-β-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 800399-12-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(methoxymethylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-13-7 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-14-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-19-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-methoxy-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 800399-20-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3R)-3-methoxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800399-21-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3S)-3-methoxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800399-24-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2S)-3-(dimethylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-25-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2S)-2-hydroxy-3-oxo-1-(phenylmethyl)-3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-26-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2S)-3-[(3S,4R)-3,4-dihydroxy-1-pyrrolidinyl]-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-27-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-oxo-1-(phenylmethyl)-3-(propylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-28-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S,2R)-3-amino-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-29-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-[(2-hydroxyethyl)amino]-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-30-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-[(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-31-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-3-(dimethylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-32-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-3-(cyclopropylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-33-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-3-(cyclobutylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-34-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-3-(cyclopentylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-35-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S,2R)-3-(1-azetidinyl)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-36-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-oxo-3-(phenylamino)-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-37-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-oxo-1-(phenylmethyl)-3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-38-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-[(3R)-3-hydroxy-1-pyrrolidinyl]-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-39-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-[(3S)-3-hydroxy-1-pyrrolidinyl]-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-40-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-oxo-1-(phenylmethyl)-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-41-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-(4-hydroxy-1-piperidiny1)-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-42-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-[4-(hydroxymethyl)-1-piperidiny1]-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-44-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-(4-methyl-1-piperazinyl)-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800399-45-5 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-(4-methyl-1-piperazinyl)-3-oxo-1-(phenylmethyl)propyl]-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 800399-44-4

CMF C23 H26 Cl N5 O3


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 800399-47-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-oxo-1-(phenylmethyl)-3-(1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800399-48-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-oxo-1-(phenylmethyl)-3-(1-piperazinyl)propyl]-, monoacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 800399-47-7

CMF C22 H24 Cl N5 O3

Absolute stereochemistry.






CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 800399-49-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-(4-morpholinyl)-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-50-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S,2R)-3-(4-acetyl-1-piperazinyl)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-51-3 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[[2-(4-morpholinyl)ethyl]amino]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-52-4 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(cyclopentylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-53-5 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(4-methyl-1-piperazinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800399-54-6 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[4-(2-hydroxyethyl)-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-55-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-(4-acetyl-1-piperazinyl)-2-oxo-1-(phenylmethyl)ethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-56-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3-hydroxypropyl)amino]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-57-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[4-(hydroxymethyl)-1-piperidiny]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-58-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-(aminocarbonyl)-1-piperidinyll]-2-oxo-1-(phenylmethyl)ethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-59-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[3-(aminocarbonyl)-1-piperidinyll]-2-oxo-1-(phenylmethyl)ethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-60-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[3-(hydroxymethyl)-1-piperidinyll]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-61-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-62-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(3,6-dihydro-1(2H)-pyridinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-63-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-1-(phenylmethyl)-2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-64-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(4-morpholinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-65-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(1,1-dioxido-4-thiomorpholinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-66-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-67-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3-methoxypropyl)amino]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-68-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-70-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(3-hydroxy-1-piperidinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-72-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(cyclopropylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-73-9 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(3S)-3-(acetylamino)-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-74-0 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-2-(3-oxo-1-piperazinyl)-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-75-1 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(4-fluoro-1-piperidinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-76-2 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(cyclobutylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-77-3 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(2-phenylpropyl)- (9CI) (CA INDEX NAME)






RN 800399-78-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 800399-79-5 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 800399-80-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(phenylmethoxy)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-81-9 HCAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2S)-2-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 800399-82-0 HCAPLUS

CN 3-Piperidinecarboxylic acid, 1-[(2S)-2-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-83-1 HCAPLUS


CN 2-Piperidinecarboxylic acid, 1-[(2S)-2-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-84-2 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-(acetyloxy)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-86-4 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-(aminomethyl)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800399-87-5 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(3R)-3-amino-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 800399-88-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(3R)-3-amino-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-89-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(3S)-3-amino-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 800399-90-0 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(3S)-3-amino-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800399-91-1 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(4-piperidinylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 800399-92-2 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(4-piperidinylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800399-93-3 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(hexahydro-1H-1,4-diazepin-1-yl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 800399-94-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(hexahydro-1H-1,4-diazepin-1-yl)-2-oxoethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800399-95-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[4-(diacetylamino)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-96-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(methylamino)-1-piperidinyl]-2-oxoethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800399-97-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-[(methylamino)methyl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-98-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(trifluoromethyl)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 800399-99-9 HCAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2S)-2-[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-00-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[3-(hydroxymethyl)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-01-5 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[1,4'-bipiperidin]-1'-yl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800400-02-6 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-(4-acetyl-1-piperidinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800400-03-7 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-fluoro-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-04-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-(aminocarbonyl)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-05-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(2-hydroxyethyl)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-06-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-(aminocarbonyl)-1-piperazinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-07-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[3-[(diethylamino)carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-08-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[3-(aminocarbonyl)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800400-09-3 HCAPLUS

CN 3-Piperidinecarboxylic acid, 1-[(2S)-2-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, ethyl ester

ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-10-6 HCAPLUS

CN 2-Piperidinecarboxylic acid, 1-[(2S)-2-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-11-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-12-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(2-methoxyethyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-13-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(3-methoxypropyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-14-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-16-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-(4-acetylhexahydro-1H-1,4-diazepin-1-yl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800400-19-5 HCAPLUS

CN D-Prolinamide, 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carbonyl-4-fluoro-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-21-9 HCAPLUS

CN Carbamic acid, [(3R)-1-[(2S)-2-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-3-pyrrolidiny]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-23-1 HCAPLUS

CN Carbamic acid, [(3S)-1-[(2S)-2-[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-25-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[4-(cyclopropylcarbonyl)-1-piperazinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800400-27-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]amino]- (9CI)



1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-29-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-oxoethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-31-1 HCAPLUS

CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[(2S)-2-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-33-3 HCAPLUS

CN L-Proline, 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxyl-4-fluoro-L-phenylalanyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-35-5 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-39-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-41-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(3-hydroxypropyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-43-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800400-45-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-

fluorophenyl)methyl]-2-oxo-2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-48-0 HCAPLUS

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-54-8 HCAPLUS

CN Carbamic acid, [[1-[(2S)-2-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-4-piperidinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-56-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(4-morpholinyl)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-58-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[hexahydro-4-(2-hydroxyethyl)-1H-1,4-diazepin-1-yl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-60-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3R)-3-hydroxy-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800400-61-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(3,6-dihydro-

1(2H)-pyridinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-63-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[2-(hydroxymethyl)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-65-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(2,5-dihydro-1H-pyrrol-1-yl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-67-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(1,1-dioxido-4-thiomorpholinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-71-9 HCAPLUS

CN 3-Piperidinecarboxylic acid, 1-[(2S)-2-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-73-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(4-hydroxy-1-piperidiny1)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800400-75-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(2S)-2-(aminocarbonyl)-

1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-77-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(2-methoxyethoxy)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-78-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(3-methoxypropoxy)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 800400-80-0 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-(acetylamino)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800400-82-2 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-[(acetylamino)methyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800400-85-5 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(methyl-4-piperidinylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-86-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[methyl(tetrahydro-2H-pyran-4-yl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-87-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[4-(dimethylamino)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-88-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-[(methylsulfonyl)amino]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-90-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(4-pyridinylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-91-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-1-(4-pyridinylmethyl)-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-92-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(1,4-dioxo-7-azaspiro[4.5]dec-7-yl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-93-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3R,4R)-3,4-dihydroxy-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-94-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3S,4S)-3,4-dihydroxy-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-96-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-2-phenyl-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-99-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-(hydroxymethyl)-2-oxo-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-00-7 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-(methoxymethyl)-2-oxo-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800401-01-8 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-oxo-2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 800401-02-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-03-0 HCAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800401-04-1 HCAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-hydroxy-1-piperidiny)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800401-05-2 HCAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(hexahydro-5-oxo-1H-1,4-diazepin-1-yl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800401-06-3 HCAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 800401-09-6 HCAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 800401-10-9P 800401-11-0P 800401-12-1P  
 800401-13-2P 800401-14-3P 800401-15-4P  
 800401-16-5P 800401-19-8P 800401-20-1P  
 800401-21-2P 800401-23-4P 800401-24-5P  
 800401-25-6P 800401-26-7P 800401-27-8P  
 800401-28-9P 800401-29-0P 800401-30-3P  
 800401-31-4P 800401-32-5P 800401-33-6P  
 800401-44-9P 800401-45-0P 800401-47-2P  
 800401-48-3P 800401-49-4P 800401-50-7P  
 800401-51-8P 800402-16-8P 800402-17-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of pyrrolopyridinecarboxylic acid amide as inhibitors of  
 glycogen phosphorylase)

RN 800401-10-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-  
 fluorophenyl)methyl]-2-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 800401-11-0 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-[(1S)-2-(4-acetyl-1-  
 piperazinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-6-chloro- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.






RN 800401-12-1 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3-methoxypropyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-13-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-14-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-morpholinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-15-4 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(4-thiomorpholinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-16-5 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 800401-19-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800401-20-1 HCAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-(2-oxo-2-phenylethyl)-  
 (9CI) (CA INDEX NAME)




RN 800401-21-2 HCAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-  
 fluorophenyl)methyl]-2-(methoxymethylamino)-2-oxoethyl]- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



RN 800401-23-4 HCAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-  
 fluorophenyl)methyl]-2-(4-morpholinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-24-5 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-25-6 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2-methyl-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-26-7 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2-hydroxyethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-27-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-[(1S)-2-(4-acetyl-1-piperazinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-28-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(3-hydroxy-1-piperidiny)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800401-29-0 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-

fluorophenyl)methyl]-2-[(3-methoxypropyl)amino]-2-oxoethyl]- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 800401-30-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(4-hydroxybutyl)amino]-2-oxoethyl]- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 800401-31-4 HCAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-2-carboxamide, 6-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-32-5 HCAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 800401-33-6 HCAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800401-44-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(1R,2R)-2-hydroxycyclohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-45-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(1S,2R)-2-(hydroxymethyl)cyclohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-47-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(4-cyclopentyl-1-piperazinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-48-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(ethylmethylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800401-49-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(4-thiomorpholinyl)ethyl]- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 800401-50-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(3-hydroxy-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-51-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(3-oxo-1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800402-16-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-(4-amino-1-piperidinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 800402-17-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-[(methylamino)methyl]-1-piperidinyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 800402-18-0


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrrolopyridinecarboxylic acid amide as inhibitors of glycogen phosphorylase)

RN 800402-18-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-[[methyl[(2-nitrophenyl)sulfonyl]amino]methyl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 800401-77-8P 800401-78-9P 800401-79-0P  
 800401-80-3P 800401-95-0P 800401-99-4P  
 800402-01-1P 800402-02-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of pyrrolopyridinecarboxylic acid amide as inhibitors of  
 glycogen phosphorylase)


RN 800401-77-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[[2-(4-methoxyphenyl)-  
 1,3-dioxolan-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 800401-78-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[[2-(3,4-  
 difluorophenyl)-1,3-dioxolan-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 800401-79-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[[2-(4-chlorophenyl)-  
 1,3-dioxolan-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 800401-80-3 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 800401-95-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-[methyl[(2-nitrophenyl)sulfonyl]amino]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-99-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-phenyl-1-(2-phenyl-1,3-dioxolan-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800402-01-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2S)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-hydroxy-2-phenylethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800402-02-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-oxo-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L164 ANSWER 7 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:757715 HCAPLUS

DOCUMENT NUMBER: 139:261088

TITLE: Preparation of broad-spectrum cephem compounds

INVENTOR(S): Nishitani, Yasuhiro; Yamano, Yoshinori

PATENT ASSIGNEE(S): Shionogi &amp; Co., Ltd., Japan

SOURCE: PCT Int. Appl., 209 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078440	A1	20030925	WO 2003-JP3249	20030318 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479354	AA	20030925	CA 2003-2479354	20030318 <--
AU 2003221080	A1	20030929	AU 2003-221080	20030318 <--
EP 1489084	A1	20041222	EP 2003-712748	20030318 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008492	A	20050503	BR 2003-8492	20030318 <--
US 2005153950	A1	20050714	US 2003-507502	20030318 <--
CN 1653072	A	20050810	CN 2003-810969	20030318 <--
PRIORITY APPLN. INFO.:			JP 2002-73526	A 20020318 <--
			WO 2003-JP3249	W 20030318 <--

OTHER SOURCE(S): MARPAT 139:261088

ED Entered STN: 26 Sep 2003

AB Cephem compds. I (T is S, SO, or O; X is halogeno, CN, carbamoyl which may be substituted with lower alkyl, lower alkyl, lower alkoxy, or lower alkylthio; A is substituted lower alkylene (wherein the substituent is optionally substituted mono-lower alkyl, optionally substituted lower alkylidene, or optionally substituted lower alkylene); and Z+ is an optionally substituted nitrogenous heterocyclic group having a cationic group), their ester, protected 7-aminothiazole, or pharmaceutically acceptable salts or solvates, are prepared I [X = Me, A = Me<sub>2</sub>C, T = S, Z = 1-(3-methylaminopropyl)-1H-imidazo[4,5-b]pyridinium-4-yl-] was prepared and showed antibacterial activities superior to that of ceftazidime.

IT 604000-76-2P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of broad-spectrum cephem compds.)

RN 604000-76-2 HCAPLUS

CN 1H-Pyrrolo[3,2-c]pyridinium, 2-(aminocarbonyl)-5-[[[(6R,7R)-7-[[[(2Z)-(2-amino-5-chloro-4-thiazolyl)][[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L164 ANSWER 8 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:610451 HCAPLUS

DOCUMENT NUMBER: 139:164811

TITLE: Preparation of 2,4a,5-triazafluorenes as 5-HT2 receptor ligands.

INVENTOR(S): Adams, David Reginald; Bentley, Jonathan Mark; Blench, Toby Jonathan; Hebeisen, Paul; Monck, Nathaniel Julius Thomas; Richter, Hans; Roevers, Stephan; Roffey, Jonathan Richard Anthony; Taylor, Sven

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.; Vernalis Research Limited

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064423	A1	20030807	WO 2003-EP459	20030117 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2472954	AA	20030807	CA 2003-2472954	20030117 <--
EP 1472255	A1	20041103	EP 2003-702462	20030117 <--
EP 1472255	B1	20060301		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003007291	A	20041207	BR 2003-7291	20030117 <--
CN 1625558	A	20050608	CN 2003-802943	20030117 <--
JP 2005521671	T2	20050721	JP 2003-564046	20030117 <--
AT 318817	E	20060315	AT 2003-702462	20030117 <--
PT 1472255	T	20060630	PT 2003-702462	20030117 <--

US 2003207888	A1	20031106	US 2003-350616	20030124 <--
US 7098337	B2	20060829		
ZA 2004005458	A	20060222	ZA 2004-5458	20040708 <--
NO 2004003547	A	20040825	NO 2004-3547	20040825 <--
PRIORITY APPLN. INFO.:			GB 2002-2015	A 20020129 <--
			WO 2003-EP459	W 20030117 <--

OTHER SOURCE(S): MARPAT 139:164811

ED Entered STN: 08 Aug 2003

AB Title compds. [I; R1 = H, halo, alkyl, cycloalkyl, alkenyl, alkoxy, alkoxyalkyl, arylalkoxy, hydroxyalkyl, cyano, cycloalkylalkoxyalkyl, alkoxyalkoxyalkyl, arylalkoxyalkyl, amino, haloalkyl, hydroxyalkoxy, alkoxyalkoxy, hydroxyalkoxyalkyl, alkylcarbonyl, haloalkylcarbonyl, alkylthio, alkenylthio, A1, A2; R2 = H, alkyl, alkoxy; R3 = alkyl, hydroxyalkyl, alkoxyalkyl; R4 = H, alkyl; A1 = RaORbRcC; Ra = H, alkyl, cycloalkyl, cycloalkylalkyl; Rb = H, alkyl; RaRb = atoms to form tetrahydrofuranyl; Rc = haloalkyl, alkyl, alkoxyalkyl, thiazolyl; A2 = RdReNCO2CRfRg; Rd = alkyl, cycloalkyl, aryl, aralkyl, alkenyl; Re = H, alkyl; RdReN = pyrrolidinyl, benzyloxycarbonylpiperazinyl; Rf, Rg = H, alkyl], were prepared To a solution of tert-Bu (R)-6-bromo-4-methyl-3,4-dihydro-1H-2,4a,5-triazafluorene-2-carboxylate (preparation given) in 1,2-dimethoxyethane was added (PPh3)4Pd; after 30 min, saturated aqueous Na2CO3 and trimethylboroxine in THF were added and the resulting suspension was heated to reflux for 5 h to give 71.1% tert-Bu (R)-4,6-dimethyl-3,4-dihydro-1H-2,4a,5-triazafluorene-2-carboxylate. The latter was treated with CF3CO2H in CH2Cl2 and then with HCl to give 57% (R)-4,6-dimethyl-1,2,3,4-tetrahydro-2,4a,5-triazafluorene hydrochloride. The latter showed functional activity at human 5-HT2C receptors with EC50 = 19.2 nM. I can be used for the treatment of disorders of the central nervous system, cardiovascular system, gastrointestinal system, diabetes, obesity, and sleep apnea.


IT 577711-82-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of triazafluorenes as 5-HT2 receptor ligands)

RN 577711-82-1 HCAPLUS

CN Pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazin-6(7H)-one, 2-chloro-8,9-dihydro-9-methyl-, (9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L164 ANSWER 9 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:221697 HCAPLUS

DOCUMENT NUMBER: 138:238006

TITLE: Preparation of N-[7-aza[2.2.1]bicycloheptanyl]arylamides for therapeutic use as nicotinic acetylcholine receptor agonists



INVENTOR(S): Wishka, Donn G.; Walker, Daniel Patrick; Corbett, Jeffrey W.; Reitz, Steven Charles; Rauckhorst, Mark R.; Groppi, Vincent E., Jr.  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
 SOURCE: PCT Int. Appl., 224 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022856	A1	20030320	WO 2002-US25959	20020904 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2460075	AA	20030320	CA 2002-2460075	20020904 <--
US 2003105089	A1	20030605	US 2002-234575	20020904 <--
EP 1425286	A1	20040609	EP 2002-757132	20020904 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002012477	A	20040824	BR 2002-12477	20020904 <--
JP 2005527472	T2	20050915	JP 2003-526930	20020904 <--
PRIORITY APPLN. INFO.:			US 2001-322100P	P 20010912 <--
			US 2001-322333P	P 20010912 <--
			US 2001-322346P	P 20010912 <--
			US 2002-399530P	P 20020730 <--
			WO 2002-US25959	W 20020904 <--

OTHER SOURCE(S): MARPAT 138:238006

ED Entered STN: 21 Mar 2003

AB 7-Aza[2.2.1]bicycloheptane derivs., such as amides I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use as nicotinic acetylcholine receptor agonists. These amides are useful for the treatment of central nervous system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, amide dihydrochloride II was prepared via a multistep synthetic sequence which included cycloaddn. of N-tert-butoxycarbonylpyrrole with BrC.tplbond.CCO2Me to form the azabicyclic ring, and subsequent amidation

reaction of tert-Bu (1S,2R,4R)-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate with 3-methylfuro[2,3-c]pyridine-5-carboxylic acid. The prepared amides were assayed for human  $\alpha$ 7-5HT3 receptor binding activity.

IT 501892-47-3P, N-[(1S,2R,4R)-7-Azabicyclo[2.2.1]hept-2-yl]-1H-pyrrolo[2,3-c]pyridine-2-carboxamide dihydrochloride


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-[7-aza[2.2.1]bicycloheptanyl]arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)

RN 501892-47-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L164 ANSWER 10 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:769282 HCAPLUS

DOCUMENT NUMBER: 135:313616

TITLE: Heterocyclic sulfonyl compounds and activated blood coagulation factor X (FXa) inhibitors containing them

INVENTOR(S): Kobayashi, Shozo; Komoritani, Satoshi; Haginoya, Noriyasu; Suzuki, Masanori; Yoshino, Toshiharu; Nagahara, Takayasu; Yoshikawa, Kenji; Muto, Akira; Ozanai, Takeshi; Nakamoto, Yumi; Mochizuki, Akiyoshi; Nagata, Tsutomu

PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 304 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001294572	A2	20011023	JP 2000-38100	20000209 <--
PRIORITY APPLN. INFO.:			JP 2000-38100	20000209 <--
OTHER SOURCE(S):		MARPAT 135:313616		

ED Entered STN: 23 Oct 2001

AB Pharmaceuticals, useful for prevention and/or treatment of thrombus and

embolus, contain Q1Q2T1SO2QA [I; Q1 = (un)substituted bicyclic or tricyclic group; Q2 = single bond, O, S, C1-6 alkylene, etc.; Q3 = N-containing cyclic group; QA = (un)substituted (hetero)arylalkenyl, bicyclic or tricyclic group, etc.; T1 = CO, (un)substituted methylene, etc.], their salts, or solvates. (2RS)-2-(N-tert-butoxycarbonylaminomethyl)-6-methoxycarbonyl-1,2,3,4-tetrahydronaphthalene was treated with NaOH, condensed with 1-[(6-chloronaphthalen-2-yl)sulfonyl]piperazine.HCl, and deprotected to give (RS)-I.HCl (Q1 = 6-aminomethyl-5,6,7,8-tetrahydronaphthalen-2-yl, Q2 = bond, T1 = CO, Q3 = 1,4-piperazinediyl, QA = 6-chloronaphthalen-2-yl). I.HCl (Q1 = 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl, Q2 = bond, T1 = CO, Q3 = 1,4-piperazinediyl, QA = 6-chloronaphthalen-2-yl) in vitro inhibited human FXa with IC50 of 20 nM.


IT 259805-69-1P 259805-70-4P 368439-39-8P  
368439-40-1P 368439-41-2P 368439-42-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic sulfonyl compds. as activated blood coagulation factor X inhibitors)


RN 259805-69-1 HCAPLUS

CN 5H-Pyrrolo[3,2-c]pyridine-5-carboxylic acid, 2-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 259805-70-4 HCAPLUS

CN 5H-Pyrrolo[3,2-c]pyridine-5-carboxylic acid, 2-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]-1,4,6,7-tetrahydro-1-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 368439-39-8 HCAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 368439-40-1 HCAPLUS  
 CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-5-methyl-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, monohydrochloride (9CI)  
 (CA INDEX NAME)




● HCl

RN 368439-41-2 HCAPLUS  
 CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(5-ethyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, monohydrochloride (9CI)  
 (CA INDEX NAME)



● HCl

RN 368439-42-3 HCAPLUS  
 CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-1-methyl-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, monohydrochloride (9CI)  
 (CA INDEX NAME)



● HCl


IT 259809-55-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic sulfonyl compds. as activated blood coagulation factor X inhibitors)

RN 259809-55-7 HCAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-1,5(4H)-dicarboxylic acid, 2-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]-6,7-dihydro-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L164 ANSWER 11 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:133658 HCAPLUS

DOCUMENT NUMBER: 132:194391

TITLE: Preparation of sulfonyl moiety-containing heterocyclic compounds as factor Xa inhibitors

INVENTOR(S): Kobayashi, Syozo; Komoriya, Satoshi; Haginoya, Noriyasu; Suzuki, Masanori; Yoshino, Toshiharu; Nagahara, Takayasu; Nagata, Tsutomu; Horino, Haruhiko; Ito, Masayuki; Mochizuki, Akiyoshi

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 883 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000009480	A1	20000224	WO 1999-JP4344	19990811 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				

DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,  
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,  
 MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 JP 2000119253 A2 20000425 JP 1999-226878 19990810 <--  
 CA 2340100 AA 20000224 CA 1999-2340100 19990811 <--  
 AU 9951963 A1 20000306 AU 1999-51963 19990811 <--  
 EP 1104754 A1 20010606 EP 1999-937024 19990811 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 JP 2000143623 A2 20000526 JP 1999-242814 19990830 <--  
 US 6747023 B1 20040608 US 2001-762888 20010212 <--  
 US 2004082611 A1 20040429 US 2003-681205 20031009 <--  
 PRIORITY APPLN. INFO.: JP 1998-227449 A 19980811 <--  
 JP 1998-244175 A 19980828 <--  
 JP 1998-251674 A 19980904 <--  
 WO 1999-JP4344 W 19990811 <--  
 US 2001-762888 A3 20010212 <--

OTHER SOURCE(S): MARPAT 132:194391

ED Entered STN: 25 Feb 2000

AB The title compds. Q1Q2T1Q3SO2QA [wherein Q1 is an optionally substituted, saturated or unsatd., five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single bond, oxygen, sulfur, C1-C6 alkylene or the like; Q3 is a heterocyclic ring (represented by several generic structures); QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like] are prepared These compds. have potent factor Xa inhibiting effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects. Several compds. of this invention in vitro showed IC50 values of 0.7 nM to 4.7 nM against factor Xa.

IT 259805-66-8P 259805-67-9P 259805-68-0P

259805-69-1P 259805-70-4P 259805-71-5P


259805-72-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfonyl moiety-containing heterocyclic compds. as factor Xa inhibitors)

RN 259805-66-8 HCAPLUS


CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (10:11) (9CI) (CA INDEX NAME)



●11/10 HCl

RN 259805-67-9 HCAPLUS


CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-5-methyl-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (10:13) (9CI) (CA INDEX NAME)



●13/10 HCl

RN 259805-68-0 HCAPLUS


CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(5-ethyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



●6/5 HCl


RN 259805-69-1 HCAPLUS

CN 5H-Pyrrolo[3,2-c]pyridine-5-carboxylic acid, 2-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 259805-70-4 HCAPLUS

CN 5H-Pyrrolo[3,2-c]pyridine-5-carboxylic acid, 2-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]-1,4,6,7-tetrahydro-1-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 259805-71-5 HCAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-1-methyl-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (5:7) (9CI) (CA INDEX NAME)




● 7/5 HCl

RN 259805-72-6 HCAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-1,5-dimethyl-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (5:7) (9CI) (CA INDEX NAME)





● 7/5 HCl


IT 259809-55-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of sulfonyl moiety-containing heterocyclic compds. as factor Xa inhibitors)

RN 259809-55-7 HCAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-1,5(4H)-dicarboxylic acid, 2-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]-6,7-dihydro-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

67

THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L164 ANSWER 12 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:222935 HCAPLUS

DOCUMENT NUMBER: 130:267423

TITLE: Preparation of N-(2-thiazolyl)indole-2-carboxamides and analogs as CCK-A receptor agonists

INVENTOR(S): Brodin, Roger; Boigegrain, Robert; Bignon, Eric; Molimard, Jean-Charles; Olliero, Dominique

PATENT ASSIGNEE(S): Sanofi, Fr.

SOURCE: PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915525	A1	19990401	WO 1998-FR2007	19980918 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

FR 2768737	A1	19990326	FR 1997-11718	19970919 <--
FR 2768737	B1	20000519		
FR 2777887	A1	19991029	FR 1998-5106	19980423 <--
FR 2777887	B3	20000707		
ZA 9807961	A	19990407	ZA 1998-7961	19980901 <--
CA 2304397	AA	19990401	CA 1998-2304397	19980918 <--
AU 9891705	A1	19990412	AU 1998-91705	19980918 <--
AU 746707	B2	20020502		
EP 1017693	A1	20000712	EP 1998-944024	19980918 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9812653	A	20000822	BR 1998-12653	19980918 <--
EE 200000168	A	20010416	EE 2000-168	19980918 <--
TW 430664	B	20010421	TW 1998-87115602	19980918 <--
TR 200001218	T2	20010521	TR 2000-200001218	19980918 <--
JP 2001517667	T2	20011009	JP 2000-512830	19980918 <--
JP 3456970	B2	20031014		
NZ 503339	A	20020328	NZ 1998-503339	19980918 <--
IL 134961	A1	20020725	IL 1998-134961	19980918 <--
NO 2000001409	A	20000516	NO 2000-1409	20000317 <--
NO 314455	B1	20030324		
HR 2000000153	A1	20010430	HR 2000-153	20000317 <--
BG 104254	A	20010831	BG 2000-104254	20000317 <--
US 6380230	B1	20020430	US 2000-508830	20000602 <--

PRIORITY APPLN. INFO.:

FR 1997-11718	A	19970919 <--
FR 1998-5106	A	19980423 <--
WO 1998-FR2007	W	19980918 <--

OTHER SOURCE(S): MARPAT 130:267423

ED Entered STN: 12 Apr 1999

AB Title compds. [I; R = NHCOR3; R1 = MeOZ; R2 = R7CH2, R7CH2S, R7SCH2, etc.; R3 = e.g., Z1(CH2)nR15 or Z1(CH2)mC6H4R15; R7 = (di)(methyl)cycloalkyl; R15 = CO2H or alkoxycarbonyl; Z = (un)substituted 1,2-phenylene; Z1 = (un)substituted indole-2,1-diyl; m = 0 or 1; n = 1-5] were prepared. Thus, I (R1 = 2,5-dimethoxy-4-methylphenyl, R2 = 2-cyclohexylethyl) (II; R = NH2) was amidated by 1-tert-butoxycarbonylmethyl-5-methylindole-2-carboxylic acid (preparation each given) to give, after saponification, II (R =

NHCOZ1CH2CO2H, Z1 = 5-methylindole-2,1-diyl). Data for biol. activity of I were given.

IT 221673-77-4P 221673-79-6P 221673-81-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(2-thiazolyl)indole-2-carboxamides and analogs as CCK-A receptor agonists)


RN 221673-77-4 HCAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 221673-76-3


CMF C29 H31 Cl N4 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 221673-79-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-5-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 221673-78-5


CMF C30 H33 Cl N4 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 221673-81-0 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 221673-80-9


CMF C29 H31 Cl N4 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L164 ANSWER 13 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1996:580282 HCAPLUS

DOCUMENT NUMBER: 125:221858  
 TITLE: Preparation of tricyclic substituted benz[e]isoindoles as  $\alpha 1$  adrenergic antagonists  
 INVENTOR(S): Meyer, Michael D.; Altenbach, Robert J.; Basha, Fatima Z.; Carroll, William A.; Drizin, Irene; Kerwin, James F., Jr.; Lebold, Suzanne A.; Lee, Edmund L.; Elmore, Steven W.; et al.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 180 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9622992	A1	19960801	WO 1996-US72	19960111 <--
W: AU, CA, JP, KR, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5597823	A	19970128	US 1995-463528	19950605 <--
AU 9647457	A1	19960814	AU 1996-47457	19960111 <--
AU 705283	B2	19990520		
EP 808318	A1	19971126	EP 1996-903340	19960111 <--
EP 808318	B1	20000628		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 194141	E	20000715	AT 1996-903340	19960111 <--
JP 2001504797	T2	20010410	JP 1996-522867	19960111 <--
GR 3034485	T3	20001229	GR 2000-402174	20000926 <--
PRIORITY APPLN. INFO.:			US 1995-379414	A 19950127 <--
			US 1995-463528	A 19950605 <--
			WO 1996-US72	W 19960111 <--

OTHER SOURCE(S): MARPAT 125:221858

ED Entered STN: 30 Sep 1996

AB The title compds. [I; R1, R2 = H, alkoxy, OH, etc.; W = tricyclic heterocyclic ring system; n = 2-6] and their salts, useful in the treatment of benign prostatic hypertrophy (BPH), were prepared. Thus, reaction of urea II with benz[e]isoindole III in the presence of (iPr)<sub>2</sub>NEt in DMSO afforded the desired product cis-IV.HCl which showed pA<sub>2</sub> of 8.37 for inhibition of phenylephrine(PE)-induced contraction of rat vas.

IT 181282-07-5P 181282-28-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic substituted benz[e]isoindoles as  $\alpha 1$  adrenergic antagonists)

RN 181282-07-5 HCAPLUS

CN 1H-Pyrido[3',2':4,5]pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 3-[2-(1,3,3a,4,5,9b-hexahydro-6-methoxy-2H-benz[e]isoindol-2-yl)ethyl]-5-methyl-, dihydrochloride, (3aR-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 181282-28-0 HCAPLUS  
 CN 1H-Pyrido[3',4':4,5]pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione,  
 3-[2-(1,3,3a,4,5,9b-hexahydro-6-methoxy-2H-benz[e]isoindol-2-yl)ethyl]-,  
 monohydrochloride, (3aR-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


L164 ANSWER 14 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1975:97970 HCAPLUS  
 DOCUMENT NUMBER: 82:97970  
 TITLE: Carbon-nitrogen vs nitrogen-nitrogen bond formation in  
 nitrenoid cyclization reactions. Pyrolysis of  
 3-azido-4-(2-pyridyl) carbostyrils  
 AUTHOR(S): Ning, Robert Y.; Madan, Pradeep B.; Sternbach, Leo H.  
 CORPORATE SOURCE: Chem. Res. Dep., Hoffmann-La Roche, Inc., Nutley, NJ,  
 USA  
 SOURCE: Journal of Organic Chemistry (1973), 38(23),  
 3995-8  
 CODEN: JOCEAH; ISSN: 0022-3263  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 ED Entered STN: 12 May 1984  
 AB Pyrolysis of I (R = H, Br; R1 = H, Et2NCH2CH2) gave mixts. of II and III.  
 IT 41895-22-1P 41895-23-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation  
 (preparation of)

RN 41895-22-1 HCAPLUS  
 CN 6H-Pyrido[2',3':4,5]pyrrolo[2,3-c]quinolin-6-one, 5,7-bis[2-(diethylamino)ethyl]-5,7-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 41895-23-2 HCAPLUS  
 CN 6H-Pyrido[2',3':4,5]pyrrolo[2,3-c]quinolin-6-one, 2-bromo-5,7-bis[2-(diethylamino)ethyl]-5,7-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L164 ANSWER 15 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1973:546440 HCAPLUS  
 DOCUMENT NUMBER: 79:146440  
 TITLE: Biosynthesis of porphyrins and related macrocycles.  
 I. Synthesis of carbon-14-labeled pyrromethanes  
 AUTHOR(S): Battersby, Alan R.; Evans, David A.; Gibson, Keith H.;  
 McDonald, Edward; Nixon, Leon  
 CORPORATE SOURCE: Univ. Chem. Lab., Univ. Camb., Cambridge, UK  
 SOURCE: Journal of the Chemical Society, Perkin Transactions  
 1: Organic and Bio-Organic Chemistry (1972-1999) (1973), (15), 1546-56  
 CODEN: JCPRB4; ISSN: 0300-922X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 ED Entered STN: 12 May 1984  
 AB Me 3-(4,5,6,7-tetrahydro-5-oxo-1H-pyrrolo[2,3-c]pyridin-3-yl)propionate-3-14C (I), prepared in 6 steps from Et [2-(benzyloxy)-5-nitro-4-


pyridyl]pyruvate K enolate, with the 4-[methoxycarbonylmethyl-14C]-5-(chloromethyl-14C) pyrrole (II), prepared in 5 steps from 2-Et 4-benzyl 3-[2-(ethoxycarbonyl)-ethyl]-5-methylpyrrole-2,4-dicarboxylate, gave the corresponding propionate [III; R = CO<sub>2</sub>CH<sub>2</sub>Ph, R<sub>1</sub> = CH<sub>2</sub>CO<sub>2</sub>Me, R<sub>2</sub> = (CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>Me]. Debenzylation and decarboxylation gave III [R = H, R<sub>1</sub> = CH<sub>2</sub>CO<sub>2</sub>Me, R<sub>2</sub> = (CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>Me]. III [R = H, R<sub>1</sub> = (CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>Me, R<sub>2</sub> = CH<sub>2</sub>CO<sub>2</sub>Me] labeled at the dipyrrolylmethyl C was prepared similarly. Mild alkaline hydrolysis of the latter two compds. gave lactam ring cleavage and deesterification.

IT 50411-49-9P 50622-86-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 50411-49-9 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 3-[(dimethylamino)methyl]-N,N-dimethyl-5-(phenylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 50622-86-1 HCAPLUS

CN Propanedioic acid, [[2-[(dimethylamino)carbonyl]-5-(phenylmethoxy)-1H-pyrrolo[2,3-c]pyridin-3-yl]methyl]-, diethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L164 ANSWER 16 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1970:450986 HCAPLUS


DOCUMENT NUMBER: 73:50986

TITLE: Gamma-ray spectroscopy of potassium-42

AUTHOR(S): Kawade, Kiyoshi; Yamamoto, Hiroshi; Yoshikawa, Kanzo;  
Iizawa, Katsuyuki; Kitamura, Isao; Amemiya, Susumu;




Kato, Toshio; Yoshizawa, Yasukazu  
CORPORATE SOURCE: Fac. Eng., Nagoya Univ., Nagoya, Japan  
SOURCE: Journal of the Physical Society of Japan (1970  
) , 29(1), 43-6  
CODEN: JUPSAU; ISSN: 0031-9015  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
ED Entered STN: 12 May 1984  
AB Decay of  $^{42}\text{K}$  was investigated by using a Ge(Li) detector and a NaI scintillation counter. Two new  $\gamma$ -ray peaks were observed at 0.692 and 1.228 MeV in the  $\gamma$ - $\gamma$  coincidence spectrum. The 0.587 MeV  $\gamma$ -ray, previously reported by McCullen, et al., could not be seen and the upper limit of the intensity of this  $\gamma$ -ray relative to the 0.900 MeV  $\gamma$ -ray was 0.7%.  
IT 1433-05-2, properties  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(gamma rays from, from potassium-42 decay)  
RN 1433-05-2 HCAPLUS  
CN 6H-Pyrrolo[2,3-c:4,5-c']dipyridin-6-one, 5,7,8,9-tetrahydro-, hydrochloride (7CI, 8CI) (CA INDEX NAME)



● HCl

L164 ANSWER 17 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1970:515129 HCAPLUS  
DOCUMENT NUMBER: 73:115129  
TITLE: Hartree-Fock and Hartree-Fock-Bogolyubov calculations for light nuclei  
AUTHOR(S): Sauer, P. U.  
CORPORATE SOURCE: Phys. Inst., Univ. Freiburg/Br., Freiburg/Br., Fed. Rep. Ger.  
SOURCE: Proceedings of the International School of Physics Enrico Fermi (1969), Volume Date 1967, No. 40, 717-29  
CODEN: PIPFA7; ISSN: 0074-784X  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
ED Entered STN: 12 May 1984  
AB The ground state properties (binding energy, quadrupole moment, deformation, and root-mean-square radius) of even-even light nuclei through Ca are calculated, by using Hartree-Fock and Hartree-Fock-Bogolyubov methods. Agreement with experiment is only fair for some nuclei, but good for others.  
IT 1433-05-2, properties  
RL: PRP (Properties)  
(nuclear)  
RN 1433-05-2 HCAPLUS  
CN 6H-Pyrrolo[2,3-c:4,5-c']dipyridin-6-one, 5,7,8,9-tetrahydro-,

hydrochloride (7CI, 8CI) (CA INDEX NAME)



● HCl

L164 ANSWER 18 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1966:420765 HCAPLUS

DOCUMENT NUMBER: 65:20765

ORIGINAL REFERENCE NO.: 65:3850h,3851a-c

TITLE: Indolization of 2,3-dioxopiperidine-3-(3-pyridylhydrazones)

AUTHOR(S): Tacconi, Gianfranco; Perotti, Angelo

CORPORATE SOURCE: Univ. Pavia, Italy

SOURCE: Annali di Chimica (Rome, Italy) (1965), 55(12), 1223-32

CODEN: ANCRAI; ISSN: 0003-4592

DOCUMENT TYPE: Journal


LANGUAGE: Italian

ED Entered STN: 22 Apr 2001

AB The Fischer indole synthesis carried out on the title compds. and on their N-oxides involves cyclization at the 2-position of the pyridine ring; if the pyridine ring is 2-substituted, the cyclization occurs at the 4-position. The title compds. were prepared as follows. A solution of 17.1 g. 3-carbethoxy-2-oxopiperidine (I), 7 g. KOH, and 200 ml. H<sub>2</sub>O kept 12 hrs. at 25-30°, 200 ml. EtOH and 12 ml. concentrated HCl added, the whole added at -10° with stirring to the diazo solution from 9.4 g. 3-aminopyridine (II), 7 g. NaNO<sub>2</sub>, 35 ml. concentrated HCl, and 70 ml. H<sub>2</sub>O, and the reaction mixture stirred 15 hrs. at -10° and 2 hrs. at room temperature yielded 12.6 g. III (X = H) (IIIa), as hydrochloride, m. 175-6° (EtOH-dilute HCl) (picrate m. 202-3°). By a similar procedure, I with the N-oxide of II gave the N-oxide (IV) of IIIa, as hydrochloride, m. 165-6°. Finally, I with 2-chloro-3-aminopyridine gave III (X = Cl) (IIIb), m. 181-2°. A mixture of 3 g. IIIa.HCl and 9 g. powdered ZnCl<sub>2</sub> was heated at 130°, then at 200-5° until gas evolution ceased. To the residue 9 ml. 2N HCl was added, the mixture refluxed 15 min., cooled, the precipitate (2.45 g., m. 259-61°) dissolved in hot H<sub>2</sub>O, and treated with picric acid to give 2.4 g. V picrate, m. 278-9°, which with resin Kastell A 300 in EtOH furnished V, m. 270-1° (H<sub>2</sub>O), λ<sub>maximum</sub> 221 and 314 mμ. Similarly, 1 g. IV.-HCl with 3 g. ZnCl<sub>2</sub> heated at 115°, then at 195°, yielded 0.8 g. of a solid which was hydrogenated in dilute EtOH and in the presence of Adams catalyst to give V. A mixture of 2 g. IIIb, 6 g. ZnCl<sub>2</sub>, and 0.6 g. NaCl heated at 140°, then at 165-70°, yielded 0.5 g. VI (X = Cl), m. >300° (H<sub>2</sub>O), λ<sub>maximum</sub> 229 and 292 mμ, which hydrogenated over Pd-C in dilute EtOH gave VI (X = H), m. >300°, λ<sub>maximum</sub> 225 and 291 mμ. The proton N.M.R. spectra of V and VI were reported.

IT 6502-52-9, 1H-Dipyrido[3,4-b:4',3'-d]pyrrol-1-one, 8-chloro 2,3,4,9-tetrahydro- (preparation of)

RN 6502-52-9 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c:5,4-c']dipyridin-1-one, 8-chloro-2,3,4,9-tetrahydro-  
 (7CI, 8CI) (CA INDEX NAME)



L164 ANSWER 19 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1966:4032 HCAPLUS  
 DOCUMENT NUMBER: 64:4032  
 ORIGINAL REFERENCE NO.: 64:686a-h,687a-d  
 TITLE: Indole derivatives. Indolization of ketones  
 4-pyridylhydrazone 1-oxides  
 AUTHOR(S): Tacconi, Gianfranco; Pietra, Silvio  
 CORPORATE SOURCE: Univ. Pavia, Italy  
 SOURCE: Annali di Chimica (Rome, Italy) (1965),  
 55(8-9), 810-21  
 CODEN: ANCRAI; ISSN: 0003-4592

DOCUMENT TYPE: Journal  
 LANGUAGE: Italian

ED Entered STN: 22 Apr 2001

AB 5-Ethyl-2-methyl-4-nitropyridine 1-oxide (18.2 g.) in 300 ml. EtOH was  
 hydrogenated at room temperature and atmospheric pressure with 1.8 g. Pd-C  
 until 3  
 moles H were adsorbed. Into the filtered solution cooled externally with ice  
 dry HCl was bubbled 30-40 min., the solution evaporated to dryness in vacuo on  
 a

steam bath, the residue taken up with Et<sub>2</sub>O and filtered to give 78%  
 5-ethyl-2-methyl-4-aminopyridine 1-oxide hydrochloride (I), m.  
 181-3° (ethanolic HCl); picrate m. 181-2°. 3-Methyl- (II)  
 (80%), m. 219-20° and 2-methyl-4-aminopyridine 1-oxide  
 hydrochloride (III) (77%), m. 191-2°, were similarly prepared from  
 related nitropyridine 1-oxides. I (9.4 g.) in 35 ml. H<sub>2</sub>O and 10 ml.  
 concentrated HCl, cooled until the internal temperature reached -15°, was  
 diazotized with 3.5 g. NaNO<sub>2</sub> in 10 ml. H<sub>2</sub>O, maintaining the internal  
 temperature

below -10°. To this solution was added with stirring and maintaining  
 the temperature below -10° a mixture prep'd, as follows: to 8.6 g.  
 3-carbethoxy-2-piperidone and 8.55 g. KOH in 100 ml. H<sub>2</sub>O, kept overnight  
 at 25-30°, 100 ml. EtOH and concentrated HCl until pH 2-3 was added.  
 Addition of this mixture to the diazo solution ended, the whole was stirred 10  
 hrs. at -12°, kept 12 hrs. at room temperature, concentrated in vacuo on a  
 steam bath to 1/3 initial volume, cooled, and filtered to give 9.5 g.  
 2,3-dioxopiperidine 3-[4-(5-ethyl-2-methyl)pyridylhydrazone 1-oxide]  
 hydrochloride (IV), m. 212-15° (aqueous ethanolic HCl). By evaporating  
 the filtrate to dryness in vacuo, dissolving the residue in 11.5 ml.  
 boiling H<sub>2</sub>O, cooling, and filtering, another 4.1 g. IV was obtained.  
 2,3-Dioxopiperidine 3-[4-(3-methyl)- (V) (60%), m. 226-8°, and  
 2,3-dioxopiperidine 3-[4-(2-methyl)-pyridylhydrazone 1-oxide]  
 hydrochloride (VI) (75%), m. 193-5°, were similarly prepared from II  
 and III resp., with the difference for VI consisting in dissolving the  
 filtrate residue in 20-25 ml. boiling EtOH, filtering, evaporating to dryness,  
 taking up the residue in 10 ml. Me<sub>2</sub>CO and 1 ml. EtOH, and filtering. IV

(3.16 g.) and 11 g.  $\text{ZnCl}_2$  immersed in an oil bath at  $110^\circ$  stirred until the bath temperature reached  $195\text{--}200^\circ$ , maintained at this temperature until gas evolved, removed, cooled, the glassy product dissolved in 8 ml. 6N HCl, boiled with charcoal, filtered, cooled, the precipitate collected and recrystd. 3 times from  $\text{H}_2\text{O}$  and once from 6N HCl to give 0.93 g. 1-hydroxy-3,4-dihydro-5-methyl-8-ethyl-6-aza- $\beta$ -carboline 6-oxide hydrochloride, m.  $>300^\circ$ . 1-Hydroxy-3,4-dihydro-8-methyl- (30%), m.  $287\text{--}9^\circ$  and 1-hydroxy-3,4 dihydro-5(7)-methyl-6-aza- $\beta$ -carboline 6-oxide hydrochloride (VII) (28%), m.  $>300^\circ$ , were similarly prepared from V and VI, resp. The position of the methyl group in VII was not defined. 4-Pyridylhydrazone 1-oxides of certain ketones formed 2 series of hydrochlorides with base to acid molar ratios 1:1 and 2:1 (normal and abnormal salt), having very different infrared spectra: those of the normal salts showed a strong OH band at  $2550\text{--}2380\text{ cm}^{-1}$ , while those of the abnormal salts lacked this band. The structure VIII was suggested for the abnormal hydrochlorides. VIII were prepared by this general procedure: to 0.02 mole 4-pyridylhydrazine 1-oxide (IX) in 0.01 mole 2N HCl was added 0.02 mole of a ketone, the precipitate collected, treated with a little

absolute

EtOH, filtered, and crystallized from absolute EtOH (ketone, % yield, and m.p. given): cyclohexanone, 85,  $207\text{--}8^\circ$ ; acetophenone, 93,  $209^\circ$ ; ethyl pyruvate, 85,  $155\text{--}7^\circ$ . The normal 4-pyridylhydrazone 1-oxide hydrochlorides (X) of certain carbonyl compds. were prepared by this general procedure: to 0.02 mole IX in 0.02 mole 2N HCl was added 0.02 mole of a carbonyl compound, dissolved in equal weight of warm EtOH if solid. After short time the solution was filtered and the residue crystallized from

absolute EtOH

(carbonyl compound, % yield, m.p., and ir spectra given): cyclohexanone, 76,  $212\text{--}13^\circ$  (decomposition), OH  $3.97\text{ }\mu$ ; acetophenone, 86,  $239\text{--}40^\circ$ , OH  $4.21\text{ }\mu$ ; ethyl pyruvate, 70,  $220\text{--}2^\circ$ , OH  $4.16\text{ }\mu$ ; cyclohexylpyruvamide, 89,  $243\text{--}4^\circ$ , OH  $4.21\text{ }\mu$ ; propionaldehyde, 70,  $174\text{--}5^\circ$ , OH  $4.1\text{ }\mu$ . Attempts to indolize the X of these carbonyl compds. was successful in the case of cyclohexanone only. Cyclohexanone 4-pyridylhydrazone 1-oxide hydrochloride (XI) (2 g.) was hydrogenated with 0.1 g.  $\text{PtO}_2$  in 60 ml. EtOH at atmospheric pressure and room temperature After

1.5 hrs.

and 250 ml. H adsorbed, the solution was filtered, evaporated to dryness in vacuo, the oily residue become crystalline after staying overnight, dissolved in 5 ml.  $\text{H}_2\text{O}$ , filtered, and the filtrate poured into 1.5 ml. of a mixture of  $\text{H}_2\text{O}$  and concentrated  $\text{NH}_4\text{H}$  (1:1) to give 2 g. cyclohexanone 4-pyridylhydrazone, m.  $169\text{--}70^\circ$  (dilute MeOH 1:1). XI (2 g.), 6 g.  $\text{ZnCl}_2$  and 1 g. NaCl immersed in an oil bath, heated to  $180^\circ$ , and kept at this temperature until gas evolved, removed, cooled, dissolved in 5 ml. boiling 6N HCl, cooled, and filtered to give 1.12 g. crude product hydrogenated directly with 0.12 g.  $\text{PtO}_2$  in 18 ml.  $\text{H}_2\text{O}$  and 0.3 ml. concentrated HCl at atmospheric

pressure

and room temperature After 3 hrs. and 74 ml. H adsorbed the liquid was filtered, 0.78 g. NaOH was added portionwise to the warm filtrate, kept overnight and filtered to give 0.11 g. 6,7,8,9-tetrahydro- $\gamma$ -carboline, m.  $269\text{--}71^\circ$  (decomposition) (EtOH). Cyclohexylpyruvamide 4-pyridylhydrazone 1-oxide hydrochloride (XII) (0.62 g.) hydrogenated with 0.05 g.  $\text{PtO}_2$  in 30 ml.  $\text{H}_2\text{O}$  and 0.3 ml. concentrated HCl at atmospheric

pressure and


room temperature, filtered after 1 hr. and 1 mole H adsorbed, and basified with  $\text{NaHCO}_3$  gave 0.45 g. cyclohexylpyruvamide 4-pyridylhydrazone, m.  $168\text{--}9^\circ$  (dilute EtOH 1:1). XII (3 g.) and 9 g.  $\text{ZnCl}_2$  warmed 30 min. in an oil bath at  $218\text{--}20^\circ$ , cooled, the glassy product crushed under Et<sub>2</sub>O, washed by decanting repeatedly with Et<sub>2</sub>O and  $\text{C}_6\text{H}_6$ , dried in vacuo, boiled in 15-20 ml.  $\text{H}_2\text{O}$  with charcoal, filtered, and cooled gave 0.68 g. pyruvamide 4-pyridylhydrazone 1-oxide (XIII), m.  $265\text{--}6^\circ$  ( $\text{H}_2\text{O}$ ). XII

(0.5 g.) and 3 g. polyphosphoric acid heated at 135-40° 5 hrs., cooled, dissolved in 7 ml. H<sub>2</sub>O, the cold solution treated with charcoal, filtered, basified with 20% NaOH until pH 5-6, kept overnight, filtered, the residue dried on a porous dish and crystallized from H<sub>2</sub>O gave 0.29 g. XIII, also prepared (0.1 g.) by boiling for a few min. 0.4 g. ethyl pyruvate 4-pyridylhydrazone 1-oxide hydrochloride in 4 ml. absolute EtOH and 2 ml. concentrated NH<sub>4</sub>OH, concentrating, cooling, and filtering.

IT 4329-61-7, 6H-Dipyrido[3,4-b:3',4'-d]pyrrol-6-one,  
5,7,8,9-tetrahydro-4-methyl-, 2-oxide, hydrochloride  
(preparation of)

RN 4329-61-7 HCAPLUS

CN 6H-Pyrrolo[2,3-c:4,5-c']dipyridin-6-one, 5,7,8,9-tetrahydro-4-methyl-,  
2-oxide, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

L164 ANSWER 20 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1965:9057 HCAPLUS

DOCUMENT NUMBER: 62:9057

ORIGINAL REFERENCE NO.: 62:1637d-h,1638d-g

TITLE: Indole derivatives. IX. Synthesis of 5-azatryptamine

AUTHOR(S): Pietra, S.; Tacconi, G.

CORPORATE SOURCE: Univ. Pavia, Italy

SOURCE: Farmaco, Edizione Scientifica (1964), 19(9),  
741-50

CODEN: FRPSAX; ISSN: 0430-0920

DOCUMENT TYPE: Journal

LANGUAGE: Italian

OTHER SOURCE(S): CASREACT 62:9057

ED Entered STN: 22 Apr 2001

AB cf. CA 59, 9954e. 4-Nitropyridine 1-oxide (5.6 g.) in 70 cc. anhydrous EtOH was hydrogenated over 0.15 g. 10% Pd-C at normal pressure and room temperature until 3 moles H was absorbed; the filtered solution was treated with HCl gas and concentrated in vacuo on a water bath to a small volume to give 3.75 g. 4-aminopyridine 1-oxide hydrochloride (I), m. 181-3° (decomposition). A suspension of 2 g. I in 55 cc. H<sub>2</sub>O and 16 cc. concentrated HCl was cooled to -15°, diazotized at -10° with a solution of 5.6 g. NaNO<sub>2</sub> in 16 cc. H<sub>2</sub>O, and maintaining the same temperature, a solution was added, which had been

prepared as follows: 13.6 g. 3-carbethoxy-2-piperidone, 5.6 g. KOH, and 160 cc. H<sub>2</sub>O was kept 12 hrs. at 25-30°, then 200 cc. EtOH and concentrated HCl was added until pH 2-3. The mixture was kept 24 hrs. at -10° and 2 hrs. at room temperature, and the precipitate filtered to give 10.7 g. 3-(4-pyridylhydrazone 1-oxide) of 2,3-dioxopiperidine hydrochloride (II), m. 256-7° (decomposition) (1:1 acidified H<sub>2</sub>O-EtOH). The concentrated mother liquor was treated with 24 cc. boiling H<sub>2</sub>O to give, after cooling, another 5.5 g. II (containing 25% inorg. salts). II (0.5 g.) in 8 cc. EtOH and 6 cc. H<sub>2</sub>O was treated with 6 cc. Kastel A 300 resin, previously treated with 4%

NaOH and washed with H<sub>2</sub>O and EtOH; after 24 hrs. the resin was filtered off and the solution evaporated to dryness to give 0.31 g. free base of II, m. 252° (70% EtOH). This same product was prepared in 8% yield by diazotization with a buffer of AcONa. A mixture of 5.1 g. II, 2.5 g. powdered NaCl, and 15 g. ZnCl<sub>2</sub> was heated at 110°, the bath temperature was raised to 195-200°, and the mixture stirred until an exothermic reaction took place, cooled, taken up in 20 cc. warm N HCl, boiled, treated with C, and filtered to give a precipitate of 1.5 g. 1-hydroxy-3,4-dihydro-6-aza-β-carboline 6-oxide hydrochloride (III), m. 264-5° (3:2 and 4:1 H<sub>2</sub>O-HCl). The free base of III (0.83 g.), m. above 300° (H<sub>2</sub>O), was prepared by treating 1 g. III in 20 cc. H<sub>2</sub>O with 10% NaOH to pH 9-10. III (2.4 g.) was suspended in 50 cc. H<sub>2</sub>O and hydrogenated over 0.5 g. Pd-C at normal pressure and room temperature; after 90 min. 1 mole H was absorbed, the mixture filtered, 30 cc. EtOH added, and the solution evaporated in vacuo to dryness to give 1.9 g. 1-hydroxy-3,4-dihydro-6-aza-β<sub>6</sub>-carboline hydrochloride (IV), m. above 300° (4:1 H<sub>2</sub>O-HCl). The free base of IV, prepared as above, m. above 300° (H<sub>2</sub>O). III (4 g.) was refluxed 5 hrs. with 60 cc. 2:1 HCl-H<sub>2</sub>O to give, after cooling, 4.25 g. 3-(2-aminoethyl)-5-azaindole-2-5azacarboxylic acid 5-oxide hydrochloride (V), m. 288-9° (decomposition) (2:1 HCl-H<sub>2</sub>O). The free base of V (1.92 g.), m. above 300° (H<sub>2</sub>O), was prepared by refluxing 2 g. III during 5 hrs. with 40 cc. 1:1 aqueous alc. KOH, concentrating in vacuo, neutralizing

with 3.5

cc. AcOH, and filtering. IV (3.9 g.) was refluxed 5 hrs. with 60 cc. 1:1 H<sub>2</sub>O-HCl and cooled to give 4.4 g. 3-(2-aminoethyl)-5azaindole-2-carboxylic acid hydrochloride (VI), m. above 300° 2:1 HCl-H<sub>2</sub>O). Hydrogenation as above of 1.4 g. V gave also 1.25 g. VI. VI free base was prepared quant. by treating a solution of VI in 4 parts H<sub>2</sub>O with NaOH to pH 8-9. Amixt. of 1 g. VI free base (dried at 135-40°/0.1-0.05 mm. 3-4 hrs.) and 0.75 g. electrolytic Cu was added in 2 portions to 16 cc. boiling quinoline; after 10-12 min. CO<sub>2</sub> development was finished, the solvent was evaporated in vacuo, the residue washed with a steam current, the aqueous solution treated

with

C, filtered, and evaporated to dryness, the residue taken up in 5 cc. EtOH, a small amount of IV filtered off, and the solution evaporated in vacuo to give

0.6

g. 5-azatryptamine (VII), as a brown oil. VII (0.54 g.) was heated 5 min. with 3.6 cc. Ac<sub>2</sub>O on a water bath, the mixture evaporated in vacuo, and the residue taken up in H<sub>2</sub>O. This procedure was repeated 4 times, 3 cc. saturated NaHCO<sub>3</sub> solution added, and the mixture kept 2 days to give 0.48 g. N-acetyl-5-azatryptamine, m. 215-16° decomposition) (H<sub>2</sub>O). VII (0.27 g.) and 0.5 g. phthalic anhydride were mixed and heated with stirring in an oil bath at 210° 15 min.; the product was taken up in Et<sub>2</sub>O, the mixture filtered, the residue suspended in 6 cc. warm H<sub>2</sub>O and cooled, 3-4 cc. saturated NaHCO<sub>3</sub> solution added, and the mixture filtered to give 0.35 g. N-phthalyl-5-azatryptamine, m. 255-6° (decomposition) (EtOH).

IT


1433-04-1, 6H-Dipyrido[3,4-b:3',4'-d]pyrrol-6-one, 5,7,8,9-tetrahydro-, 2-oxide, hydrochloride 1433-05-2, 6H-Dipyrido[3,4-b:3',4'-d]pyrrol-6-one, 5,7,8,9-tetrahydro-, hydrochloride (preparation of)

RN

1433-04-1 HCAPLUS


CN

6H-Pyrrolo[2,3-c:4,5-c']dipyridin-6-one, 5,7,8,9-tetrahydro-, 2-oxide, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 1433-05-2 HCAPLUS

CN 6H-Pyrrolo[2,3-c:4,5-c']dipyridin-6-one, 5,7,8,9-tetrahydro-,  
hydrochloride (7CI, 8CI) (CA INDEX NAME)

● HCl

=&gt; d ibib ab hitstr 21-27

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, CAOLD' - CONTINUE? (Y)/N:y

L164 ANSWER 21 OF 30 USPATFULL on STN

DUPLICATE 2

ACCESSION NUMBER: 2003:294870 USPATFULL

TITLE: Piperazine derivatives

INVENTOR(S): Adams, David Reginald, Wokingham, UNITED KINGDOM  
Bentley, Jonathan Mark, Wokingham, UNITED KINGDOM  
Blench, Toby Jonathan, Wokingham, UNITED KINGDOM  
Hebeisen, Paul, Basle, SWITZERLAND  
Monck, Nathaniel Julius Thomas, Wokingham, UNITED KINGDOM  
Richter, Hans, Grenzach-Wyhlen, GERMANY, FEDERAL REPUBLIC OF  
Roever, Stephan, Inzlingen, GERMANY, FEDERAL REPUBLIC OF  
Roffey, Jonathan Richard Anthony, Wokingham, UNITED KINGDOM  
Taylor, Sven, Riedisheim, FRANCE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003207888	A1	20031106	<--
	US 7098337	B2	20060829	
APPLICATION INFO.:	US 2003-350616	A1	20030124 (10)	<--

	NUMBER	DATE	
PRIORITY INFORMATION:	GB 2002-2015	20020129	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110		
NUMBER OF CLAIMS:	39		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3712		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	The present invention relates to compounds of formula (I)    ##STR1##		

as well as pharmaceutically acceptable salts, solvates and esters thereof. These compounds can be used to prepare pharmaceutical compositions for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes, obesity and sleep apnoea.


IT 577711-82-1P

(preparation of triazafluorenes as 5-HT<sub>2</sub> receptor ligands)

RN 577711-82-1 USPATFULL

CN Pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazin-6(7H)-one, 2-chloro-8,9-dihydro-9-methyl-, (9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L164 ANSWER 22 OF 30    USPATFULL on STN  
 ACCESSION NUMBER:    2005:177869    USPATFULL  
 TITLE:    Broad -spectrum cephem compounds  
 INVENTOR(S):    Nishitani, Yasuhiro, Osaka-shi, JAPAN  
                   Yamano, Yoshinori, Toyonaka-shi, JAPAN  
 PATENT ASSIGNEE(S):    SHIONOGI & CO., LTD., Osak-shi, JAPAN (non-U.S.  
                                  corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005153950	A1	20050714	
APPLICATION INFO.:	US 2003-507502	A1	20030318	(10) <--
	WO 2003-JP3249		20030318	<--

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 2002-73526	20020318	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007, US		



NUMBER OF CLAIMS: 26  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 4829

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula: ##STR1## (wherein, T is S, SO or O; X is halogen, CN, carbamoyl optionally substituted with lower alkyl, lower alkyl, lower alkoxy, or lower alkylthio; A is substituted lower alkylene (wherein the substituent is optionally substituted mono lower alkyl, optionally substituted lower alkylidene, or optionally substituted lower alkylene);

Z.sup.+ is an optionally substituted, a cation and an N atom-containing heterocyclic group), ester, amino-protected compound wherein the amino bonds to a thiazole ring at the 7-position, or pharmaceutically acceptable salt or solvate thereof.


IT 604000-76-2P

(preparation of broad-spectrum cephem compds.)

RN 604000-76-2 USPATFULL

CN 1H-Pyrrolo[3,2-c]pyridinium, 2-(aminocarbonyl)-5-[[[(6R,7R)-7-[[[(2Z)-(2-amino-5-chloro-4-thiazolyl)[[(1S)-1-carboxyethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



L164 ANSWER 23 OF 30 USPATFULL on STN

ACCESSION NUMBER: 2005:31488 USPATFULL

TITLE: 5HT2c receptor agonists

INVENTOR(S): Blench, Toby Jonathan, Winnersh, UNITED KINGDOM  
 Hebeisen, Paul, Basel, SWITZERLAND  
 Richter, Hans, Grenzach-Wyhlen, GERMANY, FEDERAL  
 REPUBLIC OF  
 Roever, Stephan, Inzlingen, GERMANY, FEDERAL REPUBLIC  
 OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005026925	A1	20050203
APPLICATION INFO.:	US 2004-876954	A1	20040625 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-14967	20030626
DOCUMENT TYPE:	Utility	


<--

FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340  
KINGSLAND STREET, NUTLEY, NJ, 07110  
NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
LINE COUNT: 4227  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention provides piperazine derivatives of formula (I)  
##STR1##

as well as pharmaceutically acceptable salts and esters thereof, wherein  
R.sup.1 to R.sup.5 have the significance given in the description. They  
can be used for the treatment of obesity.


IT 823217-65-8P 823217-76-1P  
(preparation of triazafluorenes as 5-HT<sub>2C</sub> receptor agonists for the  
treatment of diabetes and obesity)  
RN 823217-65-8 USPATFULL  
CN Pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazin-6(7H)-one, 2-chloro-3-ethoxy-8,9-  
dihydro-9-methyl-, (9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823217-76-1 USPATFULL  
CN Pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazin-6(7H)-one, 2-chloro-8,9-dihydro-3,9-  
dimethyl-, (9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L164 ANSWER 24 OF 30 USPATFULL on STN  
ACCESSION NUMBER: 2004:108209 USPATFULL  
TITLE: Novel sulfonyl derivatives  
INVENTOR(S): Kobayashi, Syozo, Tokyo, JAPAN  
Komoriya, Satoshi, Tokyo, JAPAN  
Haginoya, Noriyasu, Tokyo, JAPAN  
Suzuki, Masanori, Tokyo, JAPAN  
Yoshino, Toshiharu, Tokyo, JAPAN  
Nagahara, Takayasu, Tokyo, JAPAN

PATENT ASSIGNEE(S): Nagata, Tsutomu, Tokyo, JAPAN  
Horino, Haruhiko, Tokyo, JAPAN  
Ito, Masayuki, Tokyo, JAPAN  
Mochizuki, Akiyoshi, Tokyo, JAPAN  
DAIICHI PHARMACEUTICAL CO., LTD., Tokyo, JAPAN  
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004082611	A1	20040429
APPLICATION INFO.:	US 2003-681205	A1	20031009 (10) <--
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-762888, filed on 12 Feb 2001, PENDING A 371 of International Ser. No. WO 1999-JP4344, filed on 11 Aug 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-227449	19980811 <--
	JP 1998-244175	19980828 <--
	JP 1998-251674	19980904 <--
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	25945	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described in the present invention are a sulfonyl derivative represented by the following formula (I):

Q.sup.1-Q.sup.2-T.sup.1-Q.sup.3-SO.sub.2-Q.sup.A (I)

[wherein Q.sup.1 represents a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group, 5- or 6-membered heterocyclic group, dicyclic fused ring or tricyclic fused ring group which may have a substituent;

Q.sup.2 represents a single bond, an oxygen atom, a sulfur atom, a linear or branched C.sub.1-6 alkylene group or the like;

Q.sup.A represents an arylalkenyl group which may have a substituent or a heteroarylalkenyl group which may have a substituent; and


T.sup.1 represents a carbonyl group or the like] and a medicament comprising the same. The compound has strong FXa inhibitory action, provides prompt, sufficient and long-lasting anti-thrombus effects when orally administered, and has low side effects and is therefore useful as an excellent anticoagulant.

IT 259805-66-8P 259805-67-9P 259805-68-0P  
259805-69-1P 259805-70-4P 259805-71-5P  
259805-72-6P

(preparation of sulfonyl moiety-containing heterocyclic compds. as factor Xa inhibitors)


RN 259805-66-8 USPATFULL

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (10:11) (9CI)  
(CA INDEX NAME)




●11/10 HCl

RN 259805-67-9 USPATFULL  
 CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-5-methyl-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (10:13)  
 (9CI) (CA INDEX NAME)




●13/10 HCl

RN 259805-68-0 USPATFULL  
 CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(5-ethyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (5:6)  
 (9CI) (CA INDEX NAME)




●6/5 HCl

RN 259805-69-1 USPATFULL  
 CN 5H-Pyrrolo[3,2-c]pyridine-5-carboxylic acid, 2-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 259805-70-4 USPATFULL

CN 5H-Pyrrolo[3,2-c]pyridine-5-carboxylic acid, 2-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]-1,4,6,7-tetrahydro-1-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 259805-71-5 USPATFULL


CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-1-methyl-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (5:7) (9CI) (CA INDEX NAME)



●7/5 HCl

RN 259805-72-6 USPATFULL

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-1,5-dimethyl-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (5:7) (9CI) (CA INDEX NAME)




●7/5 HCl

IT 259809-55-7P

(preparation of sulfonyl moiety-containing heterocyclic compds. as factor Xa inhibitors)

RN 259809-55-7 USPATFULL

CN 1H-Pyrrolo[3,2-c]pyridine-1,5(4H)-dicarboxylic acid, 2-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]-6,7-dihydro-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L164 ANSWER 25 OF 30 USPATFULL on STN

ACCESSION NUMBER: 2004:141182 USPATFULL

TITLE: Sulfonyl derivatives

INVENTOR(S): Kobayashi, Syozo, Tokyo, JAPAN  
Komoriya, Satoshi, Tokyo, JAPAN  
Haginoya, Noriyasu, Tokyo, JAPAN  
Suzuki, Masanori, Tokyo, JAPAN  
Yoshino, Toshiharu, Tokyo, JAPAN  
Nagahara, Takayasu, Tokyo, JAPAN  
Nagata, Tsutomu, Tokyo, JAPAN  
Horino, Haruhiko, Tokyo, JAPAN  
Ito, Masayuki, Tokyo, JAPAN

PATENT ASSIGNEE(S): Mochizuki, Akiyoshi, Tokyo, JAPAN  
Daiichi Pharmaceutical Co., Ltd., Tokyo, JAPAN  
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6747023	B1	20040608	
	WO 2000009480		20000224	<--
APPLICATION INFO.:	US 2001-762888		20010212	(9) <--
	WO 1999-JP4344		19990811	<--

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1998-227449	19980811	<--
	JP 1998-244175	19980828	<--
	JP 1998-251674	19980904	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Raymond, Richard L.		
ASSISTANT EXAMINER:	Habte, Kahsay		
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	23888		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Described in the present invention are a sulfonyl derivative represented by the following formula (I):		

Q.sup.1--Q.sup.2--T.sup.1--Q.sup.3--SO.sub.2--Q.sup.A (I)

[wherein Q.sup.1 represents a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group, 5- or 6-membered heterocyclic group, dicyclic fused ring or tricyclic fused ring group which may have a substituent;

Q.sup.2 represents a single bond, an oxygen atom, a sulfur atom, a linear or branched C.sub.1-6 alkylene group or the like;

Q.sup.A represents an arylalkenyl group which may have a substituent or a heteroarylalkenyl group which may have a substituent; and


T.sup.1 represents a carbonyl group or the like] and a medicament comprising the same. The compound has strong FXa inhibitory action, provides prompt, sufficient and long-lasting anti-thrombus effects when orally administered, and has low side effects and is therefore useful as an excellent anticoagulant.

IT 259805-66-8P 259805-67-9P 259805-68-0P  
259805-69-1P 259805-70-4P 259805-71-5P  
259805-72-6P

(preparation of sulfonyl moiety-containing heterocyclic compds. as factor Xa inhibitors)


RN 259805-66-8 USPATFULL

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (10:11) (9CI)  
(CA INDEX NAME)




●11/10 HCl

RN 259805-67-9 USPATFULL  
 CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-5-methyl-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (10:13)  
 (9CI) (CA INDEX NAME)




●13/10 HCl

RN 259805-68-0 USPATFULL  
 CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(5-ethyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (5:6)  
 (9CI) (CA INDEX NAME)



●6/5 HCl


RN 259805-69-1 USPATFULL  
 CN 5H-Pyrrolo[3,2-c]pyridine-5-carboxylic acid, 2-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 259805-70-4 USPATFULL  
 CN 5H-Pyrrolo[3,2-c]pyridine-5-carboxylic acid, 2-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]-1,4,6,7-tetrahydro-1-




methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 259805-71-5 USPATFULL


CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-1-methyl-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (5:7) (9CI) (CA INDEX NAME)



● 7/5 HCl

RN 259805-72-6 USPATFULL

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-1,5-dimethyl-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (5:7) (9CI) (CA INDEX NAME)




● 7/5 HCl

IT 259809-55-7P

(preparation of sulfonyl moiety-containing heterocyclic compds. as factor Xa inhibitors)

RN 259809-55-7 USPATFULL

CN 1H-Pyrrolo[3,2-c]pyridine-1,5(4H)-dicarboxylic acid, 2-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]-6,7-dihydro-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L164 ANSWER 26 OF 30 USPTAFULL on STN

ACCESSION NUMBER: 2003:153421 USPTAFULL

TITLE: Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease

INVENTOR(S): Wishka, Donn G., Kalamazoo, MI, UNITED STATES  
 Walker, Daniel Patrick, Kalamazoo, MI, UNITED STATES  
 Corbett, Jeffrey W., Portage, MI, UNITED STATES  
 Reitz, Steven Charles, Toledo, OH, UNITED STATES  
 Rauckhorst, Mark R., Portage, MI, UNITED STATES  
 Groppi, Vincent E., JR., Kalamazoo, MI, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003105089	A1	20030605	<--
APPLICATION INFO.:	US 2002-234575	A1	20020904 (10)	<--

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-322346P	20010912 (60)	<--
	US 2001-322333P	20010912 (60)	<--
	US 2001-322100P	20010912 (60)	<--
	US 2002-399530P	20020730 (60)	<--

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: PHARMACIA & UPJOHN, 301 HENRIETTA ST, 0228-32-LAW, KALAMAZOO, MI, 49007

NUMBER OF CLAIMS: 70  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 7572

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compounds of Formula I: ##STR1##


which may be in the form of pharmaceutical acceptable salts or compositions, are useful in treating diseases or conditions in which  $\alpha 7$  nicotinic acetylcholine receptors (nAChRs) are known to be involved.

IT 501892-47-3P, N-[(1S,2R,4R)-7-Azabicyclo[2.2.1]hept-2-yl]-1H-pyrrolo[2,3-c]pyridine-2-carboxamide dihydrochloride (preparation of N-[7-aza[2.2.1]bicycloheptanyl]arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)

RN 501892-47-3 USPTAFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

L164 ANSWER 27 OF 30 USPTAFULL on STN  
 ACCESSION NUMBER: 2002:95821 USPTAFULL  
 TITLE: Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them  
 INVENTOR(S): Brodin, Roger, Montpellier, FRANCE  
 Boigegrain, Robert, Assas, FRANCE  
 Bignon, Eric, Pinsaguel, FRANCE  
 Molimard, Jean Charles, Saint Gely Du Fesc, FRANCE  
 Olliero, Dominique, Montpellier, FRANCE  
 PATENT ASSIGNEE(S): Sanofi-Synthelabo, Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6380230	B1	20020430	<--
	WO 9915525		19990401	<--
APPLICATION INFO.:	US 2000-508830		20000602 (9)	<--
	WO 1998-FR2007		19980918	<--
			20000602	PCT 371 date

	NUMBER	DATE	
PRIORITY INFORMATION:	FR 1997-11718	19970919	<--
	FR 1998-5106	19980423	<--

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Gerstl, Robert  
 LEGAL REPRESENTATIVE: Alexander, Michael D., Dupont, Paul E.  
 NUMBER OF CLAIMS: 33  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
 LINE COUNT: 2847

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to cholecystokinin (CCK)-agonist substituted thiazoles of formula: ##STR1##

in which R.sub.1 is a substituted phenyl group, R.sub.2 is a group chosen from CH.sub.2--R.sub.7, (CH.sub.2).sub.2--R.sub.7, S--CH.sub.2--R.sub.7, CH.sub.2--S--R.sub.7 and (C.sub.5-C.sub.8)alkyl with R.sub.7 being a (C.sub.5-C.sub.7)cycloalkyl group, and R.sub.3 is a group ##STR2##

with R.sub.8 being a group (CH.sub.2).sub.nR.sub.15 or ##STR3##

and R.sub.15 being COOH or COO(C.sub.1-C.sub.4)alkyl. The invention also relates to a process for the preparation of the pharmaceutical compositions containing them and to their uses for the preparation of medicines.

IT 221673-77-4P 221673-79-6P 221673-81-0P

(preparation of N-(2-thiazolyl)indole-2-carboxamides and analogs as CCK-A receptor agonists)


RN 221673-77-4 USPATFULL

CN 1H-Pyrrolo[3,2-c]pyridine-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 221673-76-3


CMF C29 H31 Cl N4 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 221673-79-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-5-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 221673-78-5


CMF C30 H33 Cl N4 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 221673-81-0 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 221673-80-9

CMF C29 H31 Cl N4 O5 S



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



=> fil caold  
FILE 'CAOLD' ENTERED AT 16:32:09 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.


=> file stnguide  
FILE 'STNGUIDE' ENTERED AT 16:32:25 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Oct 25, 2006 (20061025/UP).

=> d iall hitstr 28  
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, CAOLD' - CONTINUE? (Y)/N:y

L164 ANSWER 28 OF 30 CAOLD COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: CA65:3851c CAOLD  
TITLE: studies on the decarbonylation and decarboxylation reactions  
of 5,6-epoxy-4,5-diphenyl-2-pyrone  
AUTHOR NAME: Padwa, Albert; Hartman, R. B.  
INDEX TERM: 954-54-1 1203-80-1 2348-77-8 6496-80-6  
6502-52-9 6502-53-0 6620-27-5  
IT 6502-52-9

RN 6502-52-9 CAOLD  
CN 1H-Pyrrolo[2,3-c:5,4-c']dipyridin-1-one, 8-chloro-2,3,4,9-tetrahydro-  
(7CI, 8CI) (CA INDEX NAME)



=> d iall hitstr 29-30

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, CAOLD' - CONTINUE? (Y)/N:y

L164 ANSWER 29 OF 30 CAOLD COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: CA64:686a CAOLD

TITLE: indole derivs.-indolization of ketones 4-pyridylhydrazone  
1-oxides


AUTHOR NAME: Tacconi, Gianfranco; Pietra, S.

INDEX TERM: 1135-35-9 4329-57-1 **4329-61-7** 4329-62-8  
4329-63-9 4329-64-0 4329-69-5 4329-70-8 4329-71-9  
**4552-86-7** 6688-62-6 6688-63-7 6688-64-8  
6688-65-9 6688-66-0 6688-68-2 6688-69-3  
**6806-57-1** 13509-08-5 13553-92-9 96748-91-3  
**96776-15-7**

IT **4329-61-7** **4552-86-7** **6806-57-1**  
**96776-15-7**

RN 4329-61-7 CAOLD


CN 6H-Pyrrolo[2,3-c:4,5-c']dipyridin-6-one, 5,7,8,9-tetrahydro-4-methyl-,  
2-oxide, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 4552-86-7 CAOLD


CN 6H-Pyrrolo[2,3-c:4,5-c']dipyridin-6-one, 4-ethyl-5,7,8,9-tetrahydro-1-  
methyl-, 2-oxide, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 6806-57-1 CAOLD


CN 6H-Pyrrolo[2,3-c:4,5-c']dipyridin-6-one, 5,7,8,9-tetrahydro-3-methyl-, 2-oxide, hydrochloride (7CI, 8CI) (CA INDEX NAME)



● HCl

RN 96776-15-7 CAOLD

CN 6H-Pyrrolo[2,3-c:4,5-c']dipyridin-6-one, 5,7,8,9-tetrahydro-1-methyl-, 2-oxide, hydrochloride (7CI) (CA INDEX NAME)



● HCl

L164 ANSWER 30 OF 30 CAOLD COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: CA62:1637d CAOLD

TITLE: indole derivs. - (IX) synthesis of 5-azatryptamine

AUTHOR NAME: Pietra, Silvio; Tacconi, G.

INDEX TERM: 659-05-2 1137-00-4 1203-80-1 1207-13-2 1207-18-7  
1210-55-5 1211-96-7 1211-97-8 1433-03-0  
1433-04-1 1433-05-2 1433-06-3  
1778-74-1 1778-75-2 1778-76-3 1778-77-4 7647-01-0



10/26/2006


Shiao, 10/849,089

10/26/2006

90946-20-6 93692-35-4 94487-85-1


IT 1433-04-1 1433-05-2

RN 1433-04-1 CAOLD

CN 6H-Pyrrolo[2,3-c:4,5-c']dipyridin-6-one, 5,7,8,9-tetrahydro-, 2-oxide,  
monohydrochloride (8CI) (CA INDEX NAME)

● HCl

RN 1433-05-2 CAOLD

CN 6H-Pyrrolo[2,3-c:4,5-c']dipyridin-6-one, 5,7,8,9-tetrahydro-,  
hydrochloride (7CI, 8CI) (CA INDEX NAME)

● HCl

=> d que nos 1147

```
L1          STR
L2          45329 SEA FILE=REGISTRY SSS FUL L1
L32         STR
L34         4740 SEA FILE=REGISTRY SUB=L2 SSS FUL L32
L42         STR
L45         1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42
L46         93 SEA FILE=REGISTRY ABB=ON PLU=ON L34 AND L45
L48         13 SEA FILE=HCAPLUS ABB=ON PLU=ON L46
L49         QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY
           <2004 OR REVIEW/DT
L51         7 SEA FILE=HCAPLUS ABB=ON PLU=ON L48 AND L49
L52         6 SEA FILE=HCAPLUS ABB=ON PLU=ON L48 NOT L51
L127        608 SEA FILE=REGISTRY ABB=ON PLU=ON L45 AND CL/ELS
L143        39 SEA FILE=HCAPLUS ABB=ON PLU=ON L127
L144        24 SEA FILE=HCAPLUS ABB=ON PLU=ON L143 AND L49
L146        15 SEA FILE=HCAPLUS ABB=ON PLU=ON L143 NOT L144
L147        11 SEA FILE=HCAPLUS ABB=ON PLU=ON L146 NOT L52
```

=> d his 1153

(FILE 'USPATFULL, USPAT2, TOXCENTER, CASREACT, CHEMCATS' ENTERED AT  
15:54:34 ON 25 OCT 2006)

L153 29 S L152 NOT L84

=> d que nos 1153

```
L1          STR
L2          45329 SEA FILE=REGISTRY SSS FUL L1
L32         STR
L34         4740 SEA FILE=REGISTRY SUB=L2 SSS FUL L32
L42         STR
L45         1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42
L46         93 SEA FILE=REGISTRY ABB=ON PLU=ON L34 AND L45
L49         QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY
           <2004 OR REVIEW/DT
L82         27 SEA L46
L83         11 SEA L82 AND L49
L84         16 SEA L82 NOT L83
L127        608 SEA FILE=REGISTRY ABB=ON PLU=ON L45 AND CL/ELS
L148        55 SEA L127
L149        18 SEA L148 AND L49
L152        37 SEA L148 NOT L149
L153        29 SEA L152 NOT L84
```

=> dup rem 1147 1153

DUPLICATE IS NOT AVAILABLE IN 'CHEMCATS'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

FILE 'HCAPLUS' ENTERED AT 16:33:40 ON 25 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:33:40 ON 25 OCT 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 16:33:40 ON 25 OCT 2006

COPYRIGHT (C) 2006 ACS

FILE 'CASREACT' ENTERED AT 16:33:40 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CHEMCATS' ENTERED AT 16:33:40 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)  
PROCESSING COMPLETED FOR L147  
PROCESSING COMPLETED FOR L153  
L165           33 DUP REM L147 L153 (7 DUPLICATES REMOVED)  
              ANSWERS '1-11' FROM FILE HCAPLUS  
              ANSWER '12' FROM FILE USPATFULL  
              ANSWER '13' FROM FILE TOXCENTER  
              ANSWERS '14-33' FROM FILE CHEMCATS

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 16:33:44 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Oct 25, 2006 (20061025/UP).

=> d ibib ed ab retable hitstr

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, TOXCENTER, CHEMCATS' -  
CONTINUE? (Y)/N:y

L165 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2006:578103 HCAPLUS

DOCUMENT NUMBER: 145:62867

TITLE: Preparation of substituted aza/indoles as kinase inhibitors, and their compositions and use for treatment of angiogenesis-related diseases, especially cancer

INVENTOR(S): Halley, Frank; Souaille, Catherine; Tabart, Michel; Bacque, Eric; Viviani, Fabrice; Ronan, Baptiste; Letallec, Jean-Philippe; Filoche-Romme, Bruno

PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.

SOURCE: PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006061493	A1	20060615	WO 2005-FR3003	20051202
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
FR 2878849	A1	20060609	FR 2004-12966	20041206
PRIORITY APPLN. INFO.:			FR 2004-12966	A 20041206
			US 2005-650465P	P 20050207

OTHER SOURCE(S): MARPAT 145:62867

ED Entered STN: 16 Jun 2006

AB Title compds. I [A, Ar = independently (un)substituted hetero/aryl; R1 = H, (un)substituted alkyl; X = N, CH and derivs.; L = a bond, CO, NH, CONH, NHCO, SONH, NHSO2, NHCONH, NHCSNH, etc.; R5-R7 = independently H, halo, CF3, NO2, CN, alkoxy, alkyl, CO2H and derivs., etc.; Q = H, Me, cyclopropyl] were prepared as kinase inhibitors for treatment especially of cancer. E.g., a 7-step synthesis starting from 2-methyl-3-nitropyridine and Et oxalate, was given for azaindole II. Pyrrolopyridine II inhibited KDR and Tie2 kinases with an IC50 of 12 nM and 4 nM. Thus, I and their pharmaceutical compns. are useful for treating angiogenesis-related diseases such as cancers, psoriasis, rheumatoid arthritis, diabetic retinopathy, etc.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
=====	=====	=====	=====	=====	=====
Anon					

Anon	1973	278	Chem Ind	
Anon	1924	60	No publication given	
Anon	1970		No publication given	
Anon	1997	27	1439	Synthesis Communicat
B Frydman & Co	1968	33	3762	JOURNAL OF ORGANIC C
Brehm, W	1949	71	3541	JOURNAL OF THE AMERI
Heinz-Werner, K	2004			WO 2004007480 A
Kurt, F	1972	37	2010	JOURNAL OF ORGANIC C
Monnet, M	1993	49	5831	TETRAHEDRON
Roswell, P	2003			WO 03035621 A
S H Maddirala &co	2003	44	5665	TETRAHEDRON LETTERS
Schering Corporation Us	2003			WO 2004000831 A1
Sugen Inc	1996			WO 9640115 A1
Tang, P	2001			WO 0121589 A
Yasuoki Murakami & Co	1984		738	SYNTHESIS

HCAPLUS

HCAPLUS

HCAPLUS

HCAPLUS

HCAPLUS

HCAPLUS



HCAPLUS

IT 890435-53-7P, 3-[4-[3-(4-Chloro-3-trifluoromethylphenyl)ureido]phenyl]-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 890435-54-8P, 3-[4-[3-(2-Chloro-5-trifluoromethylphenyl)ureido]phenyl]-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 890435-67-3P, 3-[4-[3-[3-Chloro-4-(difluoromethoxy)phenyl]ureido]phenyl]-1H-pyrrolo[3,2-b]pyridine-2-carboxamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aza/indoles as kinase inhibitors for treating angiogenesis-related diseases)



RN 890435-53-7 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 3-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)





RN 890435-54-8 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 3-[4-[[[2-chloro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 890435-67-3 HCAPLUS  
 CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 3-[4-[[[3-chloro-4-(difluoromethoxy)phenyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



=> d ibib ed ab retable hitstr 2-11

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, TOXCENTER, CHEMCATS' -  
 CONTINUE? (Y)/N:y

L165 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2  
 ACCESSION NUMBER: 2006:541929 HCAPLUS  
 DOCUMENT NUMBER: 145:8468  
 TITLE: Preparation of pyrrolopyridine-2-carboxylic acid  
 phenylalaninamide derivative useful as inhibitor of  
 glycogen phosphorylase  
 INVENTOR(S): Repasi, Jozsef; Szabo, Andras  
 PATENT ASSIGNEE(S): Prosidion Ltd., UK  
 SOURCE: PCT Int. Appl., 32 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006059165	A1	20060608	WO 2005-GB50234	20051202
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2004-632463P P 20041202

OTHER SOURCE(S): CASREACT 145:8468; MARPAT 145:8468

ED Entered STN: 09 Jun 2006

AB The invention relates to pyrrolopyridine-2-carboxylic acid amide I, which is an inhibitor of glycogen phosphorylase for use in therapy. Thus, treatment of 5-chloropyrrolo[2,3-c]pyridine-2-carboxylic acid with thionyl chloride in acetonitrile afforded the acid chloride HCl salt, which was treated with L-4-fluorophenylalanine in aqueous THF containing NaOH and Na<sub>2</sub>CO<sub>3</sub> and

then 4-hydroxypiperidine in THF to afford I. Thermogravimetric anal. and X-ray diffraction measurements were performed on I.HCl.

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bartlett, J	2002			WO 0220530 A	HCAPLUS
Bradley, S	2004			WO 2004104001 A	HCAPLUS

IT 888328-02-7P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(X-ray diffraction and thermogravimetric anal.; preparation of pyrrolopyridinecarboxylic acid phenylalaninamide derivative useful as inhibitor of glycogen phosphorylase)

RN 888328-02-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 800397-99-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyridinecarboxylic acid phenylalaninamide derivative useful as inhibitor of glycogen phosphorylase)

RN 800397-99-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 800400-48-0P 888328-04-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrrolopyridinecarboxylic acid phenylalaninamide derivative useful as inhibitor of glycogen phosphorylase)

RN 800400-48-0 HCAPLUS

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 888328-04-9 HCAPLUS

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L165 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2006:542611 HCAPLUS

DOCUMENT NUMBER: 145:21196

TITLE: Treatment of diabetes and diabetes-related conditions with glycogen phosphorylase inhibitors

INVENTOR(S): Thomas, Gerard Hugh; Thomsen, Mikael

PATENT ASSIGNEE(S): Prosidion Ltd., UK

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006059163	A1	20060608	WO 2005-GB50232	20051202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2004-632591P

P 20041202

OTHER SOURCE(S): CASREACT 145:21196

ED Entered STN: 09 Jun 2006

AB The invention provides a method of treatment of diabetes, particularly type II diabetes, or a diabetes related condition, comprising night time dosing of an inhibitor of glycogen phosphorylase, optionally in combination another antidiabetic therapy. Preparation of e.g. 5-chloropyrrolo[2,3-c]pyridine-2-carboxylic acid [1-(S)-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]amide hydrochloride is described.

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Babcock, W	2001			WO 0168092 A	HCAPLUS
Barrila, M	2003			US 2003187051 A1	HCAPLUS
Bartlett, J	2003			US 2003232875 A1	HCAPLUS
Bradley, S	2004			WO 2004104001 A	HCAPLUS
Bradley, S	2005			WO 2005085194 A	HCAPLUS
Bradley, S	2005			WO 2005085245 A	HCAPLUS
Du Bois, D	2002			US 6399601 B1	HCAPLUS
Hoover	2000			US 6107329 A	HCAPLUS
Hoover, D	2001			WO 0168055 A	HCAPLUS
Hoover, D	2001			US 6277877 B1	HCAPLUS
Hulin, B	1996			WO 9639385 A	HCAPLUS
Hulin, B	2001			US 6297269 B1	HCAPLUS
Japan Tobacco Inc	2004			EP 1452526 A	HCAPLUS
Lundgren	1998			US 5854272 A	HCAPLUS
Onda, K	2003			WO 03091213 A	HCAPLUS
Pfizer Products Inc	2001			EP 1136071 A	HCAPLUS
Pfizer Products Inc	2003			EP 1340500 A	HCAPLUS
Sher, P	2004			US 2004002495 A1	
Sher, P	2004			US 2004142938 A1	
Treadway, J	2003			US 2003004162 A1	HCAPLUS

IT 800397-99-3P 888328-02-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(glycogen phosphorylase inhibitors for treatment of diabetes and diabetes-related conditions, and use with other agents)

RN 800397-99-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 888328-02-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 800397-99-3D, salts


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(glycogen phosphorylase inhibitors for treatment of diabetes and diabetes-related conditions, and use with other agents)

RN 800397-99-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 800400-48-0


RL: RCT (Reactant); RACT (Reactant or reagent)

(glycogen phosphorylase inhibitors for treatment of diabetes and diabetes-related conditions, and use with other agents)

RN 800400-48-0 HCAPLUS

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 888328-04-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(glycogen phosphorylase inhibitors for treatment of diabetes and diabetes-related conditions, and use with other agents)

RN 888328-04-9 HCAPLUS

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L165 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2004:747454 HCAPLUS

DOCUMENT NUMBER: 141:395464

TITLE: Synthesis and Conformational Analysis of a Non-Amidine Factor Xa Inhibitor That Incorporates 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 Binding Element

AUTHOR(S): Haginoya, Noriyasu; Kobayashi, Syozo; Komoriya, Satoshi; Yoshino, Toshiharu; Suzuki, Makoto; Shimada, Takashi; Watanabe, Kengo; Hirokawa, Yumiko; Furugori, Taketoshi; Nagahara, Takayasu

CORPORATE SOURCE: Medicinal Chemistry Research Laboratory, Daiichi Pharmaceutical Co. Ltd, Edogawa-ku, Tokyo, 134-8630, Japan

SOURCE: Journal of Medicinal Chemistry (2004), 47(21), 5167-5182

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:395464

ED Entered STN: 14 Sep 2004

AB Our exploratory study was based on the concept that a non-amidine factor Xa (fXa) inhibitor is suitable for an orally available anticoagulant. We synthesized and evaluated a series of N-(6-chloronaphthalen-2-yl)sulfonylpiperazine derivs. incorporating various fused-bicyclic rings containing an aliphatic amine expected to be S4 binding element. Among this series, 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine type I displayed orally potent anti-fXa activity and evident prolongation of prothrombin time (PT) with the moderate bioavailability in rats. The X-ray crystal anal. afforded an obvious binding mode that 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine and 6-chloronaphthalene resp. bound to S4 and S1 subsites. In this X-ray study, we discovered a novel intramol. S-O close contact. Ab initio energy calcns. of model compds. deduced that conformers with the most close S-O proximity were most stable. The Mulliken population anal. proposed that this energy profile was caused by both of electrostatic S-O affinity and N-O repulsion. The results of these calcns. and X-ray anal. suggested a possibility that the restricted conformation effected the affinity to S4 subsite of fXa.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Adler, M	2000	39	12534	Biochemistry	HCAPLUS
Adler, M	2002	41	15514	Biochemistry	HCAPLUS
Al-Obeidi, F	1999	9	931	Exp Opin Ther Pat	HCAPLUS
Brandstetter, H	1996	271	29988	J Biol Chem	HCAPLUS
Brieger, D	1988	31	1449	J Am Coll Cardiol	
Burling, F	1992	114	2313	J Am Chem Soc	HCAPLUS
Choi-Seledeski, Y	1999	9	2539	Bioorg Med Chem Lett	
Choi-Sledeski, Y	2003	46	681	J Med Chem	HCAPLUS
Chou, Y	2003	13	507	Bioorg Med Chem Lett	HCAPLUS
Collaborative Computati	1994	D50	760	Acta Crystallogr	
Collins, I	2002	45	1887	J Med Chem	HCAPLUS
Compudrug Chemistry Inc				Pallas ver 3.0	
Corrodi, H	1966	49	798	Helv Chim Acta	HCAPLUS
Faull, A	1996			WO 9610022	HCAPLUS
Fife, W	1984	22	93	Heterocycles	HCAPLUS
Franchetti, P	1995	38	3829	J Med Chem	HCAPLUS
Franchetti, P	2000	43	1264	J Med Chem	HCAPLUS
Galemno, R	2000	10	301	Bioorg Med Chem Lett	HCAPLUS
Goldstein, B	2000	40	405	Adv Enzyme Regul	HCAPLUS
Goldstein, B	1999	6	519	Curr Med Chem	HCAPLUS
Gong, Y	2000	10	1033	Bioorg Med Chem Lett	HCAPLUS
He, W	2000	10	1737	Bioorg Med Chem Lett	HCAPLUS
He, W	2002	12	919	Bioorg Med Chem Lett	HCAPLUS
Hellon, D	2000	43	859	J Med Chem	
Hirsh, J	1994	154	282	Arch Int Med	MEDLINE
Jia, Z	2002	12	1651	Bioorg Med Chem Lett	HCAPLUS
Jones, T	1985	115	157	Methods Enzymol	HCAPLUS
Kamata, K	1998	95	6630	Proc Natl Acad Sci U	HCAPLUS
Katano, K	1996	6	2601	Bioorg Med Chem Lett	HCAPLUS
Kumagai, T	1998	63	8145	J Org Chem	HCAPLUS
Kunitada, S	1996	2	531	Curr Pharm Des	HCAPLUS
Lam, P	2003	13	1795	Bioorg Med Chem Lett	HCAPLUS
Lam, P	2003	46	4405	J Med Chem	HCAPLUS
Leslie, A	1992			Joint CCP4 + ESF-EAM	
Maignan, S	2001	1	161	Curr Top Med Chem	HCAPLUS
Maignan, S	2000	43	3226	J Med Chem	HCAPLUS
Maignan, S	2003	46	685	J Med Chem	HCAPLUS
Makara, G	1997	40	4154	J Med Chem	HCAPLUS

Matter, H	2002	45	2749	J Med Chem	HCAPLUS
Matzsch, T	1986	56	293	Thromb Haemost	MEDLINE
Mulliken, R	1955	23	1833	J Chem Phys	HCAPLUS
Mulliken, R	1955	23	1841	J Chem Phys	HCAPLUS
Mulliken, R	1955	23	2338	J Chem Phys	HCAPLUS
Mulliken, R	1955	23	2343	J Chem Phys	HCAPLUS
Murshudov, G	1997	D53	240	Acta Cryst	HCAPLUS
Nagahara, T	1994	37	1200	J Med Chem	HCAPLUS
Nagao, Y	2001	49	1660	Chem Pharm Bull	HCAPLUS
Nagao, Y	1998	120	3104	J Am Chem Soc	HCAPLUS
Nagao, Y			35	Seminars (Naruto in	
Nishida, H	2001	49	1237	Chem Pharm Bull	HCAPLUS
Padmanabhan, K	1993	232	947	J Mol Biol	HCAPLUS
Pauls, H	2001	1	83	Curr Top Med Chem	HCAPLUS
Pinto, D	2001	44	566	J Med Chem	HCAPLUS
Preston, J	1998			WO 9821188	HCAPLUS
Pruitt, J	2003	46	5298	J Med Chem	HCAPLUS
Quan, M	2003	13	1023	Bioorg Med Chem Lett	HCAPLUS
Quan, M	2003	13	369	Bioorg Med Chem Lett	HCAPLUS
Rai, R	2001	8	101	Curr Med Chem	HCAPLUS
Schmidt, M	1993	14	1347	J Comput Chem	HCAPLUS
Sheehan, S	2003	13	2225	Bioorg Med Chem Lett	
Shiozawa, A	1984	32	2522	Chem Pharm Bull	HCAPLUS
Shrader, W	2001	11	1801	Bioorg Med Chem Lett	HCAPLUS
Song, Y	2002	12	2043	Bioorg Med Chem Lett	HCAPLUS
Stein, P	1994	70	S72	Postgrad Med	
Takahashi, T	1954	2	196	Pharm Bull	HCAPLUS
Takahashi, T	1954	2	34	Pharm Bull	HCAPLUS
Tanaka, R	1997	5	1389	Bioorg Med Chem	HCAPLUS
Trotman-Dikenson, A	1949		1293	J Chem Soc	
Tucker, T	1997	40	1565	J Med Chem	HCAPLUS
Walenga, J	1999	1	13	Curr Opin Cardiovasc	HCAPLUS
Wender, P	1983	39	3767	Tetrahedron	HCAPLUS
Zhu, B	2000	35	83	Annu Rep Med Chem	HCAPLUS


IT 259805-66-8P

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation, factor Xa inhibition activity and structure-activity relationship of (chloronaphthalenylsulfonyl)piperazines bearing fused-heterobicyclic rings)

RN 259805-66-8 HCAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (10:11) (9CI) (CA INDEX NAME)




●11/10 HCl

IT 259805-67-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation, factor Xa inhibition activity and structure-activity relationship of (chloronaphthalenylsulfonyl)piperazines bearing fused-heterobicyclic rings)

RN 259805-67-9 HCAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(4,5,6,7-tetrahydro-5-methyl-1H-pyrrolo[3,2-c]pyridin-2-yl)carbonyl]-, hydrochloride (10:13)  
(9CI) (CA INDEX NAME)




●13/10 HCl

IT 259809-55-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation, factor Xa inhibition activity and structure-activity relationship of (chloronaphthalenylsulfonyl)piperazines bearing fused-heterobicyclic rings)

RN 259809-55-7 HCAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-1,5(4H)-dicarboxylic acid, 2-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonyl]-6,7-dihydro-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L165 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2004:758616 HCAPLUS

DOCUMENT NUMBER: 141:379838

TITLE: A flexible, palladium-catalyzed indole and azaindole synthesis by direct annulation of chloroanilines and chloroaminopyridines with ketones

AUTHOR(S): Nazare, Marc; Schneider, Claudia; Lindenschmidt, Andreas; Will, David William

CORPORATE SOURCE: Medicinal Chemistry, DI&A Chemistry, Aventis Pharma  
 Deutschland GmbH, Frankfurt am Main, 65926, Germany  
 SOURCE: Angewandte Chemie, International Edition (2004),  
 43(34), 4526-4528  
 CODEN: ACIEF5; ISSN: 1433-7851  
 PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 141:379838  
 ED Entered STN: 17 Sep 2004  
 AB The "ringmaster" [Pd(tBu3P)2] served as the catalyst in the direct  
 synthesis of indoles, e.g., I, by annulation of ortho-chloroanilines with  
 ketones. This versatile method can be used to synthesize a variety of  
 functionalized indoles and azaindoles, e.g., II.

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Arcadi, A	1994	50	437	Tetrahedron	HCAPLUS
Arcadi, A	1992	33	3915	Tetrahedron Lett	HCAPLUS
Barluenga, J	2003	115	2508	Angew Chem	
Barluenga, J	2003	42	2406	Angew Chem Int Ed	HCAPLUS
Brown, J	2000	41	1623	Tetrahedron Lett	HCAPLUS
Chen, C	1997	62	2676	J Org Chem	HCAPLUS
Dai, C	2001	123	2719	J Am Chem Soc	HCAPLUS
Ezquerria, J	1996	61	5805	J Org Chem	
Fox, J	2000	122	1360	J Am Chem Soc	HCAPLUS
Gribble, G	2000		1045	J Chem Soc Perkin Tr	HCAPLUS
Hegedus, L	1988	100	1147	Angew Chem	HCAPLUS
Hegedus, L	1988	27	1113	Angew Chem Int Ed En	
Hiroya, K	2002	43	1277	Tetrahedron Lett	HCAPLUS
Horton, D	2003	103	893	Chem Rev	HCAPLUS
Iritani, K	1988	29	1799	Tetrahedron Lett	HCAPLUS
Kawatsura, M	1999	121	1473	J Am Chem Soc	HCAPLUS
Ketcha, D	1989	54	4350	J Org Chem	HCAPLUS
Knolker, H	2002	102	4303	Chem Rev	
Koerber-Pie, K	1994		759	Synlett	
Larock, R	1991	113	6689	J Am Chem Soc	HCAPLUS
Larock, R	1998	63	7653	J Org Chem	
Littke, A	2002	124	6343	J Am Chem Soc	HCAPLUS
Mason, J	1999	42	3251	J Med Chem	HCAPLUS
Masters, N	1989	45	5955	Tetrahedron	HCAPLUS
Merour, J	2001	5	471	Curr Org Chem	HCAPLUS
Nakagawa, K	1994	39	31	Heterocycles	HCAPLUS
Nishiyama, M	1998	39	617	Tetrahedron Lett	HCAPLUS
Patchett, A	1995	92	7001	Proc Natl Acad Sci U	HCAPLUS
Pindur, U	2001	8	1681	Curr Med Chem	HCAPLUS
Rodriguez, A	2000	112	2607	Angew Chem	
Rodriguez, A	2000	39	2488	Angew Chem Int Ed	HCAPLUS
Sakamoto, T	1990		215	Synthesis	HCAPLUS
Somei, M	2003	20	216	Nat Prod Rep	HCAPLUS
Yamazaki, K	2003	68	6011	J Org Chem	HCAPLUS


IT 784144-08-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (regioselective preparation of indoles and azaindoles via  
 palladium-catalyzed annulation of haloanilines or aminochloropyridines  
 with cyclic and acyclic ketones)

RN 784144-08-7 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 5-chloro-N,N-diethyl- (9CI) (CA  
 INDEX NAME)





L165 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2004:102826 HCAPLUS

DOCUMENT NUMBER: 140:303629

TITLE: Design and Synthesis of New Templates Derived from Pyrrolopyrimidine as Selective Multidrug-Resistance-Associated Protein Inhibitors in Multidrug Resistance

AUTHOR(S): Wang, Shouming; Wan, Nan Chi; Harrison, John; Miller, Warren; Chuckowree, Irina; Sohal, Sukhjit; Hancox, Timothy C.; Baker, Stewart; Folkes, Adrian; Wilson, Francis; Thompson, Deanne; Cocks, Simon; Farmer, Hayley; Boyce, Anthony; Freathy, Caroline; Broadbridge, Jan; Scott, John; Depledge, Paul; Faint, Richard; Mistry, Prakash; Charlton, Peter

CORPORATE SOURCE: Department of Medicinal Chemistry, Department of Pharmacology, Analytical Department, Xenova Ltd., Berkshire, SL1 4NL, UK

SOURCE: Journal of Medicinal Chemistry (2004), 47(6), 1339-1350

CODEN: JMCMAJ; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:303629

ED Entered STN: 09 Feb 2004

AB In a continued effort to identify selective MRP1 modulators, two novel templates, i.e., derivs. of I and II, were developed through rational drug design by identifying the key pharmacophore interaction at the 7-position of a pyrrolopyrimidine template III. Further synthesis and SAR work on these novel templates gave a number of potent MRP1 modulators with great selectivity against Pgp. Addnl. studies to reduce the CYP3A4 inhibition are also reported. Several compds. of these classes were subjected to in vivo xenograft studies and in vivo efficacies were demonstrated.

# RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Barecki, M	2001	29	1173	Drug Metab Dispos	HCAPLUS
Evstratova, M	1995	29	134	Pharm Chem J	
Kadushkin, A	1990	24	875	Pharm Chem J	
Klaubert, D	1981	24	742	J Med Chem	HCAPLUS
Lee, J	1990	27	1653	J Heterocycl Chem	HCAPLUS
Leonard, W	1956	21	1077	J Org Chem	
Merino, L	1999	54	255	Farmaco	
Nettekoven, M	2001	11	2169	Bioorg Med Chem Lett	HCAPLUS
Norman, B	1998	23	1001	Drugs Future	HCAPLUS
Persidis, A	1999	17	94	Nat Biotechnol	HCAPLUS
Shuman, R	1990	55	738	J Org Chem	HCAPLUS
Simakov, S	1983	17	707	Pharm Chem J	

Trecourt, F	1998	63	2892	J Org Chem	HCAPLUS
Wang, S	2004			J Med Chem	
Wrighton, S	1992	22	1	Crit Rev Toxicol	HCAPLUS
Yakovlev, M	1996	30	107	Pharm Chem J	


IT 676601-76-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(design and synthesis of pyrrolopyrimidine derivs. as selective multidrug-resistance-associated protein inhibitors in multidrug resistant diseases)

RN 676601-76-6 HCAPLUS

CN 4H-Pyrido[3',4':4,5]pyrrolo[3,2-d]pyrimidin-4-one, 2-(chloromethyl)-1,5-dihydro-9-methoxy-5-methyl- (9CI) (CA INDEX NAME)



L165 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:542232 HCAPLUS

DOCUMENT NUMBER: 145:46047

TITLE: Preparation of pyrrolopyridine-2-carboxylic acid amides as glycogen phosphorylase inhibitors

INVENTOR(S): Krulle, Thomas Martin; Rowley, Robert John; Thomas, Gerard Hugh

PATENT ASSIGNEE(S): Prosidion Ltd., UK

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006059164	A2	20060608	WO 2005-GB50233	20051202
WO 2006059164	A3	20060817		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-632461P P 20041202

OTHER SOURCE(S): MARPAT 145:46047

ED Entered STN: 09 Jun 2006

AB The title compds. I [one of X1-X4 is N and the others are C; when C(R4)-Y is a single bond then Y = CHR6, NH, O, S, etc.; when C(R4)-Y is a double bond then Y = CR6 or N; A = (hetero)aryl; R1, R11 = H, halo, OH, etc.; R2 = H, alkyl, aryl, etc.; R3, R33 = H, halo, OH, etc.; R4 = H, alkyl, aryl or alkenyl; R5, R6 = H, alkyl, aryl, etc.; n = 0-1] which are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants, were prepared Thus, reacting 3-amino-3,4-dihydro-1H-quinolin-2-one with 6-chloro-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (prepn. given) afforded II. The exemplified compds. I have an IC50 of < 1 mM in in vitro GP assay. Pharmaceutical composition comprising the compound

I  
is disclosed.


IT	890121-32-1P	890121-33-2P	890121-39-8P
	890121-49-0P	890121-51-4P	890121-53-6P
	890121-82-1P	890121-86-5P	890121-92-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyrrolopyridine-2-carboxamides as glycogen phosphorylase inhibitors)

RN 890121-32-1 HCAPLUS

CN 1(2H)-Quinolineacetic acid, 3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-2-oxo-, methyl ester, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 890121-33-2 HCAPLUS


CN 1(2H)-Quinolineacetic acid, 3-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-2-oxo-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 890121-39-8 HCAPLUS

CN 1(2H)-Quinolineacetic acid, 3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-7-fluoro-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 890121-49-0 HCAPLUS

CN 1(2H)-Quinolineacetic acid, 3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 890121-51-4 HCAPLUS

CN Carbamic acid, [2-[3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-2-oxo-1(2H)-quinolinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 890121-53-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[1-(2-aminoethyl)-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]-5-chloro-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)

CM 1

CRN 890121-52-5


CMF C19 H18 Cl N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 890121-82-1 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1-(cyanomethyl)-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)



RN 890121-86-5 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-[2-(methylthio)ethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)



RN 890121-92-3 HCAPLUS  
 CN 1(2H)-Quinolineacetic acid, 7-chloro-3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



IT 890121-28-5P 890121-29-6P 890121-30-9P  
 890121-31-0P 890121-34-3P 890121-35-4P  
 890121-36-5P 890121-37-6P 890121-38-7P  
 890121-40-1P 890121-41-2P 890121-42-3P  
 890121-43-4P 890121-44-5P 890121-45-6P  
 890121-46-7P 890121-47-8P 890121-48-9P  
 890121-50-3P 890121-54-7P 890121-55-8P  
 890121-56-9P 890121-57-0P 890121-58-1P  
 890121-59-2P 890121-60-5P 890121-61-6P  
 890121-62-7P 890121-63-8P 890121-64-9P  
 890121-65-0P 890121-66-1P 890121-67-2P  
 890121-68-3P 890121-69-4P 890121-70-7P  
 890121-71-8P 890121-72-9P 890121-73-0P  
 890121-74-1P 890121-75-2P 890121-76-3P  
 890121-77-4P 890121-78-5P 890121-79-6P  
 890121-80-9P 890121-81-0P 890121-83-2P  
 890121-84-3P 890121-85-4P 890121-87-6P  
 890121-88-7P 890121-89-8P 890121-90-1P  
 890121-91-2P 890121-93-4P 890121-94-5P  
 890121-95-6P 890121-96-7P 890121-97-8P  
 890121-98-9P 890121-99-0P 890122-00-6P  
 890122-01-7P 890122-02-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyridine-2-carboxamides as glycogen phosphorylase

inhibitors)


RN 890121-28-5 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)



RN 890121-29-6 HCAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-(7-chloro-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)



RN 890121-30-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(3R)-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 890121-31-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(3S)-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 890121-34-3 HCAPLUS

CN 1(2H)-Quinolineacetic acid, 3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-2-oxo-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 890121-35-4 HCAPLUS

CN 1(2H)-Quinolineacetic acid, 3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 890121-36-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(3R)-1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 890121-37-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(3S)-1,2,3,4-



516


10/25/2006

Shiao 10/849,089

10/26/2006


tetrahydro-1-(2-hydroxyethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 890121-38-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(7-fluoro-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 890121-40-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(6-fluoro-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)



RN 890121-41-2 HCAPLUS


CN 1(2H)-Quinolineacetic acid, 3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-7-fluoro-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 890121-42-3 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[7-fluoro-1,2,3,4-

tetrahydro-1-(2-hydroxyethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-43-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-(3-hydroxypropyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-44-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-[2-(hydroxyamino)-2-iminoethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-45-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-[2-(methylsulfinyl)ethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-46-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-[2-(methylsulfonyl)ethyl]-2-oxo-3-quinoliny]]- (9CI) (CA INDEX NAME)




RN 890121-47-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-2-oxo-1-(1H-tetrazol-5-ylmethyl)-3-quinoliny]]- (9CI) (CA INDEX NAME)




RN 890121-48-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-3-quinoliny]]- (9CI) (CA INDEX NAME)




RN 890121-50-3 HCAPLUS


CN 1(2H)-Quinolineacetic acid, 3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 890121-54-7 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-[2-[(methylsulfonyl)amino]ethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)



RN 890121-55-8 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[1-[2-(acetamino)ethyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]-5-chloro- (9CI) (CA INDEX NAME)




RN 890121-56-9 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-[2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)



RN 890121-57-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-[2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]-2-oxo-3-quinolinyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 890121-58-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-[2-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]-2-oxo-3-quinolinyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 890121-59-2 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1-[2-[(3S,4R)-3,4-dihydroxy-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 890121-60-5 HCAPLUS

CN 1(2H)-Quinolineacetamide, 3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-N-methoxy-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 890121-61-6 HCAPLUS

CN 1(2H)-Quinolineacetamide, 3-[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3,4-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 890121-62-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-63-8 HCAPLUS

CN 1(2H)-Quinolineacetamide, 3-[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3,4-dihydro-2-oxo-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 890121-64-9 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[1-[2-(4-acetyl-1-piperazinyl)-2-oxoethyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]-5-chloro- (9CI) (CA INDEX NAME)




RN 890121-65-0 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-[2-(3-hydroxy-1-piperidinyl)-2-oxoethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)






RN 890121-66-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-2-oxo-1-[2-oxo-2-(3-oxo-1-piperazinyl)ethyl]-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-67-2 HCAPLUS


CN 1(2H)-Quinolineacetamide, 3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-N-(2-hydroxyethyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 890121-68-3 HCAPLUS  
 CN 1(2H)-Quinolineacetamide, 3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-N-(2-methoxyethyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 890121-69-4 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[1-[2-(1-azetidiny)]-2-oxoethyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]-5-chloro- (9CI) (CA INDEX NAME)




RN 890121-70-7 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-71-8 HCAPLUS  
 CN 1(2H)-Quinolineacetamide, 3-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-N-[2-(dimethylamino)ethyl]-3,4-dihydro-2-oxo- (9CI)  
 (CA INDEX NAME)



RN 890121-72-9 HCAPLUS  
 CN 1(2H)-Quinolineacetamide, 3-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-2-oxo-N-1,3,4-thiadiazol-2-yl- (9CI) (CA INDEX NAME)




RN 890121-73-0 HCAPLUS  
 CN 1(2H)-Quinolineacetamide, 3-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-N-(1-methyl-1H-pyrazol-3-yl)-2-oxo- (9CI)  
 (CA INDEX NAME)




RN 890121-74-1 HCAPLUS

CN 1(2H)-Quinolineacetamide, 3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-2-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 890121-75-2 HCAPLUS

CN 1(2H)-Quinolineacetamide, 3-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 890121-76-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 890121-77-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(7-chloro-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 890121-78-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-2-oxo-7-(trifluoromethyl)-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-79-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 890121-80-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(5-fluoro-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 890121-81-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(1,2,3,4-tetrahydro-6-methyl-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 890121-83-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-(2-methoxyethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-84-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-(2-(2-methoxyethoxy)ethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-85-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1-[2-(dimethylamino)ethyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-87-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-2-oxo-1-[(tetrahydro-2-furanyl)methyl]-3-quinolinyl]- (9CI) (CA INDEX NAME)



RN 890121-88-7 HCAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-(7-chloro-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)



RN 890121-89-8 HCAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-

(2-methoxyethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-90-1 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-[2-(2-methoxyethoxy)ethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-91-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[1-[2-(dimethylamino)ethyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)



RN 890121-93-4 HCAPLUS


CN 1(2H)-Quinolineacetic acid, 7-chloro-3-[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 890121-94-5 HCAPLUS




CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[7-chloro-1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 890121-95-6 HCAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-2-carboxamide, 6-chloro-N-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 890121-96-7 HCAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-2-carboxamide, 6-chloro-N-(7-chloro-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 890121-97-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 890121-98-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(1,2,3,4-tetrahydro-2-oxo-1,8-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 890121-99-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(1,2,3,4-tetrahydro-2-oxo-1,6-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 890122-00-6 HCAPLUS

CN 1,6-Naphthyridine-1(2H)-acetic acid, 3-[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 890122-01-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 890122-02-8 HCAPLUS

CN 1,7-Naphthyridine-1(2H)-acetic acid, 3-[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX NAME)




IT 890122-08-4P 890122-09-5P 890122-16-4P  
890122-17-5P 890122-18-6P 890122-31-3P  
890122-32-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of pyrrolopyridine-2-carboxamides as glycogen phosphorylase  
inhibitors)

RN 890122-08-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(3R)-1-[2-[[[(1,1-  
dimethylethyl)dimethylsilyl]oxy]ethyl]-1,2,3,4-tetrahydro-2-oxo-3-  
quinolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 890122-09-5 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(3S)-1-[2-[[[(1,1-  
dimethylethyl)dimethylsilyl]oxy]ethyl]-1,2,3,4-tetrahydro-2-oxo-3-  
quinolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 890122-16-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-7-fluoro-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]]- (9CI) (CA INDEX NAME)




RN 890122-17-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]propyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]]- (9CI) (CA INDEX NAME)




RN 890122-18-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]]- (9CI) (CA INDEX NAME)




RN 890122-31-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[1-[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 890122-32-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[7-chloro-1-[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)



L165 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:87894 HCAPLUS

DOCUMENT NUMBER: 144:331406

TITLE: Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT<sub>2C</sub> receptor agonists

AUTHOR(S): Richter, Hans G. F.; Adams, D. R.; Benardeau, A.; Bickerdike, M. J.; Bentley, J. M.; Blench, T. J.; Cliffe, I. A.; Dourish, C.; Hebeisen, P.; Kennett, G. A.; Knight, A. R.; Malcolm, C. S.; Mattei, P.; Misra, A.; Mizrahi, J.; Monck, N. J. T.; Plancher, J.-M.;

Roever, S.; Roffey, J. R. A.; Taylor, S.; Vickers, S. P.  
 CORPORATE SOURCE: Discovery Research, F. Hoffmann-La Roche Ltd, Basel, 4070, Switz.  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1207-1211  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 ED Entered STN: 31 Jan 2006  
 AB Further lead optimization efforts on previously described 1,2,3,4,10,10a-hexahydro-1H-pyrazino[1,2-a]indoles led to the new class of 5,5a,6,7,8,9-hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines culminating in the discovery of (5aR,9R)-2-[(cyclopropylmethoxy)methyl]-5,5a,6,7,8,9-hexahydro-9-methyl-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazine as a potent, full 5-HT<sub>2C</sub> receptor agonist with an outstanding selectivity profile and excellent hERG and phospholipidosis properties.

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bentley, J	2002			WO 2002010169 A1	HCAPLUS
Bentley, J	2002			WO 2002051844 A1	HCAPLUS
Bickerdike, M	1999	1	207	Diabetes Obes Metab	HCAPLUS
Brodin, R	1995			WO 199915525 A1	HCAPLUS
Carek, P	1999	57	883	Drugs	HCAPLUS
Centers for Disease Con				<a href="http://www.cdc.gov/">http://www.cdc.gov/</a>	
Hoyer, D	1985	118	13	Eur J Pharmacol	HCAPLUS
Kennett, G	1997	36	609	Neuropharmacology	HCAPLUS
McKenna, D	1989	9	3482	J Neurosci	HCAPLUS
Porter, R	1999	128	13	Br J Pharmacol	HCAPLUS
Posakony, J	2002	67	5164	J Org Chem	HCAPLUS
Roever, S	2005	15	3604	Bioorg Med Chem Lett	HCAPLUS
Sargent, P	1997	133	309	Psychopharmacology	HCAPLUS
Schmuck, K	1994	342	85	FEBS Lett	HCAPLUS
Tecott, L	1995	374	542	Nature	HCAPLUS
The Cambridge Crystallo				<a href="http://www.ccdc.cam.ac.uk/d">www.ccdc.cam.ac.uk/d</a>	
Ullmann-Rauch, R	1996	110	27	Toxicology	
Vickers, S	2001	41	200	Neuropharmacology	HCAPLUS

IT 577711-82-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT<sub>2C</sub> receptor agonists)

RN 577711-82-1 HCAPLUS

CN Pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazin-6(7H)-one, 2-chloro-8,9-dihydro-9-methyl-, (9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L165 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:1123770 HCAPLUS  
 DOCUMENT NUMBER: 143:422339  
 TITLE: Preparation of 6-azaindoles as I $\kappa$ B kinase inhibitors for treating diabetes and inflammatory diseases  
 INVENTOR(S): Horiguchi, Yoshiaki; Imoto, Hiroshi; Wolf, Mark A.  
 PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan  
 SOURCE: PCT Int. Appl., 205 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097129	A2	20051020	WO 2005-US11531	20050404
WO 2005097129	A3	20060119		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW; AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-558981P P 20040405


OTHER SOURCE(S): MARPAT 143:422339

ED Entered STN: 20 Oct 2005


AB Azaindoles I [wherein R1-R3, R6 = independently H, a substituent; one of R4 and R5 is H, the other is selected from -C(:X)-R7, -C(:O)-R10, -CH(OH)-R10, -C(:O)-NH-(CH2)n-Ar, -C(:O)-Het, -CH(R12)-NR13R14; R8, R10 = independently H, or a group bonded via a C; R7 = H, or a substituent; n = 0-2; Ar = aryl; Het = (un)substituted heterocyclic group bonded via a N; R12 = H, hydrocarbyl; R13, R14 = independently H, (un)substituted hydrocarbyl, heterocyclyl, etc; with the exception of certain compds.; and their salts] were prepared as compds. having a superior I $\kappa$ B kinase inhibitory activity, and useful as pharmaceutical agents such as agents for preventing or treating diabetes and the like. For example, azaindole II $\cdot$ 2HCl was prepared by reacting of phenyl(1H-pyrrolo[2,3-c]pyridin-2-yl)methanone (preparation given) with tert-Bu 3-(aminooxy)pyrrolidine-1-carboxylate (preparation given), deprotection (no data) and acidulation with

HCl. . Pyrrolopyridine salt II•2HCl displayed an IC<sub>50</sub> of 1.7  $\mu$ M for the inhibition of IKK $\beta$ .


IT **867034-38-6P**, 7-Chloro-N-(2-pyridinylmethyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide **867034-40-0P**, 7-Chloro-N-(4-pyridinylmethyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide **867034-48-8P**, 7-Chloro-2-(1-pyrrolidinylcarbonyl)-1H-pyrrolo[2,3-c]pyridine **867034-56-8P**, 7-Chloro-N-(3-pyridinyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of 6-azaindoles as I $\kappa$ B kinase inhibitors for treating diabetes and inflammatory diseases)  
 RN 867034-38-6 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 7-chloro-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 867034-40-0 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 7-chloro-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 867034-48-8 HCAPLUS  
 CN Pyrrolidine, 1-[(7-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 867034-56-8 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 7-chloro-N-3-pyridinyl- (9CI) (CA INDEX NAME)







IT 867034-36-4P, N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 867034-37-5P, 7-Chloro-2-(4-morpholinylcarbonyl)-1H-pyrrolo[2,3-c]pyridine 867034-39-7P, 7-Chloro-N-(3-pyridinylmethyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 867034-41-1P, 7-Chloro-N-(2-furylmethyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 867034-42-2P, 7-Chloro-N-(2-thienylmethyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 867034-47-7P, 2-[(4-Acetyl-1-piperazinyl)carbonyl]-7-chloro-1H-pyrrolo[2,3-c]pyridine 867034-49-9P, 7-Chloro-2-(4-thiomorpholinylcarbonyl)-1H-pyrrolo[2,3-c]pyridine 867034-54-6P, 7-Chloro-2-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrolo[2,3-c]pyridine 867034-55-7P, 7-Chloro-N-(2-pyridinyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 867034-57-9P, 7-Chloro-N-(4-pyridinyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of 6-azaindoles as IκB kinase inhibitors for treating diabetes and inflammatory diseases)  
 RN 867034-36-4 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 7-chloro-N-(phenylmethyl)- (9CI)  
 (CA INDEX NAME)



RN 867034-37-5 HCAPLUS  
 CN Morpholine, 4-[(7-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]- (9CI)  
 (CA INDEX NAME)




RN 867034-39-7 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 7-chloro-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 867034-41-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 7-chloro-N-(2-furanylmethyl)-  
(9CI) (CA INDEX NAME)




RN 867034-42-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 7-chloro-N-(2-thienylmethyl)-  
(9CI) (CA INDEX NAME)




RN 867034-47-7 HCAPLUS

CN Piperazine, 1-acetyl-4-[(7-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-  
(9CI) (CA INDEX NAME)




RN 867034-49-9 HCAPLUS


CN Thiomorpholine, 4-[(7-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-  
(9CI) (CA INDEX NAME)




RN 867034-54-6 HCAPLUS  
CN Piperazine, 1-[(7-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-4-methyl-  
(9CI) (CA INDEX NAME)



RN 867034-55-7 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 7-chloro-N-2-pyridinyl- (9CI)  
(CA INDEX NAME)




RN 867034-57-9 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 7-chloro-N-4-pyridinyl- (9CI)  
(CA INDEX NAME)




IT 867034-12-6P, 7-Chloro-N-cyclohexyl-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 867034-33-1P, 7-Chloro-N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]-1H-pyrrolo[2,3-c]pyridine-2-carboxamide  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of 6-azaindoles as IκB kinase inhibitors for treating diabetes and inflammatory diseases)

RN 867034-12-6 HCAPLUS  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 7-chloro-N-cyclohexyl- (9CI) (CA INDEX NAME)



RN 867034-33-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 7-chloro-N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)




IT 867034-21-7, 7-Chloro-N-cyclopentyl-1H-pyrrolo[2,3-c]pyridine-2-carboxamide

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 6-azaindoles as IκB kinase inhibitors for treating diabetes and inflammatory diseases)

RN 867034-21-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 7-chloro-N-cyclopentyl- (9CI) (CA INDEX NAME)



L165 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1004744 HCAPLUS

DOCUMENT NUMBER: 143:306292

TITLE: Preparation of pyrrolopyridine-2-carboxylic acid hydrazides as glycogen phosphorylase inhibitors  
INVENTOR(S): Bradley, Stuart Edward; Jeevaratnam, Revathy Perpetua; Krulle, Thomas Martin; Procter, Martin James; Rowley, Robert John; Thomas, Gerard Hugh; Valdes, Ana

PATENT ASSIGNEE(S): Prosidion Limited, UK

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085245	A1	20050915	WO 2005-GB885	20050308
WO 2005085245	C1	20051110		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2004-551254P

P 20040308

OTHER SOURCE(S):

MARPAT 143:306292

ED Entered STN: 16 Sep 2005

AB Title compds. of formula I [one of X1-X4 is N and the others are C; Y = CO, SO<sub>2</sub>, C(NH); Z = alkylene, O, alkyleneoxy, (substituted) NH, etc.; R, R1 = H, halo, OH, CN, alkyl, alkoxy, CH<sub>2</sub>F, ethenyl, ethynyl, etc.; R2 = H, alkyl, alkoxycarbonyl, acyl, alkoxy, arylalkyl, etc.; R3 = H, alkoxycarbonyl, alkoxy, arylalkylthio, arylalkyl, etc.] are prepared as inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, or as cardioprotectants or inhibitors of abnormal cell growth. Thus, II was prepared from 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid hydrazide TFA salt (preparation given) and 2-thienyl isocyanate. The prepared compds. had IC<sub>50</sub> values better than 100µM against glycogen phosphorylase.

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bradley, S	2004			WO 2004104001 A	HCAPLUS
Nakamura, T	2003			WO 03037864 A	HCAPLUS


IT 864547-64-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrrolopyridinecarboxylic acid hydrazides as glycogen phosphorylase inhibitors)

RN 864547-64-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-[(1,1-dimethylethoxy)carbonyl]hydrazide (9CI) (CA INDEX NAME)



IT 864547-40-0P 864547-41-1P 864547-42-2P

864547-43-3P 864547-44-4P 864547-45-5P

864547-46-6P 864547-47-7P 864547-48-8P

864547-49-9P 864547-50-2P 864547-51-3P

864547-52-4P 864547-53-5P 864547-54-6P

864547-55-7P 864547-56-8P 864547-57-9P

864547-58-0P 864547-59-1P 864547-60-4P

864547-61-5P 864547-62-6P 864547-63-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyridinecarboxylic acid hydrazides as glycogen phosphorylase inhibitors)

RN 864547-40-0 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,

2-[(2-thienylamino)carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 864547-41-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-(3-thienylcarbonyl)hydrazide (9CI) (CA INDEX NAME)




RN 864547-42-2 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-(3-furanylcarbonyl)hydrazide (9CI) (CA INDEX NAME)




RN 864547-43-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-[(tetrahydro-3-furanyl)carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 864547-44-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-(1H-pyrrol-2-ylcarbonyl)hydrazide (9CI) (CA INDEX NAME)




RN 864547-45-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-, 2-benzoylhydrazide  
(9CI) (CA INDEX NAME)




RN 864547-46-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-(1,3-benzodioxol-5-ylcarbonyl)hydrazide (9CI) (CA INDEX NAME)




RN 864547-47-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-[(tetrahydro-2H-pyran-4-yl)carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 864547-48-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-(cyclopropylcarbonyl)hydrazide (9CI) (CA INDEX NAME)



RN 864547-49-9 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-(4-methylbenzoyl)hydrazide (9CI) (CA INDEX NAME)



RN 864547-50-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 1-(1,1-dimethylethyl) ester,  
2-[2-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]hydrazide], (2S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 864547-51-3 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-[(2S)-2-pyrrolidinylcarbonyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 864547-52-4 HCAPLUS

CN 1,3-Pyrrolidinedicarboxylic acid, 1-(1,1-dimethylethyl) ester,  
3-[2-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]hydrazide], (3S)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 864547-53-5 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-[(3S)-3-pyrrolidinylcarbonyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 864547-54-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-(3-pyridinylcarbonyl)hydrazide (9CI) (CA INDEX NAME)




RN 864547-55-7 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-(phenylacetyl)hydrazide (9CI) (CA INDEX NAME)




RN 864547-56-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-[[4-chlorophenyl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 864547-57-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-[(3,4-dichlorobenzoyl)hydrazide] (9CI) (CA INDEX NAME)




RN 864547-58-0 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]hydrazide (9CI) (CA INDEX  
NAME)




RN 864547-59-1 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-[(2-chlorophenoxy)acetyl]hydrazide (9CI) (CA INDEX NAME)




RN 864547-60-4 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-[(2-thienylcarbonyl)hydrazide] (9CI) (CA INDEX NAME)




RN 864547-61-5 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-(2-furanylcarbonyl)hydrazide (9CI) (CA INDEX NAME)




RN 864547-62-6 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
2-[(1-methyl-1H-pyrrol-2-yl)carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 864547-63-7 HCAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxylic acid, 5-chloro-,  
2-(3,4-dichlorobenzoyl)hydrazide (9CI) (CA INDEX NAME)




IT 864547-65-9P 864547-66-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of pyrrolopyridinecarboxylic acid hydrazides as glycogen  
phosphorylase inhibitors)

RN 864547-65-9 HCAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-, hydrazide (9CI)  
(CA INDEX NAME)



RN 864547-66-0 HCAPLUS  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-, hydrazide,  
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 864547-65-9  
 CMF C8 H7 Cl N4 O



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2



L165 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:1004705 HCAPLUS  
 DOCUMENT NUMBER: 143:306169  
 TITLE: Indole-2-carboxylic acid hydrazides  
 INVENTOR(S): Bradley, Stuart Edward; Jeevaratnam, Revathy Perpetua;  
 Krulle, Thomas Martin; Procter, Martin James; Rowley,  
 Robert John; Thomas, Gerard Hugh; Valdes, Ana  
 PATENT ASSIGNEE(S): Prosidion Limited, UK  
 SOURCE: PCT Int. Appl., 27 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----  
 WO 2005085194 A2 20050915 WO 2005-GB872 20050308  
 WO 2005085194 A3 20060105  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,  
 SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
 MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2004-551255P

P 20040308

OTHER SOURCE(S):

MARPAT 143:306169

ED Entered STN: 16 Sep 2005

AB Compds. of formula I [wherein Y = -C(O)-, -S(O)<sub>2</sub>-, or -C(NH)-; Z =  
 C1-4alkylene, O, -(CH<sub>2</sub>)<sub>m</sub>O-, -O(CH<sub>2</sub>)<sub>m</sub>, etc. (m = 1-4); R<sub>1</sub>, R<sub>2</sub> =  
 independently halogen, hydroxym cyano, etc.; R<sub>3</sub> = C0-4alkyl,  
 C1-4alkoxyC1-3alkyl-, hydroxyC1-4alkyl, etc.; R<sub>4</sub> = H, -COOC0-4alkyl,  
 C1-4alkyl, etc.] or pharmaceutically acceptable salts thereof, were prepared  
 as inhibitors of glycogen phosphorylase. Thus, a solution of  
 5-chloro-1H-indole-2-carboxylic acid hydrazide (II) in 1,4-dioxane was  
 treated with phenylmethanesulfonyl chloride and DIPEA for 16H at room  
 temperature to provide 5-chloro-1H-indole-2-carboxylic acid N'-  
 (phenylmethanesulfonyl)hydrazide (III). Compds. of formula I are useful  
 in the prophylactic or therapeutic treatment of diabetes, hyperglycemia,  
 hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension,  
 atherosclerosis or tissue ischemia, e.g. myocardial ischemia, or as  
 cardioprotectants or inhibitors of abnormal cell growth.


IT 864659-01-8P 864659-02-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of indole-2-carboxylic acid hydrazides as inhibitors of  
 glycogen phosphorylase)


RN 864659-01-8 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 2-[(5-chloro-1H-indol-2-  
 yl)carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 864659-02-9 HCAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid, 5-chloro-,  
 2-[(5-chloro-1H-indol-2-yl)carbonyl]hydrazide (9CI) (CA INDEX NAME)



=> d ibib ab hitstr 12

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, TOXCENTER, CHEMCATS' -  
CONTINUE? (Y)/N:y

L165 ANSWER 12 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2005:299603 USPATFULL

TITLE: Pyrrolopyridine-2-carboxylic acid amide inhibitors of  
glycogen phosphorylase

INVENTOR(S): Bradley, Stuart Edward, Oxford, UNITED KINGDOM  
Krulle, Thomas Martin, Oxford, UNITED KINGDOM  
Murray, Peter John, Oxford, UNITED KINGDOM  
Procter, Martin James, Oxford, UNITED KINGDOM  
Rowley, Robert John, Oxford, UNITED KINGDOM  
Sambrook Smith, Colin Peter, Oxford, UNITED KINGDOM  
Thomas, Gerard Hugh, Oxford, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005261272	A1	20051124
APPLICATION INFO.:	US 2004-851902	A1	20040520 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-551256P	20040308 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Shu M. Lee, OSI Pharmaceuticals, Inc., Suite 110, 58 South Service Road, Melville, NY, 11747, US	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4901	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds represented by Formula (I): ##STR1## or pharmaceutically  
acceptable salts thereof, are inhibitors of glycogen phosphorylase and  
are useful in the prophylactic or therapeutic treatment of diabetes,  
hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia,  
hypertension, atherosclerosis or tissue ischemia e.g. myocardial  
ischemia, and as cardioprotectants.


IT 800397-99-3P 800398-33-8P 800398-34-9P  
800398-35-0P 800398-36-1P 800398-37-2P  
800398-38-3P 800398-42-9P 800399-22-8P  
800399-23-9P 800399-85-3P 800400-37-7P  
800400-46-8P 800400-49-1P 800400-52-6P  
800400-69-5P 800400-84-4P 800400-89-9P  
800400-95-7P 800400-97-9P 800400-98-0P  
800401-07-4P 800401-08-5P 800401-17-6P  
800401-18-7P 800401-22-3P

(preparation of pyrrolopyridinecarboxylic acid amide as inhibitors of  
glycogen phosphorylase)

RN 800397-99-3 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-  
fluorophenyl)methyl]-2-(4-hydroxy-1-piperidiny)-2-oxoethyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 800398-33-8 USPATFULL

CN Glycine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 800398-34-9 USPATFULL


CN Glycine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]- (9CI) (CA INDEX NAME)



RN 800398-35-0 USPATFULL

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-36-1 USPATFULL

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl] -  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-37-2 USPATFULL

CN Benzenebutanoic acid,  $\beta$ -[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]- $\alpha$ -hydroxy-, methyl ester, ( $\alpha$ R, $\beta$ S) -  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-38-3 USPATFULL


CN Benzenebutanoic acid,  $\beta$ -[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]- $\alpha$ -hydroxy-, ( $\alpha$ R, $\beta$ S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800398-42-9 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-fluorophenyl)-2-oxoethyl] - (9CI) (CA INDEX NAME)






RN 800399-22-8 USPATFULL  
 CN Benzenebutanoic acid,  $\beta$ -[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]- $\alpha$ -hydroxy-, methyl ester, ( $\alpha$ S, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-23-9 USPATFULL  
 CN Benzenebutanoic acid,  $\beta$ -[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]- $\alpha$ -hydroxy-, ( $\alpha$ S, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-85-3 USPATFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-(4-amino-1-piperidinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800400-37-7 USPATFULL  
 CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-46-8 USPATFULL

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-4-fluoro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-49-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-52-6 USPATFULL

CN Carbamic acid, [1-[(2S)-2-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-69-5 USPATFULL

CN 4-Piperidinecarboxylic acid, 1-[(2S)-2-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-84-4 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]methylamino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-89-9 USPATFULL

CN 4-Pyridinepropanoic acid,  $\alpha$ -[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-, methyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-95-7 USPATFULL


CN 4-Pyridinepropanoic acid,  $\alpha$ -[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800400-97-9 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-hydroxy-2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 800400-98-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2S)-2-hydroxy-1-(methoxymethyl)-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-07-4 USPATFULL

CN L-Phenylalanine, N-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)carbonyl]-4-fluoro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-08-5 USPATFULL

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-17-6 USPATFULL

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)carbonyl]-4-fluoro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-18-7 USPATFULL

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-22-3 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 800397-93-7P 800397-98-2P 800398-00-9P  
 800398-03-2P 800398-04-3P 800398-05-4P  
 800398-06-5P 800398-07-6P 800398-08-7P  
 800398-09-8P 800398-10-1P 800398-11-2P  
 800398-12-3P 800398-13-4P 800398-14-5P  
 800398-21-4P 800398-22-5P 800398-23-6P  
 800398-24-7P 800398-25-8P 800398-26-9P  
 800398-27-0P 800398-28-1P 800398-29-2P

800398-30-5P 800398-31-6P 800398-32-7P  
 800398-39-4P 800398-40-7P 800398-41-8P  
 800398-43-0P 800398-44-1P 800398-45-2P  
 800398-46-3P 800398-47-4P 800398-48-5P  
 800398-49-6P 800398-50-9P 800398-51-0P  
 800398-52-1P 800398-53-2P 800398-54-3P  
 800398-55-4P 800398-56-5P 800398-57-6P  
 800398-58-7P 800398-59-8P 800398-60-1P  
 800398-61-2P 800398-62-3P 800398-63-4P  
 800398-64-5P 800398-65-6P 800398-66-7P  
 800398-67-8P 800398-68-9P 800398-69-0P  
 800398-70-3P 800398-71-4P 800398-72-5P  
 800398-73-6P 800398-74-7P 800398-75-8P  
 800398-76-9P 800398-77-0P 800398-78-1P  
 800398-79-2P 800398-80-5P 800398-81-6P  
 800398-82-7P 800398-83-8P 800398-84-9P  
 800398-86-1P 800398-87-2P 800398-89-4P  
 800398-91-8P 800398-93-0P 800398-95-2P  
 800398-97-4P 800398-98-5P 800398-99-6P  
 800399-00-2P 800399-01-3P 800399-02-4P  
 800399-03-5P 800399-04-6P 800399-05-7P  
 800399-06-8P 800399-07-9P 800399-08-0P  
 800399-09-1P 800399-10-4P 800399-11-5P  
 800399-12-6P 800399-13-7P 800399-14-8P  
 800399-19-3P 800399-20-6P 800399-21-7P  
 800399-24-0P 800399-25-1P 800399-26-2P  
 800399-27-3P 800399-28-4P 800399-29-5P  
 800399-30-8P 800399-31-9P 800399-32-0P  
 800399-33-1P 800399-34-2P 800399-35-3P  
 800399-36-4P 800399-37-5P 800399-38-6P  
 800399-39-7P 800399-40-0P 800399-41-1P  
 800399-42-2P 800399-44-4P 800399-45-5P  
 800399-47-7P 800399-48-8P 800399-49-9P  
 800399-50-2P 800399-51-3P 800399-52-4P  
 800399-53-5P 800399-54-6P 800399-55-7P  
 800399-56-8P 800399-57-9P 800399-58-0P  
 800399-59-1P 800399-60-4P 800399-61-5P  
 800399-62-6P 800399-63-7P 800399-64-8P  
 800399-65-9P 800399-66-0P 800399-67-1P  
 800399-68-2P 800399-70-6P 800399-72-8P  
 800399-73-9P 800399-74-0P 800399-75-1P  
 800399-76-2P 800399-77-3P 800399-78-4P  
 800399-79-5P 800399-80-8P 800399-81-9P  
 800399-82-0P 800399-83-1P 800399-84-2P  
 800399-86-4P 800399-87-5P 800399-88-6P  
 800399-89-7P 800399-90-0P 800399-91-1P  
 800399-92-2P 800399-93-3P 800399-94-4P  
 800399-95-5P 800399-96-6P 800399-97-7P  
 800399-98-8P 800399-99-9P 800400-00-4P  
 800400-01-5P 800400-02-6P 800400-03-7P  
 800400-04-8P 800400-05-9P 800400-06-0P  
 800400-07-1P 800400-08-2P 800400-09-3P  
 800400-10-6P 800400-11-7P 800400-12-8P  
 800400-13-9P 800400-14-0P 800400-16-2P  
 800400-19-5P 800400-21-9P 800400-23-1P  
 800400-25-3P 800400-27-5P 800400-29-7P  
 800400-31-1P 800400-33-3P 800400-35-5P  
 800400-39-9P 800400-41-3P 800400-43-5P  
 800400-45-7P 800400-48-0P 800400-54-8P  
 800400-56-0P 800400-58-2P 800400-60-6P


800400-61-7P 800400-63-9P 800400-65-1P  
 800400-67-3P 800400-71-9P 800400-73-1P  
 800400-75-3P 800400-77-5P 800400-78-6P  
 800400-80-0P 800400-82-2P 800400-85-5P  
 800400-86-6P 800400-87-7P 800400-88-8P  
 800400-90-2P 800400-91-3P 800400-92-4P  
 800400-93-5P 800400-94-6P 800400-96-8P  
 800400-99-1P 800401-00-7P 800401-01-8P  
 800401-02-9P 800401-03-0P 800401-04-1P  
 800401-05-2P 800401-06-3P

(preparation of pyrrolopyridinecarboxylic acid amide as inhibitors of glycogen phosphorylase)

RN 800397-93-7 USPTAFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800397-98-2 USPTAFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-00-9 USPTAFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-3-[(3S,4R)-3,4-dihydroxy-1-pyrrolidinyl]-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 800398-03-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(2-phenoxyethyl)-(9CI) (CA INDEX NAME)




RN 800398-04-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-morpholinyl)ethyl]-(9CI) (CA INDEX NAME)




RN 800398-05-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-methoxyphenoxy)ethyl]-(9CI) (CA INDEX NAME)




RN 800398-06-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(2-thienyl)ethyl]-(9CI) (CA INDEX NAME)




RN 800398-07-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 800398-08-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 800398-09-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-(1H-benzimidazol-2-ylmethyl)-5-chloro- (9CI) (CA INDEX NAME)




RN 800398-10-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 800398-11-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 800398-12-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-[(2-chloro-6-fluorophenyl)methyl]thio]ethyl]- (9CI) (CA INDEX NAME)




RN 800398-13-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 800398-14-5 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(1-naphthalenylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 800398-21-4 USPATFULL

CN 1H-Pyrrolo[3,2-b]pyridine-2-carboxamide, 5-chloro-N-(2-phenoxyethyl)-  
(9CI) (CA INDEX NAME)

RN 800398-22-5 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-[4-(phenylmethyl)-1-  
piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

RN 800398-23-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-  
[(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)


RN 800398-24-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-oxo-2-(phenylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 800398-25-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-oxo-2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 800398-26-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-oxo-2-[(2-thienylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 800398-27-0 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-[(4-methoxyphenyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 800398-28-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-1-(phenylmethyl)-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-29-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-30-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3S,4R)-3,4-dihydroxy-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-31-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-1-(phenylmethyl)-2-(4-thiomorpholinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-32-7 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-1-(phenylmethyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-39-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-methoxyphenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 800398-40-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(3,4-difluorophenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 800398-41-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-chlorophenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 800398-43-0 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-fluorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)



RN 800398-44-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(3-pyridinylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-45-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-1-(3-pyridinylmethyl)-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 800398-46-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(2-pyridinylmethyl)ethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-47-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-48-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(1-methylethyl)amino]-2-oxoethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-49-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-50-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(ethylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-51-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(cyclobutylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-52-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(cyclopentylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-53-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[[1R,2R]-2-hydroxycyclopentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-54-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-

fluorophenyl)methyl]-2-[[[(1S,2S)-2-hydroxycyclohexyl]amino]-2-oxoethyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-55-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[[[(1R,2S)-2-(hydroxymethyl)cyclohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-56-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[[[(tetrahydro-2-furanyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-57-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-

fluorophenyl)methyl]-2-[(2-furanylmethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-58-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-(1-azetidinyll)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-59-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(1-pyrrolidinylethyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-60-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-

fluorophenyl)methyl]-2-oxo-2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-61-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-62-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-63-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-64-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-65-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(3R)-3-(acetylamino)-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-66-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-morpholinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-67-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-68-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2-hydroxyethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 800398-69-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2-methoxyethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-70-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2-(methylthio)ethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-71-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[[2-(dimethylamino)ethyl]amino]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-72-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[bis(2-hydroxyethyl)amino]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-73-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(dimethylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-74-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(diethylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-75-8 USPTAFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-76-9 USPTAFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-77-0 USPTAFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[(3-pyridinylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-78-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(phenylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-79-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(2,5-dimethyl-1-pyrrolidinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-80-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[bis(2-methoxyethyl)amino]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-81-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3S,4R)-3,4-dimethoxy-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800398-82-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3S,4R)-3,4-dihydroxy-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 800398-83-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-

(cyclohexylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-84-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(3-thiazolidinyl)ethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-86-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-87-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[(tetrahydro-2H-thiopyran-4-yl)amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-89-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[[3-(dimethylamino)propyl]amino]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-91-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3-hydroxypropyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-93-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(2-hydroxyethyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800398-95-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(1-pyrrolidinyl)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 800398-97-4 USPTAFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(4-oxo-1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800398-98-5 USPTAFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(cyclopropylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800398-99-6 USPTAFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(4-hydroxybutyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-00-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3-methoxypropyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-01-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(2,3-dihydroxypropyl)amino]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-02-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-03-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[[3-(cyclohexylamino)propyl]amino]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-04-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[3-(4-morpholinylsulfonyl)-1-azetidiny]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-05-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[3-(1-azetidiny)sulfonyl]-1-azetidiny]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- 5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-06-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(3-hydroxy-1-azetidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-07-9 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(3-hydroxy-1-azetidinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-08-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(3-hydroxy-1-azetidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 800399-09-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-hydroxy-1-piperidiny)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 800399-10-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-morpholinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 800399-11-5 USPATFULL


CN Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-β-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 800399-12-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(methoxymethylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-13-7 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-14-8 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-19-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-methoxy-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-20-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3R)-3-methoxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-21-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3S)-3-methoxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-24-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2S)-3-(dimethylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-25-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2S)-2-hydroxy-3-oxo-1-(phenylmethyl)-3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-26-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2S)-3-[(3S,4R)-3,4-dihydroxy-1-pyrrolidinyl]-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-27-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-oxo-1-(phenylmethyl)-3-(propylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 800399-28-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S,2R)-3-amino-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-29-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-[(2-hydroxyethyl)amino]-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-30-8 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-[(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-31-9 USPTAFULL  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-3-(dimethylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-32-0 USPTAFULL  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-3-(cyclopropylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-33-1 USPTAFULL  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-3-(cyclobutylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800399-34-2 USPTAFULL  
CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-3-(cyclopentylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-35-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S,2R)-3-(1-azetidinyl)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-36-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-oxo-3-(phenylamino)-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-37-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-oxo-1-(phenylmethyl)-3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-38-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-[(3R)-3-hydroxy-1-pyrrolidinyl]-3-oxo-1-(phenylmethyl)propyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800399-39-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-[(3S)-3-hydroxy-1-pyrrolidinyl]-3-oxo-1-(phenylmethyl)propyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800399-40-0 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-oxo-1-(phenylmethyl)-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-41-1 USPTAFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-(4-hydroxy-1-piperidiny)-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-42-2 USPTAFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-[4-(hydroxymethyl)-1-piperidiny]-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800399-44-4 USPTAFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-(4-methyl-1-piperazinyl)-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-45-5 USPTAFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-(4-methyl-1-piperazinyl)-3-oxo-1-(phenylmethyl)propyl]-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 800399-44-4

CMF C23 H26 Cl N5 O3


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 800399-47-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-oxo-1-(phenylmethyl)-3-(1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800399-48-8 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-oxo-1-(phenylmethyl)-3-(1-piperazinyl)propyl]-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 800399-47-7

CMF C22 H24 Cl N5 O3


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 800399-49-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2R)-2-hydroxy-3-(4-morpholinyl)-3-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-50-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S,2R)-3-(4-acetyl-1-piperazinyl)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-51-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[[2-(4-morpholinyl)ethyl]amino]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-52-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(cyclopentylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-53-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(4-methyl-1-piperazinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-54-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[4-(2-hydroxyethyl)-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 800399-55-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-(4-acetyl-1-piperazinyl)-2-oxo-1-(phenylmethyl)ethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-56-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3-hydroxypropyl)amino]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-57-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[4-(hydroxymethyl)-1-piperidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-58-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-(aminocarbonyl)-1-piperidinyl]-2-oxo-1-(phenylmethyl)ethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-59-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[3-(aminocarbonyl)-1-piperidinyl]-2-oxo-1-(phenylmethyl)ethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-60-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[3-(hydroxymethyl)-1-piperidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-61-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-62-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(3,6-dihydro-1(2H)-pyridinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-63-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-1-(phenylmethyl)-2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-64-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(4-morpholinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-65-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(1,1-dioxido-4-thiomorpholinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-66-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-67-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3-methoxypropyl)amino]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-68-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-70-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(3-hydroxy-1-piperidinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-72-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(cyclopropylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-73-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(3S)-3-(acetylamino)-1'-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-74-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-2-(3-oxo-1-piperazinyl)-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-75-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(4-fluoro-1-piperidinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-76-2 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(cyclobutylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-77-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-(2-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 800399-78-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(4-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 800399-79-5 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 800399-80-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(phenylmethoxy)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-81-9 USPATFULL

CN 4-Piperidinecarboxylic acid, 1-[(2S)-2-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 800399-82-0 USPATFULL

CN 3-Piperidinecarboxylic acid, 1-[(2S)-2-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800399-83-1 USPATFULL

CN 2-Piperidinecarboxylic acid, 1-[(2S)-2-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.






RN 800399-84-2 USPATFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-(acetyloxy)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-86-4 USPATFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-(aminomethyl)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800399-87-5 USPATFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(3R)-3-amino-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 800399-88-6 USPATFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(3R)-3-amino-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 800399-89-7 USPATFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(3S)-3-amino-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro-,  
 monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 800399-90-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(3S)-3-amino-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800399-91-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(4-piperidinylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 800399-92-2 USPATFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(4-piperidinylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800399-93-3 USPATFULL  
 CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(hexahydro-1H-1,4-diazepin-1-yl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

6/6

Shiao 10/849,089

10/26/2006




● HCl

RN 800399-94-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(hexahydro-1H-1,4-diazepin-1-yl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-95-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[4-(diacetylamino)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-96-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(methylamino)-1-piperidinyl]-2-oxoethyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-97-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-[(methylamino)methyl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-98-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(trifluoromethyl)-1-piperidinyl]ethyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800399-99-9 USPATFULL

CN 4-Piperidinecarboxylic acid, 1-[(2S)-2-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-00-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[3-(hydroxymethyl)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800400-01-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[1,4'-bipiperidin]-1'-yl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 800400-02-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-(4-acetyl-1-piperidinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-03-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-fluoro-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 800400-04-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-(aminocarbonyl)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-05-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(2-hydroxyethyl)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-06-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-(aminocarbonyl)-1-piperazinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-07-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[3-  
[(diethylamino)carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-  
oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-08-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[3-(aminocarbonyl)-1-  
piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 800400-09-3 USPATFULL

CN 3-Piperidinecarboxylic acid, 1-[(2S)-2-[[[5-chloro-1H-pyrrolo[2,3-  
c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, ethyl

ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-10-6 USPATFULL

CN 2-Piperidinecarboxylic acid, 1-[(2S)-2-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-11-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[[[3-(4-morpholinyl)propyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-12-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(2-methoxyethyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-13-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(3-methoxypropyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-14-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-16-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-(4-acetylhexahydro-1H-1,4-diazepin-1-yl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-19-5 USPATFULL

CN D-Prolinamide, 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carbonyl-4-fluoro-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800400-21-9 USPATFULL

CN Carbamic acid, [(3R)-1-[(2S)-2-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-29-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(hexahydro-5-oxo-1H-1,4-diazepin-1-yl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-31-1 USPATFULL

CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[(2S)-2-[[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-33-3 USPATFULL

CN L-Proline, 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxyl-4-fluoro-L-phenylalanyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-35-5 USPATFULL

CN 1-Piperazinecarboxylic acid, 4-[(2S)-2-[[5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl]carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800400-39-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 800400-41-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(3-hydroxypropyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-43-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800400-45-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-

fluorophenyl)methyl]-2-oxo-2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-48-0 USPATFULL

CN L-Phenylalanine, N-[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-54-8 USPATFULL

CN Carbamic acid, [[1-[(2S)-2-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-4-piperidinyl]methyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-56-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(4-morpholinyl)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-58-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[hexahydro-4-(2-hydroxyethyl)-1H-1,4-diazepin-1-yl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-60-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3R)-3-hydroxy-1-piperidiny]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-61-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(3,6-dihydro-1(2H)-pyridinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-63-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[2-(hydroxymethyl)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-65-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(2,5-dihydro-1H-pyrrol-1-yl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-67-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(1,1-dioxido-4-thiomorpholinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-71-9 USPATFULL

CN 3-Piperidinecarboxylic acid, 1-[(2S)-2-[[[(5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-73-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(4-hydroxy-1-piperidinyl)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-75-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[(2S)-2-(aminocarbonyl)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800400-77-5 USPATFULL

CN	1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(2-methoxyethoxy)-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)
----	--


Absolute stereochemistry.



RN 800400-78-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(3-methoxypropoxy)-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-80-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-(acetylamino)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-82-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-[4-[(acetylamino)methyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800400-85-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(methyl-4-piperidinylamino)-2-oxoethyl]- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 800400-86-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[methyl(tetrahydro-2H-pyran-4-yl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800400-87-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[4-(dimethylamino)-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 800400-88-8 USPTFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-1-(4-{(methylsulfonyl)amino}-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-90-2 USPTFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(4-pyridinylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-91-3 USPTFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-1-(4-pyridinylmethyl)-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-92-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(1,4-dioxo-7-azaspiro[4.5]dec-7-yl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800400-93-5 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3R,4R)-3,4-dihydroxy-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 800400-94-6 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-[(3S,4S)-3,4-

dihydroxy-1-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800400-96-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-oxo-2-phenyl-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800400-99-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-(hydroxymethyl)-2-oxo-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-00-7 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-(methoxymethyl)-2-oxo-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800401-01-8 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[2-oxo-2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 800401-02-9 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-03-0 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-04-1 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-hydroxy-1-piperidiny)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-05-2 USPATFULL


CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(hexahydro-5-oxo-1H-1,4-diazepin-1-yl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 800401-06-3 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



IT 800401-09-6P 800401-10-9P 800401-11-0P  
800401-12-1P 800401-13-2P 800401-14-3P  
800401-15-4P 800401-16-5P 800401-19-8P  
800401-20-1P 800401-21-2P 800401-23-4P  
800401-24-5P 800401-25-6P 800401-26-7P  
800401-27-8P 800401-28-9P 800401-29-0P  
800401-30-3P 800401-31-4P 800401-32-5P


800401-33-6P 800401-44-9P 800401-45-0P  
 800401-47-2P 800401-48-3P 800401-49-4P  
 800401-50-7P 800401-51-8P 800402-16-8P  
 800402-17-9P

(preparation of pyrrolopyridinecarboxylic acid amide as inhibitors of  
 glycogen phosphorylase)

RN 800401-09-6 USPTAFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-10-9 USPTAFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-11-0 USPTAFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-[(1S)-2-(4-acetyl-1-piperazinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-6-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-12-1 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3-methoxypropyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-13-2 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-14-3 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-morpholinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-15-4 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(4-thiomorpholinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-16-5 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800401-19-8 USPATFULL


CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 800401-20-1 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-(2-oxo-2-phenylethyl)-  
(9CI) (CA INDEX NAME)

RN 800401-21-2 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(methoxymethylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-23-4 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-morpholinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-24-5 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-25-6 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(2-hydroxyethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-26-7 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-(2-hydroxyethyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-27-8 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, N-[(1S)-2-(4-acetyl-1-piperazinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-28-9 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(3-hydroxy-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 800401-29-0 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-

fluorophenyl)methyl]-2-[(3-methoxypropyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-30-3 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(4-hydroxybutyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-31-4 USPATFULL

CN 1H-Pyrrolo[3,2-c]pyridine-2-carboxamide, 6-chloro-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-32-5 USPATFULL

CN 1H-Pyrrolo[3,2-c]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-33-6 USPATFULL

CN 1H-Pyrrolo[3,2-c]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-44-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(1R,2R)-2-hydroxycyclohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-45-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[(1S,2R)-2-(hydroxymethyl)cyclohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-47-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(4-cyclopentyl-1-piperazinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-48-3 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-(ethylmethylamino)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-49-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(4-thiomorpholinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-50-7 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(3-hydroxy-1-piperidinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-51-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-(3-oxo-1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800402-16-8 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-[(1S)-2-(4-amino-1-piperidinyl)-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-5-chloro-, hydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 800402-17-9 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-[(methylamino)methyl]-1-piperidinyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 800402-18-0


(preparation of pyrrolopyridinecarboxylic acid amide as inhibitors of glycogen phosphorylase)

RN 800402-18-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-[[methyl[(2-nitrophenyl)sulfonyl]amino]methyl]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 800401-77-8P 800401-78-9P 800401-79-0P


800401-80-3P 800401-95-0P 800401-99-4P

800402-01-1P 800402-02-2P

(preparation of pyrrolopyridinecarboxylic acid amide as inhibitors of glycogen phosphorylase)


RN 800401-77-8 USPTAFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[[2-(4-methoxyphenyl)-1,3-dioxolan-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 800401-78-9 USPTAFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[[2-(3,4-difluorophenyl)-1,3-dioxolan-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 800401-79-0 USPTAFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 800401-80-3 USPATFULL


CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 800401-95-0 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-[4-[methyl[(2-nitrophenyl)sulfonyl]amino]-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800401-99-4 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-2-phenyl-1-(2-phenyl-1,3-dioxolan-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800402-01-1 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S,2S)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-hydroxy-2-phenylethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 800402-02-2 USPATFULL

CN 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, 5-chloro-N-[(1S)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-oxo-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=&gt; d ibib ed ab hitind 13

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, TOXCENTER, CHEMCATS' -  
CONTINUE? (Y)/N:y

L165 ANSWER 13 OF 33 TOXCENTER COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:22645 TOXCENTER

COPYRIGHT: Copyright 2006 ACS

DOCUMENT NUMBER: CA14207114103S

TITLE: Preparation of triazafluorenes as 5-HT<sub>2C</sub> receptor agonists  
for the treatment of diabetes and obesity.

AUTHOR(S): Blench, Toby Jonathan; Hebeisen, Paul; Richter, Hans;

CORPORATE SOURCE: Roever, Stephan  
ASSIGNEE: Vernalis Research Limited  
PATENT INFORMATION: WO 2005000849 A1 6 Jan 2005  
SOURCE: (2005) PCT Int. Appl., 148 pp.  
CODEN: PIXXD2.

COUNTRY: SWITZERLAND  
DOCUMENT TYPE: Patent  
FILE SEGMENT: CAPLUS  
OTHER SOURCE: CAPLUS 2005:14399  
LANGUAGE: English  
ENTRY DATE: Entered STN: 1 Feb 2005  
Last Updated on STN: 29 Nov 2005

ED Entered STN: 1 Feb 2005

Last Updated on STN: 29 Nov 2005

AB Title compds. (I; R1 = H, alkyl, haloalkyl, cycloalkyl, halo, alkoxy, cycloalkoxy, hydroxyalkyl, etc.; R2 = alkyl, cycloalkyl, alkoxy, cycloalkoxy, halo, OH, hydroxyalkyl, alkoxyalkyl, aralkoxyalkyl, etc.; R3 = H, alkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkoxyalkyl, etc.; R4 = H, alkyl; R5 = alkyl), were prepared Thus, tert-Bu (4R,9aR)-7-fluoro-8-hydroxymethyl-4-methyl-3,4,9,9a-tetrahydro-1H-2,4a,5-triazafluorene-2-carboxylate (preparation given) was stirred 2.5 h with CBr<sub>4</sub> and Ph<sub>3</sub>P in CH<sub>2</sub>Cl<sub>2</sub> to give an oil which was stirred 0.5 h with polymethylhydrosilane and Pd(OAc)<sub>2</sub> in THF to give a residue which was stirred 0.5 h with CF<sub>3</sub>CO<sub>2</sub>H to give (4R,9aR)-7-fluoro-4,8-dimethyl-3,4,9,9a-tetrahydro-1H-2,4a,5-triazafluorene. The latter in a functional assay using human 5-HT<sub>2C</sub> receptors showed an EC<sub>50</sub> of 13 nM.

CC 28-17

ST Miscellaneous Descriptors

triazafluorene prepn 5HT<sub>2C</sub> receptor agonist diabetes obesity treatment

RN 96829-58-2 (Orlistat)  
68-12-2 (Dimethylformamide)  
74-96-4 (Ethyl bromide)  
75-07-0 (Acetaldehyde)  
75-26-3 (2-Bromopropane)  
97-94-9 (Triethylborane)  
100-39-0 (Benzyl bromide)  
110-81-6 (Diethyl disulfide)  
127-19-5 (Dimethylacetamide)  
541-41-3 (Ethyl chloroformate)  
593-56-6 (O-Methylhydroxylamine hydrochloride)  
629-19-6 (Propyl disulfide)  
4333-56-6 (Cyclopropyl bromide)  
5720-07-0 (4-Methoxyphenylboronic acid)  
6482-24-2 (2-Bromoethyl methyl ether)  
7051-34-5 (Bromomethylcyclopropane)  
17739-45-6 (2-(2-Bromoethoxy)tetrahydro-2H-pyran)  
21717-96-4 (2-Amino-5-fluoropyridine)  
220474-36-2 (Dimethylprop-2-ynyloxy-(1,1,2-trimethylpropyl)silane)  
396074-50-3 ((S)-5-Methyl-2,2-dioxo-[1,2,3]oxathiazolidine-3-carboxylic acid tert-butyl ester)  
784155-54-0 (N-(5-Fluoropyridin-2-yl)-2,2-dimethylpropionamide)  
823218-50-4 (N-(5-Fluoro-3-iodopyridin-2-yl)-2,2-dimethylpropionamide)  
823218-51-5 (5-Fluoro-3-iodopyridin-2-ylamine)  
RN 823216-64-4; 823216-65-5; 823216-66-6; 823216-67-7; 823216-68-8;  
823216-69-9; 823216-70-2; 823216-71-3; 823216-72-4; 823216-73-5;  
823216-74-6; 823216-75-7; 823216-76-8; 823216-77-9; 823216-78-0;  
823216-79-1; 823216-81-5; 823216-82-6; 823216-83-7; 823216-84-8;  
823216-86-0; 823216-87-1; 823216-88-2; 823216-89-3; 823216-90-6;  
823216-91-7; 823216-92-8; 823216-93-9; 823216-94-0; 823216-95-1;  
823216-96-2; 823216-97-3; 823216-98-4; 823216-99-5; 823217-00-1;


823217-01-2; 823217-02-3; 823217-03-4; 823217-04-5; 823217-05-6;  
823217-06-7; 823217-07-8; 823217-08-9; 823217-09-0; 823217-10-3;  
823217-11-4; 823217-12-5; 823217-13-6; 823217-14-7; 823217-15-8;  
823217-16-9; 823217-17-0; 823217-18-1; 823217-19-2; 823217-20-5;  
823217-21-6; 823217-22-7; 823217-23-8; 823217-24-9; 823217-25-0;  
823217-26-1; 823217-27-2; 823217-29-4; 823217-30-7; 823217-32-9;  
823217-34-1; 823217-35-2; 823217-36-3; 823217-37-4; 823217-38-5;  
823217-39-6; 823217-40-9; 823217-42-1; 823217-43-2; 823217-44-3;  
823217-45-4; 823217-47-6; 823217-49-8; 823217-51-2; 823217-53-4;  
823217-54-5; 823217-55-6; 823217-56-7; 823217-57-8; 823217-58-9;  
221675-35-0; 577712-30-2; 577712-85-7; 577712-96-0; 823218-86-6;  
823218-89-9; 577710-82-8; 577711-88-7; 577711-90-1; 577711-92-3;  
577711-94-5; 577711-96-7; 577711-98-9; 577712-00-6; 577712-02-8;  
577712-06-2; 577712-10-8; 577712-26-6; 577712-28-8; 577712-50-6;  
577712-52-8; 577712-57-3; 577712-59-5; 577712-70-0; 577712-80-2;  
577712-82-4; 577712-90-4; 577712-91-5; 577712-92-6; 577713-15-6;  
577713-69-0; 823217-59-0; 823217-60-3; 823217-61-4; 823217-62-5;  
823217-63-6; 823217-64-7; 823217-65-8; 823217-66-9; 823217-67-0;  
823217-68-1; 823217-69-2; 823217-70-5; 823217-71-6; 823217-72-7;  
823217-73-8; 823217-74-9; 823217-75-0; 823217-76-1; 823217-77-2;  
823217-78-3; 823217-79-4; 823217-80-7; 823217-81-8; 823217-82-9;  
823217-83-0; 823217-84-1; 823217-85-2; 823217-86-3; 823217-87-4;  
823217-88-5; 823217-89-6; 823217-90-9; 823217-91-0; 823217-92-1;  
823217-93-2; 823217-94-3; 823217-95-4; 823217-96-5; 823217-97-6;  
823217-98-7; 823217-99-8; 823218-00-4; 823218-01-5; 823218-02-6;  
823218-03-7; 823218-04-8; 823218-05-9; 823218-07-1; 823218-08-2;  
823218-09-3; 823218-10-6; 823218-11-7; 823218-12-8; 823218-13-9;  
823218-14-0; 823218-15-1; 823218-16-2; 823218-17-3; 823218-18-4;  
823218-19-5; 823218-20-8; 823218-21-9; 823218-22-0; 823218-23-1;  
823218-24-2; 823218-25-3; 823218-27-5; 823218-29-7; 823218-30-0;  
823218-31-1; 823218-32-2; 823218-33-3; 823218-34-4; 823218-35-5;  
823218-36-6; 823218-37-7; 823218-38-8; 823218-39-9; 823218-40-2;  
823218-41-3; 823218-42-4; 823218-43-5; 823218-44-6; 823218-45-7;  
823218-46-8; 823218-47-9; 823218-48-0; 823218-49-1; 823218-52-6;  
823218-53-7; 823218-54-8; 823218-55-9; 823218-56-0; 823218-57-1;  
823218-58-2; 823218-59-3; 823218-60-6; 823218-61-7; 823218-62-8;  
823218-63-9; 823218-64-0; 823218-65-1; 823218-66-2; 823218-67-3;  
823218-68-4; 823218-69-5; 823218-70-8; 823218-71-9; 823218-72-0;  
823218-73-1; 823218-74-2; 823218-75-3; 823218-76-4; 823218-78-6;  
823218-79-7; 823218-80-0; 823218-81-1; 823218-82-2; 823218-83-3;  
823218-84-4; 823218-85-5; 823218-87-7; 823218-88-8; 823218-90-2;  
823218-91-3; 823218-92-4; 823218-93-5

=> d ide 14-33


YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, TOXCENTER, CHEMCATS' -  
CONTINUE? (Y)/N:y

L165 ANSWER 14 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STM


Accession No. (AN): 2006:4499996 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-383972  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 904455-47-6  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :



L165 ANSWER 15 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4498824 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-384029  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 904443-62-5  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L165 ANSWER 16 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4498808 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-383999  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 904443-46-5  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L165 ANSWER 17 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4498802 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006


Order Number (ON): kcd-383988  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 904443-40-9  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L165 ANSWER 18 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4498770 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-383934  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 904443-08-9  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L165 ANSWER 19 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4498762 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-383920  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 904443-00-1  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :



L165 ANSWER 20 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4478799 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-384046  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 902561-84-6  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L165 ANSWER 21 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4478787 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-384028  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 902561-72-2  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L165 ANSWER 22 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN




Accession No. (AN): 2006:4478763 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-383992  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 902561-48-2  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L165 ANSWER 23 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4478702 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-383926  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 902560-87-6  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L165 ANSWER 24 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4476851 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-369235  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 902509-15-3  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :



L165 ANSWER 25 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4476790 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-369136  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 902508-54-7  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L165 ANSWER 26 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4476787 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-369132  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 902508-51-4  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L165 ANSWER 27 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4473938 CHEMCATS  
Catalog Name (CO): Aurora Screening Library


Publication Date (PD): 10 May 2006  
 Order Number (ON): kcd-383918  
 Chemical Name (CN): Chemical name not yet assigned  
 CAS Registry No. (RN): 902471-45-8  
 Supplementary Term (ST): CHEMICAL LIBRARY  
 Structure :




L165 ANSWER 28 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
 Accession No. (AN): 2006:4473937 CHEMCATS  
 Catalog Name (CO): Aurora Screening Library  
 Publication Date (PD): 10 May 2006  
 Order Number (ON): kcd-383913  
 Chemical Name (CN): Chemical name not yet assigned  
 CAS Registry No. (RN): 902471-44-7  
 Supplementary Term (ST): CHEMICAL LIBRARY  
 Structure :




L165 ANSWER 29 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
 Accession No. (AN): 2006:4465885 CHEMCATS  
 Catalog Name (CO): Aurora Screening Library  
 Publication Date (PD): 10 May 2006  
 Order Number (ON): kcd-369215  
 Chemical Name (CN): Chemical name not yet assigned  
 CAS Registry No. (RN): 901862-38-2  
 Supplementary Term (ST): CHEMICAL LIBRARY  
 Structure :



L165 ANSWER 30 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4465852 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-369150  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 901862-05-3  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L165 ANSWER 31 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4465843 CHEMCATS  
Catalog Name (CO): Aurora Screening Library  
Publication Date (PD): 10 May 2006  
Order Number (ON): kcd-369138  
Chemical Name (CN): Chemical name not yet assigned  
CAS Registry No. (RN): 901861-96-9  
Supplementary Term (ST): CHEMICAL LIBRARY  
Structure :




L165 ANSWER 32 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
Accession No. (AN): 2006:4464593 CHEMCATS  
Catalog Name (CO): Aurora Screening Library


Publication Date (PD): 10 May 2006  
 Order Number (ON): kcd-369208  
 Chemical Name (CN): Chemical name not yet assigned  
 CAS Registry No. (RN): 901747-63-5  
 Supplementary Term (ST): CHEMICAL LIBRARY  
 Structure :



L165 ANSWER 33 OF 33 CHEMCATS COPYRIGHT 2006 ACS on STN  
 Accession No. (AN): 2006:4464591 CHEMCATS  
 Catalog Name (CO): Aurora Screening Library  
 Publication Date (PD): 10 May 2006  
 Order Number (ON): kcd-369204  
 Chemical Name (CN): Chemical name not yet assigned  
 CAS Registry No. (RN): 901747-61-3  
 Supplementary Term (ST): CHEMICAL LIBRARY  
 Structure :





L1	STR
----	-----



DEFAULT ECLEVEL IS LIMITED

NUMBER OF NODES IS 12

L42 STR



DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE

L45 1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42  
L69 QUE ABB=ON PLU=ON NAZARE, M?/AU  
L70 QUE ABB=ON PLU=ON WEHNER, V?/AU  
L71 QUE ABB=ON PLU=ON WILL, D?/AU  
L72 QUE ABB=ON PLU=ON RITTER, K?/AU  
L73 QUE ABB=ON PLU=ON MATTER, H?/AU  
L74 QUE ABB=ON PLU=ON URMANN, M?/AU  
L75 QUE ABB=ON PLU=ON (AVENTIS OR SANOFI)/CS,SO,PA  
L77 129 SEA FILE=HCAPLUS ABB=ON PLU=ON L2 AND (L69 OR L70 OR L71 OR  
L72 OR L73 OR L74 OR L75)  
L78 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 AND L45

=> d his 185

(FILE 'USPATFULL, USPAT2, TOXCENTER, CASREACT, CHEMCATS' ENTERED AT  
13:14:58 ON 25 OCT 2006)


L85 6 S L82 AND L69-L75

=> d que nos 185

L1 STR  
L2 45329 SEA FILE=REGISTRY SSS FUL L1  
L32 STR  
L34 4740 SEA FILE=REGISTRY SUB=L2 SSS FUL L32  
L42 STR  
L45 1247 SEA FILE=REGISTRY SUB=L2 SSS FUL L42  
L46 93 SEA FILE=REGISTRY ABB=ON PLU=ON L34 AND L45  
L69 QUE ABB=ON PLU=ON NAZARE, M?/AU  
L70 QUE ABB=ON PLU=ON WEHNER, V?/AU  
L71 QUE ABB=ON PLU=ON WILL, D?/AU  
L72 QUE ABB=ON PLU=ON RITTER, K?/AU  
L73 QUE ABB=ON PLU=ON MATTER, H?/AU  
L74 QUE ABB=ON PLU=ON URMANN, M?/AU  
L75 QUE ABB=ON PLU=ON (AVENTIS OR SANOFI)/CS,SO,PA  
L82 27 SEA L46  
L85 6 SEA L82 AND (L69 OR L70 OR L71 OR L72 OR L73 OR L74 OR L75)

=> d que 1113

L32 STR



Cy @14

C~Cy  
@15 16

N~Cy  
@17 18


S~Cy  
@19 20

O~Cy  
@21 22

VAR G1=C/N  
 VAR G2=C/N  
 VAR G3=C/N  
 VAR G4=C/N  
 VAR G5=14/15/17/19/21  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 10  
 NSPEC IS RC AT 11  
 NSPEC IS RC AT 15  
 NSPEC IS RC AT 17  
 NSPEC IS RC AT 19  
 NSPEC IS RC AT 21  
 CONNECT IS E1 RC AT 12  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE  
 L42 STR



VAR G1=12/21/30/39  
 NODE ATTRIBUTES:  
 NSPEC IS RC AT 1  
 NSPEC IS RC AT 2  
 CONNECT IS E1 RC AT 3  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE  
 L69 QUE ABB=ON PLU=ON NAZARE, M?/AU  
 L70 QUE ABB=ON PLU=ON WEHNER, V?/AU  
 L71 QUE ABB=ON PLU=ON WILL, D?/AU  
 L72 QUE ABB=ON PLU=ON RITTER, K?/AU  
 L73 QUE ABB=ON PLU=ON MATTER, H?/AU



L74 QUE ABB=ON PLU=ON URMANN, M?/AU  
L75 QUE ABB=ON PLU=ON (AVENTIS OR SANOFI)/CS,SO,PA  
L101 QUE ABB=ON PLU=ON D720/M0,M1,M2,M3,M4,M5,M6  
L103 347 SEA FILE=WPIX SSS FUL L32  
L105 49 SEA FILE=WPIX SUB=L103 SSS FUL L42  
L106 72 SEA FILE=WPIX ABB=ON PLU=ON (RA0XZP/DCN OR RAAHRA/DCN OR  
RAAHRY/DCN OR RAAZSD/DCN OR RAAZSF/DCN OR RAAZSH/DCN OR  
RAAZSI/DCN OR RAAZSJ/DCN OR RAAZSK/DCN OR RAAZSL/DCN OR  
RAAZSM/DCN OR RAAZSN/DCN OR RAAZSO/DCN OR RAAZSX/DCN OR  
RAA1TM/DCN OR RAB2D0/DCN OR RACKXP/DCN OR RAETE4/DCN OR  
RAE3EB/DCN OR RAE3EC/DCN OR RAE3ED/DCN OR RAE3EE/DCN OR  
RAE3EF/DCN OR RAE3EG/DCN OR RAE3EK/DCN OR RAE3EL/DCN OR  
RAE3EM/DCN OR RAE3EN/DCN OR RAE3EQ/DCN OR RAE3EU/DCN OR  
RAE3EV/DCN OR RAE3EW/DCN OR RAE3EX/DCN OR RAE3F2/DCN OR  
RAFI3X/DCN OR RAFI3Y/DCN OR RAFI41/DCN OR RAFZM3/DCN OR  
RAFZM4/DCN OR RAFZM6/DCN OR RAF8IU/DCN OR RAF8IV/DCN OR  
RAF8IW/DCN OR RAF8IX/DCN OR RAGFDN/DCN OR RAGFDO/DCN OR  
RAGFDP/DCN OR RAGFDQ/DCN OR RAGFDS/DCN OR RAGFDT/DCN OR  
RAGFDU/DCN OR RAGFDV/DCN OR RAGFDW/DCN OR RAGFDX/DCN OR  
RAGFDY/DCN OR RAGFDZ/DCN OR RAGFEB/DCN OR RAGFEC/DCN OR  
RAGFED/DCN OR RAGFEG/DCN OR RAGFEH/DCN OR RAGFEI/DCN OR  
RAGFEJ/DCN OR RAGFEM/DCN OR RAGFEN/DCN OR RAGFEO/DCN OR  
RAGFEP/DCN OR RAGFEQ/DCN OR RAGFE0/DCN OR RAGFE1/DCN OR  
RAGFE2/DCN OR RAGFE3/DCN OR RAGFE4/DCN OR RAGFE5/DCN OR  
RAGFE6/DCN OR RAGFE7/DCN OR RAGFE8/DCN OR RAGFE9/DCN OR  
RAGFFQ/DCN OR RAGFFR/DCN OR RAGFFS/DCN OR RAGFFT/DCN OR  
RAGFFU/DCN OR RAGSRH/DCN OR RAGSRO/DCN OR RAGSRP/DCN OR  
RAGSRQ/DCN OR RAGSRR/DCN OR RAG3GM/DCN OR RAG3GN/DCN OR  
RAG6CZ/DCN OR RAG6DA/DCN OR RAG6DD/DCN OR RAG6DF/DCN OR  
RAG6DI/DCN OR RAG6D2/DCN OR RAG6D3/DCN OR RAG6D5/DCN OR  
RAG6D6/DCN OR RAG6D8/DCN OR RAG7BA/DCN OR RAG7BB/DCN OR  
RAG7BC/DCN OR RAG7BI/DCN OR RAG7BK/DCN OR RAG7BM/DCN OR  
RAHI2S/DCN OR RAHI2U/DCN OR RAHI2V/DCN OR RAHOVW/DCN OR  
RAIO1E/DCN OR RAIO19/DCN OR RAKGLI/DCN OR RAKGLK/DCN OR  
RAKGLP/DCN OR RAKGLW/DCN OR RAKGLX/DCN OR RAKGLY/DCN OR  
RAKGLZ/DCN OR RAKGM0/DCN OR RAKNAV/DCN OR RAKW9U/DCN OR  
RALDFO/DCN OR RALDFP/DCN OR RALDFQ/DCN OR RALDFR/DCN OR  
RALDFS/DCN OR RALDFT/DCN OR RALDFU/DCN OR RALDFV/DCN OR  
RALDFW/DCN OR RALDFX/DCN OR RALDFY/DCN OR RALDFZ/DCN OR  
RALDG0/DCN OR RALDG1/DCN OR RALDG2/DCN OR RALDG3/DCN OR  
RALDG4/DCN OR RALDG5/DCN OR RALHNR/DCN OR RALHO3/DCN OR RAL  
L107 72 SEA FILE=WPIX ABB=ON PLU=ON L103/DCR  
L108 10 SEA FILE=WPIX ABB=ON PLU=ON (L106 OR L107) AND L101  
L109 5 SEA FILE=WPIX ABB=ON PLU=ON (RAE3EB/DCN OR RAE3EC/DCN OR  
RAE3ED/DCN OR RAE3EE/DCN OR RAE3EF/DCN OR RAE3EG/DCN OR  
RAE3EK/DCN OR RAE3EL/DCN OR RAE3EM/DCN OR RAE3EN/DCN OR  
RAE3EQ/DCN OR RAE3EU/DCN OR RAE3EV/DCN OR RAE3EW/DCN OR  
RAE3EX/DCN OR RAE3F2/DCN OR RAG7BA/DCN OR RAG7BB/DCN OR  
RAG7BC/DCN OR RAG7BI/DCN OR RAG7BK/DCN OR RAG7BM/DCN OR  
RALDFO/DCN OR RALDFP/DCN OR RALDFQ/DCN OR RALDFR/DCN OR  
RALDFS/DCN OR RALDFT/DCN OR RALDFU/DCN OR RALDFV/DCN OR  
RALDFW/DCN OR RALDFX/DCN OR RALDFY/DCN OR RALDFZ/DCN OR  
RALDG0/DCN OR RALDG1/DCN OR RALDG2/DCN OR RALDG3/DCN OR  
RALDG4/DCN OR RALDG5/DCN OR RAMQJD/DCN OR RAMQJF/DCN OR  
RAMQJT/DCN OR RAMQJV/DCN OR RAMQJX/DCN OR RA211B/DCN OR  
RA2117/DCN OR RA2118/DCN OR RA2119/DCN)  
L110 5 SEA FILE=WPIX ABB=ON PLU=ON L105/DCR  
L111 10 SEA FILE=WPIX ABB=ON PLU=ON (L108 OR L109 OR L110)  
L112 14 SEA FILE=WPIX ABB=ON PLU=ON (L111 OR L106 OR L107) AND (L69  
OR L70 OR L71 OR L72 OR L73 OR L74 OR L75)

L113 3 SEA FILE=WPIX ABB=ON PLU=ON L112 AND L111

=> d his l160

(FILE 'MEDLINE, BIOSIS, EMBASE, PASCAL, JICST-EPLUS, JAPIO, LIFESCI,  
BIOENG, BIOTECHNO, BIOTECHDS, DRUGU, DRUGB, VETU, VETB, SCISEARCH, CABA,  
CONFSCI, DISSABS' ENTERED AT 16:00:07 ON 25 OCT 2006)

L160 16 S L158-L159

=> d que l160

L69 QUE ABB=ON PLU=ON NAZARE, M?/AU  
L70 QUE ABB=ON PLU=ON WEHNER, V?/AU  
L71 QUE ABB=ON PLU=ON WILL, D?/AU  
L72 QUE ABB=ON PLU=ON RITTER, K?/AU  
L73 QUE ABB=ON PLU=ON MATTER, H?/AU  
L74 QUE ABB=ON PLU=ON URMANN, M?/AU  
L75 QUE ABB=ON PLU=ON (AVENTIS OR SANOFI)/CS,SO,PA  
L155 40725 SEA (L69 OR L70 OR L71 OR L72 OR L73 OR L74 OR L75)  
L157 25 SEA L155 AND (?AZAINDOL? OR (AZA (W) INDOL?))  
L158 16 SEA L155 AND (?PYRROL?(10A) ?PYRIDIN?)  
L159 1 SEA L157 AND L158  
L160 16 SEA (L158 OR L159)

=> dup rem 178 185 l113 l160

DUPLICATE IS NOT AVAILABLE IN 'CHEMCATS'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
FILE 'HCAPLUS' ENTERED AT 16:38:07 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:38:07 ON 25 OCT 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 16:38:07 ON 25 OCT 2006  
COPYRIGHT (C) 2006 ACS

FILE 'CASREACT' ENTERED AT 16:38:07 ON 25 OCT 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 16:38:07 ON 25 OCT 2006  
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'MEDLINE' ENTERED AT 16:38:07 ON 25 OCT 2006

FILE 'BIOSIS' ENTERED AT 16:38:07 ON 25 OCT 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 16:38:07 ON 25 OCT 2006  
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'PASCAL' ENTERED AT 16:38:07 ON 25 OCT 2006  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

FILE 'JAPIO' ENTERED AT 16:38:07 ON 25 OCT 2006  
COPYRIGHT (C) 2006 Japanese Patent Office (JPO)- JAPIO

FILE 'LIFESCI' ENTERED AT 16:38:07 ON 25 OCT 2006  
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'DRUGU' ENTERED AT 16:38:07 ON 25 OCT 2006  
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'SCISEARCH' ENTERED AT 16:38:07 ON 25 OCT 2006  
Copyright (c) 2006 The Thomson Corporation

PROCESSING COMPLETED FOR L78

PROCESSING COMPLETED FOR L85

PROCESSING COMPLETED FOR L113

PROCESSING COMPLETED FOR L160

L166 27 DUP REM L78 L85 L113 L160 (6 DUPLICATES REMOVED)

ANSWERS '1-8' FROM FILE HCAPLUS

ANSWERS '9-12' FROM FILE USPATFULL

ANSWERS '13-14' FROM FILE WPIX

ANSWER '15' FROM FILE MEDLINE

ANSWER '16' FROM FILE BIOSIS

ANSWERS '17-19' FROM FILE EMBASE

ANSWERS '20-22' FROM FILE PASCAL

ANSWERS '23-25' FROM FILE JAPIO

ANSWER '26' FROM FILE LIFESCI

ANSWER '27' FROM FILE DRUGU

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 16:38:18 ON 25 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Oct 25, 2006 (20061025/UP).

=> d ibib ed ab 1-22

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, WPIX, MEDLINE, BIOSIS, EMBASE, PASCAL, JAPIO, LIFESCI, DRUGU' - CONTINUE? (Y)/N:y

L166 ANSWER 1 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2004:1011968 HCAPLUS

DOCUMENT NUMBER: 142:6514

TITLE: Preparation of thienylisoxazolylmethylazaindoles as factor Xa and/or factor VIIa inhibitors

INVENTOR(S): Nazare, Marc; Wehner, Volkmar; Will, David William; Ritter, Kurt; Urmann, Matthias; Matter, Hans

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: Eur. Pat. Appl., 82 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1479680	A1	20041124	EP 2003-11304	20030519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004238500	A1	20041125	AU 2004-238500	20040505
CA 2526084	AA	20041125	CA 2004-2526084	20040505
WO 2004101563	A1	20041125	WO 2004-EP4754	20040505
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1636226	A1	20060322	EP 2004-731161	20040505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010429	A	20060606	BR 2004-10429	20040505
CN 1791601	A	20060621	CN 2004-80013936	20040505
US 2005009828	A1	20050113	US 2004-849089	20040519
NO 2005005911	A	20060210	NO 2005-5911	20051213
PRIORITY APPLN. INFO.:			EP 2003-11304	A 20030519
			US 2003-507141P	P 20030930
			WO 2004-EP4754	W 20040505

OTHER SOURCE(S): CASREACT 142:6514; MARPAT 142:6514

ED Entered STN: 24 Nov 2004

AB Title compds. [I; R = (substituted) mono- or bicyclic aryl, heterocyclyl; R1 = H, (substituted) alkyl, aminocarbonylalkyl, mono- or bicyclic aryl, heterocyclyl, etc.; R2 = bond, alkylene; R3 = H, halo, NO2, cyano, perfluoroalkyl, (substituted) alkyl, Ph, etc.; R1R3 = atoms to form a (substituted) 6-8 membered ring containing 1-4 heteroatoms; R1NR2V = atoms to form a (substituted) 4-7 membered ring containing 1-4 heteroatoms; V = (substituted) 3-7 membered heterocyclyl, 6-14 membered aryl, 4-15 membered

heterocyclyl; G = (CH<sub>2</sub>)<sub>m</sub>, (CH<sub>2</sub>)<sub>m</sub>O(CH<sub>2</sub>)<sub>n</sub>, CH<sub>2</sub>SO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>, (CH<sub>2</sub>)<sub>m</sub>NR<sub>10</sub>SO<sub>2</sub>NR<sub>10</sub>(CH<sub>2</sub>)<sub>n</sub>, (CH<sub>2</sub>)<sub>m</sub>CH(OH)(CH<sub>2</sub>)<sub>n</sub>, etc.; M = H, (substituted) alkyl, 6-14 membered aryl, 4-15 membered heterocyclyl, cycloalkyl, etc.; m, n = 0-6; R<sub>10</sub> = H, alkyl, hydroxyalkyl, alkoxyalkyl, perfluoroalkyl; D = atoms to form a (substituted) (aromatic) 4-8 membered ring containing 0-4 heteroatoms], were prepared. Thus, 1-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (preparation given), N-ethylmorpholine, and TOTU were stirred together for 20 min. in DMF; 1-isopropylpiperidin-4-ylamine dihydrochloride was added followed by stirring for 4 h to give 1-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (1-isopropylpiperidin-4-yl)amide. This inhibited factor Xa with K<sub>i</sub> = 0.006 μM.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L166 ANSWER 2 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 1994:508763 HCAPLUS

DOCUMENT NUMBER: 121:108763

TITLE: Preparation of condensed pyridine derivatives as inhibitors of the biological effects of oxygen free radicals

INVENTOR(S): Bachy, Andre; Fraisse, Laurent; Keane, Peter; Mendes, Etienne; Vernieres, Jean Claude; Simiand, Jacques

PATENT ASSIGNEE(S): Elf Sanofi SA, Fr.

SOURCE: Eur. Pat. Appl., 24 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 587473	A1	19940316	EP 1993-402095	19930825
EP 587473	B1	19981111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
FR 2695126	A1	19940304	FR 1992-10329	19920827
FR 2695126	B1	19941110		
US 5360799	A	19941101	US 1993-109073	19930819
AU 9344747	A1	19940303	AU 1993-44747	19930820
AU 659027	B2	19950504		
AT 173258	E	19981115	AT 1993-402095	19930825
ES 2125315	T3	19990301	ES 1993-402095	19930825
CA 2104883	AA	19940228	CA 1993-2104883	19930826
NO 9303051	A	19940228	NO 1993-3051	19930826
HU 64957	A2	19940328	HU 1993-2425	19930826
HU 217623	B	20000328		
JP 06184145	A2	19940705	JP 1993-211451	19930826
FI 103889	B1	19991015	FI 1993-3756	19930826
US 5468750	A	19951121	US 1994-273943	19940712
FI 9602714	A	19960701	FI 1996-2714	19960701
FI 103277	B1	19990531		

PRIORITY APPLN. INFO.: FR 1992-10329 A 19920827  
US 1993-109073 A3 19930819  
FI 1993-3756 A 19930826

OTHER SOURCE(S): MARPAT 121:108763

ED Entered STN: 03 Sep 1994

AB Title compds. [I; R<sub>1</sub> = OH, alkyl, alkoxy, Ph, PhCH<sub>2</sub>, PhCH<sub>2</sub>O, (substituted) amino, aminoalkyl; R<sub>2</sub> = OH, SH, alkoxy, alkylthio, (substituted) amino; R<sub>3</sub> = H, alkyl, alkylthio, alkoxy, Ph, PhCH<sub>2</sub>; A = S, N; R = null, H,

(substituted) alkyl; B = (substituted) Ph, pyridyl, or thienyl nucleus], were prepared. Thus, aminoacetate II was stirred 10 h with KOCMe<sub>3</sub> in PhMe/HOCMe<sub>3</sub> to give title compound III. I inhibited the toxic effects of KCN in mice with IC<sub>50</sub> = 2-30 mg/kg i.v.

L166 ANSWER 3 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:578103 HCAPLUS

DOCUMENT NUMBER: 145:62867

TITLE: Preparation of substituted aza/indoles as kinase inhibitors, and their compositions and use for treatment of angiogenesis-related diseases, especially cancer

INVENTOR(S): Halley, Frank; Souaille, Catherine; Tabart, Michel; Bacque, Eric; Viviani, Fabrice; Ronan, Baptiste; Letallec, Jean-Philippe; Filoche-Romme, Bruno

PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.

SOURCE: PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006061493	A1	20060615	WO 2005-FR3003	20051202
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
FR 2878849	A1	20060609	FR 2004-12966	20041206
PRIORITY APPLN. INFO.:			FR 2004-12966	A 20041206
			US 2005-650465P	P 20050207

OTHER SOURCE(S): MARPAT 145:62867

ED Entered STN: 16 Jun 2006

AB Title compds. I [A, Ar = independently (un)substituted hetero/aryl; R1 = H, (un)substituted alkyl; X = N, CH and derivs.; L = a bond, CO, NH, CONH, NHCO, SONH, NHSO<sub>2</sub>, NHCONH, NHCSNH, etc.; R5-R7 = independently H, halo, CF<sub>3</sub>, NO<sub>2</sub>, CN, alkoxy, alkyl, CO<sub>2</sub>H and derivs., etc.; Q = H, Me, cyclopropyl] were prepared as kinase inhibitors for treatment especially of cancer. E.g., a 7-step synthesis starting from 2-methyl-3-nitropyridine and Et oxalate, was given for azaindole II. Pyrrolopyridine II inhibited KDR and Tie2 kinases with an IC<sub>50</sub> of 12 nM and 4 nM. Thus, I and their pharmaceutical compns. are useful for treating angiogenesis-related diseases such as cancers, psoriasis, rheumatoid arthritis, diabetic retinopathy, etc.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L166 ANSWER 4 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:542506 HCAPLUS

DOCUMENT NUMBER: 145:27851

TITLE: Preparation of substituted indoles as kinase inhibitors, and their compositions and use for treatment of cancer  
INVENTOR(S): Halley, Frank; Souaille, Catherine; Tabart, Michel; Bacque, Eric; Viviani, Fabrice; Ronan, Baptiste; Letallec, Jean Philippe  
PATENT ASSIGNEE(S): Aventis Pharma SA, Fr.  
SOURCE: Fr. Demande, 50 pp.  
CODEN: FRXXBL  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2878849	A1	20060609	FR 2004-12966	20041206
WO 2006061493	A1	20060615	WO 2005-FR3003	20051202

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: FR 2004-12966 A 20041206  
US 2005-650465P P 20050207

OTHER SOURCE(S): MARPAT 145:27851

ED Entered STN: 09 Jun 2006

AB Title compds. I [A, Ar = independently (un)substituted hetero/aryl; R1 = H, (un)substituted alkyl; X = N, CH and derivs.; L = a bond, CO, NH, CONH, NHCO, SONH, NHSO2, NHCONH, NHCSNH, etc.; R5-R7 = independently H, halo, CF3, NO2, CN, alkoxy, alkyl, CO2H and derivs., etc.; Q = H, Me, cyclopropyl] were prepared as kinase inhibitors for treatment especially of cancer. E.g., a 5-step synthesis starting from Et indole-2-carboxylate was given for indole II. Indole II inhibited KDR and Tie2 kinases with an IC50 of 4 nM and 43 nM. Thus, I and their pharmaceutical compns. are useful as antitumor agents (no data).

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L166 ANSWER 5 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:527395 HCAPLUS

DOCUMENT NUMBER: 143:43870

TITLE: Preparation of substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase 1 $\alpha$

INVENTOR(S): Metz, William A.; Halley, Frank; Dutruc-Rosset, Gilles; Choi-Sledeski, Yong Mi; Bernard, Poli Gregory; Fink, David Marc; Doerflinger, Gilles; Huang, Bao-Guo; Gelormini, Ann Marie; Gamboa, Juan Antonio; Giovanni, Andrew; Roehr, Joachim E.; Tsay, Joseph T.; Camacho, Fernando; Hurst, William Joseph; Harnish, Stephen Wayne; Chiang, Yulin

PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 30 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005131012	A1	20050616	US 2004-1533	20041201
AU 2004303826	A1	20050707	AU 2004-303826	20041201
CA 2549183	AA	20050707	CA 2004-2549183	20041201
WO 2005061498	A1	20050707	WO 2004-US40080	20041201

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-528764P P 20031211  
WO 2004-US40080 W 20041201

OTHER SOURCE(S): CASREACT 143:43870; MARPAT 143:43870

ED Entered STN: 19 Jun 2005

AB The present invention discloses and claims compds. of formula (I) [wherein: R1 = H, alkyl; R2 = NR5R6; R3 = aryl, heterocyclyl; R4 = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, CF3, halogen, SH, S-C1-6 alkyl, NO2, NH2 or NR5R6; R5 = H, C1-6 alkyl; R6 = H, C1-6 alkyl; X = S, S(O)n; one of K, L or M is N and the other two members of K, L or M are each C wherein R4 is bonded only to a K, L, M or other ring atom that is C; m = 1-3; n = 1, 2] or a pharmaceutically acceptable salts or stereoisomers thereof as inhibitors of human casein kinase 1 $\epsilon$ , and methods of using said compds. of formula I for treating central nervous system diseases and disorders including mood disorders and sleep disorders, more specifically depression, bipolar disorder, circadian rhythm sleep disorder, jet lag syndrome, advanced sleep phase syndrome, and delayed sleep phase syndrome. Thus, to 1H-pyrrolo[3,2-b]pyridine-2-carboxamide (0.42 mmol) dissolved in dry DMF (10 mL) was added Cs2CO3 (100 mg, 0.31 mmol) and then bis(3-bromophenyl)disulfide (1.1 equivalent, 0.46 mmol), and the resulting mixture was heated under N2 at 95° for 16 h to give 3-(3-Bromophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide/1H-pyrrolo[3,2-b]pyridine-2-carboxamide (II). II showed IC50 of 25 nM against human casein kinase 1 $\epsilon$ .

L166 ANSWER 6 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:758616 HCAPLUS

DOCUMENT NUMBER: 141:379838

TITLE: A flexible, palladium-catalyzed indole and azaindole synthesis by direct annulation of chloroanilines and chloroaminopyridines with ketones

AUTHOR(S): Nazare, Marc; Schneider, Claudia; Lindenschmidt, Andreas; Will, David William

CORPORATE SOURCE: Medicinal Chemistry, DI&A Chemistry, Aventis Pharma Deutschland GmbH, Frankfurt am Main, 65926, Germany

SOURCE: Angewandte Chemie, International Edition (2004),



43(34), 4526-4528  
CODEN: ACIEF5; ISSN: 1433-7851  
PUBLISHER: Wiley-VCH Verlag GmbH & Co: KGaA  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 141:379838  
ED Entered STN: 17 Sep 2004  
AB The "ringmaster" [Pd(tBu3P)2] served as the catalyst in the direct synthesis of indoles, e.g., I, by annulation of ortho-chloroanilines with ketones. This versatile method can be used to synthesize a variety of functionalized indoles and azaindoles, e.g., II.  
REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L166 ANSWER 7 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1999:222935 HCAPLUS  
DOCUMENT NUMBER: 130:267423  
TITLE: Preparation of N-(2-thiazolyl)indole-2-carboxamides and analogs as CCK-A receptor agonists  
INVENTOR(S): Brodin, Roger; Boigegrain, Robert; Bignon, Eric; Molimard, Jean-Charles; Olliero, Dominique  
PATENT ASSIGNEE(S): Sanofi, Fr.  
SOURCE: PCT Int. Appl., 121 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915525	A1	19990401	WO 1998-FR2007	19980918
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
FR 2768737	A1	19990326	FR 1997-11718	19970919
FR 2768737	B1	20000519		
FR 2777887	A1	19991029	FR 1998-5106	19980423
FR 2777887	B3	20000707		
ZA 9807961	A	19990407	ZA 1998-7961	19980901
CA 2304397	AA	19990401	CA 1998-2304397	19980918
AU 9891705	A1	19990412	AU 1998-91705	19980918
AU 746707	B2	20020502		
EP 1017693	A1	20000712	EP 1998-944024	19980918
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 9812653	A	20000822	BR 1998-12653	19980918
EE 200000168	A	20010416	EE 2000-168	19980918
TW 430664	B	20010421	TW 1998-87115602	19980918
TR 200001218	T2	20010521	TR 2000-200001218	19980918
JP 2001517667	T2	20011009	JP 2000-512830	19980918
JP 3456970	B2	20031014		
NZ 503339	A	20020328	NZ 1998-503339	19980918
IL 134961	A1	20020725	IL 1998-134961	19980918
NO 2000001409	A	20000516	NO 2000-1409	20000317

NO 314455 B1 20030324  
HR 2000000153 A1 20010430 HR 2000-153 20000317  
BG 104254 A 20010831 BG 2000-104254 20000317  
US 6380230 B1 20020430 US 2000-508830 20000602  
PRIORITY APPLN. INFO.: FR 1997-11718 A 19970919  
FR 1998-5106 A 19980423  
WO 1998-FR2007 W 19980918

OTHER SOURCE(S): MARPAT 130:267423

ED Entered STN: 12 Apr 1999

AB Title compds. [I; R = NHCOR3; R1 = MeOZ; R2 = R7CH2, R7CH2S, R7SCH2, etc.;  
R3 = e.g., Z1(CH2)nR15 or Z1(CH2)mC6H4R15; R7 = (di)(methyl)cycloalkyl;  
R15 = CO2H or alkoxycarbonyl; Z = (un)substituted 1,2-phenylene; Z1 =  
(un)substituted indole-2,1-diyl; m = 0 or 1; n = 1-5] were prepared Thus, I  
(R1 = 2,5-dimethoxy-4-methylphenyl, R2 = 2-cyclohexylethyl)(II; R = NH2)  
was amidated by 1-tert-butoxycarbonylmethyl-5-methylindole-2-carboxylic  
acid (preparation each given) to give, after saponification, II (R =  
NHCOZ1CH2CO2H, Z1  
= 5-methylindole-2,1-diyl). Data for biol. activity of I were given.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L166 ANSWER 8 OF 27 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1987:439778 HCAPLUS

DOCUMENT NUMBER: 107:39778

TITLE: Pyrrolopyridines

INVENTOR(S): Dormoy, Jean Robert; Heymes, Alain

PATENT ASSIGNEE(S): SANOFI, Fr.

SOURCE: Fr. Demande, 20 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2574406	A1	19860613	FR 1984-19029	19841212
FR 2574406	B1	19870227		
EP 187631	A1	19860716	EP 1985-870178	19851211
EP 187631	B1	19900905		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 56212	E	19900915	AT 1985-870178	19851211
CA 1299183	A1	19920421	CA 1985-497380	19851211
DK 8505768	A	19860613	DK 1985-5768	19851212
JP 61155385	A2	19860715	JP 1985-280176	19851212
US 4831144	A	19890516	US 1988-141508	19880107

PRIORITY APPLN. INFO.: FR 1984-19029 A 19841212  
US 1985-806544 A2 19851209  
EP 1985-870178 A 19851211

OTHER SOURCE(S): CASREACT 107:39778; MARPAT 107:39778

ED Entered STN: 08 Aug 1987

AB The title compds. [I; R = protecting group; R1 = H, Li, alkyl, CHO, CO2H,  
alkoxycarbonyl, etc.], useful as intermediates for anthelmintics, are  
prepared PhSO2Cl was added to a mixture of I (R = R1 = H), NaOH, and Bu4NHSO4  
in CH2Cl2 over for 1 h. The temperature of the reaction mixture rose from  
20° to 40°. The resulting mixture was then stirred for 1 h to  
give 83-85% I (R = PhSO2, R1 = H).

L166 ANSWER 9 OF 27 USPATFULL on STN

DUPLICATE 2

ACCESSION NUMBER: 95:103512 USPATFULL

TITLE: Heterocycle-coupled substituted pyrrolo[3,2-c]pyridin-2-carboxylic acids

INVENTOR(S): Bachy, Andre, Toulouse, France  
 Fraisse, Laurent, Jurancon, France  
 Keane, Peter, Portet sur Garonne, France  
 Mendes, Etienne, Toulouse, France  
 Vernieres, Jean-Claude, Muret, France  
 Simiand, Jacques, Muret, France

PATENT ASSIGNEE(S): Elf **Sanofi**, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5468750		19951121
APPLICATION INFO.:	US 1994-273943		19940712 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-109073, filed on 19 Aug 1993, now patented, Pat. No. US 5360799		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1992-10329	19920827
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Henley, III, Raymond	
ASSISTANT EXAMINER:	Spivack, Phyllis G.	
LEGAL REPRESENTATIVE:	Jacobson, Price, Holman & Stern	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1001	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of formula ##STR1## in which A represents S;

R.sub.1 is selected from the group consisting of OH, (C.sub.1 -C.sub.12)alkyl, (C.sub.1 -C.sub.12)alkoxy, benzyloxy, phenyl, benzyl (C.sub.1 -C.sub.4)alkyl NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 ;

R.sub.2 is selected from the group consisting of OH, SH, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)alkylthio, and NZ.sub.1 Z.sub.2 ;

R.sub.3 is selected from the group consisting of H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)alkoxy, phenyl, and benzyl;

B is selected from the group consisting of phenyl; pyridyl; phenyl substituted by one or more groups selected from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 wherein Z.sub.1 and Z.sub.2 are selected, independently of each other, from the group consisting of H, (C.sub.1 -C.sub.6)alkyl, formyl, and benzyl or --NZ.sub.1 Z.sub.2 is selected from the group consisting of pyrrolidinyl, piperidinyl, morpholino, hexahydroazepino, ##STR2## piperazino, piperazino substituted in position 4 by (C.sub.1 -C.sub.8)alkyl, benzyl or diphenylmethyl; and pyridyl substituted by one or more groups selected from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 wherein Z.sub.1 and Z.sub.2 are selected, independently of each other, from the group consisting of H, (C.sub.1 -C.sub.6)alkyl, formyl, and benzyl, or NZ.sub.1 Z.sub.2 is selected from the group consisting of pyrrolidinyl, piperidinyl, morpholino, hexahydroazepino, ##STR3## piperazino, and piperazino substituted in position 4 by (C.sub.1 -C.sub.8)alkyl, benzyl or diphenylmethyl; or its

salt with an acid or a base.

L166 ANSWER 10 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2005:11693 USPATFULL

TITLE: Azaindole-derivatives as factor Xa inhibitors

INVENTOR(S): **Nazare, Marc**, Idstein, GERMANY, FEDERAL  
REPUBLIC OF

**Wehner, Volkmar**, Sandberg, GERMANY, FEDERAL  
REPUBLIC OF

**Will, David William**, Kriftel, GERMANY,  
FEDERAL REPUBLIC OF

**Ritter, Kurt**, Frankfurt am Main, GERMANY,  
FEDERAL REPUBLIC OF

**Urmann, Matthias**, Eschborn, GERMANY, FEDERAL  
REPUBLIC OF

**Matter, Hans**, Langenselbold, GERMANY, FEDERAL  
REPUBLIC OF

PATENT ASSIGNEE(S): **Aventis** Pharma Deutschland, Frankfurt am  
Main, GERMANY, FEDERAL REPUBLIC OF (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005009828	A1	20050113
APPLICATION INFO.:	US 2004-849089	A1	20040519 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2003-11304	20030519
	US 2003-507141P	20030930 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4713	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of the formula I ##STR1##

wherein R.sup.0, R.sup.1, R.sup.2, R.sup.3, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

L166 ANSWER 11 OF 27 USPATFULL on STN

ACCESSION NUMBER: 94:95413 USPATFULL

TITLE: Substituted thienyl- or pyrrolylcarboxylic acid  
derivatives, their preparation and medicines containing  
them

INVENTOR(S): **Bachy, Andre**, Toulouse, France

Fraisse, Laurent, Jurancon, France  
 Keane, Peter, Portet Sur Garonne, France  
 Mendes, Etienne, Toulouse, France  
 Vernieres, Jean-Claude, Muret, France  
 Simiand, Jacques, Muret, France  
 Elf **Sanofi**, Paris, France (non-U.S.  
 corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5360799		19941101
APPLICATION INFO.:	US 1993-109073		19930819

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1992-10329	19920827
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Cintins, Marianne M.	
ASSISTANT EXAMINER:	Spivack, Phyllis G.	
LEGAL REPRESENTATIVE:	Wegner, Cantor, Mueller & Player	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	997	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of formula ##STR1## in which R.sub.1 represents OH, (C.sub.1 -C.sub.12)alkyl, (C.sub.1 -C.sub.12)alkoxy, benzyloxy, benzyl, phenyl, (C.sub.1 -C.sub.4)alkylNZ.sub.1 Z.sub.2 or NZ.sub.1 Z.sub.2 ; R.sub.2 represents OH, SH, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)alkylthio or NZ.sub.1 Z.sub.2 ; R.sub.3 represents H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)alkoxy, phenyl or benzyl; A represents N and R represents H or (C.sub.1 -C.sub.4)alkyl which can be substituted by phenyl or NZ.sub.1 Z.sub.2 ; B represents phenyl which is coupled to the pyridyl ring and is optionally substituted by one or more groups chosen from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2 or NZ.sub.1 Z.sub.2 ; and Z.sub.1 and Z.sub.2 represent, independently of each other, H, (C.sub.1 -C.sub.6) alkyl, formyl or benzyl, or they form with the nitrogen atom to which they are attached an optionally substituted saturated heterocycle and their salts.

L166 ANSWER 12 OF 27 USPATFULL on STN

ACCESSION NUMBER: 89:39083 USPATFULL

TITLE: 1H-pyrrolo [3,2-c]pyrrolidines protected in 1-position  
 useful as intermediates

INVENTOR(S): Dormoy, Jean-Robert, Sisteron, France  
 Heymes, Alain, Sisteron, France

PATENT ASSIGNEE(S): **SANOFI**, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4831144		19890516
APPLICATION INFO.:	US 1988-141508		19880107 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1985-806544, filed on 9 Dec 1985, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1984-19029	19841212
DOCUMENT TYPE:	Utility	

FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Lee, Mary C.  
 ASSISTANT EXAMINER: Dentz, Bernard I.  
 LEGAL REPRESENTATIVE: Bacon & Thomas  
 NUMBER OF CLAIMS: 6  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 754

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a process for fixing an electrophilic group in the 2-position of 1H-pyrrolo[3,2-c]pyridine N-protected in the 1-position, process which consists in protecting the 1-position in question with a labile protecting group, reacting the compound so obtained with a lithiation agent selected from a lithium amide and an alkyl lithium at a temperature between -80° C. and -20° C. and in the presence of tetramethylethylenediamine to obtain the corresponding 2-lithio derivative and then condensing the metal derivative so obtained at a temperature between -80° C. and room-temperature with a reagent capable of giving rise to an electrophilic group to form N-protected 1H-pyrrolo[3,2-c]pyridine substituted in the 2-position by an electrophilic group.

L166 ANSWER 13 OF 27 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 ACCESSION NUMBER: 2005-114567 [13] WPIX  
 DOC. NO. CPI: C2005-038578 [13]  
 TITLE: New piperazine and tetrahydropyridine derivatives are tubulin polymerization inhibitors used for treating cancer and disaggregating cell masses derived from vascular tissue  
 DERWENT CLASS: B02  
 INVENTOR: LE BRUN A; LE-BRUN A; MAILLIET P; THOMPSON F; TIRABOSCHI G  
 PATENT ASSIGNEE: (AVET-C) AVENTIS PHARMA; (AVET-C) AVENTIS PHARMA SA  
 COUNTRY COUNT: 106

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
FR 2857966	A1	20050128	(200513)*	FR	31	[0]
US 20050020593	A1	20050127	(200513)	EN		
WO 2005009947	A2	20050203	(200513)	FR		
MX 2006000479	A1	20060401	(200654)	ES		
AU 2004259112	A1	20050203	(200660)	EN		
BR 2004012254	A	20060919	(200663)	PT		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
FR 2857966	A1	FR 2003-9092	20030724
US 20050020593	A1 Provisional	US 2003-505184P	20030923
AU 2004259112	A1	AU 2004-259112	20040722
WO 2005009947	A2	WO 2004-FR1944	20040722
MX 2006000479	A1	WO 2004-FR1944	20040722
US 20050020593	A1	US 2004-898517	20040723
MX 2006000479	A1	MX 2006-479	20060111
BR 2004012254	A	BR 2004-12254	20040722
BR 2004012254	A	WO 2004-FR1944	20040722

## FILING DETAILS:

PATENT NO	KIND	PATENT NO
MX 2006000479	A1	Based on WO 2005009947 A
AU 2004259112	A1	Based on WO 2005009947 A
BR 2004012254	A	Based on WO 2005009947 A

PRIORITY APPLN. INFO: FR 2003-9092 20030724

ED 20050708

AB FR 2857966 A1 UPAB: 20060121

NOVELTY - Piperazine and tetrahydropyridine derivatives (I) and (II), are new.

DETAILED DESCRIPTION - Piperazine and tetrahydropyridine derivatives of formula (I) and (II), their racemates, enriched in one enantiomer or diastereoisomer, tautomers, prodrugs and salts, are new, excluding compounds of formula (III).

A, B', U', V', W', X, Y = nitrogen or carbon;

L-G-R1 = a group of formula (i) or (ii);

E = CR<sub>4</sub>, N, NR<sub>4</sub> or S;

R1, R2 = aryl or heteroaryl (both optionally substituted);

L = CO, CS or C(=NR<sub>7</sub>);

R3 = halo, trifluoromethyl, cyano, nitro, 1-3C alkyl, 1-3C alkenyl, 1-3C alkynyl, OR<sub>7</sub>, SR<sub>7</sub>, SOR<sub>7</sub>, SO<sub>2</sub>R<sub>7</sub>, NR<sub>7</sub>R<sub>8</sub>, COOR<sub>7</sub>, CONR<sub>7</sub>R<sub>8</sub>, SO<sub>2</sub>NR<sub>7</sub>R<sub>8</sub>, NR<sub>7</sub>COR<sub>8</sub> or NR<sub>7</sub>SO<sub>2</sub>(1-3C)alkyl;

n = 0-3;

R4-R6 = H or 1-3C alkyl;

R7, R8 = H or optionally substituted 1-3C alkyl;

R1a = optionally substituted 2-pyridyl or its N-oxide;

R2a = 2-thienyl, 2-, 3- or 4-pyridyl or their N-oxides, phenyl (optionally substituted by at least one fluoro, hydroxy, methyl, trifluoromethyl, methoxy or nitro);

R4a = methyl, ethyl or 2-fluoroethyl, and

T, U1 = H, methyl, chloro or fluoro, or

R1a = 3- or 4-pyridyl;

R2a = 2-thienyl or phenyl;

R4a = methyl or 2-fluoroethyl, and

T, U1 = H, methyl, chloro or fluoro,

provided that when n = 2, X and Y are not both substituted by R3.

ACTIVITY - Cytostatic.

MECHANISM OF ACTION - Tubulin polymerization inhibitor.

In an in vitro test using pig brain, results showed that (4-(3-chlorophenyl)piperazin-1-yl)(1-phenyl-1H-indol-2-yl)methanone (Ia) exhibited an IC<sub>50</sub> value of 0.8 micro-M for inhibition of tubulin.

USE - Used to treat cancer and to promote disaggregation of a mass of cells derived from vascular tissue.

L166 ANSWER 14 OF 27 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 ACCESSION NUMBER: 2000-023259 [02] WPIX  
 DOC. NO. CPI: C2000-005636 [02]  
 TITLE: Compositions for treating e.g. cardiac disorders, renal disorders and central nervous system disorders  
 DERWENT CLASS: B02  
 INVENTOR: NISATO D  
 PATENT ASSIGNEE: (SNFI-C) SANOFI SA; (SNFI-C) SANOFI-SYNTHELABO  
 COUNTRY COUNT: 83

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 9955340	A1	19991104	(200002)*	FR	20[0]	
FR 2778103	A1	19991105	(200002)	FR		
AU 9934259	A	19991116	(200015)	EN		

## APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9955340	A1	WO 1999-FR959	19990422
FR 2778103	A1	FR 1998-5591	19980429
AU 9934259	A	AU 1999-34259	19990422

## FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9934259	A	Based on
		WO 9955340

PRIORITY APPLN. INFO: FR 1998-5591 19980429

ED 20050705

AB WO 1999055340 A1 UPAB: 20050705

NOVELTY - Compositions comprise an association of arginine-vasopressin V1a receptor antagonist (A) and an angiotensin II AT1 receptor antagonist (B).

DETAILED DESCRIPTION - (A) may be any arginine-vasopressin V1a receptor antagonist compound described e.g. in US5612334, WO9622282, WO9622294, EP469984, EP450097, JP8143565 or JP8059624. (B) may be any known angiotensin II AT1 receptor antagonist described in e.g. EP28834, EP253310, EP324377, US4207324, US4340598, US4576958, WO9114679, WO9117148, or WO9220662.

ACTIVITY - Cardiant; hypotensive; antiarrhythmic; cerebroprotective; antidiabetic; anorectic; nootropic; neuroprotective.

Spontaneously hypertensive rats were treated with an angiotensin (II) antagonist and SR 49059, alone or in combination. Measurement of arterial pressure and cardiac frequency showed that the angiotensin (II) antagonist decreased the arterial pressure and this effect was potentiated by the presence of SR 49059, which had no effect on arterial pressure when administered alone.

MECHANISM OF ACTION - Arginine-vasopressin V1a receptor antagonist and angiotensin II AT1 receptor antagonist.

USE - Treatment of cardiac disorders, especially hypertension, cardiac enfeeblement, venous insufficiency, cardiac ischemia, dilative cardiomyopathy, prevention of death following infarction, and arrhythmias, renal disorders such as nephropathias, central nervous system disorders such as cerebral ischemia, dementia, especially associated with Alzheimer's, memory loss, treatment of diabetes and obesity, sexual disorders, especially loss of erectile function.

ADVANTAGE - There is synergism between (I) and (II), allowing lower doses to be given without loss of therapeutic effect.

L166 ANSWER 15 OF 27

MEDLINE on STN

DUPLICATE 4

ACCESSION NUMBER: 89246586 MEDLINE

DOCUMENT NUMBER: PubMed ID: 2719718

TITLE: Interrelationship between affinity for DNA, cytotoxicity and induction of DNA-breaks in cultured L1210 cells for two series of tricyclic intercalators. Simplified analogues of ellipticine derivatives.

AUTHOR: Pierson V; Pierre A; de Cointet P; Nguyen C H; Bisagni E;



Gros P  
CORPORATE SOURCE: **Sanofi** Recherche, Toulouse, France.  
SOURCE: Biochemical pharmacology, (1989 May 1) Vol. 38, No. 9, pp. 1395-406.  
Journal code: 0101032. ISSN: 0006-2952.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 198906  
ENTRY DATE: Entered STN: 6 Mar 1990  
Last Updated on STN: 3 Feb 1997  
Entered Medline: 12 Jun 1989  
ED Entered STN: 6 Mar 1990  
Last Updated on STN: 3 Feb 1997  
Entered Medline: 12 Jun 1989  
AB The interrelationship between affinity for DNA, cytotoxicity and induction of single-strand DNA breaks in cultured L1210 cells was studied for 21 compounds belonging to two series of tricyclic intercalators: 1-amino-substituted 4-methyl-5H-pyrido[4,3-b]indoles (gamma CARB) and 1-amino-substituted 4-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-c]pyridines (PPP), which are simplified analogues of Ellipticine derivatives obtained by deletion of one cycle. Adriamycin, m-AMSA (4'-(9-acridinylamino) methanesulfon-m-anisidide), PZE (10-[diethylaminopropyl amino]-6-methyl-5H-pyrido[3',4':4,5]-pyrrolo[2,3-g] isoquinoline and RTE [(1-(3-diethylaminopropylamino)-9-methoxy ellipticine, bimaleate) are used as reference compounds. The intercalation of these compounds into DNA was strongly suggested by three experimental observations: (i) the competitive inhibition of ethidium bromide intercalation, (ii) bathochromic and hypochromic effects on absorption spectra induced by DNA, and (iii) drug-induced increase of the DNA length, measured by viscosimetry. PPP derivatives are generally less cytotoxic and induce DNA breaks less efficiently than the gamma CARB ones, both in terms of maximum breakage frequencies and required drug concentrations. The most active compounds induced SSB in the DNA of L1210 cells, in a bell-shaped manner: the SSB frequency increased, rose to a maximum and then decreased as the drug concentrations increased. The maximum SSB frequencies induced by the most active compounds are of the same order as those of reference compounds Adriamycin and PZE. The structurally important requirements are essentially the same for both DNA breakage activity and cytotoxicity: (i) a N-CH<sub>3</sub> in the 5-position, (ii) a CH<sub>3</sub> in the 4-position, (iii) a hydroxy in the 8-position and (iv) the presence of an (aminoalkyl)amino side chain with preferentially a 3 carbon unit. There is no direct relationship between DNA affinity in vitro and induction of DNA breaks in cells, although a relatively high affinity seemed to be a necessary condition, since the most active compounds have the highest affinities and compounds having a very low affinity are totally inactive. The close correlation between cytotoxicity and extent of induction of DNA breaks suggests that these breaks may be in fact the lethal lesions responsible for cell death and thereby for the antitumor properties of these tricyclic intercalators.

L166 ANSWER 16 OF 27 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1987:97170 BIOSIS  
DOCUMENT NUMBER: PREV198732046971; BR32:46971  
TITLE: 5H PYRIDO-3' 4' 4 5-PYRROLO-3 2-C-PYRIDINES NEW EXPERIMENTAL ANTITUMOR AGENTS.  
AUTHOR(S): PIERRE A [Reprint author]; CHI-HUNG N; PEPIN O; BISAGNI E  
CORPORATE SOURCE: SANOFI RECHERCHE, TOULOUSE, FR

SOURCE: (1986) pp. 935. UICC (UNION INTERNATIONALE CONTRE LE CANCER, INTERNATIONAL UNION AGAINST CANCER). 14TH INTERNATIONAL CANCER CONGRESS, BUDAPEST, HUNGARY, AUG. 21-27, 1986. ABSTRACTS, LECTURES, SYMPOSIA AND FREE COMMUNICATIONS, VOLS. 1, 2, 3, LATE ABSTRACTS, AND REGISTER. XVI+479P.(VOL. 1); XVI+298P.(VOL. 2); XVI+531P.(VOL. 3); 15P.(LATE ABSTRACTS); 40P.(REGISTER) S. KARGER AG: BASEL, SWITZERLAND; NEW YORK, N.Y., USA; AKADEMIAI KIADO: BUDAPEST, HUNGARY. PAPER. ISBN: 3-8055-4434-0(KARGER), 963-05-4422-9(VOL. 1), 963-05-4423-7(VOL. 2), 963-05-4424-5(VOL. 3), 963-05-4439-3(LATE ABSTRACTS), 963-05-4425-3(REGISTER), 963-05-4421-0(GENERAL).

DOCUMENT TYPE: Book  
Conference; (Meeting)  
FILE SEGMENT: BR  
LANGUAGE: ENGLISH  
ENTRY DATE: Entered STN: 14 Feb 1987  
Last Updated on STN: 14 Feb 1987  
ED Entered STN: 14 Feb 1987  
Last Updated on STN: 14 Feb 1987

L166 ANSWER 17 OF 27 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005006667 EMBASE  
TITLE: The search for novel antipsychotics: Pharmacological and molecular targets.  
AUTHOR: Sanger D.J.  
CORPORATE SOURCE: D.J. Sanger, Sanofi-Synthelabo Research, 31 Avenue Paul Vaillant Couturier, 92220 Bagneux, France. david.sanger@sanofi-synthelabo.com  
SOURCE: Expert Opinion on Therapeutic Targets, (2004) Vol. 8, No. 6, pp. 631-641. .  
Refs: 66  
ISSN: 1472-8222 CODEN: EOTTAO

COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 005 General Pathology and Pathological Anatomy  
030 Pharmacology  
032 Psychiatry  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 13 Jan 2005  
Last Updated on STN: 13 Jan 2005

ED Entered STN: 13 Jan 2005  
Last Updated on STN: 13 Jan 2005

AB There can be little doubt that the newer, atypical, antipsychotic drugs provide improved treatment for many patients suffering from schizophrenia. However, the significant gains in tolerability produced by these drugs have not generally been accompanied by major advances in clinical efficacy. In particular, negative and cognitive symptoms, which may represent the core deficit of the disease, remain inadequately treated. There is, therefore, a pressing need for more effective drugs. A number of drug discovery and development programmes are currently underway in parallel with significant research into the basic neurobiology of the disease. All antipsychotic drugs currently used in the clinic are antagonists at dopamine D2 receptors, and dopamine neurotransmission seems likely to remain a major biological target for research. However, novel

approaches to modulate dopaminergic neurotransmission selectively in relevant brain regions may be required. In addition, a range of non-dopaminergic targets including glutamate, serotonin, neurokinins and acetylcholine are also of major interest. It is likely, however, that the importance of many of these targets may lie in their relationships to and interactions with dopaminergic mechanisms. Finally, advances in genetics and molecular biology are identifying genes associated with a susceptibility to develop schizophrenia. It remains to be seen whether or not these genes and their associated proteins will provide molecular targets for successful drug discovery. .COPYRGT. 2004 Ashley Publications Ltd.

L166 ANSWER 18 OF 27 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002370569 EMBASE  
TITLE: Synthesis and structure-activity relationship of the isoindoliny1 benzisoxazolpiperidines as potent, selective, and orally active human dopamine D(4) receptor antagonists.  
AUTHOR: Hendrix J.A.; Shimshock S.J.; Shutske G.M.; Tomer IV J.D.; Kapples K.J.; Palermo M.G.; Corbett T.J.; Vargas H.M.; Kafka S.; Brooks K.M.; Laws-Ricker L.; Lee D.K.H.; De Lannoy I.; Bordeleau M.; Rizkalla G.; Owolabi J.; Kamboj R.K.  
CORPORATE SOURCE: Dr. J.A. Hendrix, **Aventis** Pharmaceuticals, Route 202-206, Bridgewater, NJ 08807-0800, United States. james.hendrix@**aventis**.com  
SOURCE: ChemBioChem, (4 Oct 2002) Vol. 3, No. 10, pp. 999-1009. . Refs: 30  
ISSN: 1439-4227 CODEN: CBCHFX  
COUNTRY: Germany  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 030 Pharmacology  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 7 Nov 2002  
Last Updated on STN: 7 Nov 2002

ED Entered STN: 7 Nov 2002

Last Updated on STN: 7 Nov 2002

AB A new class of potent dopamine D(4) antagonists was discovered with selectivity over dopamine D(2) and the  $\alpha$ -1 adrenoceptor. The lead compound was discovered by screening our compound collection. The structure-activity relationships of substituted isoindoline rings and the chirality about the hydroxymethyl side chain were explored. The isoindoline analogues showed modest differences in potency and selectivity. The S enantiomer proved to be the more potent enantiomer at the D(4) receptor. Several analogues with greater than 100-fold selectivity for D(4) over D(2) and the  $\alpha$ -1 adrenoceptor were discovered. Several selective analogues were active in vivo upon oral or intraperitoneal administration. A chiral synthesis starting from either D- or L-O-benzylserine is also described.

L166 ANSWER 19 OF 27 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000267896 EMBASE  
TITLE: The dopamine D4 receptor: A controversial therapeutic target.  
AUTHOR: Hrib N.J.  
CORPORATE SOURCE: N.J. Hrib, Department of Medicinal Chemistry, **Aventis** Pharmaceuticals, Route 202-206 North,

SOURCE: Bridgewater, NJ 08807, United States  
Drugs of the Future, (2000) Vol. 25, No. 6, pp. 587-611. .  
Refs: 219  
ISSN: 0377-8282 CODEN: DRFUD4  
COUNTRY: Spain  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 030 Pharmacology  
032 Psychiatry  
037 Drug Literature Index  
LANGUAGE: English  
ENTRY DATE: Entered STN: 17 Aug 2000  
Last Updated on STN: 17 Aug 2000  
ED Entered STN: 17 Aug 2000  
Last Updated on STN: 17 Aug 2000

L166 ANSWER 20 OF 27 PASCAL COPYRIGHT 2006 INIST-CNRS. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 2003-0216305 PASCAL  
COPYRIGHT NOTICE: Copyright .COPYRGT. 2003 INIST-CNRS. All rights reserved.  
TITLE (IN ENGLISH): Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: Preference for a neutral group in the S1 pocket  
AUTHOR: Maignan Sebastien; Guilloteau Jean-Pierre; Choi-Sledeski Yong Mi; Becker Michael R.; Ewing William R.; Pauls Henry W.; Spada Alfred P.; Mikol Vincent  
CORPORATE SOURCE: Department of Structural Biology, **Aventis** Pharma, 13, Quai J. Guesde, 94403 Vitry/Seine, France; Department of Medicinal Chemistry, **Aventis** Pharma, 500 Arcola Road, Collegeville, Pennsylvania 19426, United States  
SOURCE: Journal of medicinal chemistry : (Print), (2003), 46(5), 685-690, 21 refs.  
ISSN: 0022-2623 CODEN: JMCMAR  
DOCUMENT TYPE: Journal  
BIBLIOGRAPHIC LEVEL: Analytic  
COUNTRY: United States  
LANGUAGE: English  
AVAILABILITY: INIST-9165, 354000104279130060

UP 20030521

AB The structures of the noncovalent complex of human factor Xa (fXa) with four non-peptide inhibitors containing a central sulfonylpiperazinone scaffold have been determined to about 2.1 Å resolution. Highly potent fXa inhibitors containing both neutral groups such as chlorobenzothiophene or chlorothiophene and basic groups such as benzamidine were shown to interact in the S1 pocket through the neutral group whereas the S4 pocket is occupied by the basic moiety. The scaffold comprising the sulfonyl keto piperazine moiety might play a pivotal role in the orientation of substituents, since there is a strong hydrogen bond between Gly219 of fXa and the carbonyl oxygen of the piperazine. This unique "reverse" binding mode is heretofore unreported in fXa and shows that electrostatic interactions in the S1 subsite are not an absolute requirement to maintain high affinity. Selectivity against other serine proteases can be readily explained in light of these structural results. It has opened up new prospects for designing fXa inhibitors with increased oral bioavailability.

L166 ANSWER 21 OF 27 PASCAL COPYRIGHT 2006 INIST-CNRS. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 2003-0216304 PASCAL  
COPYRIGHT NOTICE: Copyright .COPYRGT. 2003 INIST-CNRS. All rights reserved.  
TITLE (IN ENGLISH): Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P.sub.1 ligand  
AUTHOR: CHOI-SLEDESKI Yong Mi; KEARNEY Robert; POLI Gregory; PAULS Henry; GARDNER Charles; YONG GONG; BECKER Michael; DAVIS Roderick; SPADA Alfred; GUYAN LIANG; CHU Valeria; BROWN Karen; COLLUSSI Dennis; LEADLEY Robert JR; REBELLO Sam; MOXEY Phillip; MORGAN Suzanne; BENTLEY Ross; KASIEWSKI Charles; MAIGNAN Sebastien; GUILLOTEAU Jean-Pierre; MIKOL Vincent  
CORPORATE SOURCE: Department of Medicinal Chemistry and Department of Biology, **Aventis Pharmaceuticals**, Route 202-206, Bridgewater, New Jersey 08807-0800, United States; Department of Structural Biology, **Aventis Pharmaceuticals**, 13, Quai J. Guesde, 94403 Vitry/Seine, France  
SOURCE: Journal of medicinal chemistry : (Print), (2003), 46(5), 681-684, 17 refs.  
ISSN: 0022-2623 CODEN: JMCMAR  
DOCUMENT TYPE: Journal; Letter  
BIBLIOGRAPHIC LEVEL: Analytic  
COUNTRY: United States  
LANGUAGE: English  
AVAILABILITY: INIST-9165, 354000104279130050  
UP 20030521  
AB The discovery and SAR of ketopiperazino methylazaindole factor Xa inhibitors are described. Structure-activity data suggesting that this class of inhibitors does not bind in the canonical mode were confirmed by an X-ray crystal structure showing the neutral haloaromatic bound in the S.sub.1 subsite. The most potent **azaindole**, 33 (RPR209685), is selective against related serine proteases and attains higher levels of exposure upon oral dosing than comparable benzamidines and benzamidine isosteres. Compound 33 was efficacious in the canine AV model of thrombosis.

L166 ANSWER 22 OF 27 PASCAL COPYRIGHT 2006 INIST-CNRS. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 1993-0436205 PASCAL  
TITLE (IN ENGLISH): Industrial synthesis in ellipticine serie. I: Elaboration of a new access to 6H-pyrido [4,3-b] carbazoles and analogs. A: Synthesis and study of precursor  
TITLE (IN FRENCH): Synthese industrielle en serie ellipticine. I: Elaboration d'une nouvelle voie d'accès aux 6H-pyrido[4,3-b]carbazoles et analogues : a synthese et etude des precurseurs  
AUTHOR: DORMOY J.-R.; HEYMES A.  
CORPORATE SOURCE: **SANOFI** Chimie, dep. rech. dev. chim., 04201 Sisteron, France  
SOURCE: Tetrahedron, (1993), 49(14), 2885-2914, 45 refs.  
ISSN: 0040-4020 CODEN: TETRAB  
DOCUMENT TYPE: Journal  
BIBLIOGRAPHIC LEVEL: Analytic  
COUNTRY: United Kingdom  
LANGUAGE: French  
SUMMARY LANGUAGE: English  
AVAILABILITY: INIST-8899, 354000033414280080

UP 20001027

=&gt; d ibib ed ab 23

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, WPIX, MEDLINE, BIOSIS, EMBASE, PASCAL, JAPIO, LIFESCI, DRUGU' - CONTINUE? (Y)/N:y

L166 ANSWER 23 OF 27 JAPIO (C) 2006 EPO on STN

ACCESSION NUMBER: 1987-123187 JAPIO

TITLE: 5-H PYRIDO(3',4':4,5) **PYRROLO**(3,2-C)**PYRIDINE** DERIVATIVE, MANUFACTURE AND MEDICINE

INVENTOR: EMIIRU BISAGUNI; NIYUIEN SHI HAN; ODEIIRU PEPIN

PATENT ASSIGNEE(S): **SANOFI SA**

CENTRE NATL RECH SCIENT &lt;CNRS&gt;

PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 62123187	A	19870604	Showa	C07D471-14

APPLICATION INFORMATION

STN FORMAT: JP 1986-64668 19860322

ORIGINAL: JP6164668 Showa

PRIORITY APPLN. INFO.: FR 1985-4872 19850322

SOURCE: INPADOC

ED 20020808

=&gt; d ibib ed ab 24-27

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, WPIX, MEDLINE, BIOSIS, EMBASE, PASCAL, JAPIO, LIFESCI, DRUGU' - CONTINUE? (Y)/N:y

L166 ANSWER 24 OF 27 JAPIO (C) 2006 EPO on STN

ACCESSION NUMBER: 1986-275278 JAPIO

TITLE: NOVEL 5-H-PYRIDO(3',4':4,5) **PYRROLO**(3,2-C)**PYRIDINE** AND MANUFACTURE

INVENTOR: EMIIRU BISAGUNI; NIYUIEN SHI HAN; POORU DO KOINTE

PATENT ASSIGNEE(S): **SANOFI SA**

CENTRE NATL RECH SCIENT &lt;CNRS&gt;

PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 61275278	A	19861205	Showa	C07D471-14

APPLICATION INFORMATION

STN FORMAT: JP 1986-64669 19860322

ORIGINAL: JP6164669 Showa

PRIORITY APPLN. INFO.: FR 1985-4871 19850322

SOURCE: INPADOC

ED 20020808

L166 ANSWER 25 OF 27 JAPIO (C) 2006 EPO on STN

ACCESSION NUMBER: 1986-155385 JAPIO

TITLE: NOVEL **PYRROLO-PYRIDINE** DERIVATIVE  
AND MANUFACTURE

INVENTOR: JIYAN ROBEERU DORUMOA; ARAN EIMU  
PATENT ASSIGNEE(S): SANOFI SA  
PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 61155385	A	19860715	Showa	C07D471-04

## APPLICATION INFORMATION

STN FORMAT: JP 1985-280176 19851212  
ORIGINAL: JP60280176 Showa  
PRIORITY APPLN. INFO.: FR 1984-19029 19841212  
SOURCE: INPADOC  
ED 20020808

L166 ANSWER 26 OF 27 LIFESCI COPYRIGHT 2006 CSA on STN

ACCESSION NUMBER: 87:62379 LIFESCI

TITLE: PAF binding sites: Characterization by ( super(3)H)52770  
RP, a pyrrolo-(1,2-c)-thiazole derivative, in rabbit  
platelets.

AUTHOR: Robaut, C.; Durand, G.; James, C.; Lave, D.; Sedivy, P.;  
Floch, A.; Mondot, S.; Pacot, D.; Caverio, I.; Le Fur, G.

CORPORATE SOURCE: Sanofi Rech., 37 Ave. Pierre 1er de Serbie, 75008  
Paris, France

SOURCE: BIOCHEM. PHARMACOL., (1987) vol. 36, no. 19, pp. 3221-3229.

DOCUMENT TYPE: Journal

FILE SEGMENT: M

LANGUAGE: English

SUMMARY LANGUAGE: English

AB 52770 RP, the N-(3-chlorophenyl)-3-(3-pyridinyl)-1H,3H-  
**pyrrolo**-(1,2-c)-thiazole-7-carboxamide, displaces in a potent,  
specific and competitive manner ( super(3)H)PAF from its binding sites on  
rabbit platelets. Since 52770 RP is not structurally related to PAF and  
has low liposolubility with respect to PAF, it was selected as a potential  
radioligand for PAF receptor sites. ( super(3)H)52770 RP might represent a  
novel interesting tool for furthering understanding of the role of PAF  
binding sites in pathophysiological processes.

L166 ANSWER 27 OF 27 DRUGU COPYRIGHT 2006 THE THOMSON CORP on STN DUPLICATE  
5

ACCESSION NUMBER: 1987-46684 DRUGU C P

TITLE: 1-Amino-Substituted 4-Methyl 5H-Pyridol(3',4',5')

**Pyrrolo** (3,2-c)**Pyridines**: A New Class of  
Antineoplastic Agents.

AUTHOR: Nguyen C H; Bisagni E; Pepin O; Pierre A; Cointet P de

CORPORATE SOURCE: Sanofi

LOCATION: Orsay, Toulouse, France

SOURCE: J.Med.Chem. (30, No. 9, 1642-47, 1987) 2 Fig. 3 Tab. 27 Ref.

CODEN: JMCMAR ISSN: 0022-2623

AVAIL. OF DOC.: UA 533 CNRS, Laboratoire de Synthèse Organique, Institut  
Curie, Section de Biologie, Bat 110-112, 91405 Orsay, France.

LANGUAGE: English

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT; MPC

FILE SEGMENT: Literature

AB A series of 1-aminp-substituted 4-methyl 5H-pyrido(3',4'-4,5)  
**pyrrolo** (3,2-c)**pyridines**, tricyclic analogs of  
9-azaellipticines, was prepared. They were tested for in vitro  
cytotoxicity against L1210 DNA, and i.p. against L1210 and P388 leukemias  
in mice, using fluorouracil as standard. Structure activity

relationships were evaluated.

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 16:39:40 ON 25 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Oct 25, 2006 (20061025/UP).



=> d his ful

(FILE 'HOME' ENTERED AT 12:19:21 ON 25 OCT 2006)

FILE 'REGISTRY' ENTERED AT 12:19:44 ON 25 OCT 2006  
ACT SHI089PSET1/A

-----  
L1 STR  
L2 45329 SEA SSS FUL L1  
-----  
ACT SHI089RSET6/A  
-----  
L3 STR  
L4 ( 45329)SEA SSS FUL L3  
L5 ( 103939)SEA ABB=ON PLU=ON NC4-NC5/ES  
L6 STR  
L7 ( 733)SEA SUB=L4 SSS FUL L6  
L8 STR  
L9 ( 3990)SEA SUB=L4 SSS FUL L8  
L10 ( 77)SEA ABB=ON PLU=ON L5 AND L9  
L11 ( 82)SEA ABB=ON PLU=ON L7 AND L9  
L12 82 SEA ABB=ON PLU=ON (L10 OR L11)  
-----

FILE 'BEILSTEIN' ENTERED AT 12:21:31 ON 25 OCT 2006  
ACT SHI089BEIP/A

-----  
L13 STR  
L14 8608 SEA SSS FUL L13  
-----  
ACT SHI089BEIR3/A  
-----  
L15 STR  
L16 STR  
L17 STR  
L18 ( 8608)SEA SSS FUL L15  
L19 ( 96)SEA SUB=L18 SSS FUL L16  
L20 ( 29)SEA SUB=L18 SSS FUL L17  
L21 8 SEA ABB=ON PLU=ON L19 AND L20  
-----

ACT SHI089BEIR5/A  
-----  
L22 STR  
L23 STR  
L24 ( 8608)SEA SSS FUL L22  
L25 ( 29)SEA SUB=L24 SSS FUL L23  
L26 STR  
L27 ( 610)SEA SUB=L24 SSS FUL L26  
L28 8 SEA ABB=ON PLU=ON L25 AND L27  
-----  
L29 8 SEA ABB=ON PLU=ON L21 OR L28

FILE 'CHEMINFORMRX' ENTERED AT 12:22:48 ON 25 OCT 2006  
ACT SHI089CHMP/A

-----  
L30 STR  
L31 215 SEA SSS FUL L30 ( 1481 REACTIONS)  
-----

FILE 'LREGISTRY' ENTERED AT 12:23:11 ON 25 OCT 2006

L32 STR L1

FILE 'REGISTRY' ENTERED AT 12:29:46 ON 25 OCT 2006  
L33 50 SEA SUB=L2 SSS SAM L32  
D QUE STAT

FILE 'STNGUIDE' ENTERED AT 12:31:23 ON 25 OCT 2006

FILE 'REGISTRY' ENTERED AT 12:34:20 ON 25 OCT 2006  
D QUE STAT

L34 4740 SEA SUB=L2 SSS FUL L32  
SAVE TEMP L34 SHI089RSETA/A  
ACT SHI089REGAPP/A  
-----

L35 ( 1)SEA ABB=ON PLU=ON US2004-849089/APPS  
L36 SEL PLU=ON L35 1- RN : 34 TERMS  
L37 34 SEA ABB=ON PLU=ON L36  
-----

L38 25 SEA ABB=ON PLU=ON L37 NOT L34  
D SCAN

FILE 'LREGISTRY' ENTERED AT 12:38:16 ON 25 OCT 2006  
L39 STR

FILE 'STNGUIDE' ENTERED AT 12:41:01 ON 25 OCT 2006

FILE 'REGISTRY' ENTERED AT 12:43:09 ON 25 OCT 2006  
L40 300638 SEA ABB=ON PLU=ON (NC4(S)NC5)/ESS  
L41 363 SEA ABB=ON PLU=ON L40 AND L34  
SAVE TEMP L41 SHI089RSETB/A

FILE 'LREGISTRY' ENTERED AT 12:46:56 ON 25 OCT 2006  
L42 STR

FILE 'REGISTRY' ENTERED AT 12:52:08 ON 25 OCT 2006  
L43 7 SEA SUB=L34 SSS SAM L42  
D SCAN  
D QUE STAT

FILE 'STNGUIDE' ENTERED AT 12:52:44 ON 25 OCT 2006

FILE 'REGISTRY' ENTERED AT 12:54:07 ON 25 OCT 2006  
L44 50 SEA SUB=L2 SSS SAM L42  
D QUE STAT  
D QUE STAT

L45 1247 SEA SUB=L2 SSS FUL L42  
SAVE TEMP L45 SHI089RSETC/A  
D QUE L34

L46 93 SEA ABB=ON PLU=ON L34 AND L45  
SAVE TEMP L46 SHI089RSETD/A

L47 ANALYZE PLU=ON L46 1- LC : 7 TERMS  
D 1-7

FILE 'STNGUIDE' ENTERED AT 13:01:46 ON 25 OCT 2006  
D SAVED

FILE 'HCAPLUS' ENTERED AT 13:03:16 ON 25 OCT 2006

FILE 'STNGUIDE' ENTERED AT 13:03:18 ON 25 OCT 2006  
D QUE STAT L46

L48 FILE 'HCAPLUS' ENTERED AT 13:04:08 ON 25 OCT 2006  
13 SEA ABB=ON PLU=ON L46

FILE 'STNGUIDE' ENTERED AT 13:04:23 ON 25 OCT 2006

L49 FILE 'ZCAPLUS' ENTERED AT 13:04:39 ON 25 OCT 2006  
QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY<2004  
OR REVIEW/DT

L50 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004

L51 FILE 'HCAPLUS' ENTERED AT 13:06:51 ON 25 OCT 2006  
7 SEA ABB=ON PLU=ON L48 AND L49  
SAVE TEMP L51 SHI089HCA2B/A

L52 6 SEA ABB=ON PLU=ON L48 NOT L51  
SAVE TEMP L52 SHI089HCA2A/A  
ACT SHI089HCAIN1/A

-----

L53 STR

L54 ( 45329)SEA SSS FUL L53

L55 ( 103939)SEA ABB=ON PLU=ON NC4-NC5/ES

L56 STR

L57 ( 753)SEA SUB=L54 SSS FUL L56

L58 ( 0)SEA ABB=ON PLU=ON L55 AND L57

L59 STR

L60 ( 733)SEA SUB=L54 SSS FUL L59

L61 ( 0)SEA ABB=ON PLU=ON L57 AND L60

L62 STR

L63 ( 3990)SEA SUB=L54 SSS FUL L62

L64 ( 77)SEA ABB=ON PLU=ON L55 AND L63

L65 ( 82)SEA ABB=ON PLU=ON L60 AND L63

L66 ( 82)SEA ABB=ON PLU=ON (L64 OR L65)

L67 ( 82)SEA ABB=ON PLU=ON L66 OR L61 OR L58

L68 ( 11)SEA ABB=ON PLU=ON L66 OR L67

L69 QUE ABB=ON PLU=ON NAZARE, M?/AU

L70 QUE ABB=ON PLU=ON WEHNER, V?/AU

L71 QUE ABB=ON PLU=ON WILL, D?/AU

L72 QUE ABB=ON PLU=ON RITTER, K?/AU

L73 QUE ABB=ON PLU=ON MATTER, H?/AU

L74 QUE ABB=ON PLU=ON URMANN, M?/AU

L75 QUE ABB=ON PLU=ON (AVENTIS OR SANOFI)/CS,SO,PA

L76 4 SEA ABB=ON PLU=ON L68 AND (L69 OR L70 OR L71 OR L72 OR L73  
OR L74 OR L75)

-----

FILE 'STNGUIDE' ENTERED AT 13:08:27 ON 25 OCT 2006

FILE 'HCAPLUS' ENTERED AT 13:10:09 ON 25 OCT 2006

L77 129 SEA ABB=ON PLU=ON L2 AND (L69 OR L70 OR L71 OR L72 OR L73 OR  
L74 OR L75)

FILE 'STNGUIDE' ENTERED AT 13:11:04 ON 25 OCT 2006  
D QUE L45

FILE 'HCAPLUS' ENTERED AT 13:11:14 ON 25 OCT 2006

L78 8 SEA ABB=ON PLU=ON L77 AND L45  
SAVE TEMP L78 SHI089HCAINV/A  
ACT SHI089HCAAPP/A

-----

L79 1 SEA ABB=ON PLU=ON US2004-849089/APPS

-----  
L80 0 SEA ABB=ON PLU=ON L79 NOT L78  
FILE 'REGISTRY' ENTERED AT 13:12:12 ON 25 OCT 2006  
L81 25 SEA ABB=ON PLU=ON L37 NOT L46  
D SCAN  
FILE 'STNGUIDE' ENTERED AT 13:12:42 ON 25 OCT 2006  
FILE 'USPATFULL, USPAT2, TOXCENTER, CASREACT, CHEMCATS' ENTERED AT  
13:14:58 ON 25 OCT 2006  
L82 27 SEA ABB=ON PLU=ON L46  
L83 11 SEA ABB=ON PLU=ON L82 AND L49  
SAVE TEMP L83 SHI089MULS2B/A  
D QUE STAT L46  
L84 16 SEA ABB=ON PLU=ON L82 NOT L83  
SAVE TEMP L84 SHI089MULS2A/A  
L85 6 SEA ABB=ON PLU=ON L82 AND (L69 OR L70 OR L71 OR L72 OR L73  
OR L74 OR L75)  
SAVE TEMP L85 SHI089MULI2/A  
D SAVED  
FILE 'STNGUIDE' ENTERED AT 13:18:08 ON 25 OCT 2006  
D SAVED  
FILE 'BABS' ENTERED AT 14:00:22 ON 25 OCT 2006  
ACT SHI089BAB/A  
-----  
L86 1 SEA ABB=ON PLU=ON 5632319/BABSAN  
-----  
ACT SHI089BAB2/A  
-----  
L87 ( 1)SEA FILE=BABS ABB=ON PLU=ON 5632319/BABSAN  
L88 ( 1)SEA FILE=BABS ABB=ON PLU=ON 5632319/AN  
L89 1 SEA ABB=ON PLU=ON L88 OR L87  
-----  
FILE 'BEILSTEIN' ENTERED AT 14:01:05 ON 25 OCT 2006  
D QUE L32  
L90 698 SEA SUB=L14 SSS FUL L32  
SAVE TEMP L90 SHI089BEIRA/A  
D QUE STAT  
D QUE L32  
D QUE L42  
L91 86 SEA SUB=L14 SSS FUL L42  
SAVE TEMP L91 SHI089BEIRB/A  
D QUE STAT  
L92 10 SEA ABB=ON PLU=ON L90 AND L91  
SAVE TEMP L92 SHI089BEIRC/A  
D QUE STAT  
D QUE L29  
L93 10 SEA ABB=ON PLU=ON L92 NOT L29  
D QUE L29  
L94 1 SEA ABB=ON PLU=ON L93 NOT BABSAN/FA  
SELECT L92 1- BABSAN  
FILE 'BABS' ENTERED AT 14:08:26 ON 25 OCT 2006  
L95 1 SEA ABB=ON PLU=ON 6410903/BABSAN  
D BIBI  
SAVE TEMP L95 SHI089BAB3B/A

FILE 'STNGUIDE' ENTERED AT 14:09:19 ON 25 OCT 2006  
D SAVED

FILE 'CHEMINFORMRX' ENTERED AT 14:10:39 ON 25 OCT 2006

D QUE L31  
D QUE L32  
L96 0 SEA SUB=L31 SSS SAM L32 ( 0 REACTIONS)  
D QUE STAT  
L97 13 SEA SUB=L31 SSS FUL L32 ( 73 REACTIONS)  
SAVE TEMP L97 SHI089CHMRA/A  
L98 0 SEA SUB=L31 SSS SAM L42 ( 0 REACTIONS)  
D QUE STAT  
L99 3 SEA SUB=L31 SSS FUL L42 ( 16 REACTIONS)  
SAVE TEMP L99 SHI089CHMRB/A  
L100 0 SEA ABB=ON PLU=ON L97 AND L99  
SAVE TEMP L100 SHI089CHMRC/A  
D QUE STAT

FILE 'STNGUIDE' ENTERED AT 14:15:39 ON 25 OCT 2006  
D SAVED

FILE 'WPIX' ENTERED AT 14:27:58 ON 25 OCT 2006

L101 QUE ABB=ON PLU=ON D720/M0,M1,M2,M3,M4,M5,M6  
D QUE L32  
L102 7 SEA SSS SAM L32  
D TRI 1-7  
D QUE STAT  
L103 347 SEA SSS FUL L32  
SAVE TEMP L103 SHI089WPIS1/A  
D QUE STAT  
D QUE L42  
L104 4 SEA SUB=L103 SSS SAM L42  
D TRI 1-4  
D QUE STAT  
L105 49 SEA SUB=L103 SSS FUL L42  
SAVE TEMP L105 SHI089WPIS2/A  
SELECT L103 SDCN 1-  
L106 72 SEA ABB=ON PLU=ON (RA0XZP/DCN OR RAAHRA/DCN OR RAAHRY/DCN OR  
RAAZSD/DCN OR RAAZSF/DCN OR RAAZSH/DCN OR RAAZSI/DCN OR  
RAAZSJ/DCN OR RAAZSK/DCN OR RAAZSL/DCN OR RAAZSM/DCN OR  
RAAZSN/DCN OR RAAZSO/DCN OR RAAZSX/DCN OR RAA1TM/DCN OR  
RAB2D0/DCN OR RACKXP/DCN OR RAETE4/DCN OR RAE3EB/DCN OR  
RAE3EC/DCN OR RAE3ED/DCN OR RAE3EE/DCN OR RAE3EF/DCN OR  
RAE3EG/DCN OR RAE3EK/DCN OR RAE3EL/DCN OR RAE3EM/DCN OR  
RAE3EN/DCN OR RAE3EQ/DCN OR RAE3EU/DCN OR RAE3EV/DCN OR  
RAE3EW/DCN OR RAE3EX/DCN OR RAE3F2/DCN OR RAFI3X/DCN OR  
RAFI3Y/DCN OR RAFI41/DCN OR RAFZM3/DCN OR RAFZM4/DCN OR  
RAFZM6/DCN OR RAF8IU/DCN OR RAF8IV/DCN OR RAF8IW/DCN OR  
RAF8IX/DCN OR RAGFDN/DCN OR RAGFDO/DCN OR RAGFDP/DCN OR  
RAGFDQ/DCN OR RAGFDS/DCN OR RAGFDT/DCN OR RAGFDU/DCN OR  
RAGFDV/DCN OR RAGFDW/DCN OR RAGFDX/DCN OR RAGFDY/DCN OR  
RAGFDZ/DCN OR RAGFEB/DCN OR RAGFEC/DCN OR RAGFED/DCN OR  
RAGFEG/DCN OR RAGFEH/DCN OR RAGFEI/DCN OR RAGFEJ/DCN OR  
RAGFEM/DCN OR RAGFEN/DCN OR RAGFEO/DCN OR RAGFEP/DCN OR  
RAGFEQ/DCN OR RAGFE0/DCN OR RAGFE1/DCN OR RAGFE2/DCN OR  
RAGFE3/DCN OR RAGFE4/DCN OR RAGFE5/DCN OR RAGFE6/DCN OR  
RAGFE7/DCN OR RAGFE8/DCN OR RAGFE9/DCN OR RAGFFQ/DCN OR  
RAGFFR/DCN OR RAGFFS/DCN OR RAGFFT/DCN OR RAGFFU/DCN OR  
RAGSRH/DCN OR RAGSRO/DCN OR RAGSRP/DCN OR RAGSRQ/DCN OR

RAGSRR/DCN OR RAG3GM/DCN OR RAG3GN/DCN OR RAG6CZ/DCN OR  
 RAG6DA/DCN OR RAG6DD/DCN OR RAG6DF/DCN OR RAG6DI/DCN OR  
 RAG6D2/DCN OR RAG6D3/DCN OR RAG6D5/DCN OR RAG6D6/DCN OR  
 RAG6D8/DCN OR RAG7BA/DCN OR RAG7BB/DCN OR RAG7BC/DCN OR  
 RAG7BI/DCN OR RAG7BK/DCN OR RAG7BM/DCN OR RAHI2S/DCN OR  
 RAHI2U/DCN OR RAHI2V/DCN OR RAHOVW/DCN OR RAI01E/DCN OR  
 RAI019/DCN OR RAKGLI/DCN OR RAKGLK/DCN OR RAKGLP/DCN OR  
 RAKGLW/DCN OR RAKGLX/DCN OR RAKGLY/DCN OR RAKGLZ/DCN OR  
 RAKGM0/DCN OR RAKNAV/DCN OR RAKW9U/DCN OR RALDFO/DCN OR  
 RALDFP/DCN OR RALDFQ/DCN OR RALDFR/DCN OR RALDFS/DCN OR  
 RALDFT/DCN OR RALDFU/DCN OR RALDFV/DCN OR RALDFW/DCN OR  
 RALDFX/DCN OR RALDFY/DCN OR RALDFZ/DCN OR RALDG0/DCN OR  
 RALDG1/DCN OR RALDG2/DCN OR RALDG3/DCN OR RALDG4/DCN OR  
 RALDG5/DCN OR RALHNR/DCN OR RALHO3/DCN OR RAL  
 L107 72 SEA ABB=ON PLU=ON L103/DCR  
 L108 10 SEA ABB=ON PLU=ON (L106 OR L107) AND L101  
 SELECT L105 1- SDCN  
 L109 5 SEA ABB=ON PLU=ON (RAE3EB/DCN OR RAE3EC/DCN OR RAE3ED/DCN OR  
 RAE3EE/DCN OR RAE3EF/DCN OR RAE3EG/DCN OR RAE3EK/DCN OR  
 RAE3EL/DCN OR RAE3EM/DCN OR RAE3EN/DCN OR RAE3EQ/DCN OR  
 RAE3EU/DCN OR RAE3EV/DCN OR RAE3EW/DCN OR RAE3EX/DCN OR  
 RAE3F2/DCN OR RAG7BA/DCN OR RAG7BB/DCN OR RAG7BC/DCN OR  
 RAG7BI/DCN OR RAG7BK/DCN OR RAG7BM/DCN OR RALDFO/DCN OR  
 RALDFP/DCN OR RALDFQ/DCN OR RALDFR/DCN OR RALDFS/DCN OR  
 RALDFT/DCN OR RALDFU/DCN OR RALDFV/DCN OR RALDFW/DCN OR  
 RALDFX/DCN OR RALDFY/DCN OR RALDFZ/DCN OR RALDG0/DCN OR  
 RALDG1/DCN OR RALDG2/DCN OR RALDG3/DCN OR RALDG4/DCN OR  
 RALDG5/DCN OR RAMQJD/DCN OR RAMQJF/DCN OR RAMQJT/DCN OR  
 RAMQJV/DCN OR RAMQJX/DCN OR RA211B/DCN OR RA2117/DCN OR  
 RA2118/DCN OR RA2119/DCN)  
 L110 5 SEA ABB=ON PLU=ON L105/DCR  
 L111 10 SEA ABB=ON PLU=ON (L108 OR L109 OR L110)  
 L112 14 SEA ABB=ON PLU=ON (L111 OR L106 OR L107) AND (L69 OR L70 OR  
 L71 OR L72 OR L73 OR L74 OR L75)  
 L113 3 SEA ABB=ON PLU=ON L112 AND L111  
 SAVE TEMP L113 SHI089WPIINV/A  
 L114 8 SEA ABB=ON PLU=ON L111 AND L50  
 SAVE TEMP L114 SHI089WPI1B/A  
 L115 2 SEA ABB=ON PLU=ON L111 NOT L114  
 SAVE TEMP L115 SHI089WPI1A/A  
 L116 5 SEA ABB=ON PLU=ON L114 NOT L112  
 D TRI 1-5

FILE 'STNGUIDE' ENTERED AT 14:40:21 ON 25 OCT 2006  
D SAVED

FILE 'REGISTRY' ENTERED AT 14:46:50 ON 25 OCT 2006  
D QUE L45

L117 11 SEA ABB=ON PLU=ON L37 AND L45  
D SCAN

FILE 'STNGUIDE' ENTERED AT 14:47:53 ON 25 OCT 2006

FILE 'ZREGISTRY' ENTERED AT 14:58:37 ON 25 OCT 2006

E PIPERIDINE/CN  
 E ISOXAZOLE/CN  
 E THIOPHENE/CN  
 L118 QUE ABB=ON PLU=ON (?THIOPHEN? OR ?PIPERIDIN? OR ?ISOXAZOL?)/C  
 NS

FILE 'REGISTRY' ENTERED AT 15:00:06 ON 25 OCT 2006

L119 10 SEA ABB=ON PLU=ON L118 AND L46  
L120 QUE ABB=ON PLU=ON ?THIEN?/CNS  
L121 10 SEA ABB=ON PLU=ON L46 AND L120  
L122 10 SEA ABB=ON PLU=ON L119 OR L121

FILE 'STNGUIDE' ENTERED AT 15:02:19 ON 25 OCT 2006

FILE 'REGISTRY' ENTERED AT 15:03:32 ON 25 OCT 2006

L123 105 SEA ABB=ON PLU=ON L45 AND (L118 OR L120)  
L124 0 SEA ABB=ON PLU=ON L117 NOT L123

FILE 'STNGUIDE' ENTERED AT 15:04:18 ON 25 OCT 2006

FILE 'REGISTRY' ENTERED AT 15:10:54 ON 25 OCT 2006

D COST

L125 10 SEA ABB=ON PLU=ON L123 AND (?THIOPHEN? OR ?THIEN?)/CNS AND  
?ISOXAZOL?/CNS  
L126 95 SEA ABB=ON PLU=ON L123 AND ?PIPERIDIN?  
L\*\*\* DEL 0 S L45 AND CL/ES  
L127 608 SEA ABB=ON PLU=ON L45 AND CL/ELS  
L128 84 SEA ABB=ON PLU=ON L127 AND (L125 OR L126)

FILE 'STNGUIDE' ENTERED AT 15:15:51 ON 25 OCT 2006

FILE 'REGISTRY' ENTERED AT 15:17:01 ON 25 OCT 2006

L129 0 SEA ABB=ON PLU=ON L128 AND (?ISOPROPYL? OR ?BIPYRIDIN?)/CNS  
D SCAN L128  
L130 2 SEA ABB=ON PLU=ON (L37 AND L45) NOT L128  
D SCAN

FILE 'STNGUIDE' ENTERED AT 15:19:10 ON 25 OCT 2006

FILE 'REGISTRY' ENTERED AT 15:36:16 ON 25 OCT 2006

L131 QUE ABB=ON PLU=ON NOC3/ES  
L132 QUE ABB=ON PLU=ON SC4/ES  
L133 QUE ABB=ON PLU=ON NC5/ES  
D QUE L127  
L134 10 SEA ABB=ON PLU=ON L127 AND L131  
D QUE L2  
L135 12213 SEA ABB=ON PLU=ON L2 AND CL/ELS  
L136 237 SEA ABB=ON PLU=ON L135 AND L131  
L137 348 SEA ABB=ON PLU=ON L135 AND L132  
L138 1681 SEA ABB=ON PLU=ON L135 AND L133  
L139 111 SEA ABB=ON PLU=ON L45 AND (L136 OR L137 OR L138)  
L140 27 SEA ABB=ON PLU=ON L139 NOT L128  
D SCAN

FILE 'STNGUIDE' ENTERED AT 15:40:57 ON 25 OCT 2006

D QUE L127

FILE 'HCAPLUS' ENTERED AT 15:43:52 ON 25 OCT 2006

L141 39 SEA ABB=ON PLU=ON L127

FILE 'STNGUIDE' ENTERED AT 15:44:03 ON 25 OCT 2006

D QUE STAT

FILE 'REGISTRY' ENTERED AT 15:45:16 ON 25 OCT 2006

D QUE STAT L127

FILE 'STNGUIDE' ENTERED AT 15:45:45 ON 25 OCT 2006

FILE 'REGISTRY' ENTERED AT 15:48:43 ON 25 OCT 2006

SAVE TEMP L127 SHI089REGCLM/A

L142 ANALYZE PLU=ON L127 1- LC : 9 TERMS  
D 1-9

FILE 'HCAPLUS' ENTERED AT 15:51:40 ON 25 OCT 2006

L143 39 SEA ABB=ON PLU=ON L127  
L144 24 SEA ABB=ON PLU=ON L143 AND L49  
L145 20 SEA ABB=ON PLU=ON L144 NOT L51  
SAVE TEMP L145 SHI089HCA3B/A  
L146 15 SEA ABB=ON PLU=ON L143 NOT L144  
L147 11 SEA ABB=ON PLU=ON L146 NOT L52  
SAVE TEMP L147 SHI089HCA3A/A

FILE 'STNGUIDE' ENTERED AT 15:53:24 ON 25 OCT 2006  
D SAVED

FILE 'USPATFULL, USPAT2, TOXCENTER, CASREACT, CHEMCATS' ENTERED AT  
15:54:34 ON 25 OCT 2006

L148 55 SEA ABB=ON PLU=ON L127  
L149 18 SEA ABB=ON PLU=ON L148 AND L49  
L150 11 SEA ABB=ON PLU=ON L149 NOT L83  
SAVE TEMP L150 SHI089MULS3B/A  
L151 0 SEA ABB=ON PLU=ON L149 NOT L149  
L152 37 SEA ABB=ON PLU=ON L148 NOT L149  
L153 29 SEA ABB=ON PLU=ON L152 NOT L84  
SAVE TEMP L153 SHI089MULS3A/A

FILE 'STNGUIDE' ENTERED AT 15:56:35 ON 25 OCT 2006

D SAVED  
D QUE L145  
D QUE L147

FILE 'CAOLD' ENTERED AT 15:57:42 ON 25 OCT 2006

L154 3 SEA ABB=ON PLU=ON L127  
SAVE TEMP L154 SHI089CAOLD/A

FILE 'STNGUIDE' ENTERED AT 15:58:08 ON 25 OCT 2006

D SAVED  
D COST

FILE 'MEDLINE, BIOSIS, EMBASE, PASCAL, JICST-EPLUS, JAPIO, LIFESCI,  
BIOENG, BIOTECHNO, BIOTECHDS, DRUGU, DRUGB, VETU, VETB, SCISEARCH, CABA,  
CONFSCI, DISSABS' ENTERED AT 16:00:07 ON 25 OCT 2006

L155 40725 SEA ABB=ON PLU=ON (L69 OR L70 OR L71 OR L72 OR L73 OR L74 OR  
L75)  
L156 4622 SEA ABB=ON PLU=ON L155 AND ?FACTOR?  
L157 25 SEA ABB=ON PLU=ON L155 AND (?AZAINDOL? OR (AZA (W) INDOL?))  
  
L158 16 SEA ABB=ON PLU=ON L155 AND (?PYRROL?(10A) ?PYRIDIN?)  
L159 1 SEA ABB=ON PLU=ON L157 AND L158  
L160 16 SEA ABB=ON PLU=ON (L158 OR L159)  
SAVE TEMP L160 SHI089OTHINV/A  
D SAVED

FILE 'STNGUIDE' ENTERED AT 16:06:02 ON 25 OCT 2006

D QUE STAT L2  
D QUE STAT L34



D QUE STAT L45  
D QUE NOS L46  
D QUE STAT L46  
D QUE NOS L47  
D L47 1-  
D QUE NOS L51  
D QUE NOS L83  
D QUE STAT L14  
D QUE STAT L90  
D QUE STAT L91  
D QUE STAT L92  
D QUE STAT L95  
D QUE STAT L31  
D QUE STAT L97  
D QUE STAT L99  
D QUE STAT L100  
D QUE STAT L103  
D QUE STAT L105  
D QUE NOS L114

FILE 'BEILSTEIN' ENTERED AT 16:19:43 ON 25 OCT 2006  
D L94 IDE

FILE 'STNGUIDE' ENTERED AT 16:19:49 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, USPAT2, TOXCENTER, CASREACT, BABS, WPIX'  
ENTERED AT 16:21:26 ON 25 OCT 2006

L161 17 DUP REM L51 L83 L95 L114 (10 DUPLICATES REMOVED)  
ANSWERS '1-7' FROM FILE HCAPLUS  
ANSWERS '8-13' FROM FILE USPATFULL  
ANSWERS '14-17' FROM FILE WPIX

FILE 'STNGUIDE' ENTERED AT 16:21:34 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, WPIX' ENTERED AT 16:21:52 ON 25 OCT 2006  
D IBIB ED AB HITSTR

FILE 'STNGUIDE' ENTERED AT 16:21:55 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, WPIX' ENTERED AT 16:22:16 ON 25 OCT 2006  
D IBIB ED AB HITSTR 2-7

FILE 'STNGUIDE' ENTERED AT 16:22:22 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, WPIX' ENTERED AT 16:22:49 ON 25 OCT 2006  
D IBIB AB HITSTR 8-13

FILE 'STNGUIDE' ENTERED AT 16:23:01 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, WPIX' ENTERED AT 16:23:26 ON 25 OCT 2006  
D IALL ABEQ TECH ABEX HITSTR 14-17

FILE 'STNGUIDE' ENTERED AT 16:23:33 ON 25 OCT 2006

L162 FILE 'HCAPLUS' ENTERED AT 16:23:51 ON 25 OCT 2006  
0 SEA ABB=ON PLU=ON L79 NOT L51  
D QUE L162

FILE 'STNGUIDE' ENTERED AT 16:24:24 ON 25 OCT 2006  
D QUE NOS L52

D QUE NOS L85  
D QUE NOS L115

FILE 'HCAPLUS, USPATFULL, TOXCENTER, CASREACT, CHEMCATS, WPIX' ENTERED AT  
16:26:07 ON 25 OCT 2006

L163 19 DUP REM L52 L84 L115 (5 DUPLICATES REMOVED)  
ANSWERS '1-6' FROM FILE HCAPLUS  
ANSWER '7' FROM FILE USPATFULL  
ANSWERS '8-19' FROM FILE CHEMCATS

FILE 'CHEMCATS' ENTERED AT 16:26:36 ON 25 OCT 2006

FILE 'STNGUIDE' ENTERED AT 16:26:46 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, CHEMCATS' ENTERED AT 16:27:01 ON 25 OCT 2006  
D IBIB ED AB RETABLE HITSTR

FILE 'STNGUIDE' ENTERED AT 16:27:02 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, CHEMCATS' ENTERED AT 16:27:20 ON 25 OCT 2006  
D IBIB ED AB RETABLE HITSTR 2-6

FILE 'STNGUIDE' ENTERED AT 16:27:24 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, CHEMCATS' ENTERED AT 16:27:40 ON 25 OCT 2006  
D IBIB AB HITSTR 7

FILE 'STNGUIDE' ENTERED AT 16:27:41 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, CHEMCATS' ENTERED AT 16:27:53 ON 25 OCT 2006  
D IDE 8-19

FILE 'STNGUIDE' ENTERED AT 16:27:54 ON 25 OCT 2006  
D QUE STAT L127  
D QUE NOS L142  
D L142 1-  
D QUE NOS L145  
D QUE NOS L150  
D QUE NOS L154

FILE 'HCAPLUS, USPATFULL, USPAT2, CASREACT, CAOLD' ENTERED AT 16:29:32 ON  
25 OCT 2006

L164 30 DUP REM L145 L150 L154 (4 DUPLICATES REMOVED)  
ANSWERS '1-20' FROM FILE HCAPLUS  
ANSWERS '21-27' FROM FILE USPATFULL  
ANSWERS '28-30' FROM FILE CAOLD

FILE 'STNGUIDE' ENTERED AT 16:29:42 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, CAOLD' ENTERED AT 16:30:04 ON 25 OCT 2006  
D IBIB ED AB HITSTR

FILE 'STNGUIDE' ENTERED AT 16:30:06 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, CAOLD' ENTERED AT 16:30:21 ON 25 OCT 2006  
D IBIB ED AB HITSTR 2-20

FILE 'STNGUIDE' ENTERED AT 16:30:52 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, CAOLD' ENTERED AT 16:31:44 ON 25 OCT 2006

D IBIB AB HITSTR 21-27

FILE 'STNGUIDE' ENTERED AT 16:31:49 ON 25 OCT 2006

FILE 'CAOLD' ENTERED AT 16:32:09 ON 25 OCT 2006

FILE 'STNGUIDE' ENTERED AT 16:32:25 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, CAOLD' ENTERED AT 16:32:32 ON 25 OCT 2006  
D IALL HITSTR 28

FILE 'STNGUIDE' ENTERED AT 16:32:32 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, CAOLD' ENTERED AT 16:32:44 ON 25 OCT 2006  
D IALL HITSTR 29-30

FILE 'STNGUIDE' ENTERED AT 16:32:45 ON 25 OCT 2006  
D QUE NOS L147  
D QUE NOS L153

FILE 'HCAPLUS, USPATFULL, TOXCENTER, CASREACT, CHEMCATS' ENTERED AT  
16:33:40 ON 25 OCT 2006  
L165 33 DUP REM L147 L153 (7 DUPLICATES REMOVED)  
ANSWERS '1-11' FROM FILE HCAPLUS  
ANSWER '12' FROM FILE USPATFULL  
ANSWER '13' FROM FILE TOXCENTER  
ANSWERS '14-33' FROM FILE CHEMCATS

FILE 'STNGUIDE' ENTERED AT 16:33:44 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, TOXCENTER, CHEMCATS' ENTERED AT 16:34:11 ON 25  
OCT 2006  
D IBIB ED AB RETABLE HITSTR

FILE 'STNGUIDE' ENTERED AT 16:34:12 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, TOXCENTER, CHEMCATS' ENTERED AT 16:34:19 ON 25  
OCT 2006  
D IBIB ED AB RETABLE HITSTR 2-11

FILE 'STNGUIDE' ENTERED AT 16:34:27 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, TOXCENTER, CHEMCATS' ENTERED AT 16:35:09 ON 25  
OCT 2006  
D IBIB AB HITSTR 12

FILE 'STNGUIDE' ENTERED AT 16:35:20 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, TOXCENTER, CHEMCATS' ENTERED AT 16:36:07 ON 25  
OCT 2006  
D IBIB ED AB HITIND 13

FILE 'STNGUIDE' ENTERED AT 16:36:07 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, TOXCENTER, CHEMCATS' ENTERED AT 16:36:27 ON 25  
OCT 2006  
D IDE 14-33

FILE 'STNGUIDE' ENTERED AT 16:36:30 ON 25 OCT 2006  
D QUE STAT L78

D QUE NOS L85  
D QUE L113  
D QUE L160

FILE 'HCAPLUS, USPATFULL, TOXCENTER, CASREACT, WPIX, MEDLINE, BIOSIS, EMBASE, PASCAL, JAPIO, LIFESCI, DRUGU, SCISEARCH' ENTERED AT 16:38:07 ON 25 OCT 2006

L166 27 DUP REM L78 L85 L113 L160 (6 DUPLICATES REMOVED)  
ANSWERS '1-8' FROM FILE HCAPLUS  
ANSWERS '9-12' FROM FILE USPATFULL  
ANSWERS '13-14' FROM FILE WPIX  
ANSWER '15' FROM FILE MEDLINE  
ANSWER '16' FROM FILE BIOSIS  
ANSWERS '17-19' FROM FILE EMBASE  
ANSWERS '20-22' FROM FILE PASCAL  
ANSWERS '23-25' FROM FILE JAPIO  
ANSWER '26' FROM FILE LIFESCI  
ANSWER '27' FROM FILE DRUGU

FILE 'STNGUIDE' ENTERED AT 16:38:18 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, WPIX, MEDLINE, BIOSIS, EMBASE, PASCAL, JAPIO, LIFESCI, DRUGU' ENTERED AT 16:38:40 ON 25 OCT 2006  
D IBIB ED AB 1-22

FILE 'STNGUIDE' ENTERED AT 16:38:45 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, WPIX, MEDLINE, BIOSIS, EMBASE, PASCAL, JAPIO, LIFESCI, DRUGU' ENTERED AT 16:39:14 ON 25 OCT 2006  
D IBIB ED AB 23

FILE 'STNGUIDE' ENTERED AT 16:39:16 ON 25 OCT 2006

FILE 'HCAPLUS, USPATFULL, WPIX, MEDLINE, BIOSIS, EMBASE, PASCAL, JAPIO, LIFESCI, DRUGU' ENTERED AT 16:39:33 ON 25 OCT 2006  
D IBIB ED AB 24-27

FILE 'STNGUIDE' ENTERED AT 16:39:36 ON 25 OCT 2006

FILE 'STNGUIDE' ENTERED AT 16:39:40 ON 25 OCT 2006

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 OCT 2006 HIGHEST RN 911193-70-9  
DICTIONARY FILE UPDATES: 24 OCT 2006 HIGHEST RN 911193-70-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of

experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE BEILSTEIN

FILE LAST UPDATED ON JUNE 16, 2006

FILE COVERS 1771 TO 2006.

**FILE CONTAINS 9,606,495 SUBSTANCES**

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

\*\*\*\*\*  
\* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. \*  
\* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE \*  
\* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE \*  
\* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. \*  
\* FOR PRICE INFORMATION SEE HELP COST \*  
\*\*\*\*\*

**NEW**

\* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.  
\* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

FILE CHEMINFORMRX

FILE LAST UPDATED: 19 SEP 2006 <20060919/UP>

>>> CAS Registry Numbers are available for substances prior to 1995 <<<

FILE LREGISTRY

LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Oct 25, 2006 (20061025/UP).

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Oct 2006 VOL 145 ISS 18  
FILE LAST UPDATED: 24 Oct 2006 (20061024/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

#### FILE ZCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 25 Oct 2006 VOL 145 ISS 18  
FILE LAST UPDATED: 24 Oct 2006 (20061024/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

#### FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 Oct 2006 (20061024/PD)  
FILE LAST UPDATED: 24 Oct 2006 (20061024/ED)  
HIGHEST GRANTED PATENT NUMBER: US7127745  
HIGHEST APPLICATION PUBLICATION NUMBER: US2006236437  
CA INDEXING IS CURRENT THROUGH 24 Oct 2006 (20061024/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Oct 2006 (20061024/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2006  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2006

#### FILE USPAT2

FILE COVERS 2001 TO PUBLICATION DATE: 24 Oct 2006 (20061024/PD)  
FILE LAST UPDATED: 24 Oct 2006 (20061024/ED)  
HIGHEST GRANTED PATENT NUMBER: US2006139723  
HIGHEST APPLICATION PUBLICATION NUMBER: US2006236276  
CA INDEXING IS CURRENT THROUGH 24 Oct 2006 (20061024/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Oct 2006 (20061024/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2006  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2006

#### FILE TOXCENTER

FILE COVERS 1907 TO 24 Oct 2006 (20061024/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The MEDLINE file segment has been updated with 2006 MEDLINE data and features. See HELP RLOAD for details.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

See <http://www.nlm.nih.gov/mesh/>

[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_med\\_data\\_changes.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html)

[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_2006\\_MeSH.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html)

for a description of changes.

#### FILE CASREACT

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 22 Oct 2006 VOL 145 ISS 17

New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
*****
*
*      CASREACT now has more than 10 million reactions
*
*****
```

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

#### FILE CHEMCATS

FILE LAST UPDATED 21 OCTOBER 2006 (20061021/UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow prompt. For the list of suppliers currently in the file, enter HELP SPA, HELP SPBC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPQZ. For the list of current catalogs, enter HELP CTA, HELP CTBC, HELP CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis. Please consult the suppliers for current information regarding pricing, regional availability, available quantities, purities, etc. THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not liable for any loss of profit, goodwill or any other damages arising out of the use of this database.

CHEMCATS now contains more than 10 million records. See HELP CONTENT and NEWS FILE for details.

#### FILE BABS

FILE LAST UPDATED: 25 SEP 2006

<20060925/UP>

FILE COVERS 1980 TO DATE.

## FILE WPIX

FILE LAST UPDATED: 23 OCT 2006 <20061023/UP>  
MOST RECENT THOMSON SCIENTIFIC UPDATE: 200668 <200668/DW>  
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX  
PLEASE VISIT:  
[http://www.stn-international.de/stndatabases/details/dwpi\\_r.html](http://www.stn-international.de/stndatabases/details/dwpi_r.html) <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf)

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE  
[http://www.stn-international.de/stndatabases/details/ipc\\_reform.html](http://www.stn-international.de/stndatabases/details/ipc_reform.html) and  
<http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf>

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX  
PLEASE SEE  
[http://www.stn-international.de/stndatabases/details/dwpi\\_r.html](http://www.stn-international.de/stndatabases/details/dwpi_r.html) <<<

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

A preliminary version of the Database Summary Sheet is available at:  
<http://www.stn-international.de/stndatabases/details/wpi.pdf>

## FILE ZREGISTRY

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 OCT 2006 HIGHEST RN 911193-70-9  
DICTIONARY FILE UPDATES: 24 OCT 2006 HIGHEST RN 911193-70-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

## FILE CAOLD

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)



This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

#### FILE MEDLINE

FILE LAST UPDATED: 24 Oct 2006 (20061024/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).  
See also:

<http://www.nlm.nih.gov/mesh/>  
[http://www.nlm.nih.gov/pubs/techbull/nd04/nd04\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html)  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_med\\_data\\_changes.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html)  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_2006\\_MeSH.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html)

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

#### FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT  
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 18 October 2006 (20061018/ED)

#### FILE EMBASE

FILE COVERS 1974 TO 25 Oct 2006 (20061025/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

#### FILE PASCAL

FILE LAST UPDATED: 23 OCT 2006 <20061023/UP>

FILE COVERS 1977 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE  
IN THE BASIC INDEX (/BI) FIELD <<<

FILE JICST-EPLUS  
FILE COVERS 1985 TO 24 OCT 2006 (20061024/ED)

THE JICST-EPLUS FILE HAS BEEN RELOADED TO REFLECT THE 1999 CONTROLLED  
TERM (/CT) THESAURUS RELOAD.

FILE JAPIO  
FILE LAST UPDATED: 3 APR 2006 <20060403/UP>  
FILE COVERS APRIL 1973 TO DECEMBER 22, 2005

>>> GRAPHIC IMAGES AVAILABLE <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOT YET AVAILABLE IN THIS FILE.  
USE IPC7 FORMAT FOR SEARCHING THE IPC. WATCH THIS SPACE FOR FURTHER  
DEVELOPMENTS AND SEE OUR NEWS SECTION FOR FURTHER INFORMATION  
ABOUT THE IPC REFORM <<<

FILE LIFESCI  
FILE COVERS 1978 TO 18 Oct 2006 (20061018/ED)

FILE BIOENG  
FILE LAST UPDATED: 20 OCT 2006 <20061020/UP>  
FILE COVERS 1982 TO DATE

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN  
THE BASIC INDEX <<<

FILE BIOTECHNO  
FILE LAST UPDATED: 7 JAN 2004 <20040107/UP>  
FILE COVERS 1980 TO 2003.

>>> BIOTECHNO IS NO LONGER BEING UPDATED AS OF 2004 <<<

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN  
/CT AND BASIC INDEX <<<

FILE BIOTECHDS  
FILE LAST UPDATED: 19 OCT 2006 <20061019/UP>  
FILE COVERS 1982 TO DATE

>>> USE OF THIS FILE IS LIMITED TO BIOTECH SUBSCRIBERS <<<

FILE DRUGU  
FILE LAST UPDATED: 23 OCT 2006 <20061023/UP>  
>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<  
>>> THESAURUS AVAILABLE IN /CT <<<

FILE DRUGB  
>>> FILE COVERS 1964 TO 1982 - CLOSED FILE <<<

FILE VETU  
FILE LAST UPDATED: 02 JAN 2002 <20020102/UP>  
FILE COVERS 1983-2001

FILE VETB  
FILE LAST UPDATED: 25 SEP 94 <940925/UP>

FILE COVERS 1968-1982

FILE SCISEARCH

FILE COVERS 1974 TO 20 Oct 2006 (20061020/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details.

FILE CABA

FILE COVERS 1973 TO 6 Oct 2006 (20061006/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The CABA file was reloaded 7 December 2003. Enter HELP RLOAD for details.

FILE CONFSCI

FILE COVERS 1973 TO 29 Aug 2006 (20060829/ED)

CSA has resumed updates, see NEWS FILE

FILE DISSABS

FILE COVERS 1861 TO 28 SEP 2006 (20060928/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

=>

This Page Blank (uspte)